Abstracts
Skip to Late-Breaking Abstracts »
Poster Presentation Dates
All odd numbered posters will be presented on Friday, November 8, 2019, while even numbered posters will be presented on Saturday, November 9, 2019.
Posters will be on display from 7 a.m. - 8 p.m., with the presenting authors required to be at their posters during lunch (12:30 - 2 p.m. on Friday, Nov. 8, and 12:35 - 2:05 p.m. on Saturday, Nov. 9) and also during the poster reception (6:30 - 8p.m. on Friday, Nov. 8, and 7 - 8:30 p.m. on Saturday, Nov. 9).
| # | Title | Authors | Category | Keywords |
|---|---|---|---|---|
| O1 | Flexible Copper-64-nanoparticle-based cell labeling system allows for in vivo tracking of adoptively transferred T-cells by PET/CT | Hólmfridur R. Halldórsdóttir, MSc; Lars Ringgaard, PhD; Martin Bak, PhD; Ditte Jæhger, MSc; Esben Christensen, MSc; Fredrik Melander, PhD; Mie L. Hübbe, MSc; Rasmus Eliasen, PhD; Frederikke P. Fliedner, MSc; Andreas Kjaer, MD, PhD; Anders E. Hansen, DVM, PhD; Jonas R. Henriksen, PhD; Thomas L. Andresen, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy; Immune monitoring; Solid tumors; T cell; TLR |
| O2 | Combining transcriptomic and tissue-based immune biomarkers to improve recurrence prediction in stage II-III melanoma | Robyn Gartrell, MD; Andrew X. Chen, BS; Emanuelle M. Rizk, BA; Douglas K. Marks, MD; Margaret H. Bogardus, BA; Basil A. Horst, MD; Rui Chang, MD; Anthea Monod, PhD; Raúl Rabadán, PhD; Yvonne Saenger, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Gene expression; Monocyte/Macrophage; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| O3 | Immune infiltration correlates with TP53 mutational status in a multi-cohort acute myeloid leukemia study. | Sergio Rutella, MD, PhD, FRCPath; Jayakumar Vadakekolathu, PhD; Stephen Reeder, BS; Jenny Ashforth, Miss; Melissa Courtney, Miss; Amanda Coutts, PhD; Tressa Hood, MS; Sarah E. Church, PhD; Clare Coveney, PhD; Jan Davidson-Moncada, MD, PhD; Jorn Meinel, MD; Marc Schmitz, MD; Francesco M. Marincola, MD; Martin Bornhauser, MD; Sergio Rutella, MD, PhD, FRCPath; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Gene expression; Immune contexture; Immune suppression; Leukemia/Lymphoma; Systems biology; Tumor microenvironment |
| O4 | Preclinical CAR-T cell target safety, biodistribution, and tumor infiltration analysis using in situ hybridization technology | Courtney M. Anderson, PhD; Helly Xiao Yan Pimentel; Helen Jarnagin; Hailing Zong; Courtney Todorov; Kenneth Ganley; Fay Eng; Kevin Friedman, PhD; Molly R. Perkins; Shannon Grande, PhD; Bingqing Zhang; Christopher Bunker; Xiao-Jun Ma; James R. Rottman; Courtney M. Anderson, PhD; | Cellular Therapies | CAR T cells; Cytokine; Gene expression; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor microenvironment |
| O5 | The road-map to Tumor-Infiltrating Lymphocyte (TIL) therapy: Understanding genetic alterations for improved patient treatment | Caitlin Creasy, MS; Yuzhong J. Meng, PhD; Tatiana Karpinets, MS; Cara Haymaker, PhD; Marie Andrée Forget, PhD; Chip Stewart, PhD; Carlos Antonio Torres Cabala, MD; Shari A. Pilon-Thomas, PhD; Amod A. Sarnaik, MD; Levi A. Garraway, MD, PhD; Patrick Hwu, MD; Rodabe N. Amaria, MD; Rameen Beroukhim, M.D, PhD; Chantale Bernatchez; | Cellular Therapies | Adoptive immunotherapy; Clinical trial; Gene expression; Immune contexture; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O6 | Enhanced presence of a myeloid-like NK cell subpopulation is associated with MHC class I-deficient tumor escape | Yimin Du, PhD; Curtis J. Perry, MD/PhD; William Damsky, MD, PhD; Katherine Hastings, PhD; Patricia Rodriguez-Morales; Dan Chen, PhD; Kacie Traina; Ivy Phung; Ting Zhou; Aaron M. Ring, MD, PhD; Katerina Politi, PhD; Susan M. Kaech, PhD; | Cellular Therapies | Immune suppression; Myeloid cells; NK/NK T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| O7 | P-BCMA-ALLO1 — a Nonviral, Allogeneic Anti-BCMA CAR-T Therapy with Potent Antitumor Function for the Treatment of Multiple Myeloma | Maximilian Richter, PhD; Stacey Cranert, PhD; Yening Tan, MS; Min Tong, MS; Christine Domingo, BS; Elvira Argus, PhD; Samad A. Ibitokou, PhD; Jenessa B. Smith, PhD; Christopher E. Martin, PhD; Xinxin Wang, PhD; Burton E. Barnett, PhD; Eric M. Ostertag, MD, PhD; Julia Coronella, PhD; Devon J. Shedlock, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells |
| O8 | The Thrombospondin-1/CD47 signaling axis serve as potential markers of immune checkpoint blockade response modulating immune cell bioenergetics in the tumor microenvironment. | Elizabeth R. Stirling, MS; Adam Wilson; Mitra Kooshki; Lilya Yamaleyeva; Guanxu Jin; Wei Zhang; Lance D. Miller, MS, PhD; Pierre L. Triozzi, MD; David R. Soto-Pantoja, PhD; | Cellular Therapies | Biomarkers; Checkpoint blockade; Metabolism; Tumor microenvironment |
| O9 | Enhancing affinity of CD22-directed CAR T cells increases activation signaling and in vivo response to CD22lo leukemia | Zachary H. Walsh, BA; Mark Kohler, MD, PhD; Terry J. Fry, MD; Zachary H. Walsh, BA; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma; Pediatric tumors; T cell; Targeted therapy; Tumor evasion |
| O10 | Licensing of CAR-T cell persistence and function by STING agonist in breast cancer | Nuo Xu, PHD candidate; Jonathan S. Serody, MD; Nuo Xu, PHD candidate; Nicholas P. Restifo, MD; Douglas C. Palmer; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Solid tumors; T cell; Targeted therapy; Tumor microenvironment |
| O11 | Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockade | Shuming Chen, PhD; Abha Soni; Tracee McMiller; John-William Sidhom, MSE; Farah Succaria, MD; Alan Berger; Jody Hooper; Drew M. Pardoll, MD, PhD; Evan Lipson; Janis M. Taube, MD, MSC; Suzanne L. Topalian, MD; | Checkpoint Blockade Therapy | Autoimmunity; Checkpoint blockade; Gene expression; Immune suppression; Immune toxicity; Inflammation; Solid tumors; Tumor microenvironment |
| O12 | B-cells activated by checkpoint blockade immunotherapy and radiation improve overall survival in squamous cell carcinomas | Sangwoo S. Kim, B.A.; Sarek Shen; Sayuri Miyauchi; Philip D. Sanders; Loren K. Mell, MD; J. Silvio Gutkind; Ezra Cohen, MD; Joseph Califano; Andrew B. Sharabi, MD, PhD; | Checkpoint Blockade Therapy | Antibody; B cell; Checkpoint blockade; Radiotherapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O14 | Immune selection for IFN-g signaling mutant cancer cells involves tumor heterogeneity and clonal cooperation | Thomas F. Gajewski, MD, PhD; Shuyin Li, PhD; Jason B. Williams; Emily Higgs; Alexandra Cabanov; Xiaozhong Wang; Haochu Huang; | Checkpoint Blockade Therapy | Checkpoint blockade; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| O15 | Replication stress response defects predict response to immune checkpoint blockade across multiple cancer lineages | Daniel J. McGrail, PhD; Patrick G. Pilie, MD; Truong Nguyen Anh Lam; Hui Dai, MD; Eric Jonasch, MD; Shiaw-Yih Lin, PhD; | Checkpoint Blockade Therapy | Bioinformatics; Biomarkers; Checkpoint blockade; Gene expression; Immunoscore; Systems biology |
| O16 | Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC) – Final Results of the phase II AVETUX trial (AIO-KRK-0216) | Alexander Stein, MD; Mascha Binder; Eray Goekkurt; Sylvie Lorenzen; Jorge Riera-Knorrenschild; Reinhard Depenbusch; Thomas Ettrich; Steffen Doerfel; Salah Al-Batran; Meinolf Karthaus; Uwe Pelzer; Donjete Simnica; Lisa Waberer; Axel Hinke; Carsten Bokemeyer; Susanna Hegewisch-Becker; Joseph Tintelnot, MD; | Clinical Trial Completed | Checkpoint blockade; Chemotherapy; Clinical trial; Immune monitoring; Solid tumors; Targeted therapy |
| O17 | A Novel Enantio-Specific Cationic Lipid R-DOTAP + HPV16 E6 & E7 Antigens Induces Potent Antigen-Specific CD8+ T Cell Responses In-Vivo in Subjects with CIN and High-Risk Human Papillomavirus Infection | Lauren V. Wood, MD; Lance H. Edwards, MD; Daron G. Ferris, MD; Nicole S. Nevadunsky, MD; Sara Isani, MD; Greg Conn, PhD; Frank Bedu-Addo, PhD; Mark Einstein, MD; | Clinical Trial Completed | Clinical study; Clinical trial; Immune adjuvant; T cell; Vaccine |
| O18 | Neoantigen vaccination targeting shared epidermal growth factor receptor (EGFR) mutations induces clinical and immunological responses in non-small cell lung cancer patients | Gregory A. Lizee, PhD; Fenge Li; Ligang Deng; Amjad Talukder; Kyle Jackson; Arjun Katailiha; Sherille Bradley; Heather Sonnemann; Qingwei Zhou; Caixia Chen; Chong Huo; Yulun Chiu; Matthew Stair; Weihong Feng; Aleksander Bagaev; Nikita Kotlov; Viktor Svekolkin; Ravshan Ataullakhanov; Natalia Miheecheva; Felix Frenkel; Yaling Wang; Minying Zhang; Jason Roszik, PhD; Ling Han; Shuo Zhou; Yan Zhang; Zhenglu Wang; Marie-Andree Forget; Chantale Bernatchez; Cassian Yee, MD; Patrick Hwu, MD; Xueming Du; Gregory A. Lizee, PhD; | Clinical Trial Completed | Clinical study; Clinical trial; Immune monitoring; Neoantigens; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor microenvironment; Vaccine |
| O19 | Final results from a phase 2 study using off-the-shelf activated natural killer (aNK) cells in combination with N-803, an IL-15 superagonist, in patients with metastatic Merkel cell carcinoma (MCC) | Shailender Bhatia, MD; Candice Church, PhD; Kelly G. Paulson, MD, PhD; Robert H. Pierce, Jr., MD; Paul Nghiem, MD, PhD; John H. Lee, MD; Bridget M. Adcock, BS; Patrick Soon-Shiong, MD; Sunandana Chandra, MD; | Clinical Trial Completed | Adoptive immunotherapy; Checkpoint blockade; Clinical study; Cytokine; NK/NK T cell; Solid tumors; T cell |
| O20 | A pilot study of engineered adenovirus ONCOS-102 in combination with pembrolizumab in checkpoint inhibitor refractory advanced or unresectable melanoma | Alexander N. Shoushtari, MD; Anthony J. Olszanski, MD, RPh; Thomas J. Hornyak, MD; Jedd D. Wolchok, MD, PhD; Sylvia Vetrhus; Karianne Risberg Handeland; Lukasz Kuryk, PhD; Magnus Jaderberg, MD; | Clinical Trial Completed | Checkpoint blockade; Clinical trial; Immune monitoring; Tumor microenvironment; Tumor stroma |
| O21 | Safety and clinical activity of avelumab (MSB0010718C), an anti-programed death-ligand 1 (PD-L1) antibody, in recurrent thymic epithelial tumors (TETs) | Arun Rajan, MD; Haobin Chen; Chen Zhao, MD; Shannon Swift; Andrew L. Mammen; Alessandra Brofferio; Emerson Padiernos; Eva Szabo, MD; Udayan Guha; Raffit Hassan, MD; Seth M. Steinberg; Yo-Ting Tsai; Renee N. Donahue, PhD; Jeffrey Schlom; James L. Gulley, MD, PhD, FACP; | Clinical Trial Completed | Autoimmunity; Checkpoint blockade; Clinical trial; Immune monitoring; Immune toxicity; Solid tumors |
| O22 | Phase II trial of therapeutic vaccine consisting of autologous dendritic cells loaded with autologous tumor cell antigens from self-renewing cancer cells in patients with newly diagnosed glioblastoma | Daniela Bota; David E. Piccioni, MD, PhD; Renato V. LaRocca, MD; Christopher M. Duma, MD; Robert D. Aiken, MD; Santosh Kesari, MD, PhD; Jose A. Carrillo, MD; Thomas H. Taylor, PhD; Candace Hsieh; Gabriel I. Nistor, MD; Robert O. Dillman, MD, FACP; | Clinical Trial In Progress | Clinical trial; Dendritic cell; Immune monitoring; Neoantigens; Stem cell/cancer-initiating cell; Vaccine |
| O23 | Sitravatinib in combination with nivolumab demonstrates clinical activity in platinum-experienced patients with urothelial carcinoma (UC) who progressed on prior immune checkpoint inhibitor (CPI) | Pavlos Msaouel, MD, PhD; Arlene Siefker-Radtke, MD; Randy F. Sweis, MD; Amir Mortazavi; Nicholas J. Vogelzang, MD; Ulka N. Vaishampayan, MD; Thomas Bradley, MD; Manojkumar Bupathi; Luke T. Nordquist, MD, FACP; David R. Shaffer; Joel Picus; Jeffrey Yorio, MD; Shifeng Mao; Gurjyot K. Doshi; Daniel L. Spitz; Sunil Gandhi; Daniel Chong; Arash Rezazadeh Kalebasty; James Christensen; Peter Olson; Demiana Faltaos, PharmD, PhD; Ronald L. Shazer; Maria Winter; Delia Alvarez; Hirak Del-Torossian; Jonathan E. Rosenberg, MD; | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; Targeted therapy; Tumor microenvironment |
| O24 | Phase II Trial of Concurrent Nivolumab and Radiation Therapy in Chemotherapy Ineligible Muscle Invasive Bladder Cancer [NUTRA trial NCT03421652] | Ulka N. Vaishampayan, MD; Saby George, MD, FACP; Lance Heilbrun; Jordan Maier, MD; Brenda Dickow; Michael Kuettel, MD; Arthur Frazier, MD; Stacey M. Suisham, RN BSN OCN CcRP; Prahlad Parajuli, PhD; Nitin Vaishampayan, MD; Ulka N. Vaishampayan, MD | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Clinical trial; Tumor microenvironment |
| O25 | Dominant Negative PD1 Armored CART Cells Induce Remission in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Patients | Cheng fei Pu; Lei Xiao, PhD | Clinical Trial In Progress | B cell; CAR T cells; Checkpoint blockade; Clinical study; Clinical trial; Leukemia/Lymphoma; T cell lineages; Targeted therapy; Tumor microenvironment |
| O26 | A phase II study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC: Updated analysis | Matthew G. Krebs, MD PhD; Paal F. Brunsvig, MD PhD; Åslaug Helland; Nuria Vinolas Segarra; Santiago Ponce Aix, MD; Enric Carcereny Costa, MD; Manuel Dómine Gomez, MD, PhD; Jose Manuel Trigo Perez; Edurne Arriola; Rosario Garcia Campelo; James Spicer, MD, PhD; Jonathan Thompson, MD MS; Ana Laura Ortega Granados; Robert Holt, PhD; James Lorens, PhD; Muhammad Shoaib, MD; Abdul Siddiqui; Emmett Schmidt, MD PhD; Michael J. Chisamore, PhD; Enriqueta Felip, MD PhD; | Clinical Trial In Progress | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors |
| O27 | Clinical Response to Tumor Infiltrating Lymphocytes (TIL) in Stage 4 Non-small Cell Lung Cancer (NSCLC) Correlates with Neoantigen-Specificity: a Phase I Trial | Chao Wang, PhD; Jamie Teer; Jiqiang Yao, PhD; Anadon Galindo Carmen M; David Noyes; Eric Toloza; John E. Mullinax, MD; Ana Landin; Jhanelle Gray; Tawee Tanvetyanon; Andreas Saltos; Linda L. Kelley, PhD; Bin Fang, PhD; John Koomen, PhD; Amod A. Sarnaik, MD; Sungjune Kim, MD PhD; Shari A. Pilon-Thomas, PhD; Jose R. Conejo-Garcia, MD, PhD; Scott J. Antonia, MD. PhD; Eric Haura, MD; Ben C. Creelan, MD, MS; | Clinical Trial In Progress | Adoptive immunotherapy; Checkpoint blockade; Clinical trial; Neoantigens; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| O28 | First-in-Class Small Molecule CA-170 Targeting VISTA: A Report on Efficacy Outcomes from a Cohort of 12 Malignant Pleural Mesothelioma (MPM) Patients in Study CA-170-101 | Marjorie G. Zauderer, MD, MS, FACP; Joshua Brody, MD; Thomas U. Marron, MD PhD; Simon Pacey; Robert Martell; Hongwei Wang; James Spicer, MD, PhD; | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; Targeted therapy |
| O29 | Phase I study of multisite stereotactic body radiotherapy plus nivolumab and urelumab or nivolumab and cabiralizumab in patients with advanced solid tumors | Corey C. Foster, MD, MS; Jason J. Luke, MD, FACP; Robyn Hseu, CCRP, MLIS; Linda Janisch; Gini Fleming, MD; Steven J. Chmura, MD, PhD; | Clinical Trial In Progress | Checkpoint blockade; Clinical trial; Radiotherapy; Solid tumors |
| O30 | A Phase 1 study of AK104, a tetrameric bispecific antibody that targets PD-1 and CTLA-4 in patients with advanced solid tumors | Ben Markman, MBBS FRACP; Ben Tran; Hui Gan, MBBS PhD; Amy Prawira, MD; Jermaine Coward; Xiaoping Jin; Baiyong Li; Max Wang; Yu Xia; Jayesh Desai, MBBS FRACP; Jayesh Desai, MBBS FRACP; Michael Millward; | Clinical Trial In Progress | Antibody; Biomarkers; Clinical trial; Solid tumors |
| O31 | Intratumoral INT230-6 injection into solid tumors kills tumors and induces immune cell infiltration leading to abscopal responses and prolonged disease control in multiple refractory cancer types | Jacob Thomas, MD; Anthony J. Olszanski, MD, RPh; Nilofer Azad, MD; Lewis H. Bender, M.S., M.A, M.B.A.; Ian B. Walters, MD; Giles F. Whalen, MD; Diana Hanna, MD; Vinay Duddalwar, MD; Phillip Cheng, MD; Kevin King, MD; Lilian L. Siu, MD; Anthony El-Khoueiry, MD; | Clinical Trial In Progress | Chemotherapy; Clinical trial; Dendritic cell; Immune monitoring; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| O32 | Single agent anti-tumor activity in PD-1 refractory NSCLC: phase 1 data from the first-in-human trial of NC318, a Siglec-15-targeted antibody | Anthony Tolcher, MD; Omid Hamid, MD; Jeffrey S. Weber, MD, PhD; Patricia LoRusso, DO; Kathryn Shantz; Kevin N. Heller, MD; Kevin Heller, MD; Martin Gutierrez, MD; | Clinical Trial In Progress | Antibody; Biomarkers; Clinical study; Clinical trial; Monocyte/Macrophage; Solid tumors; T cell; Tumor antigens; Tumor evasion; Tumor microenvironment |
| O33 | Immune enrichment and functional T-cell receptor (TCR) frequencies predict response to immune checkpoint blockade (ICB) in selected fusion-associated sarcomas | Akash Mitra, BS; Neeta Somaiah, MD, MBBS; Anthony P. Conley, MD; Behrang Amini; Heather Lin; Beatriz Sanchez Espiridion; Celia Garcia-Prieto; Grace Mathew; Latasha Little, BS; Xingshi Song; Curtis Gumbs, BS; Cara Haymaker, PhD; Jianhua Zhang; Zachary A. Cooper, PhD; Michael D. Oberst, PhD; Chantale Bernatchez; Vinod Ravi; Dejka Araujo, MD; Maria Zarzour; John Livingston; Christina Roland, MD, MS, FACS; Najat Daw, MD; Jaime Rodriguez-Canales, MD; Alexander J. Lazar, MD, PhD; Wei-Lien Wang; Ignacio Wistuba, MD; Jean-Charles Soria, MD, PhD; Robert Benjamin; Shreyaskumar Patel; Patrick Hwu, MD; Phillip Andrew Futreal, PhD; | Clinical Trial In Progress | Bioinformatics; Checkpoint blockade; Clinical trial; Gene expression; Immune monitoring; Immunoscore; Systems biology; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O34 | Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (IT) CMP-001 in High Risk Resectable Melanoma (MEL): Preliminary Results. | Diwakar Davar, MD; Arivarasan Karunamurthy; Douglas Hartman; Mignane Ka; Carmine Menna; Julie Burkette; Joe-Marc JM. Chauvin, PhD; Lucas Rubuffet; Shuowen Zhang; Quanquan Ding; Amy Rose; Kellie Sellitto; Yana G. Najjar, MD; Matthew Holtzman; James Pingpank; Shaum Sridharan; Umamaheshwar Duvvuri; Hagop Youssoufian; Barry Labinger; Arthur Krieg; John M. Kirkwood, MD; Hassane M. Zarour, MD; | Clinical Trial In Progress | Clinical trial; T cell; TLR |
| O35 | Clinical activity of BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: updated results from the phase 1/2 PIVOT-02 study | Adi Diab, MD; Igor Puzanov, MD, MSCI, FACP; Michele Maio, MD, PhD; Brendan D. Curti, MD; Mehmet A. Bilen; Karl D. Lewis, MD; Scott S. Tykodi, MD, PhD; Gregory A. Daniels, MD, PhD; Alexander I. Spira, MD, PhD, FACP; Chantale Bernatchez; Salah Eddine Bentebibel; Michael K. Wong, MD PhD FRCPC; James Larkin, MD; Ewa Kalinka, PhD, MD; Sunny Xie; Sue Currie; Ute Hoch, PhD; Wei Lin; Mary A. Tagliaferri, MD; Stina Singel; Michael E. Hurwitz, MD, PhD; | Clinical Trial In Progress | Checkpoint blockade; Clinical trial; Cytokine; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O36 | A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors | Thomas Eigentler, Dr.; Juergen Krauss; Jutta Schreiber, Dr; Carsten Weishaupt; Patrick Terheyden; Lucie Heinzerling; Peter Mohr; Benjamin Weide, MD; Sebastian Ochsenreither; Juergen C. Becker, MD, PhD; Franz-Georg Bauernfeind, Dr; Peter Brossart; Fatma Funkner; Regina Heidenreich; Sarah-Katharina Kays; Anke Muth; Tobias Seibel, II; Birgit Scheel; Oliver Schoenborn-Kellenberger; Claudia Stosnach; Angelika Daehling; Tanja Strack; Roman P. Korolkiewicz; Ulrike Gnad-Vogt, MD | Clinical Trial In Progress | Antigen presenting cells; Checkpoint blockade; Clinical study; Clinical trial; Inflammation; TLR; Tumor microenvironment; Vaccine |
| O37 | PD1 Blockade Augments Adoptive T Cell Therapy via Endogenous T cells Rather than Direct Enhancement of Transferred T Cells | John S. Davies, PhD; Farrah Karimipour, BS.; Ling Zhang, PhD; Carylinda Serna; Christian S. Hinrichs, MD; | Combination Immunotherapies | Adoptive immunotherapy; Checkpoint blockade; Coinhibition; Neoantigens; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| O38 | A Single-dose immunotherapy that remodels the tumor microenvironment for subsequent curative responses to checkpoint blockade | Chensu Wang, PhD; Chensu Wang, PhD; Ang Cui; Ayush Thomas; Simon Liang; Maurice Bukenya; Heikyun Suh; K. Dane Wittrup, PhD; Nir Hacohen, PhD; Darrell J. Irvine, PhD; | Combination Immunotherapies | Angiogenesis; Antibody; Checkpoint blockade; Cytokine; Dendritic cell; Monocyte/Macrophage; NK/NK T cell; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O39 | Soluble TNFα induced mucin 4 is a mediator of trastuzumab resistance and of an immunosuppressive tumor microenvironment in HER2+ breast cancer | Sofia Bruni, MS; Mara De Martino, PhD; Florencia L. Mauro, MS; Lucia Santa maria de la Parra; Patricia V. Elizalde, PhD; Roxana Schillaci; Roxana Schillaci; | Combination Immunotherapies | Antibody; Immune suppression; Myeloid cells; MDSC; NK/NK T cell; Solid tumors; Targeted therapy; Tumor microenvironment |
| O40 | Immunobiology and clinical activity of CPI-006, an anti-CD73 antibody with immunomodulating properties in a phase 1/1b trial in advanced cancers | Jason J. Luke, MD, FACP; Jaime Merchan; Lauren Harshman, MD; Thomas U. Marron, MD PhD; John D. Powderly, II, MD, CPI; Minal Barve; Patricia LoRusso, DO; Melissa Johnson; Andrew Hotson, PhD; Rachel Gittelman, PhD; Brian Munneke; Joseph J. Buggy; Stephen Willingham, PhD; Emily C. Piccione, PhD; Mehrdad Mobasher; Richard A. Miller, MD; Richard A. Miller; | Combination Immunotherapies | Antibody; Antigen presenting cells; B cell; Checkpoint blockade; Clinical trial; Targeted therapy |
| O41 | Vasoactive intestinal peptide: a novel checkpoint pathway in pancreatic ductal adenocarcinoma | Sruthi Ravindranathan, PhD; Shuhua Wang, MD; Brandon Ware; Mohammad Y. Zaidi, MD, MS; Jingru Zhu; Rohan K. Dhamsania, BS; Susan N. Thomas, PhD, BS; Yiwen Li, MS; Bassel El-rayes, MD; Gregory B. Lesinski, PhD, MPH; Edmund K. Waller, MD, PhD, FACP; | Combination Immunotherapies | Adoptive immunotherapy; Solid tumors; Targeted therapy |
| O42 | Transcriptional dissection reveals antitumor role of T follicular helper cells in head and neck cancer | Anthony R. Cillo, PhD; Dario A. Vignali, PhD; | Immune Cell Biology | B cell; Bioinformatics; Biomarkers; Gene expression; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O43 | Immune profiling of the tumor microenvironment in classic Hodgkin lymphoma using high-complexity mass cytometry is feasible and reveals significant multi-compartment heterogeneity between patients | El-ad David Amir, PhD; Jose C. Villasboas, MD; Kaitlyn R. McGrath, M.S.; Stephen M. Ansell, MD, PhD; | Immune Cell Biology | Bioinformatics; Immune monitoring; Systems biology; T cell; Tumor microenvironment |
| O44 | Intratumoral CD163+ DC amplify the type 1 immune response of CD4+CD161+ T cells in HPV16-associated cancers and are associated with better survival | Chantal Duurland, PhD; Saskia Santegoets; Nikki M. Loof; Vanessa J. van Ham; Ilina Ehsan; Marij JP. Welters, PhD; Sjoerd H. van der Burg; | Immune Cell Biology | Antigen presenting cells; Cytokine; Dendritic cell; Immune contexture; Myeloid cells; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O45 | Overexpression of CD200 is a stem cell-specific mechanism of T cell evasion in AML | Shelley Herbrich, MS; Gheath Alatrash, DO, PhD; Richard E. Davis, MD; Michael A. Curran, PhD; Marina Konopleva, MD, PhD; Shelley Herbrich, MS; | Immune Cell Biology | Leukemia/Lymphoma; T cell; Tumor evasion |
| O46 | Characterization of tumor infiltrating and post HSCT NK and T cells in human cancer patients | Sean J. Judge, MD, MS; Cordelia Dunai; Ian Sturgill; Kevin M. Stoffel, MS; Patrice Chevallier; Christelle Retière; Arta Monjazeb; Robert Canter, MD, MAS, FACS; William J. Murphy, PhD; | Immune Cell Biology | Checkpoint blockade; NK/NK T cell; Solid tumors; Surgery; T cell; Tumor microenvironment |
| O47 | IL-35+ B cells regulates anti-tumor immune response in pancreatic cancer | Bhalchandra Mirlekar, PhD; Yuliya Pylayeva-Gupta; Bhalchandra Mirlekar, PhD; | Immune Cell Biology | B cell; Cytokine; Immune suppression; Targeted therapy; Tumor microenvironment |
| O48 | Characterizing the anti-tumor immune response to an array of tumor cell lines expressing unique neoantigens | Christopher J. Copeland; Kim B. Nguyen, B.A.; Kim B. Nguyen, B.A.; Stefani Spranger, PhD; | Immune Cell Biology | Checkpoint blockade; Neoantigens; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |
| O49 | Chronic activation under hypoxia drives T cell differentiation to exhaustion | Nicole E. Scharping, PhD; Yiyang Wang, N/A; Ashley Menk, MS; Greg M. Delgoffe, PhD; | Immune Cell Biology | Checkpoint blockade; Coinhibition; Metabolism; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O51 | Sirt2 inhibition enhances anti-tumor immunity by promoting T cell metabolism | Imene Hamaidi, PhD; Lin Zhang, MD. Ph.D; Nayoung Kim, Ph.D; Min-Hsuan Wang; Cristina Iclozan, PhD; Bin Fang, PhD; Min Liu, PhD; John Koomen, PhD; Anders E. Berglund, PhD; Sean J. Yoder; Jiqiang Yao, PhD; Ben C. Creelan, MD, MS; Scott J. Antonia, MD. PhD; Sungjune Kim, MD PhD; | Immune Cell Biology | Checkpoint blockade; Clinical trial; Metabolism; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| O52 | ADT-mediated IL-8 Promotes Myeloid Infiltration and Prostate Cancer Progression | Zoila A. Lopez Bujanda, MS; Michael C. Haffner, MD; Matthew G. Chaimowitz; Nivedita Chowdhury; Nicholas J. Venturini; Aleksandar Obradovic; Corey S. Hansen; Joanna Jacków; Karen S. Sfanos; Charles J. Bieberich; Paula J. Hurley; Mark J. Selby; Alan J. Korman; Angela Christiano, PhD; Angelo M. De Marzo; Charles G. Drake, MD, PhD; Zoila A. Lopez Bujanda, MS; | Immune Cell Biology | Chemokine; Granulocyte; Immune suppression; Inflammation; Myeloid cells; MDSC; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O53 | Altered T-cell clonotype composition is strongly associated with differential functional orientation of colon cancer microenvironment | Jessica Roelands, Master; Peter Kuppen; Lisa Mathew; Amany Awad; Francesco M. Marincola, MD; Darawan Rinchai, PhD; Davide Bedognetti, MD, PhD; Wouter RL. Hendrickx, PhD; | Immune Cell Biology | Gene expression; Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs) |
| O54 | Germline Genetic Variation affects the Immune Response in Cancer | Rosalyn W. Sayaman, PhD; Mohamad Saad, PhD; Vésteinn Thorsson, PhD; Younes Mokrab; Wouter RL. Hendrickx, PhD; Farshad Farshidfar; Tomas Kirchhoff, PhD; Randy F. Sweis, MD; Najeeb Syed; Oliver Bathe; Eduard Porta-Pardo; Cynthia Stretch; Donglei Hu; Scott Huntsman; Jessica Roelands, Master; Simon Shelley; Denise Wolf; Jerome Galon; Francesco M. Marincola; Michele Ceccarelli; Elad Ziv; Davide Bedognetti, MD, PhD; | Immune Cell Biology | Bioinformatics; Gene expression; Genetic polymorphism; Immune contexture; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O55 | Antigen-cross presentation promotes the development of terminally differentiated CD8 T cells in young individuals | Ardiana Moustaki, PhD; Shanta Alli, PhD; Anthony E. Zamora; Jeremy C. Crawford; Paul G. Thomas; Shannon Boi; Natalie MN. McDonald; Alberto S. Pappo; Michael A. Dyer; Elizabeth Stewart; Sara Federico; Ben Youngblood; | Immune Cell Biology | Antigen presenting cells; Checkpoint blockade; Immune suppression; Monocyte/Macrophage; Myeloid cells; Pediatric tumors; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O56 | Expression of ART1, an extracellular mono ADP-ribosylase, promotes lung cancer growth and dissemination by limiting tumor infiltration of P2X7R+ CD8+ T cells and CD103+ dendritic cells | Erik Wennerberg, PhD; Clarey Hung; Amanda Valeta; Timothy E. McGraw; Sandra Demaria, MD; Brendon Stiles, MD; | Immune Cell Biology | Biomarkers; Dendritic cell; Immune suppression; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| O57 | Novel dsRNA-sensing dendritic cells enhance anti-tumor immunity | Ellen Duong, Sc.B.; Stefani Spranger, PhD; | Immune Cell Biology | Antigen presenting cells; Dendritic cell; Myeloid cells; Tumor microenvironment |
| O58 | Human tumor-infiltrating MAIT cells display hallmarks of antigen-recognition that are associated with tumor bacterial infiltration | Shamin Li, PhD; Shamin Li, PhD; Evan W. Newell, PhD; | Immune Cell Biology | Microbiome; T cell; Tumor antigens; Tumor microenvironment |
| O59 | CD8 T-cell infiltration into renal tumors requires a supportive antigen presenting niche and is independent of PD-L1 status | Caroline S. Jansen, BS; Nataliya Prokhnevska, BS; Viraj A. Master, MD, PhD; Jennifer Carlisle, MD; Mehmet A. Bilen; Maria A. Cardenas; Scott Wilkinson, PhD; Ross Lake; Adam G. Sowalsky, PhD; Adeboye O. Osunkoya, MD; Patrick Mullane, MD; Carla Ellis; Adriana M. Reyes; Yuan Liu, PhD; Haydn T. Kissick; | Immune Cell Biology | Antigen presenting cells; Dendritic cell; Immune contexture; Immunoscore; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| O60 | Tumor cell-intrinsic defects in STING pathway signaling and IFN-β gene regulation | Blake Flood, BS; Leticia Corrales; Thomas F. Gajewski, MD, PhD; | Immune-stimulants and immune modulators | Cytokine; Gene expression; Inflammation; TLR |
| O61 | Myeloid Cell-Targeted miR-146a Mimic Alleviates NF-κB-Driven Cytokine Storm without Interfering with CD19-Specific CAR T-cell Activity against B-Cell Lymphoma | Marcin Kortylewski, PhD; Yu-Lin Su; Xiuli Wang, PhD; Mati Mann; Dayson F. Moreira, PhD; Zhuoran Zhnag; Ching Ouyang; Piotr Swiderski; Stephen J. Forman, MD; David Baltimore, PhD; Ling Li; Guido Marcucci; Mark Boldin; | Immune-stimulants and immune modulators | CAR T cells; Cytokine; Inflammation; Leukemia/Lymphoma; Monocyte/Macrophage; Myeloid cells |
| O62 | Targeting myeloid tumors by Off-the-Shelf NK cells using an NKG2C-IL15-CD33 Trispecific Killer Engager | Emily Chiu, BA; Martin Felices; Frank Cichocki, PhD; Zachary Davis, PhD; Hongbo Wang; Katie Tuininga; Daniel Vallera; Tom Lee, PhD; Ryan Bjordahl; Dan S. Kaufman, CAMD, PhD; Karl Johan Malmberg; Bahram Valamehr; Jeffrey S. Miller, MD; | Immuno-conjugates and chimeric molecules | Adoptive immunotherapy; NK/NK T cell; Targeted therapy |
| O63 | Gastric toxicity associated with PD-1 blockade therapy revealed by Multiplexed Ion Beam Imaging | Selena Ferrian, PhD; Theodore S. Nowicki, MD, PhD; David W. Dawson; Alex Baranski; John Glaspy, MD; Antoni Ribas, MD, PhD; Michael Angelo, MD, PhD; | Immunotherapy Toxicities | Autoimmunity; Checkpoint blockade; Inflammation; Systems biology |
| O64 | Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease | Hamzah Abu-Sbeih, MD; David Faleck; Biagio Ricciuti, MD; Robin Mendelsohn; Abdul Rafeh Naqash, MD; Justine V. Cohen, DO; MacLean C. Sellars; Aanika Balaji; Guy Ben-betzalel; Ibraheim Hajir; Jiajia Zhang, MD, MPH; Mark Awad, MD PhD; Giulia Leonardi; Douglas B. Johnson, MD, MSCI; David J. Pinato, MD, MRes, PhD; Dwight Owen; Sarah A. Weiss, MD; Giuseppe Lamberti, MD; Mark Lythgoe; Lisa Manuzzi; Christina Arnold; Wei Qiao, PhD; Jarushka Naidoo, MD; Gal Markel; Nick Powell; Sai-Ching J. Yeung, MD, PhD; Elad Sharon, MD, MPH; Michael Dougan, MD, PhD; Yinghong Wang, MD, PhD; | Immunotherapy Toxicities | Autoimmunity; Checkpoint blockade; Immune suppression; Immune toxicity; Inflammation |
| O65 | Artificial intelligence-powered retrospective analysis of PD-L1 expression in nivolumab trials of advanced non-small cell lung cancer | Vipul Baxi, MS; Andrew Beck, MD, PhD; Dimple Pandya; George Lee, PhD; Cyrus Hedvat, MD, PhD; Aditya Khosla; Dayong Wang; Hunter Elliott; Harsha Pokkalla; Abhik Lahiri; Benjamin Glass; Jennifer K. Kerner; Ilan Wapinski; Scott D. Chasalow; Han Chang, PhD; Robin H. Edwards, PhD; Michael Montalto; | Machine Learning, Artificial Intelligence, and Computational Modeling | Bioinformatics; Biomarkers; Inflammation; Monocyte/Macrophage |
| O66 | Patient-derived microbiota germ-free mouse model for identifying mechanisms of checkpoint blockade efficacy modulation | Vyara Matson, PhD; Jessica L. Fessler, BS; Yuanyuan Zha, PhD; Thomas F. Gajewski, MD, PhD; | Microbiome and other environmental factors | Checkpoint blockade; Microbiome |
| O67 | Variation in the commensal urinary microbiome is associated with response to Bacillus Calmette-Guérin (BCG) immunotherapy in early stage urothelial bladder cancer. | Randy F. Sweis, MD; Randy F. Sweis, MD; Ciro Andolfi; Jeffrey Bloodworth; Shay Golan, MD; Nimrod Barashi; Elle Hill; Ryan Werntz; Thomas F. Gajewski, MD, PhD; Gary D. Steinberg, MD; | Microbiome and other environmental factors | Biomarkers; Chemokine; Clinical study; Cytokine; Immune contexture; Microbiome; Solid tumors; Tumor microenvironment |
| O68 | Characteristics of the microbiome form and function of complete responders to Anti-PD1 and healthy individuals implicate donor selection for clinical trial design | Md Abdul Wadud Khan, PhD; Jennifer A. Wargo, MD, MMSc; Beth Helmink, MD PhD; Elizabeth Burton; Christine N. Spencer, PhD; Jennifer L. McQuade, MD; Miles Andrews, MD, PhD; Alexandria Cogdill; Lauren E. Haydu, MS, BChe, MIPH; Reetakshi Arora; Angela L. Harris; Vanessa B. Jensen, DVM; Adrienne F. Duran, B.A.S.; Linsey Martin; Elizabeth Sirmans; Sapna Patel, MD; Tim Heffernan; Robert Jenq, MD; Michael K. Wong, MD PhD FRCPC; Jeffrey E. Gershenwald, MD; Tawbi Hussein; Isabella C. Glitza, MD, PhD; Patrick Hwu, MD; Michael Davies, MD, PhD; David Cook; Jennifer Wortman; Theresa LaVallee, PhD; Adi Diab, MD; Vancheswaran Gopalakrishnan; Md Abdul Wadud Khan, PhD; | Microbiome and other environmental factors | Bioinformatics; Biomarkers; Checkpoint blockade; Clinical study; Microbiome |
| O69 | Helicobacter hepaticus remodels the tumor immune microenvironment and reduces colorectal tumor burden | Abigail E. Overacre-Delgoffe, PhD; Hannah Bumgarner; Ansen HP. Burr; Timothy W. Hand, PhD; | Microbiome and other environmental factors | Dendritic cell; Immune suppression; Microbiome; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O70 | CD122-selective IL-2 complexes treat ovarian carcinomas, possibly by dysregulating Treg differentiation and reducing suppression, and promoting T cell stem cells | Yilun Deng, MD, PhD; Justin M. Drerup; Xinyue Zhang; Ryan M. Reyes; Jenny A. Mendez; Myrna G. Garcia; Alvaro S. Padron; Harshita B. Gupta, PhD; Tyler Curiel, MD; | Novel Single-Agent Immunotherapies | Checkpoint blockade; Cytokine; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| O71 | AMV564, a novel bivalent, bispecific T-cell engager, targets myeloid-derived suppressor cells | Sterling C. Eckard, PhD; Leah N. Gehrs; Victoria Smith; Jeanmarie Guenot; John F. DiPersio; Sheng Wei, MD; Michael P. Rettig; | Novel Single-Agent Immunotherapies | Clinical trial; Immune suppression; Leukemia/Lymphoma; Myeloid cells; MDSC; Solid tumors; T cell; Targeted therapy |
| O72 | Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers | Fan Zhang, PhD; Neha Parayath, PhD; Michael Coon, MS; Sirkka Stephan, PhD; Matthias Stephan, MD, PhD; | Novel Single-Agent Immunotherapies | Dendritic cell; Immune adjuvant; Immune suppression; Inflammation; Monocyte/Macrophage; Myeloid cells; MDSC; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O73 | Designed improvement to T-cell immunotherapy by integrated single cell profiling. | Irfan N. Bandey, PhD; Jay RT. Adolacion, PhD; Gabrielle Romain, PhD; Melisa Martinez, PhD; An Xingyue, PhD; Arash Saeedi; Rasindu Rajanayke; Ivan Liadi, PhD; Harjeet Singh, PhD; Laurence JN. Cooper, MD, PhD; Navin Varadarajan, PhD; | Other | Antibody; Bioinformatics; Biomarkers; Chemokine; Costimulation; Gene expression; Immune suppression; Leukemia/Lymphoma; Metabolism; Proteomics |
| O74 | Fibroblast activation protein is expressed by human and murine leukocytes and nonspecific inhibition of FAP enhances anti-PD-1 therapy in murine models of PDAC | Louis M. Weiner, MD; Allison Fitzgerald, MD/PhD Candidate; Shangzi Wang, PhD; | Tumor and Stromal Cell Biology | Checkpoint blockade; NK/NK T cell; Solid tumors; Tumor microenvironment; Tumor stroma |
| O75 | Selective induction of S100a8/a9 heterodimer protein in pancreatic cancer in response to immune selection pressure | Louis M. Weiner, MD; Reham Ajina, MS | Tumor and Stromal Cell Biology | Immune suppression; Inflammation; Proteomics; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment; Tumor stroma |
| O76 | Interferon-Gamma Mediated T Cell Exhaustion Generates Distinct Tumor Microenvironments in Synchronous Melanoma via PD-1/PD-L1 Axis | Peter A. Prieto, MD, MPH; Shuyang S. Qin, BS; Alyssa Williams; Booyeon Han, BS; Rachel Jewell; Katherine M. Jackson, MD; Alexander C. Chacon, MD; Edward Englerth III, BS; Brian A. Belt, JD; Goran Micevic, MD, PhD; David C. Linehan, MD; Scott Gerber, PhD; Alexandre Reuben; | Tumor and Stromal Cell Biology | Chemokine; Costimulation; Immune suppression; Immune tolerance; T cell; Tumor evasion; Tumor microenvironment; Tumor stroma |
| O77 | Clinicopathological and genomic correlates of PD-L1 expression in nonsquamous non-small cell lung cancer. | Giuseppe Lamberti, MD; Liam Spurr; Yvonne Li; Biagio Ricciuti, MD; Gonzalo Recondo, MD; Renato Umeton; Andrew Cherniak; Matthew L. Meyerson, MD, PhD; Mark Awad, MD PhD; | Tumor and Stromal Cell Biology | Bioinformatics; Biomarkers; Checkpoint blockade; Solid tumors |
| O78 | Identification of breast cancer neoantigens exposed by radiation therapy | Claire Lhuillier, PhD; Nils Rudqvist; Takahiro Yamazaki, PhD; Lorenzo Galluzzi; Sandra Demaria, MD; | Tumor and Stromal Cell Biology | Neoantigens; Radiotherapy; Solid tumors; Tumor antigens; Vaccine |
| O79 | Mapping the spatial architecture of acute myeloid leukemia in the bone marrow microenvironment by multiplexed ion beam imaging | Xavier Rovira-Clave, PhD; Sizun Jiang, PhD; Xavier Rovira-Clave, PhD; Yunhao Bai, BS; Bokai Zhu; Marc Bosse, PhD; Michael Angelo, MD, PhD; Yara Banz, MD, PhD; Christian M. Schürch, MD, PhD; Garry P. Nolan, PhD; | Tumor and Stromal Cell Biology | B cell; Checkpoint blockade; Immune monitoring; Leukemia/Lymphoma; Myeloid cells; Proteomics; T cell; Tumor evasion; Tumor microenvironment; Tumor stroma |
| O80 | Atlas of clinically-distinct cell states and cellular ecosystems across human solid tumors | Bogdan Luca; Ash Alizadeh; Max Diehn; Aaron Newman; Andrew Gentles, PhD; Chloé Steen; Andrew Gentles, PhD; | Tumor and Stromal Cell Biology | Bioinformatics; Biomarkers; Gene expression; Immune contexture; Systems biology; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| O81 | IMpower110: Interim overall survival (OS) analysis of a Phase III study of atezolizumab (atezo) monotherapy vs platinum-based chemotherapy (chemo) as first-line (1L) treatment in PD-L1–selected NSCLC | Roy Herbst, MD, PhD, Filippo De Marinis, Giuseppe Giaccone, Niels Reinmuth, Alain Vergnenegre, Carlos Barrios, Masahiro Morise, Enriqueta Font, Zoran Andric, Sarayut Geater0, Mustafa Ozguroglu, Simonetta Mocci, Mark McCleland, Ida Enquist, Kim Komatsubara, Yu Deng, Hiroshi Kuriki, Xiaohui Wen, Jacek Jassem, David Spigel, MD | Clinical Trial Completed | Antibody; Biomarkers; Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; Solid tumors |
| O82 | A Phase 1 Dose Escalation Study of PRS-343, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-positive Malignancies | Sarina Piha-Paul, MD, Johanna Bendell, MD, Anthony Tolcher, Sara Hurvitz, MD, Amita Patnaik, MD FRCP(C), Rachna Shroff, Paula Pohlmann, Markus Zettl, Noah Hahn, MD, Anuradha Krishnamurthy, MD0, Manuela Duerr, Jian Mei, Kayti Aviano, Rushdia Yusuf, MD, MPH, Louis Matis, MD, Shane Olwill, PhD, Ingmar Bruns* , Geoffrey Ku | Clinical Trial In Progress | Clinical study; Clinical trial; Costimulation; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| O83 | Phase 1 study of an anti-CD27 agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors | Ronnie Shapira-Frommer, Marloes G. J. van Dongen, Konstantin Dobrenkov, Elliot Chartash, Fang Liu, PhD, Claire Li, Richard Wnek, Manish Patel, MD | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Solid tumors; Targeted therapy |
| O85 | Durable responses in anti-PD-1 refractory melanoma following intratumoral injection of a Toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab | Mohammed Milhem, MBBS, Yousef Zakharia, MD, Diwakar Davar, MD, Elizabeth Buchbinder, MD, Theresa Medina, MD, Adil Daud, MD, Antoni Ribas, MD, PhD, Jiaxin Niu, Geoffrey Gibney, MD, Kim Margolin, MD, Anthony Olszanski, MD, RPh0, Interjit Mehmi, Takami Sato, MD, Montaser Shaheen, Aaron Morris, David Mauro, Katie Campbell, Riyue Bao, George Weiner, MD, Jason Luke, MD, FACP, Arthur Krieg, John Kirkwood, MD | Clinical Trial In Progress | Antigen presenting cells; Checkpoint blockade; Clinical trial; Cytokine; Dendritic cell; Inflammation; Regulatory T cell (Treg cell); Solid tumors; TLR; Tumor microenvironment |
| P1 | Peritumoral Neutrophil Infiltration Predicts Recurrence of Hepatocellular Carcinoma Following Liver Transplantation | Marc Najjar, MD; Michael Ross; Ayush Srivastava; Robyn Gartrell, MD; Emanuelle M. Rizk, BA; Olivia Perez; Evan Lieberman; Charles G. Drake, MD, PhD; Ladan Fazlollahi; Helen Remotti; Elizabeth Verna; Karim Halazun; Jean Emond; Yvonne Saenger, MD; | Biomarkers- Immune Monitoring- and Novel Technologies | Biomarkers; Carcinogenesis; Immune contexture; Immune monitoring; Solid tumors; Surgery; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P3 | Predicting patient response to checkpoint blockade therapy using in vitro 3D cultures | Kathryn Appleton, PhD; Ashley K. Elrod; Qi Jin Guo; Dennis Ruder; Tessa DesRochers, PhD; Tessa DesRochers, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Checkpoint blockade; Chemokine; Cytokine; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P4 | Novel immune competent murine glioblastoma models derived from Nestin-CreERT2; QuakingL/L; P53L/L; PTENL/L mice | Chao-Hsien Chen, MD; Renee Chin, MS; Genevieve P. Hartley, PhD; Cheng-En Hsieh, MD; Rishika Prasad, MS; Takashi Shingu, PhD; David S. Hong, MD; Jian Hu, PhD; Michael A. Curran, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Checkpoint blockade; Myeloid cells; MDSC; T cell; Tumor microenvironment |
| P5 | Laminar Wash™ AUTO system: a reliable walk-away sample preparation solution for better TIL recovery without centrifugation | Ira Kim; Melvin Lye; Roberta Zappasodi, PhD; Isabell Schulze; Christoph CE. Eberle, PhD; Chyan Ying Ke; Kong Leong Cheng; Ih Chin Kon; Royce Pek; Taha Merghoub, PhD; Namyong Kim, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Clinical trial; Cytokine; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P6 | Development of a peripheral blood mononuclear cells (PBMC) ImmunoGraft platform to evaluate the pharmacodynamics of Immuno-oncology therapeutics | Bhavana Verma, PhD; Bruce Ruggeri; Amy Wesa, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy; Antigen presenting cells; Checkpoint blockade; Immune monitoring; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma; Vaccine |
| P7 | Development of a Natural Killer (NK) ImmunoGraft Platform for the Evaluation of the Pharmacodynamics of Immuno-Oncology Therapeutics | Bhavana Verma, PhD; Bruce Ruggeri; Jon Weidanz, PhD; Amy Wesa, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy; Checkpoint blockade; Immune monitoring; NK/NK T cell; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P8 | Monoclonal antibody detection from formalin-fixed paraffin-embedded tumor tissues using Fab-selective proteolysis nSMOL coupled with liquid chromatography and triple quadrupole mass spectrometry | Takashi Shimada, PhD; Noriko Iwamoto, PhD; Noriko Iwamoto, PhD; Yoshinobu Koguchi, MD, PhD; John Cha; Brian Piening, PhD; Eric Tran, PhD; Hong-Ming Hu, PhD; Bernard Fox, PhD; William L. Redmond, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Biomarkers; Tumor microenvironment |
| P9 | Immune checkpoint biomarkers in hepatocellular carcinoma (HCC): Assessment of PD-L1 and tumour mutation burden in tumour samples from clinical patients | Hisani Horne, PhD, MPH; Young S. Lee; Todd Creasy; Rebecca Fish; Jonathan Cairns; Paul Scorer; Janine Feng; Marietta Scott, PhD; Mark Gustavson; Aleksandra Dudek-Madej; Craig Barker; Nicholas Holoweckyi; Rebecca Halpin; Peiyi Wang; Quinea Lassiter; Xiaoling Xia; Mohammed Abdelwahab; Weimin Li; Alejandra Negro; Jill Walker; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Immunoscore |
| P10 | Inertial Microfluidics Enables Highly Consistent Separation and Concentration of Leukocytes from Human Peripheral Blood for Downstream B-Cell and T-Cell Functional Assays | Sarah M. Mickool; Eric V. Smith; Aleksander J. Jonca; Gustavo Arnal; Mary Vincent Larcom; Melanie Scully; Peng Megn Kou, PhD; Nitin Kulkarni; Kyle C. Smith; | Biomarkers, Immune Monitoring, and Novel Technologies | B cell; Immune monitoring; T cell |
| P11 | Early detection of breast cancer (BCa) through MDSC and lymphocyte immunophenotyping: from manual gating to pattern recognition neural networks | George A. Dominguez, PhD; John Roop; Alexander Aa. Polo, BS; Anthony Campisi, BS; Dmitry I. Gabrilovich, MD/PhD; Amit Kumar, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Clinical study; Immune monitoring; Myeloid cells; MDSC |
| P12 | Deep characterization of the depleted plasma proteome in subjects with NSCLC using data independent acquisition mass spectrometry reveal host immune response mechanisms | Nicholas Dupuis, PhD; Linda Sensbach; Sebastian Müller; Lukas Reiter; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Inflammation; Proteomics; Systems biology |
| P13 | Immunomodulatory effects of Interleukin 2 in the circulation of melanoma patients and the added impact of VEGF inhibition with Ziv-aflibercept | Arjun Khunger, MD; Ghanashyam Sarikonda; Paul Frankel, PhD; Jenn Tsau, PhD; Zeni Alfonso, PhD; Jane Gao, MS; Anil Pahuja, BSc; Christine A. Vaupel, PhD; Naveen Dakappagari; Shabnam Tangri, PhD; Ahmad A. Tarhini, MD, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Clinical study; Clinical trial; Cytokine; Immune monitoring; Immune suppression; Myeloid cells; MDSC; Regulatory T cell (Treg cell); T cell |
| P14 | Validation of Dendritic Cell and Natural Killer Cell Signatures for Clinical Biomarker Development | Bolan Linghu, PHD; Pei Zhang, PhD; Marylens Hernandez; Mingchao Xie, PhD; Christine Barbon; Srimathi Srinivasan; Deanna Russell, M.S.; Anna Coenen-Stass; Deanna A. Mele, PhD; Patricia McCoon, PhD; Jonathan Dry; Ben Sidders; Kris Sachsenmeier, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Dendritic cell; Gene expression; Immune monitoring; NK/NK T cell |
| P15 | Microsatellite instability detection with cell-free DNA next-generation sequencing | Ariane Lozac'hmeur, MS; Jason Perera, PhD; Denise Lau, PhD; Aly Khan, PhD; Ariane Lozac'hmeur, MS; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers |
| P16 | Circulating immunological biomarkers for predicting response to neoadjuvant chemotherapy in TNBC patients | Charlotte K. Milton, PhD; Thanussuyah Alaguthurai; Atousa khiabany, Mres; Sheeba Irshad, MD PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | B cell; Bioinformatics; Biomarkers; Chemokine; Chemotherapy; Clinical study; Cytokine; Immune contexture; Immune monitoring; Solid tumors |
| P17 | Role of plasma-derived exosome in monitoring immunotherapy response and toxicity | Arnav Mehta, MD PhD; Gyulnara Kasumova; Alvin Shi; Lina Hultin Rosenberg; Emmett Sprecher; Dennie Frederick; Ryan J. Sullivan, MD; Keith T. Flaherty; Nir Hacohen; Genevieve M. Boland; Marijana Rucevic, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Immune monitoring; Immune toxicity; Proteomics; Solid tumors |
| P18 | Liquid biopsy protein biomarkers to predict responses and elucidate resistance to cancer immunotherapy | Arnav Mehta, MD PhD; Marijana Rucevic, PhD; Marijana Rucevic, PhD; Marijana Rucevic, PhD; Gyulnara Kasumova; Emmett Sprecher; Lina Hultin Rosenberg; Dennie Frederick; Ryan J. Sullivan, MD; Nir Hacohen; Keith T. Flaherty; Genevieve Boland; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Immune monitoring; Proteomics; Solid tumors |
| P20 | Semaphorin 4D in peripheral blood of head and neck squamous cell carcinoma reads the histological pattern of tumor inflammation in real time | Ioana Ghita; Manar Elnaggar; Risa Chaisuparat; John Papadimitriou; Joshua Lubek; Rania H. Younis, B.D.S., MDS., PhD; Soren M. Bentzen, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Immune monitoring; Inflammation; Tumor stroma |
| P21 | Activation Profiling of tumor infiltrating CD8+ T cells reveals CTLA-4 mean fluorescence intensity correlates with response in treatment naïve melanoma. | Lauren S. Levine, MD; Katy Tsai, MD; James C. Lee, MD; Clinton Wu, BS; Kelly Mahuron, MD; Alain Algazi, MD; Michael G. Rosenblum, MD PhD; Adil Daud, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Clinical study; Immune monitoring; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P22 | Transcriptomic Characterization of Immune Response within Diverse Tumor Environments using the NanoString® nCounter® PanCancer IO 360™ Assay | Jessica Perez, PhD; Lei Yang; David Henderson, PhD; Heather A. Brauer, PhD; Sarah Warren, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | B cell; Bioinformatics; Biomarkers; Gene expression; Immune monitoring; Inflammation; Regulatory T cell (Treg cell); T cell; Tumor microenvironment |
| P23 | High dimensional immune monitoring of peripheral blood samples from breast cancer patients using mass cytometry (CyTOF) | Jose C. Villasboas, MD; Kaitlyn R. McGrath, M.S.; El-ad David Amir, PhD; Roberto A. Leon-Ferre, MD; Matthew P. Goetz, MD; Judy Boughey, MD; Jody Carter, MD, PhD; Krishna R. Kalari, PhD; Liewei Wang, MD, PhD; Vera J. Suman, PhD; Richard Weinshilboum, MD; Stephen M. Ansell, MD, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Chemotherapy; Immune monitoring; Immune suppression; Immune tolerance; Myeloid cells; NK/NK T cell; Solid tumors |
| P24 | Molecularly guided digital spatial profiling for highly multiplexed analysis of gene expression with spatial and single cell resolution | Anushka Dikshit, PhD; Chris Merritt, PhD; Jamie Rose Kuhar; Karen Nyugen; Kristina Sorg; Bingqing Zhang; Courtney M. Anderson, PhD; Xiao-Jun Ma; | Biomarkers, Immune Monitoring, and Novel Technologies | Chemokine; Cytokine; Inflammation; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P25 | A Conserved MART-1 T Cell Receptor Motif is Predictive of Responses to Checkpoint Blockade | Ariel Y. Isser, BS.; Tatsuya Yoshida; Junya Ichikawa; Jeffrey S. Weber, MD, PhD; Jonathan P. Schneck, MD, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade; Solid tumors; T cell |
| P26 | Murine T cell phenotype and function in a single-well format: a novel, multiplexed and high-throughput assay workflow using the iQue platform | Veronica Bruce, PhD; Caroline Weldon; John O'Rourke; Veronica Bruce, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Biomarkers; Cytokine; Immune contexture; Immune monitoring; Immune suppression; T cell |
| P27 | Functional 3D-plEX quantitative multiplex immunofluorescence platform to assess IO drug impact on tumor microenvironment in ex vivo treated intact 3D-tumor organoids of fresh patient tumor tissue. | Jenny Kreahling, PhD; Vijayendra Agrawal, PhD; Melba Page, PhD; Mibel Pabon, PhD; Soner Altiok, MD, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Cytokine; Immune contexture; Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P28 | Mass spectroscopy-based highly multiplexed super-resolution imaging method for fine details of tumor microenvironment monitoring and tumor-immune cell interactions | Yunhao Bai, BS; Bokai Zhu; Michael Angelo, MD, PhD; Yongxin Zhao; Sizun Jiang, PhD; Xavier Rovira Clave, PhD; Garry P. Nolan, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Bioinformatics; Biomarkers; Immune contexture; Immune monitoring; Systems biology; T cell; Tumor microenvironment |
| P29 | Comprehensive Image Analysis of Immunostained NSCLC Tissues Provides Necessary Context for Immune Oncology Biomarker Profiling | Charles Caldwell, Jr., PhD; Jenifer Caldara, BS; Will Paces, BS; Kelsey Weigel, PhD; Roberto Gianani, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Immune contexture; Immune monitoring; Immune tolerance; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P30 | Deep Spatial Profiling of the Immune Landscape of MSI and MSS Colorectal Tumors | Sarah E. Church, PhD; Jason W. Reeves; Daniel R. Zollinger; Jill McKay-Fleisch; Andrew M. White, BSc; Michael D. Bailey; Arya Bahrami, PhD; Chris Merritt, PhD; Margaret Hoang; Sarah Warren, PhD; Joseph M. Beechem, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Gene expression; Immune contexture; Monocyte/Macrophage; Solid tumors; Systems biology; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P31 | Applying Multispectral Unmixing and Spatial Analyses to Explore Tumor Heterogeneity with a Pre-Optimized 7-color Immuno-Oncology Workflow | Carla Coltharp, PhD; Bethany Remeniuk, PhD; Chichung Wang; Rachel Schaefer; Linying Liu; Glenn Milton; Victoria Duckworth; Michael McLane; Peter Miller; Yi Zheng; Carla Coltharp, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Biomarkers; Checkpoint blockade; Immune contexture; Immunoscore; Inflammation; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P32 | Differential immune contexture of human colorectal carcinomas with mismatch repair deficiency (MSI-H) and increased DNA damage responses (DDR). | Shruti Desai, PhD; Venkata Nagineni; Micaela Morgada; Aravind N. Kalathil; Ila Datar; Charles Fuchs, MD, MPH; Patricia LoRusso, DO; Ranjit S. Bindra; Kurt A. Schalper, MD, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P33 | DNA damage response (DDR) is associated with increased adaptive anti-tumor responses and PD-L1 expression in human non-small cell lung cancer. | Shruti Desai, PhD; Aravind N. Kalathil; Roy S. Herbst, MD, PhD; Ranjit S. Bindra; Patricia LoRusso, DO; Kurt A. Schalper, MD, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Neoantigens; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| P34 | A fully optimized end-to-end solution for I/O multiplex immunofluorescence staining using Opal Polaris 7-Color PD1/PD-L1 Panel Kits for lung cancer and melanoma | Yi Zheng; Rachel Schaefer; Linying Liu; Glenn Milton; CARLA COLTHARP, PhD; Victoria Duckworth; Victoria Duckworth, MS; Michael McLane; Peter Miller, MS; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Biomarkers; Checkpoint blockade; Immune contexture; Immunoscore; Inflammation; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P35 | Pick-Seq®: a spatial analysis tool for immuno-oncology biomarker discovery utilizing multi-parameter imaging and RNA sequencing of tissue micro-regions | Nolan Ericson; Rebecca Podyminogin; Jennifer Chow, PhD; Yu-An Chen; Jia-Ren Lin; Zoltan Maliga; Peter Sorger; Kyla Teplitz; Melinda R. Duplessis, PhD; Eric Kaldjian, MD; Tad George, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | B cell; Bioinformatics; Biomarkers; Gene expression; Immune contexture; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P36 | The complexity of myeloid-derived suppressor cells in non-small cell lung cancer: A combinatorial multiplex IHC and flow cytometry approach | Amanda Finan, PhD; Muriel Smet; Maroua Tliba; Manon Motte; Jean-Philippe Coton; Domenico Lazzaro; Renaud Burrer; | Biomarkers, Immune Monitoring, and Novel Technologies | MDSC; Tumor microenvironment |
| P37 | ImmunoPET imaging of glioma-infiltrating myeloid cells using Zirconium-89-labeled anti-CD11b antibody | Alexandra P. Foster, BS; Rajeev Kumar; Shubhanchi Nigam; Lauren McCarl; Robert S. Edinger; Ian Pollack; Carolyn Anderson; Wilson B. Edwards; Gary Kohanbash; Alexandra P. Foster, BS; | Biomarkers, Immune Monitoring, and Novel Technologies | Monocyte/Macrophage; Myeloid cells; MDSC; Pediatric tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P38 | Sensitive methodologies for tracking T cell immunotherapy by MRI | Brooke M. Helfer, PhD; Deanne Lister; Charles F. O'Hanlon III; Eric Ahrens; Brooke M. Helfer, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; CAR T cells; Solid tumors; T cell; T cell lineages |
| P39 | Looking beyond the assay: Comparison of multiplex chromogenic and fluorescent immunohistochemistry for standardized immune oncology profiling in non-small cell lung carcinoma patients | Ana Hidalgo Sastre, PhD; Lorenz Rognoni, PhD; Monika Baehner; Marco Testori; Jessica Chan; Andreas Spitzmüller; Nicolas Brieu, PhD; Bonnie Phillips, PhD; Katir K. Patel, PhD; Sean R. Downing, PhD; Alex Haragan; John K. Field; Florian Leiss, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Immune contexture; Inflammation; Monocyte/Macrophage; T cell; Tumor microenvironment; Tumor stroma |
| P40 | Tumour immunity signatures to expand current diagnostic approaches in mismatch repair deficient cancers in the context of Lynch Syndrome through InSituPlex technology and Tissue Phenomics integration | Ryan A. Hutchinson, Fellow; Armin Meier, PhD; Bonnie Philips; Katir K. Patel, PhD; Sean R. Downing, PhD; Karan Sharma; Julia Como; Simin Daneshvar; Gillian Livock; Ingrid M. Winship; Christophe Rosty; Mark Jenkins; Gunter Schmidt; Daniel D. Buchanan; Ryan A. Hutchinson, Fellow; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Immune contexture; Immunoscore; Inflammation; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P41 | Multiplexed Imaging for the simultaneous detection of nucleic acids and proteins to dissect the tissue immune landscape and microenvironment of viral diseases | Sizun Jiang, PhD; Xavier Rovira Clave, PhD; Chi Ngai Chan, PhD; Bokai Zhu; Yunhao Bai, BS; Marc Bosse, PhD; David McIlwain, PhD; Sean C. Bendall, PhD; Michael Angelo, MD, PhD; Jacob Estes, PhD; Garry P. Nolan, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Bioinformatics; Biomarkers; Immune contexture; Immune monitoring; Leukemia/Lymphoma; Proteomics; Systems biology; T cell; Tumor microenvironment |
| P42 | An Integrated Multiplexing Approach for the Immunoprofiling of the Tumor Microenvironment of Ovarian Granulosa Cell Tumors | Tyvette S. Hilliard; Nicholas Stavrou; Erinn Parnell; Judy Kuo; Eric Leones; Flora Sahafi; Josette William, PhD, MD; Sharon Stack; Anna Juncker-Jensen; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Gene expression; Monocyte/Macrophage; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P43 | A novel platform for highly multiplexed, single-cell imaging of cell suspensions | Anum Khan; Won-Mean Lee; Jon Mulholland; Anum Khan; Dhananjay Wagh; John Coller; Gabriel Mercado; | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy; Antibody; Autoimmunity; B cell; Bioinformatics; Biomarkers; Immune monitoring; Inflammation; Proteomics; T cell |
| P44 | Solar-IHC: Cell-to-cell distances in the tumour immune microenvironment of Hepatocellular Carcinoma has the potential to prognosticate survival | Matthew Leong, N.A.; Toh Han Chong; Choo Su Pin; Kiat Hon Lim Tony; Joycelyn Lee; David Wai; Poh Sheng Joe Yeong; Jin Miao Chen, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | B cell; Bioinformatics; Cytokine; Immune contexture; Solid tumors; T cell; Tumor microenvironment |
| P45 | Multiplex Immunofluorescence Staining, Whole Slide Imaging, and Spatial Phenotyping of T-cell Exhaustion, Regulatory T cells, and Myeloid-Derived Suppressor Cells in Tumor FFPE Samples | Katherine lillard, PhD; Kyla Teplitz; Katir K. Patel, PhD; Michael Tomac, MS; Kate Lillard, PhD; Anne Hellebust, PhD; Mael Manesse, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; MDSC; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P46 | Same-slide multiplex immunofluorescence and brightfield histological staining as a new research tool for fast and comprehensive pathology assessment of the tumor microenvironment | Mael Manesse, PhD; Douglas Wood, PhD; Heike Boisvert, PhD; Sean R. Downing, PhD; Mael Manesse, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Immune contexture; Immune suppression; Monocyte/Macrophage; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor microenvironment; Tumor stroma |
| P47 | Imaging cancer immunology: Systemic tracking of immune cells in vivo with magnetic particle imaging | James R. Mansfield, Msc; Gang Ren; Jeff Gaudet; Yanrong Zhang; Sara N. Ghobadi; James R. Mansfield, Msc; Max Wintermark; Patrick Goodwill; | Biomarkers, Immune Monitoring, and Novel Technologies | Immune monitoring; Inflammation; Monocyte/Macrophage; Solid tumors |
| P48 | Turning ‘cold’ tumours ‘hot’: Guided magnetic hyperthermia for tumour immune stimulation | Patrick Goodwill; Daniel Hensley; Zhi Wei Tay; Elaine Yu; James R. Mansfield, Msc; James R. Mansfield, Msc; Blayne Kettlewell; Ryan Orendorff; Kyle Fields; Steve Conolly; | Biomarkers, Immune Monitoring, and Novel Technologies | Checkpoint blockade; Immune adjuvant; Inflammation; Solid tumors; Tumor microenvironment |
| P49 | Use of Ultivue InSituPlex® multiplex immunofluorescence to localize and quantify regulatory T lymphocytes in formalin-fixed paraffin-embedded human tissue sections | Shawn P. O'Neil, DVM, PhD; Renee E. Huynh; Courtney Hebert; Jamie Buell; Sean R. Downing, PhD; John L. Jakubczak, PhD; Yutian Zhan, MS; | Biomarkers, Immune Monitoring, and Novel Technologies | Autoimmunity; Inflammation; Regulatory T cell (Treg cell); T cell; T cell lineages |
| P50 | Rapid high-plex staining and simultaneous imaging for immunophenotyping of tissue sections | Benjamin Pelz, PhD; Daniel Migliozzi; Diego G. Dupouy; Anne-Laure Leblond; Alex Soltermann; Martin AM. Gijs, Prof.; | Biomarkers, Immune Monitoring, and Novel Technologies | Antigen presenting cells; B cell; Biomarkers; Dendritic cell; Granulocyte; NK/NK T cell; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P51 | Phenotypic and Spatial Analysis of Inter- and Intra-tumor Heterogeneity Using Multiplexed Ion Beam Imaging (MIBI) | Jason Ptacek, PhD; Robert Johnson, PH.D; Joann Palma, PH.D; Jay Tarolli; Rachel Finck; Murat Aksoy; Yi Zhang; Jessica Finn; Jason Ptacek, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Immune monitoring; Immune suppression; Monocyte/Macrophage; Myeloid cells; Systems biology; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P52 | CyTOF in anti-ILT3 mAb drug discovery - humanized tumor model selection and in vivo PD/biomarker exploration | Yujie Qu, MD; Alan Byford; Caniga Michael; Ying Huo; Barbara Joyce-Shaikh, BS.; Laurence Fayadat-dilman; Veronica Juan; Carl Mieczkowski; Laura Bald; Jeanne Baker; Michael Meehl; Scott Pruitt, MD, PhD; Stephen Alves; Lily Moy; Philip E. Brandish, PhD; Jie Zhang-Hoover; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Immune monitoring; Myeloid cells; Regulatory T cell (Treg cell); Tumor infiltrating lymphocytes (TILs) |
| P53 | Pixelwise H-score: a novel digital image analysis-based metric to quantify membrane biomarker expression from IHC images | Sripad Ram, PhD; Amy-Jackson Fisher; Pamela Whalen; Cory Painter; Pamela Vizcarra; Eric L. Powell, MD; Sripad Ram, PhD; Sripad Ram, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade |
| P54 | Development of a 9-color immunofluorescence assay using tyramide signal amplification and multispectral imaging for high-throughput studies on FFPE tissue sections | Bethany Remeniuk, PhD; Carla Coltharp, PhD; Kristin Roman, MS; Chichung Wang; Clifford C. Hoyt, MS; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Biomarkers; Checkpoint blockade; Immune contexture; Immune monitoring; Inflammation; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P55 | Combining the best of two worlds: Transfer of multiplex immunofluorescence images from non-small cell lung carcinoma patients into pseudo multiplex chromogenic immunohistochemistry images | Lorenz Rognoni, PhD; Ana Hidalgo Sastre, PhD; Ana Hidalgo Sastre, PhD; Linda Brützel; Philipp Wortmann; Monika Baehner; Marco Testori; Jessica Chan; Bonnie Phillips, PhD; Katir K. Patel, PhD; Sean R. Downing, PhD; Alex Haragan; John K. Field; Florian Leiss, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Carcinogenesis; Immune contexture; Inflammation; Monocyte/Macrophage |
| P56 | Interrogating the effect of oncolytic Herpes simplex virus-1 on spatial arrangement of myeloid cells in glioblastoma multiforme using an ex vivo human system and multiplex immunohistochemistry | Munisha Smalley, PhD; Misti Jain, PhD; Saravanan Thyiagarajan; Emily Alonzo; Katherine Crosby; Douglas Best; Hans Gertje, BS; Basavaraja U. Shanthappa; Ralph Pulchalski; Charles Cobbs; E. Antonio Chiocca; Sean Lawler, PhD; Aaron Goldman; Munisha Smalley; | Biomarkers, Immune Monitoring, and Novel Technologies | Dendritic cell; Immune monitoring; Myeloid cells; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P57 | An ex-vivo human system elucidates a role for natural killer cells in the anticancer effect of drug combinations in triple negative breast cancer | Aaron Goldman; Douglas Best; Saravanan Thiyagarajan; Misti Jain, PhD; Basavaraja U. Shanthappa; Munisha Smalley, PhD; Hans Gertje, BS; Aaron Goldman; | Biomarkers, Immune Monitoring, and Novel Technologies | Checkpoint blockade; Immune suppression; Immune tolerance; NK/NK T cell; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor stroma |
| P58 | Brain MRI Performed within 4 Weeks of PD-1 Inhibitors as a Potential Prognostic Marker for Non-small Cell Lung Cancer (NSCLC) | Ammar Sukari, MD; Misako Nagasaka, MD; Seongho Kim, PhD; Tahmida Chowdhury; Natasha Robinette, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade |
| P59 | Highly Consistent automated multiplex immunofluorescence for immunoprofiling of solid tumors in clinical trials: assay validation study using multispectral imaging and digital analysis. | Jaime Rodriguez-Canales, MD; Michael J. Surace, PhD; Lorenz Rognoni, PhD; Farzad Sekhavati; Andrew Fisher, PhD; Andreas Spitzmueller; Sara Batelli, PhD; Karma Dacosta; Vinay Pawar; Clifford Hoyt; Edwin R. Parra, MD., PhD; Jaime Rodriguez-Canales, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Immune contexture; Solid tumors |
| P60 | Combining transcriptomic immune population inference with automated digital masking of H&E images finds immune effectors preferentially distribute within stroma regions | Christopher W. Szeto, PhD; Mustafa Jaber, PhD; Liudmila Beziaeva; Kevin Kazmierczak; Steve Benz; Shahrooz Rabizadeh; | Biomarkers, Immune Monitoring, and Novel Technologies | MDSC; NK/NK T cell; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment; Tumor stroma |
| P61 | Segmentation and Classification of Single Cells using Multiplexed Ion Beam Imaging | Jay G. Tarolli; Jay Tarolli; Jay Tarolli; Rachel Finck; Murat Aksoy; Yari Sigal; Noah Newgren; Jessica Finn; Jason Ptacek, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | B cell; Bioinformatics; Biomarkers; T cell; Targeted therapy; Tumor microenvironment |
| P62 | Bringing the tumor microenvironment into focus: Simplified development of seven-color multiplex immunohistochemistry-Immunofluorescence (mIF) panels | Melissa Whiteman, PhD; Eric McIntush, PhD; Mike Spencer; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Immune monitoring; Tumor infiltrating lymphocytes (TILs) |
| P63 | Clinical Assay Development and Validation of Multiplex Immunofluorescent (mIHC) Marker Panel for Evaluation of Tumor Infiltration Myeloid Cells in FFPE Tissue Sections | Lan Yi, Ph.D; Jonathan Juco, MD; Ashhad Mahmood, MD; Omar F. Laterza; Charo Garrido; Lan Yi, Ph.D; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Granulocyte; Immune monitoring; Immune suppression; Inflammation; Monocyte/Macrophage; Myeloid cells; MDSC; Tumor microenvironment |
| P64 | Highly multiplexed single-cell spatial analysis of FFPE tumor tissues using CODEX® | Jessica X. Yuan, PhD; Gajalakshmi Dakshinamoorthy; Joseph Kim; Sejal Mistry; Nadya Nikulina; Roya Bashier; Cassandra Hempel; Maria Elena Gallina; Julia Kennedy-Darling; Jessica X. Yuan, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Tumor microenvironment; Tumor stroma |
| P65 | Mutation-Targeted T Cell Responses in Blood from Patients with Solid Tumors Prior to Treatment and which Evolve with Clinical Benefit from Anti-PD-1 Therapies | Benjamin T. Yuen, PhD; Fangfang Yin, PhD; Duo An, PhD; Boi Quach; Linlin Guo, PhD; Joanne BL. Tan, PhD; Songming Peng, PhD; Zheng Pan, PhD; Olivier Dalmas, PhD; Robert Bao, PhD; Kyle Jacoby, PhD; Barbara Sennino, PhD; Stefanie J. Mandl, PhD; Matt Walters, PhD; Juan C. Jaen, PhD; Alex Franzusoff, PhD; Benjamin T. Yuen, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy; Immune monitoring; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| P66 | A novel mass cytometry-based immunomonitoring platform for characterizing the peptide vaccine-induced immune response of HLA-A*0201+ patients with K27M+ diffuse midline gliomas | Jared Taitt, BA; Payal Watchmaker, PhD; Takahide Nejo, MD, PhD; Neil Almeida; Kaori Okada; Sabine Mueller, MD PhD; Hideho Okada, MD, PhD; Jared Taitt, BA; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Clinical trial; Immune monitoring; Immune suppression; MDSC; Neoantigens; Pediatric tumors; T cell; Vaccine |
| P67 | Use of a Regional Integrated Health Record Data Network to Identify Patients who Received Checkpoint Therapy Following Cancer Diagnosis as a Foundation for Exploring Immunotoxic Events | Theresa Walunas, PhD; Carlos Galvez; Saya Jacob; Jeffrey A. Sosman, MD; Abel Kho; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Checkpoint blockade; Epidemiology; Immune toxicity |
| P68 | Innate inflammatory pathways are associated with TIL growth and response to adoptive immunotherapy | Suhendan Ekmekcioglu, PhD; Dai Ogata, MD, PhD; Caitlin Creasy, MS; Marie A. Forget, PhD; Sun-Hee Kim, PhD; Jason Roszik, PhD; Mike Spencer; Patrick Hwu, MD; Elizabeth A. Grimm, PhD; Chantale Bernatchez, PhD; Suhendan Ekmekcioglu, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy; Biomarkers; Immune suppression; Inflammation; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P69 | Highly multiplexed single cell spatial analysis of the tumor microenvironment in lymphoma | Monirath Hav, MD, PhD; Anthony Colombo; Erik Gerdtsson; Mohan Singh; Denaly Chen; Imran Siddiqi, MD PhD; James Hicks; Peter Kuhn, PhD; Akil Merchant, MD; Akil Merchant, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Immune contexture; Leukemia/Lymphoma; Tumor microenvironment |
| P70 | Tissue-based characterization of T cell exhaustion in inflammatory bowel disease and colorectal cancer using multiplex IHC | Marina Bleck, PhD; Diane Mierz; Ania Mikucki; Marie Marcher; Sidharth Kerkar, MD; Gerald Nabozny, PhD; Sean R. Downing, PhD; Alexander C. Klimowicz, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Autoimmunity; Biomarkers; Checkpoint blockade; Inflammation; T cell |
| P71 | Refining tumor mutation burden values using variant expression | Shannon T. Bailey, PhD; Muhammad Ekram, PhD; Jim Lund; Jeffrey R. Gulcher; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| P72 | Comprehensive and accurate prediction of presented neoantigens using ImmunoID NeXT and advanced machine learning algorithms | Dattatreya Mellacheruvu, PhD; Rachel Pyke; Charles Abbott, PhD; Nick Phillips; Rena McClory; John S. West, MBA; Richard Chen; Sean M. Boyle, PhD; Dattatreya Mellacheruvu, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Neoantigens; Proteomics; Vaccine |
| P73 | Large scale multiomics reveals a marked bias in driver mutations toward areas not reliably presented to the immune system | Alex S. Powlesland, PhD; Michael J. Cundell, PhD; Floriana Capuano, PhD; Brandon W. Higgs; David Lowne, BS; Ricardo J. Carreira, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Neoantigens; Proteomics; T cell; Targeted therapy; Tumor antigens |
| P74 | Integrating CD8 and CD4 effector neo-epitope content with regulatory T cell epitope exclusion is a superior prognostic biomarker for bladder cancer patient compared to their tumor mutation burden | Guilhem Richard, PhD; Randy F. Sweis, MD; Matthew Ardito, BA; Tzintzuni Garcia; Leonard Moise, PhD; Michael F. Princiotta, MS, PhD; Dominique Bridon; William Martin, BA MD; Gad Berdugo, MSc, MBA; Arjun Balar; Gary Steinberg; Anne S. de Groot, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Neoantigens; Regulatory T cell (Treg cell); T cell |
| P75 | targetSCAPE and ultraSCAPE: Simultaneous identification and deep profiling of human antigen-specific T cells and other immune cell subsets by mass cytometry | David Roumanes, PhD; Faris Kairi; Alessandra Nardin, DVM; Evan Newell, PHD; Michael Fehlings; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Immune monitoring; Neoantigens; T cell |
| P76 | Development of immunopeptidomic platform for human leucocyte antigens class I using microflow liquid chromatography and quadrupole time-of-flight mass spectrometry | Takashi Shimada, PhD; Noriko Iwamoto, PhD; Yoshinobu Koguchi, MD, PhD; John Cha; Brian Piening, PhD; Eric Tran, PhD; Hong-Ming Hu, PhD; Bernard Fox, PhD; William L. Redmond, PhD; Takashi Shimada, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Immune monitoring; Neoantigens; Proteomics; Tumor antigens |
| P77 | Comprehensive profiling of tumor-immune interaction in anti-PD-1 treated melanoma patients reveals subject-specific tumor escape mechanisms | Charles Abbott, PhD; Eric Levy, PhD; Rachel Pyke; Rena McClory; Sekwon Jang, MD; Richard Z. Chen, PhD; Sean M. Boyle, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Antigen presenting cells; Bioinformatics; Biomarkers; Checkpoint blockade; Gene expression; Neoantigens; T cell; Tumor microenvironment |
| P78 | Optimization of Tumor Mutation Burden Measurement in FFPE DNA | Janice K. Au-Young, PhD; Iris Casuga, PhD; Vinay Mittal; Dinesh Cyanam, MS; Elaine Wong-Ho; Fiona Hyland; Seth Sadis; Warren Tom, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Neoantigens; Solid tumors |
| P79 | Molecular comparison of tumor microenvironment in primary lung, melanoma, and kidney tumors versus paired lung metastases reveals shared perturbations of the immune milieu during oligoprogression | Davide Bedognetti, MD, PhD; Jessica Roelands, Master; Angelo Manfredi; Norma Maugeri; Francesca De Nicola; Ludovica Ciuffreda; Matteo Pallocca; Maurizio Fanciulli; Francesca Di Modugno, PhD; Paolo Visca; Barbara Antoniani; Gabriele Alessandrini; Darawan Rinchai, PhD; Wouter RL. Hendrickx, PhD; Paola Nistico', MD; Gennaro Ciliberto, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Immune contexture; Tumor infiltrating lymphocytes (TILs) |
| P80 | HER2 is associated with prolonged survival in advanced gastroesophageal adenocarcinoma patients treated with checkpoint blockade | Carrie B. Brachmann, PhD; Emon Elboudwarej; Manish Shah, MD; David Cunningham; Jean-Philippe Metges; Eric Van Cutsem, MD, PhD; Zev Wainberg, MD; Jingzhu Zhou; Dung Thai; Pankaj Bhargava; Daniel V. Catenacci, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade; Clinical trial; Gene expression; Solid tumors; Tumor microenvironment |
| P81 | Association of tumor mutational burden with clinical, genomic, and treatment characteristics in advanced non-small cell lung cancer | Connor Willis, PharmD; Hillevi Bauer, PharmD; Trang H. Au, PharmD; Sudhir Unni, PhD, MBA; Wallace Akerley, MD; Ashley Sekhon, MD; Firas Badin, MD; John L. Villano, MD, PhD; Matthew B. Schabath, PhD; Bing Xia, MD; Beth Gustafson, PharmD; Komal Gupte-Singh, PhD; Beata Korytowsky; John-michael Thomas, PharmD; Gabriel Krigsfield, PhD; Solomon J. Lubinga, PhD; diana brixner, PhD; David Stenehjem, PharmD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Solid tumors |
| P82 | High-throughput pairing of single T-cell α and β chains along with phenotypic expression profiling | Brittany Brown, BS; Miranda Byrne-Steele, PhD; Wenjing Pan, PhD; Song Li; Mary Eisenhower, BS; Daniel Weber; Mollye Depinet, MS; Xiahong Hou, PhD, MD; Alex Moore; Jian Han, MD PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Autoimmunity; CAR T cells; Gene expression; Immune monitoring; Immune tolerance; Regulatory T cell (Treg cell); T cell; T cell lineages; Targeted therapy |
| P83 | Pan-cancer assessment of composite genomic biomarkers in immuno-oncology to predict responses and resistances to immune checkpoint inhibitor therapy | Gustavo C. Cerqueira; Laurel A. Keefer; Kelly Gerding, PhD; Kenneth Valkenburg; Christina Oliveras; James R. White; Leila Ettehadieh; Christopher Gault; James Hernandez; Eric Kong; Isabell Loftin; Samuel Angiuoli; Abigail McElhinny; John K. Simmons, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Checkpoint blockade; Solid tumors; Tumor evasion |
| P84 | Panel-derived tumor mutational burden (TMB) correlates with immune checkpoint inhibitors (ICIs) response in gastrointestinal cancers | San-chi Chen, MD; Kien-Thiam Tan, PhD; Ming-Huang Chen; Yi-Ping Hung, MD; Yi-Lin Hsieh; Yi-Hua Jan; Yee chao; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Solid tumors |
| P85 | Development of a pan-cancer NGS assay for detection of tumor mutational burden and targeted biomarkers from FFPE samples | Dinesh Cyanam, MS; Vinay Mittal; Nickolay Khazanov; Paul Williams; Janice Au-Young; Gary Bee; Sameh El-Difrawy; Aren Ewing; Jennifer Kilzer; Anelia kraltcheva, Ph.D; Scott Myrand, MS; Yu-Ting Tseng; Cristina Van Loy; Elaine Wong-Ho; Chenchen Yang; Dinesh Cyanam, MS; Warren Tom, PhD; Santhoshi Bandla; Seth Sadis; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Immune monitoring; Solid tumors; Targeted therapy |
| P86 | Predictive Immune Modeling enables biomarker discovery in NSCLC patients treated with second line immunotherapy | Natalie A. LaFranzo, PhD; Steve Daniel, PhD; Walt Carney, PhD; Milan Bhagat; Natalie A. LaFranzo, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Gene expression; Immune contexture; Immune monitoring; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P87 | All-in-One, quantitative immune repertoire profiling of PBMC and FFPE for renal cancer treatment evaluation | Mollye Depinet, MS; Wenjing Pan, PhD; Sang-gin Wu, MD, PhD; Xiaohong Hou, MD PhD; Brittany Brown, BS; Mary Eisenhower, BS; Daniel Weber; Miranda Byrne-Steele, PhD; Michael Lotze; Jian Han, MD PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Autoimmunity; B cell; Cytokine; Immune monitoring; Solid tumors; T cell; T cell lineages; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| P88 | Evaluation of a tumor-only pan-cancer targeted semi-conductor based next-generation sequencing (NGS) test for microsatellite instability in FFPE samples | Sameh El-Difrawy, Ph. D; Anelia kraltcheva, Ph.D; Vinay Mittal; Elaine Wong-Ho; Dinesh Cyanam, MS; Seth Sadis; Jennifer Kilzer; Cristina Van Loy; Janice Au-Young, PhD; Aren Ewing; Sameh El-Difrawy; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Solid tumors |
| P89 | Obesity related changes in AXL-driven inflammatory signaling impact survival in melanoma | Alicia A. Gingrich, MD; Alexander Merleev, PhD; Kylie Abeson, BS; Robert Canter, MD, MAS, FACS; Emanual Maverakis; Amanda Kirane, MD; Alicia A. Gingrich, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Gene expression; Immune monitoring; Inflammation; Tumor microenvironment |
| P90 | Unique tumor immune microenvironments of potentially PD-L1/TGF-β trap responsive tumors | Sean T. Glenn, PhD; Sarabjot Pabla, MSc, PhD, BS; Erik Van Roey; Jonathan Andreas, MS; Blake Burgher, BS, RN; Jeffrey Conroy, BS; Mary Nesline, MS; Antonios Papanicolau-Sengos, MD; Vincent Giamo, BS, MS; Felicia L. Lenzo; Yirong Wang, M.S.; Carl D. Morrison, MD, DVM; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Immune contexture; Inflammation; Tumor microenvironment |
| P91 | Expression profiling of T cells using nanoscale automation with a full-length RNA sequencing library preparation kit on a microfluidic circuit platform | Thomas J. Goralski, PhD; Sangpen J. Chamnongpol; Michael J. Phelan; Jennifer Snyder-Cappione; Julie J. Alipaz; Joel J. Brockman; Brian J. Fowler; Jennifer A. Geis; Christopher J. Kubu; Raphael J. Kung; Benjamin J. Lacar; Naveen Ramalingam, PhD; Mandi Wong; Charles J. Park; David J. King; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Gene expression |
| P92 | Survival Benefits of Comprehensive Genomic Profiling and Treatment in Metastatic Non-Small Cell Lung Cancer | Alison Sexton Ward, PhD; Jennifer Johnson, MD; Komal Gupte-Singh, PhD; Mohammad Ashraf Chaudhary, PhD; Devender Dhanda, PhD; Oliver Diaz, PhD; Katherine Batt, MD, MSc; John Fox; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Solid tumors; Targeted therapy |
| P93 | The advanced immune-centric NGS cohort for colon cancer. | Wouter RL. Hendrickx, PhD; Jessica Roelands, Master; Peter Kuppen; Francesco M. Marincola, MD; Najeeb Syed; Davide Bedognetti, MD, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Gene expression; Immunoscore; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P94 | A potential mechanism of anti-cancer immune response activated by immune-related adverse events (irAEs) in urological cancer patients | Taigo Kato, MD, PhD; Motohide Uemura; Koji Hatano; Atsunari Kawashima; Takeshi Ujike; Kazutoshi Fujita; Kazuma Kioytani; Norio Nonomura; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Immune monitoring; Immune toxicity; T cell; Tumor antigens |
| P95 | Single-cell RNA-sequencing from clinically relevant core needle biopsies for evaluation of tumor-immune cell interactions in the tumor microenvironment | Namit Kumar, PhD; Mohan Bolisetty; Peter Szabo, PhD; Xuan Li; Becky Penhallow; Ryan Golhar; Alice M. Walsh; Saumya Pant; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Myeloid cells; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P96 | T-cell receptor alpha and beta repertoire profiling using an augmented transcriptome | Eric Levy, PhD; Pamela Milani; Sean M. Boyle, PhD; Gabor Bartha; Charles Abbott, PhD; Robert Power; Rena McClory; Robin Li; John S. West, MBA; Richard Chen; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P97 | TCRB repertoire convergence and clonal expansion define the NSCLC tumor microenvironment of responders to anti-PD-1 monotherapy | Timothy Looney, PhD; Katharina Leonards; Ilaria Alborelli; Luca Quagliatta; Philip Jermann; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade; Immune contexture; Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P98 | Automated rarefaction analysis for precision human and mouse B and T cell receptor repertoire profiling from peripheral blood and FFPE-preserved specimens | Timothy Looney, PhD; Geoffrey M. Lowman, PhD; Michelle Toro; Jayde Chang; Denise S. Topacio-Hall, BS, MA; Loni Pickle, PhD; Fiona Hyland; Timothy Looney, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | B cell; Bioinformatics; Biomarkers; Immune monitoring; T cell; Tumor microenvironment |
| P99 | TMBler: a bioinformatic tool for measuring and optimizing Tumor Mutational Burden quantification from targeted sequencing panels | Laura Fancello; Luca Mazzarella, MD PhD; Alessandro Guida; Arnaud Ceol; Piergiuseppe Pelicci; Luca Mazzarella, MD PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Neoantigens |
| P100 | Impact of obesity on immunity in gastroesophageal adenocarcinoma [GEAC] | Sarbajit Mukherjee, MD, MS; Sami Ibrahimi; Yali Zhang; Jianmin Wang; Pawel Kalinski, MD, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Gene expression; Solid tumors |
| P101 | Immune-based classification of pleural malignant mesothelioma by using integrative transcriptome analysis. | Ernest Nadal, MD, PhD; Ania Alay; David Cordero; Elisabeth Aliagas; José C. Ruffinelli; Ramón Palmero; Ricard Ramos; Ivan Macía; Anna Ureña; Fran Rivas; Xavier Solé; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Gene expression; Immune contexture; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P102 | CT antigens are frequently expressed non-inflamed tumors | Sarabjot Pabla, MSc, PhD, BS; Erik Van Roey; Sean T. Glenn, PhD; Jonathan Andreas, MS; Blake Burgher, BS, RN; Jeffrey Conroy, BS; Mary Nesline, MS; Antonios Papanicolau-Sengos, MD; Vincent Giamo, BS, MS; Felicia L. Lenzo; Yirong Wang, M.S.; Carl D. Morrison, MD, DVM; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Gene expression; Immune contexture; Neoantigens; Tumor microenvironment; Tumor stroma |
| P103 | Detection of human leukocyte antigen class I loss of heterozygosity in solid tumor types by next-generation DNA sequencing | Jason Perera, PhD; Brandon Mapes, PhD; Denise Lau, PhD; Ameen Salahudeen; Aly Khan, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Antigen presenting cells; Bioinformatics; Biomarkers; Tumor evasion |
| P104 | Impact of chemotherapy (chemo) on peripheral T-cell diversity and implications for subsequent immunotherapy response in breast cancer | Joanna Pucilowska, PhD; Paul Fields, PhD; Valerie K. Conrad, BS; David B. Page, MD; Alison K. Conlin, MD; Joanna Pucilowska, PhD; Catherine Sanders, PhD; Raina A. Tamakawa, MS; Brie M. Chun, MD; Isaac K. Kim, MD; Mark Schmidt; | Biomarkers, Immune Monitoring, and Novel Technologies | Chemotherapy; Clinical study; Immune monitoring; T cell |
| P105 | PD-L1 isoform as a potential biomarker to predict response for anti-PD-(L)1 treatment | Kunbin Qu, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade; Gene expression; Tumor evasion |
| P106 | Tumor Mutational Burden profile (TMB) of Oncogenic Driver Mutations in Non Small Cell Lung Cancer | Nitika Sharma; Paul R. Walker, MD; Nitika Sharma; | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy; Angiogenesis; Biomarkers; Checkpoint blockade; Clinical study; Immune monitoring; Solid tumors; Targeted therapy |
| P107 | Changes in tumor mutational burden in serially biopsied non-small cell lung cancer | James W. Smithy, MD, MHS; David H. Hwang, MD; Yvonne Li; Liam Spurr; Andrew D. Cherniack, PhD; Lynette M. Sholl; Mark Awad, MD PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Solid tumors |
| P108 | Working Towards Precision Medicine of the Tumor Microenvironment | Kristen Strand-Tibbitts, PhD; Kyung Kim, PhD; Jeeyun Kim; Seung-Tae Kim; Jung-Yong Hong; Laura Benjamin; Kristen Strand-Tibbitts, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Gene expression; Solid tumors; Targeted therapy; Tumor microenvironment |
| P109 | Predictive performance of a CD8-derived signature by gene expression profiling in patients with urothelial carcinoma from CheckMate 275 | Peter Szabo, PhD; Padmanee Sharma, MD, PhD; George Lee, PhD; Scott Ely; Vipul Baxi, MS; Keyur Desai, PhD; Lisu Wang; Robin H. Edwards, PhD; Saumya Pant; Abdel Saci; Neeraj Adya; Matthew D. Galsky, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Clinical trial; Gene expression; Inflammation; T cell |
| P110 | Tumor CD8+ T-cell infiltration assessed by gene expression profiling alone or by immunohistochemistry plus epithelial-mesenchymal transition gene expression in urothelial carcinoma in CheckMate 275 | Peter Szabo, PhD; Abdel Saci; Padmanee Sharma, MD, PhD; George Lee, PhD; Scott Ely; Vipul Baxi, MS; Keyur Desai, PhD; Lisu Wang; Scott D. Chasalow; Michael Montalto; Robin H. Edwards, PhD; Saumya Pant; Neeraj Adya; Bruce Fischer, MD; Matthew D. Galsky, MD | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Clinical trial; Gene expression; Inflammation; T cell |
| P111 | Clinical and Immunologic Implications of a Microsatellite Instability Score in Lung Cancer | Pedro Viveiros, MD; Misuk Lee; Bhoomika Sukhadia, MD; Kyunghoon Rhee; Victor Wang; Jeffrey Chuang; Young Kwang Chae, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Immunoscore; Neoantigens; Solid tumors |
| P112 | A new way of immunity exploration by linking highly multiplexed antigen recognition to immune repertoire and phenotype | Dagmar Walter, PhD; Stephane C. Boutet; Michael JT. Stubbington, PhD; Katherine A. Pfeiffer; Josephine Y. Lee; Luz Montesclaros; Julia K. Lau; Daniel P. Riordan; Alvaro Martinez Barrio; Liselotte Brix, phd; Kivin KJ. Jacobsen, PhD; Bertrand Yeung; Xinfang Zhao; Tarjei Mikkelsen; | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy; Antibody; Biomarkers; Gene expression; Genetic polymorphism; T cell; T cell lineages |
| P113 | Dynamic analysis and visualization of the immune infiltration in human cancer by integrating TCGA data | Mingchao Xie, PhD; Bolan Linghu, PHD; Zhongwu Lai, PhD; Jonathan Dry; Ben Sidders; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Immune contexture; Immunoscore; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P114 | TISSUTAL IMMUNE PROFILE AND PATHOLOGICAL COMPLETE RESPONSE IN TRIPLE NEGATIVE BREAST CANCER. | Andrea Botticelli, MD; Bruna Cerbelli; Simone Scagnoli; Maria Ida Amabile; Alessandro De Luca; Lucio Fortunato; Leopoldo Costarelli; Marianna Nuti, PhD; Giulia D'Amati; Paolo Marchetti; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Chemotherapy; Immune adjuvant; Immune suppression; Immunoscore; Tumor microenvironment |
| P115 | Deep proteomic characterization of FFPE tumor samples from late-stage melanoma subjects treated with anti-PD-1 immunotherapy | Nicholas Dupuis, PhD; Jakob Vowinckel, PhD; Domenico Mallardo, MD; Mariaelena Capone, MD; Madonna Gabriele; Antonio Sorrentino; Vito Vanella; Daniel Heinzmann; Paolo Antonio A. Ascierto, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Proteomics; Solid tumors; Systems biology |
| P116 | Centrifuge-free red blood cell lysis and immunostaining of whole blood for flow cytometry using Laminar Wash™ system | Ira Kim; Melvin Lye; Chyan Ying Ke; Nadiezda Fernandez Oropeza; Sigeeta Rajaram; Kong Leong Cheng; Ih Chin Kon; Royce Pek; Namyong Kim, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Immune suppression; Metabolism; NK/NK T cell; Pediatric tumors; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P117 | Immunogram to decipher PD1/L1 ICI resistance: a proof of concept in advanced Non-small cell lung cancer patients of the PIONeeR Project | Florence Monville, PhD; Frederic Vely; Joseph Ciccolini; Florence Sabatier; Stephane Garcia; Vanina Leca; Marion Fabre; Christelle Piperoglou; Pernelle Outters; Laurent Arnaud; Laurent Vanhille, PhD; Caroline Lauge, BA; Anna Martirosyan, Dr; Aurelie Collignon; Marie Roumieux; Julien Mazieres; Maurice Perol; Françoise Dignat-George; Eric Vivier; Fabrice Barlesi, MD, PhD; Jacques Fieschi, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Gene expression; Immune contexture; Immune monitoring; Immunoscore; MDSC; Tumor infiltrating lymphocytes (TILs) |
| P118 | HYDRA platform development to investigate Siglec-engaging tumor immunosuppressive glyco-codes | Li Peng, PhD; Adam Petrone; Adam Shoemaker; Jillian Prendergast, PhD; Zakir Siddiquee; Jenny Che; Lihui Xu, BS; Karl Normington, PhD, MBA; James Broderick; Li Peng, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Tumor evasion; Tumor microenvironment |
| P119 | Analytical validation of run-to-run and site-to-site performance of a human immune profiling assay and automated data analysis solution for CyTOF mass cytometry technology | Clare Rogers, MS | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Granulocyte; Immune contexture; Immune monitoring; Myeloid cells; Proteomics; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs) |
| P120 | Evaluation of CD8 score by automated quantitative image analysis in metastatic melanoma treated with PD1 blockade: preliminary results | Anjali Rohatgi, MD PhD; Douglas Hartman; Arivarasan Karunamurthy; Julie Burkette; Yana G. Najjar, MD; John M. Kirkwood, MD; Hassane M. Zarour, MD; Liron Pantanowitz; Diwakar Davar, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Immune monitoring; Immunoscore; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P121 | Cancer Immunogram: combining multi-parameter approach and machine learning to capture the complexity of tumor immune contexture | Thomas Sbarrato, PhD; Laurent Vanhille, PhD; Mounia Filahi; Anna Martirosyan, Dr; Véronique Frayssinet; Caroline Davin, BA; Caroline Laugé; Assil Benchaaben; Alboukadel Kassambara; Felipe Guimaraes; Régis Perbost; Jérôme Galon; Hélène Girardi; Jacques Fieschi, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Immune contexture; Immune suppression; Immunoscore; Monocyte/Macrophage; MDSC; Regulatory T cell (Treg cell); Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P122 | Microfluidic-based Cell Separation Method Improves Workflow for Evaluation of Rare Lymphocytes from Cancer Patient Samples | Jodi Stone, BS.; Megan E. Nichols, AAS in Biotechnology; Amy Austin; Kala Bradshaw; Jessica E. Norris, BS, MT; Jennifer Montague, PhD; Peng Meng Kou, PhD; Nitin Kulkarni; Nirav Sheth; Anya Manning, MBA; Sarah M. Mickool; Kyle C. Smith; Ravi Kapur; John D. Powderly, II, MD, CPI; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Immune monitoring; T cell |
| P123 | Identification of mRNA signatures that predict response to immunotherapy in melanoma patients | Ioannis A. Vathiotis, MD; Amy Sullivan; Sarah Warren, PhD; Nicole Gianino; Sandra Martinez-Morilla, PhD; Pok Fai Wong, MD, MPhil; Harriet Kluger, MD; Konstantinos N. Syrigos; David L. Rimm, MD, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Gene expression; Inflammation; NK/NK T cell; Tumor microenvironment |
| P124 | A Novel Cell-Mediated Immunotherapy for Treatment of Lung and Breast Cancer | Indu Venugopal, PhD; Kathlynn C. Brown; Michael J. McGuire; Claire Gormley; | Biomarkers, Immune Monitoring, and Novel Technologies | T cell; Targeted therapy |
| P125 | ADENOSINE AND AMP GENE EXPRESSION PROFILES PREDICT RESPONSE TO ADENOSINE PATHWAY THERAPIES AND INDICATE A NEED FOR DUAL BLOCKADE OF CD73 AND A2AR WITH CD73 INHIBITORS. | Stephen Willingham, PhD; Drew Hotson, PhD; Jessica Hsieh; Brian Munneke; Long Kwei, PhD; Joseph J. Buggy; Richard A. Miller, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Antigen presenting cells; Biomarkers; Checkpoint blockade; Immune suppression; MDSC; Solid tumors; T cell; Tumor evasion; Tumor microenvironment |
| P126 | Discovery of biomarkers associated with benefit from PD-1 checkpoint blockade in non-small-cell lung cancer (NSCLC) using high-plex digital spatial profiling | Jon Zugazagoitia, MD; Swati Gupta, PhD; Kit Fuhrman, MS PhD; Scott N. Gettinger, MD; Roy S. Herbst, MD, PhD; Kurt A. Schalper, MD, PhD; David L. Rimm, MD, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; NK/NK T cell; T cell |
| P127 | Development of a 12-marker immunofluorescence multiplex panel for the in-depth investigation of the tumor immune landscape analyzing 4,096 phenotypes | Courtney Hauck; Aditi Sharma; Monique Johnson; Wenya Yang; Bonnie Phillips, PhD; Mark Burton, HTL ASCP; Douglas Wood, PhD; Stephanie Hennek, PhD; Mael Manesse, PhD; J Kent Moore, PhD; Katir K. Patel, PhD; Jamie Buell; Sean R. Downing, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | B cell; Bioinformatics; Biomarkers; Immune contexture; Monocyte/Macrophage; NK/NK T cell; Proteomics; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P128 | Pooled analysis of Programmed Death Factor Ligand 1 (PD-L1) expression as a predictive biomarker using individual data on 7,918 randomized study patients | Andrea Arfe; Geoffrey Fell; Brian Alexander, MD MPH; Mark Awad, MD PhD; Scott J. Rodig, MD, PhD; Lorenzo Trippa; Jonathan Schoenfeld, MD, MPH; Jonathan Schoenfeld, MD, MPH; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Clinical study; Solid tumors |
| P129 | Correlation of circulating CD8 T cell activation with response to immunotherapy in advanced renal cell carcinoma | Jennifer Carlisle, MD; Caroline S. Jansen, BS; Adriana M. Reyes; Nataliya Prokhnevska, BS; Deborah Baumgarten, MD; Viraj A. Master, MD, PhD; R. Donald Harvey, PharmD; Bradley C. Carthon, MD, PhD; Omer Kucuk, MD; Mehmet A. Bilen; Haydn T. Kissick; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Immune monitoring; Solid tumors; T cell |
| P130 | Melanoma patients harbor pre-existing IgG autoantibodies targeting neuronal proteins that associate with differential clinical outcomes following checkpoint blockade | Tyler Hulett, PhD; Michael Gowen, MD; Keith Giles; Danny Simpson; Jeremy Tchack; Una Moran; Zarmeena Dawood; Anna C. Pavlick, MD, MBA; Shaohui Hu; Hua Zhong; Michelle Krogsgaard; Tomas Kirchhoff, PhD; Iman Osman; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Autoimmunity; B cell; Bioinformatics; Biomarkers; Checkpoint blockade; Clinical trial; Immune monitoring; Proteomics; Tumor antigens |
| P131 | Single cellular interrogation of tumor microenvironment enables diagnosis and prognostication of malignancies | Wei Jian Tan; Jian Hang Lam; Mona Meng Wang; Paola Ricciardi-Castagnoli; Anita Sook Yee Chan; Tony Kiat Hon Lim; Joe Poh Sheng Yeong; Tong Seng Lim, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | B cell; Biomarkers; Clinical study; Immune monitoring; Leukemia/Lymphoma; Monocyte/Macrophage; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P132 | Harmony: Integrative tool to analyse and visualise Multiplex-Immunofluorescence Single-Cell Data | Duoduo Wu; Joe P. Yeong, MBBS, PhD; Grace S. Tan; Marion Chevrier; Josh J. Loh; Tony K. Lim; Jinmiao Chen; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Tumor microenvironment |
| P133 | High tumor expression of DKK1 is associated with improved clinical benefit and longer progression free survival across multiple solid tumors when treated with a targeted anti-DKK1 antibody (DKN-01) | Michael Kagey, PhD; Girish Naik, MD; Michael Haas, PhD; Heidi Heath; Franziska Schurpf-Huber; Walter Newman, PhD; Cynthia Sirard, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Biomarkers; Checkpoint blockade; Clinical trial; Gene expression; NK/NK T cell; Solid tumors |
| P134 | Prognostic value of tumor microenvironment based on PD-L1 expression and CD8+ TILs density in locally advanced NSCLC treated with concurrent chemoradiotherapy | Lukas Kaesmann, MD; Kathrin Gennen; Julian Taugner; Chukwuka Eze; Monika Karin; Olarn Roengvoraphoj; Jens Neumann; Amanda Tufman; Michael Orth; Simone Reu; Claus Belka; | Biomarkers, Immune Monitoring, and Novel Technologies | Chemotherapy; Radiotherapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P135 | Studying Loss of Y chromosome in colorectal and prostate cancers in males for non-invasive cancer biomarkers | AMBREEN ASIM, PhD; Sarita Agarwal; Rakesh Kapoor; Neeraj Rastogi; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers |
| P136 | Quantitative/spatial analysis of Tregs reveal a prominent biomarker role in human non-small cell lung cancer (NSCLC) | Richa Gupta, BS; Nicolas Rodriguez-Arriagada; Shruti Desai, PhD; Konstantinos N. Syrigos; Roy S. Herbst, MD, PhD; Vamsidhar Velcheti, MD FACP; David L. Rimm, MD, PhD; Sarah B. Goldberg, MD, MPH; Kurt A. Schalper, MD, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs) |
| P137 | Development and high specification validation of a recombinant rabbit monoclonal antibody to accurately detect human PD-L2 expression in FFPE tissue sections by immunohistochemistry | Simon Renshaw; Will Howat, PhD; Subham Basu, PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Biomarkers; Checkpoint blockade; Immunoscore; Proteomics; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P138 | Review of evidence for predictive value of microsatellite instability/mismatch repair status in response to non-anti-PD-(L)1 therapies in patients with advanced or recurrent endometrial cancer | Cara Mathews, MD; Ellie Im; Liliana Alfaya; Cara Mathews, MD; Cara Mathews, MD; Karin Travers; Craig Gibson; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Chemotherapy; Targeted therapy |
| P139 | Expression of GITR and GITR-L by Head and Neck Squamous Cell Cancer | Rachna L. Moudgil, MS; Christopher C. Paustian, PhD; Carmen Ballesteros-Merino, PhD; Shawn M. Jensen, PhD; Hong-Ming Hu, PhD; Walter J. Urba, MD, PhD; Carlo B. Bifulco, MD; Marcus A. Couey, MD, DDS; Traci L. Hilton, PhD; Bernard A. Fox, PhD; Rom Leidner, MD; R. Bryan Bell, DDS, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Antigen presenting cells; Costimulation; Immune contexture; Immune monitoring; Regulatory T cell (Treg cell); Solid tumors; Tumor stroma |
| P140 | Myeloid cell contexture and IL-8 expression as a candidate immunotherapy target in Non-Small Cell Lung Cancer (NSCLC). | Venkata Vamsi Nagineni, MD; Kurt A. Schalper, MD, PhD; Shruti Desai, PhD; Ignacio Melero, MD; Miguel F. Sanmamed, MD, PhD; Richa Gupta; Roy S. Herbst, MD, PhD; Venkata Vamsi Nagineni, MD; | Biomarkers, Immune Monitoring, and Novel Technologies | Checkpoint blockade; Chemokine; Granulocyte; Targeted therapy; Tumor microenvironment; Tumor stroma |
| P141 | One-year progression-free survival in lung cancer patients treated with immune checkpoint inhibitors is significantly associated with a novel immunomodulatory signature but not PD-L1 staining | Harsha A. Ranganath, MD; Amit Jain; Justin R. Smith; Julie Ryder; Amina Chaudry; Emily Miller; Felicia Hare; Poojitha Valasareddy; Rob Seitz; David R. Hout; Brock L. Schweitzer; Tyler J. Nielsen; Janice Mullins; Gregory Vidal; | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade; Clinical study; Gene expression; Immune monitoring; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P142 | Development and validation of baseline predictive biomarkers for response to avelumab in second-line (2L) non-small cell lung cancer (NSCLC) using EpiSwitchTM epigenetic profiling | Parantu Shah, PhD; Ewan Hunter; Shobha Potluri; Sen Zhang; Mehrnoush Dezfouli; Jennifer Back; Louis James; Navin Jandor; Ryan Powell; Matthew Salter; Aroul Ramadass; Jayne Green; Willem Westra; Haidong Dong, MD, PhD; Roxana Dronca, MD; Svetomir N. Markovic, MD, PhD; Alexandre Akoulitchev; Ti Cai; Paul B. Robbins; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Bioinformatics; Biomarkers; Checkpoint blockade; Immune suppression; Solid tumors; Targeted therapy |
| P143 | Development and Validation of Baseline Predictive Biomarkers for Response to Immuno-Checkpoint Treatments in the Context of Multi-line and Multi-Therapy Cohorts using EpiSwitchTM epigenetic profiling. | Parantu Shah, PhD; Ewan Hunter; Shobha Potluri; Sen Zhang; Mehrnoush Dezfouli; Jennifer Back; Louis James; Navin Jandor; Ryan Powell; Matthew Salter; Aroul Ramadass; Jayne Green; Willem Westra; Haidong Dong, MD, PhD; Roxana Dronca, MD; Svetomir N. Markovic, MD, PhD; Alexandre Akoulitchev; Ti Cai; Paul B. Robbins; | Biomarkers, Immune Monitoring, and Novel Technologies | Antibody; Bioinformatics; Biomarkers; Checkpoint blockade; Immune suppression; Solid tumors; Targeted therapy |
| P144 | Quantification of tumor-stroma-immune contexture by multiplex fluorescent immunohistochemistry and whole-slide digital image analysis | Adriana Racolta, PhD; Mehrnoush Khojasteh, PhD; Jennifer Giltnane; Antony Hubbard, BS; Hongjun Zhang; Miriam Matei; Jessica Baumann; Wenjun Zhang, MD, PhD; Tsu-Shuen Tsao, PhD; Hartmut Koeppen; Lisa Ryner; Xingwei Wang; Jim Martin; Auranuch Lorsakul; Ilya Ravkin; Smadar Shiffman; Lidija Pestic-Dragovich; Lei Tang, PhD; Yulei Wang, BA PhD; | Biomarkers, Immune Monitoring, and Novel Technologies | Biomarkers; Checkpoint blockade; Immune contexture; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P145 | Expanding Iovance’s tumor infiltrating lymphocytes (TIL) from core biopsies for adoptive T cell therapy using a 22-day manufacturing process | Michelle R. Abelson, PhD; Kenneth D'Arigo; Florangel Hilton; Maria Fardis, PhD, MBA; Cecile Chartier; Cecile Chartier | Cellular Therapies | Adoptive immunotherapy; Immune monitoring; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P146 | AUTO6NG: Next generation GD2-targeting CAR T-cell therapy with improved persistence and insensitivity to TGFb and checkpoint inhibition for relapsed/refractory neuroblastoma | Daniela Achkova, PhD; Adrian Zarzoso; Yusuf Demir; Fernando J. Gallardo; Maria Stavrou; Marco Della Peruta; Saket Srivastava; Mathew Robson; Shimobi Onuoha; Simon Thomas; Shaun Cordoba; Martin Pule; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Checkpoint blockade; Cytokine; Solid tumors |
| P147 | Effect of chemotherapy on cellular kinetics of NKG2D-based CAR T-cells in metastatic colorectal cancer patients. | Erik Marcelo Alcantar Orozco; Eytan Breman, MSc; Marie-Sophie Dheur, PhD; Fabian Borghese, PhD; Emilie Cerf, PhD; Nathalie Braun; Caroline Lonez, PhD; Anne Flament; Frederic Lehmann, MD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Chemotherapy; Clinical trial; Immune monitoring; Solid tumors; T cell |
| P148 | High affinity NK cells expressing a PD-L1 chimeric antigen receptor demonstrate anti-tumor activity in head and neck cancer through multiple distinct mechanisms | Yevtte Robbins; Jay Friedman, PhD; Sarah Greene; Kellsye Fabian, PhD; Michelle Padget; John Lee, MD; Patrick Soon-Shiong, MD; Kayvan Niazi; Lennie Sender; Laurent Boissel; Jeffrey Schlom, PhD; James W. Hodge, PhD, MBA; Clint T. Allen, MD; | Cellular Therapies | MDSC; NK/NK T cell; Tumor microenvironment |
| P149 | Silencing PD-1 using self-delivering RNAi PH-762- to improve Iovance TIL effector function using Gen 2 manufacturing method | Inbar Azoulay-Alfaguter, PhD; Michelle R. Abelson, PhD; Krit Ritthipichai, DVM, PhD; Kenneth D’Arigo; Florangel Hilton; Marcus Machin, BS; Dingxue Yan; James Cardia; Maria Fardis, PhD, MBA; Cecile Chartier; | Cellular Therapies | Adoptive immunotherapy; Gene expression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P150 | 1st-in-human CAR T clinical trial for metastatic breast cancers | Cynthia C. Bamdad, PhD; Andrew K. Stewart, PhD; Pengyu Huang, PhD; Benoit J. Smagghe, PhD; Scott T. Moe, PhD; Tyler E. Swanson; Thomas G. Jeon; Danica M. Page; Ketan M. Mathavan, PhD; Trevor J. Grant, PhD; Rachel M. Herrup; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| P151 | Solid tumor cytotoxicity by natural killer cells expressing a HER2-directed chimeric antigen receptor enhanced by MyD88/CD40 (MC) | Xiaomei Wang, PhD; Daniel E. Jasinski, PhD; Jan L. Medina; David M. Spencer, PhD; Aaron E. Foster, PhD; Joseph H. Bayle, PhD; | Cellular Therapies | Adoptive immunotherapy; NK/NK T cell; Solid tumors; Targeted therapy |
| P152 | Antigen delivery to PBMCs by microfluidic squeezing primes anti-tumor immunity | Matthew G. Booty, PhD; Kelan A. Hlavaty; Emrah I. Ozay, PhD; Carolyne Smith, PhD; Katherine Seidl, PhD; Howard Bernstein, MD, PhD; Armon Sharei; Scott M. Loughhead; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; T cell; Tumor antigens; Vaccine |
| P153 | Memory CD8+ T cells are more resistant to cancer stem cell (CSC) suppression than effector CD8+ T cells and are more effective at targeting CSC in a murine melanoma model | Brooke C. Bredbeck, MD; Shibin Qu; Alicia A. Kevelin; Ashley A. Pepple; amy E. Felsted; Anutosh Ganguly; Clifford S. Cho, MD, FACS; Brooke C. Bredbeck; | Cellular Therapies | Adoptive immunotherapy; Immune suppression; Stem cell/cancer-initiating cell; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| P154 | Development of an Antigen-Presenting Bead Kit for Activation and Expansion of Human Antigen-Specific T Cells | Yelena Bronevetsky, PhD; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; CAR T cells; Cytokine; Immune monitoring; T cell; T cell lineages; Tumor antigens |
| P155 | Prospective Translational Study Evaluating Vaccine-Enhanced Adoptive T cell Therapy for Treatment of Osteosarcoma in Companion Dogs | Tammie A. Wahaus, BSBA; Noe Reyes, DVM; Jeffrey N. Bryan, DVM, MS, PhD, DACVIM-Oncology; Jeffrey N. Bryan, DVM, MS, PhD, DACVIM-Oncology; Gary W. Wood, PhD; Brian K. Flesner, DVM, MS, DACVIM-Oncology; Debbie Tate, RVT, VTS (Oncology); Lindsay L. Donnelly, DVM, MS, DACVIM-Oncology; | Cellular Therapies | Adoptive immunotherapy; Neoantigens; Solid tumors; T cell; Tumor antigens; Vaccine |
| P156 | Lung cancer sub-types exhibit differential susceptibility to natural killer cell cytotoxicity | Jason G. Cahoon, BS; Shilan Dong, MS; Rafet N. Amoor; Donna L. Sonntag, M.S.; Alexander F. Spurrell; Rachit Ohri, PhD; | Cellular Therapies | Biomarkers; Chemokine; Cytokine; Immune toxicity; NK/NK T cell; Solid tumors; Targeted therapy; Tumor antigens; Tumor microenvironment |
| P157 | Optimized process for manufacturing Deep-Primed™ T cells creates product with improved functional characteristics and reactivity against multiple tumor-associated antigens | Shawn P. Carey, PhD; Christine M. McInnis, PhD; Alicia Worthylake; Angela Forte; Elisabeth Brown; Darren Smith; Kate Sackton, PhD; Rosemary Soucy; Tap Maniar, MD; Karsten Sauer, PhD; Thomas L. Andresen, PhD; Andy Rakestraw, PhD; | Cellular Therapies | Adoptive immunotherapy; Cytokine; Solid tumors; T cell; T cell lineages; Targeted therapy; Tumor antigens |
| P158 | Suboptimal ER stress Induced Autophagy Regulates Anti-Tumor T Cell Response | Shilpak Chatterjee; Danh T. Tran; Kim Dosung; Satish N. Nadig; Carl Atkinson; Hongjun Wang; J. Alan Dieh; Shikhar Mehrotra, PhD; Paramita Chakraborty, PhD; | Cellular Therapies | Adoptive immunotherapy; Metabolism; T cell; Tumor infiltrating lymphocytes (TILs) |
| P159 | TCR fingerprinting and off-target peptide identification | Armen Karapetyan; Chawaree Chaipan; Katharina Winkelbach; Sandra Wimberger; Jun Seop Jeong; Bishnu Joshi; Robert N. Stein, MD PhD; Dennis Underwood, PhD; Eleni Chantzoura, PhD; Alvaro Yague; Jan Bergmann; John C. Castle, PhD; Marc A. Van Dijk, PhD; Marc A. Van Dijk, PhD; Volker Seibert; | Cellular Therapies | Bioinformatics; Immune toxicity; Neoantigens; T cell |
| P160 | Engineered natural killer cells redirected against adenosinergic immunometabolic suppression for the immunotherapy of lung carcinoma | Andrea Chambers, MS; Kyle B. Lupo, BS; Jiao Wang, PhD; Sandro Matosevic, PhD; | Cellular Therapies | Adoptive immunotherapy; Cytokine; Gene expression; Metabolism; NK/NK T cell; Solid tumors; Targeted therapy; Tumor microenvironment |
| P161 | High-efficiency CAR-T cell manufacturing by improved scalable electroporation | Jian Chen, PhD; George Sun; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Gene expression; NK/NK T cell; T cell |
| P162 | Development of CD4+ and CD8+ TCRαβ-deficient bioluminescent reporter T cells for screening and characterization of neoantigen-specific TCRs | Zhijie J. cheng, PhD; Jamison J. Grailer, PhD; Michael Slater; Pete Stecha; Jim Hartnett; Frank Fan, PhD; Mei Cong, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Neoantigens; T cell; Targeted therapy |
| P163 | Effect of common gamma-chain cytokines on myeloid-derived suppressor cell and M2 macrophage suppressive function: Implications for cellular immunotherapy | Anna Cole, BA; Charlotte Rivas; Josue Pineda; Corrine Baumgartner; Stephanie Fetzko; Robin Parihar; | Cellular Therapies | CAR T cells; Cytokine; Immune suppression; Monocyte/Macrophage; Myeloid cells; MDSC; Solid tumors; Tumor microenvironment |
| P164 | Effect of NK cell treatment on PD-L1 expression and anti-PD-L1 response | Alicja Copik, PhD; Jeremiah L. Oyer; Sarah B. Gitto; Deborah A. Altomare, PhD; | Cellular Therapies | Adoptive immunotherapy; Checkpoint blockade; NK/NK T cell; Solid tumors |
| P165 | Robust, reproducible and highly scalable manufacturing of P-BCMA-ALLO1, an allogeneic CAR-T stem cell memory product for Multiple Myeloma, from numerous healthy donors | Stacey Cranert, PhD; Maximilian Richter, PhD; Min Tong, MS; Leslie Weiss, M.S.; Yening Tan, MS; Eric Ostertag, MD/PhD; Julia Coronella, PhD; Devon Shedlock, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; T cell; Targeted therapy |
| P166 | ET140202 T-cell therapy for the treatment of liver cancer is built upon a novel antibody-T cell receptor (AbTCR) ARTEMIS™ T-cell platform | Jun Cui, PhD; Pengbo Zhang; Hongruo Yun; Yiyang Xu; Lucas Horan, PhD; Shaohua Xu; Sean Xu; Hong Liu; | Cellular Therapies | CAR T cells; Solid tumors; T cell |
| P167 | Improved efficacy leveraging CAR-T therapeutics that produce tightly controlled, tumor proximal, immunomodulatory outputs | Michon Pinnix; Krista McNally; Jay Danao, BS; Melissa Fardy; Rachel Hovde, MS; Charlotte Davis; Nicole Grant; Dianna Lester-Zeiner; David Mai; Ben Wang, PhD; Gus Zeiner, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Cytokine; Gene expression; Immune suppression; Solid tumors; T cell; Tumor microenvironment |
| P168 | Role and Function of T-cell immunoglobulin– and mucin domain–containing (TIM)–3 Receptor on Natural Killer Cells in Solid Tumors | Tram N. Dao; Sandro Matosevic, PhD; | Cellular Therapies | Immune suppression; NK/NK T cell; Solid tumors |
| P169 | Enriching non-genetically modified antigen specific marrow infiltrating lymphocytes (MILs) to target HPV+ oropharyngeal squamous cell carcinoma | Danielle W. Dillard, PhD Candidate; Vanessa Chan; LAKSHMI RUDRARAJU, MS; Elizabeth DeOliveira; Amy Thomas; Ervin Griffin; Megan K. Heimann, PhD candidate; Luca Biavati, MD; Elizabeth Zawidzka; Marguerrita El Asmar; Drew M. Pardoll, MD, PhD; Kellie N. Smith, PhD; Carole Fakhry, MD; Ivan M. Borrello, MD; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; Bioinformatics; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| P170 | Sequential anti-CD19, anti-CD22, and anti-CD20 autologous chimeric antigen receptor T cell (CAR-T) therapies treating a child with relapsed refractory Burkitt lymphoma | Juan Du, MD; Yonghong Zhang, Professor; | Cellular Therapies | B cell; CAR T cells; Leukemia/Lymphoma; Pediatric tumors |
| P171 | T cell receptor gene therapy for a public neoantigen derived from mutated PIK3CA, a dominant driver oncogene in breast and endometrial cancers | Smita S. Chandran, PhD; Jiaqi Ma; Martin Klatt, PhD; Friederike Dundar, PhD; Paul Zumbo; Matthew R. Femia; Doron Betel, PhD; David Scheinberg; Brian M. Baker, PhD; Christopher A. Klebanoff, MD; Smita S. Chandran, PhD; | Cellular Therapies | Adoptive immunotherapy; Gene expression; Neoantigens; Proteomics; T cell |
| P172 | Shape and Material Properties Increase Artificial Antigen Presenting Cell Effectiveness | Savannah Est Witte, BS; Kaitlyn G. Calebrisi; Jordan J. Green, PhD; Savannah Est Witte, BS; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; T cell; Targeted therapy |
| P173 | Case reports: Correlates of response following adoptive transfer of ADP-A2M4, affinity-enhanced T-cells targeting MAGE-A4, in synovial sarcoma | Svetlana Fayngerts, PhD; Zohar Wolchinsky; Shravani Shitole; Joana Senra; Rebecca Dryer-Minnerly, PhD; Ruoxi Wang; Jean-Marc Navenot, PhD; Olga Ochkur; Gareth Betts, PhD; Natalie Bath, MSc; Erin Van Winkle; Tom Holdich; Malini Iyengar, PhD; Rafael Amado, MD; Marcus O. Butler, MD; David S. Hong, MD; Alex J. Tipping, PhD; Samik Basu, MD; Indu Ramachandran, PhD | Cellular Therapies | Adoptive immunotherapy; Clinical study; Cytokine; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor microenvironment |
| P174 | Combinatorial tumor targeting using a novel switchable RevCAR system | Anja Feldmann, PhD; Anja Hoffmann; Ralf Bergmann; Liliana Loureiro, PhD; Enrico Kittel-Boselli; Nicola Mitwasi; Stefanie Koristka; Justyna Jureczek; Nicole Berndt; Claudia Arndt; Michael Bachmann; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Targeted therapy |
| P175 | PD-L1: A side-effect of T cell engagement or a main player in MDS tumor immune evasion? | Valentina Ferrari, BA; Alison Tarke; Hannah Fields; Tiffany Tanaka; Rafael Bejar; Thomas A. Lane, MD; Antonella Vitiello, PhD; Maurizio Zanetti, MD; | Cellular Therapies | Adoptive immunotherapy; Myeloid cells; Neoantigens; T cell; Tumor evasion; Tumor microenvironment |
| P176 | Adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) for metastatic uveal melanoma: feasibility of treatment using a product generated from the primary tumor | Marie-Andree Forget, PhD; Cara Haymaker, PhD; Orenthial J. Fulbright, BS; Shawne Thorsen, BS; Esteban Flores, BS; Arely Wahl, MSc; Rene J. Tavera, BS; Benjamin Tintera, BS; Timothy L. Woody; Michelle Williams; Yun Shin Chun; Patrick Hwu, MD; Dan S. Gombos; Sapna Patel, MD; Rodabe N. Amaria, MD; Chantale Bernatchez; | Cellular Therapies | Adoptive immunotherapy; Clinical study; Clinical trial; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P177 | NF-kB p50-deficient immature myeloid cell (p50-IMC) adoptive transfer slows the growth of murine prostate and pancreatic ductal carcinoma | Rahul Suresh, PhD; David Barakat, PhD; Theresa Barberi, PhD; Lei Zheng, PhD MD; Elizabeth M. Jaffee, MD; Kenneth J. Pienta, MD; Alan D. Friedman, MD; | Cellular Therapies | Adoptive immunotherapy; Dendritic cell; Monocyte/Macrophage; Myeloid cells; Tumor microenvironment |
| P178 | Dual inhibition of PI3Kdelta and PI3Kgamma to enhance mitochondrial mass and ex vivo expansion of central and stem cell memory T cells from CLL patients | Christopher R. Funk, BS; Shuhua Wang, MD; Alexandra Waller, BS; Lauren C. Fleischer, BS; Aditi Sharma; Harold T. Spencer, PhD; Vikas Gupta, MD, PhD; Sruthi Ravindranathan, PhD; Mala Shanmugam, PhD; Christopher Flowers, MD, MS; Edmund K. Waller, MD, PhD, FACP; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Costimulation; Leukemia/Lymphoma; T cell |
| P179 | Checkpoint Cbl-b siRNA-based APN401 adoptive cell therapy: Superior efficacy & immune memory induction in murine hepatocellular carcinoma following APN401 monotherapy and synergism with anti-PD1. | Anderson Gaweco, MD, PhD; Anderson Gaweco, MD, PhD; Kathrin Thell; Maria Urban; Julia Harrauer; Isabella Haslinger; Josef Penninger; Vincent Chung; Anthony El-Khoueiry, MD; Carlos Becerra, MD; | Cellular Therapies | Adoptive immunotherapy; Checkpoint blockade; Coinhibition; NK/NK T cell; Solid tumors; T cell; Targeted therapy |
| P180 | SENTI-101, an allogeneic cell product, induces potent and durable anti-tumor immunity in pre-clinical models of peritoneal carcinomatosis | Alba Gonzalez Junca, PhD; Gary Lee, PhD; Alba Gonzalez Junca, PhD; Archana Nagaraja, PhD; Alyssa Mullenix; Russell M. Gordley, PhD; Daniel O. Frimannson, PhD; Anissa Benabbas; Chen-Ting Lee, PhD; Tiffany A. Truong; Mengxi Tian; Allison Bi. Quach; Rishi Savur; Rowena Martinez; Alyssa Perry-McNamara; Don-Hong Wang, PhD; Ori Maller, PhD; Dharini Iyer, PhD; Ashita Magal; Christina J. Huynh; Carmina C. Blanco; Jack T. Lin, PhD; Brian S. Garrison, PhD; Philip Lee, PhD; Sravani Mangalampalli; Timothy K. Lu, MD, PhD; | Cellular Therapies | Adoptive immunotherapy; Cytokine; Solid tumors; Tumor microenvironment |
| P181 | Multi-phenotype CRISPR-Cas9 screens identify p38 kinase as a target for adoptive immunotherapies | Devikala Gurusamy, PhD; Suman Vodnala; Amanda Henning; Rigel Kishton; Tori N. Yamamoto; Arash Eidizadeh; Li Jia; Christine M. Kariya; Mary Black; Robert L. Eil; Douglas Palmer; Zhiya Yu; Jenny Pan, MD; Madhusudhanan Sukumar; Shashank J. Patel; Nicholas P. Restifo, MD; | Cellular Therapies | Adoptive immunotherapy; Bioinformatics; CAR T cells; Leukemia/Lymphoma; Metabolism; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| P182 | GAIA-102: a new class NK cell-like phenotype manufactured in accordance with GMP/GCTP that can eliminate solid tumors | Yui Harada, PhD; Yoshikazu Yonemitsu, MD, PhD; | Cellular Therapies | Adoptive immunotherapy; MDSC; NK/NK T cell; Solid tumors |
| P183 | Development of novel chimeric antigen receptor T cells for immunotherapy of hepatocellular carcinoma | Yukai He, PhD; Leidy Caraballo Galva; Xiaotao Jiang; | Cellular Therapies | Adoptive immunotherapy; Antibody |
| P184 | Activating marrow infiltrating lymphocytes in hypoxia enhances their efficacy in adoptive T-cell therapy | Megan K. Heimann, PhD candidate; Ervin Griffin; Luca Biavati, MD; Amy Thomas; Danielle Dillard; Elizabeth Zawidzka; Brianna Richardson; Robert D. Leone; Gregory Szeto; Kimberly A. Noonan, PhD; Ivan M. Borrello, MD; | Cellular Therapies | Adoptive immunotherapy; Cytokine; Gene expression; Metabolism; T cell; Tumor antigens; Tumor microenvironment |
| P185 | T cell antigen presenting cell (tAPC) is a strategy to induce CAR T expansion in vivo in the absence of a tumor for on-target toxicity studies | Yen Ho, BS; Jon Jones, BA; Jon Jones, BA; Patrick Carlson, BS; Patrick Carlson, BS; Cyr de Imus; Rebekah Turk; Dina Alcorn; Kyle Kolaja; Ruth Salmon, PhD; Thomas Long; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; CAR T cells; Immune toxicity; T cell |
| P186 | Evaluation of antigen-specific T-cell immunity at the single cell level using large panels of DNA barcoded MHC multimers | Kivin KJ. Jacobsen, PhD; Dagmar Walter; Michael Stubbington; Katherine Pfeiffer; Charlotte Halgreen; Liselotte Brix, phd; Stephane Boutet; Kivin KJ. Jacobsen, PhD; | Cellular Therapies | Adoptive immunotherapy; Biomarkers; Gene expression; Immune monitoring; Neoantigens; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| P187 | Single-cell RNA sequencing and functional assessment of healthy donor- and cancer patient-derived T and CAR-T cells | Zinkal Padalia, MS; Konstantinos Karagiannis, PhD; Brigid Mcewan, MA; Vahan Simonyan, PhD; Jonathan Terrett, PhD; Demetrios Kalaitzidis, PhD; Demetrios Kalaitzidis, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma; Systems biology; T cell; Targeted therapy; Tumor antigens |
| P188 | Enhanced anti-tumor activity of human placental CD34+ derived natural killer cells in combination with ACY-241 for multiple myeloma immunotherapy | Lin Kang, PhD; Xiaokui Zhang; Shuyang He; Vanessa Voskinarian-Berse; Bhavani Stout; Valentina Rousseva; William van der Touw; James Edinger; Robert Hariri; | Cellular Therapies | Adoptive immunotherapy; Chemotherapy; NK/NK T cell |
| P189 | Tumor Treating Fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy | Noa Kaynan, PhD; Tali Voloshin; Shiri Davidi; Yaara Porat; Anna Shteingauz; Mijal Munster; Rosa S. Schnaiderman; Catherine Tempel Brami; Yaniv Alon; Einav Zeevi; Karnit Gotlib; Roni Blat; Orni Tal Yitzhaki; Shay Cahal; Aviran Itzhaki; Eilon D. Kirson; Uri Weinberg, MD PhD; Adrian Kinzel; Yoram Palti; Noa Kaynan, PhD; Moshe Giladi; | Cellular Therapies | Checkpoint blockade; Dendritic cell; Immune adjuvant; Solid tumors |
| P190 | Single-day CAR manufacturing platform using mRNA and Flow Electroporation Technology | Michael Kuo; Robert Keefe, PhD; Linhong Li, PhD; Angelia Viley; Mary Loveras; Brian Mulhern; Melanie Hartsough; Robert Keefe, PhD; Claudio A. Dansky Ullmann, MD; Dhana Chinnasamy; | Cellular Therapies | CAR T cells; Clinical study; Clinical trial; Solid tumors; T cell; Targeted therapy |
| P192 | Anti-HLA-G Antigen Receptor T-Cells Exhibit Potent Anti-Tumor Effects Against Human Solid Tumors | Alan L. Epstein, MD, PhD; Aida Kouhi, PhD candidate; | Cellular Therapies | CAR T cells; Neoantigens; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| P193 | CoStAR (Costimulatory Antigen Receptor) Enhancement of Tumour Infiltrating Lymphocyte Therapy | Gray Kueberuwa, PhD; John S. Bridgeman, PhD; Martina Sykorova; milena Kalaitsidou; Michelle L. Le Brocq; Martina Sykorova; Robert Hawkins; | Cellular Therapies | Adoptive immunotherapy; Costimulation; Immune contexture; T cell; Tumor infiltrating lymphocytes (TILs) |
| P194 | Use of stimulatory cells in conjunction with IL-12 and IL-18 augments NK cell expansion and transduction, drives a memory phenotype, and improves in vitro and in vivo CAR NK activity | Anmol Vohra, MS; Katherine Jamboretz, MS; Sasha Lazetic; Denise Gonzalez; Daofeng Liu, PhD; Ivan Chan, PhD; James B. Trager, PhD; | Cellular Therapies | Cytokine; NK/NK T cell |
| P195 | Loss of function of the TSC1-TSC2 complex renders tumors eligible for GD3 CART therapy | Ancy Thomas; Saurav Sumughan; Zhussipbek Mukhatayev; Emilia Dellacecca; Nicola Lancki; Levi Barse; Jesus Zamora-Pineda; Suhail Akhtar; Maria Picken; Denise Scholtens; Daniel Dilling; Richard P. Junghans, PhD, MD; Caroline Le Poole; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; NK/NK T cell; Solid tumors; T cell; Tumor antigens |
| P196 | The first step toward the universal cell therapy: Simultaneous removal of HLAs (Human leukocyte antigens) using CRISPR-mediated quadruple genome editing in allogeneic T cells | Jeewon Lee, Ph D; Munkyung Kim; Joong Hyuk Sheen; Jihye Ryu; Yu Young Kim; Okjae Lim; | Cellular Therapies | Adoptive immunotherapy; Gene expression; T cell |
| P197 | The development of an autologous neoantigen specific T cell product from peripheral blood, NEO-PTC-01, through the ex-vivo induction protocol, NEO-STIM™ | Divya R. Lenkala; Marit M. Van Buuren, PhD; Brian McCarthy; Jessica Kohler, PhD; Michael Nelson; Flavian Brown; Yvonne Ware, Masters; Yuting Huang, Master of Science; Janani Sridar; Yusuf S. Nasrullah, Master's in Biological Research, United Kingdom; Dewi Harjanto; Joost H. Van Den Berg, PharmD; Matthew Goldstein, MD, PhD; Richard B. Gaynor, MD; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; Bioinformatics; Immune monitoring; Neoantigens; T cell |
| P198 | Short-lived and extended half-life target modules for redirecting UniCAR T-cells against sialyl-Tn expressing cancer cells | Liliana Loureiro, PhD; Liliana Loureiro, PhD; Anja Feldmann, PhD; Ralf Bergmann; Stefanie Koristka; Nicole Berndt; Nikolett Hegedüs; Domokos Máthé; Paula Videira; Michael Bachmann; Claudia Arndt; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Solid tumors; Targeted therapy |
| P199 | Generation of functionally and phenotypically mature, allogeneic natural killer cells from human induced pluripotent stem cells under chemically-defined, feeder- and serum- free culture conditions | Kyle B. Lupo, BS; Andrea Chambers, MS; Sandro Matosevic, PhD; | Cellular Therapies | Adoptive immunotherapy; NK/NK T cell; Stem cell/cancer-initiating cell; Solid tumors |
| P200 | CART-engineered Marrow-infiltrating Lymphocytes (MILsTM) are more polyfunctional than their matched peripheral blood counterparts | Eric R. Lutz, PhD; LAKSHMI RUDRARAJU, MS; Elizabeth DeOliveira; Srikanta Jana; Jing Zhou, MD, PhD; Sean G. Mackay, MBA; Ivan M. Borrello, MD; Kimberly A. Noonan, PhD; Eric R. Lutz, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; T cell |
| P201 | Comparison of phenotype and anti-tumor profile of CD19-CAR-T cells generated from either umbilical cord blood- or peripheral blood-derived T lymphocytes | Cristina Maccalli, PhD; Dhanya Kizhakayil, PhD; Shilpa Ravindran, BSc.; Saad Rasool; Rebecca Mathew; Valentina Mattei; Monica Casucci, PhD; Sara Deola, MD, PhD; Chiara Cugno, MD; Damien Chaussabel; Sara Tomei, PhD; Christof von Kalle; Cristina Maccalli, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Cytokine; Gene expression; Immune monitoring; Leukemia/Lymphoma; Systems biology; T cell; Tumor antigens |
| P202 | Mechanisms underlying human placental CD34+-derived natural killer cell cytotoxicity against glioblastoma | Tanel Mahlakoiv, PhD; Bhavani Stout; Valentina Rousseva; Irene Raitman; Lin Kang, PhD; Robert Hariri; Xiaokui Zhang; William van der Touw; Tanel Mahlakõiv; | Cellular Therapies | Adoptive immunotherapy; Gene expression; NK/NK T cell; Solid tumors |
| P203 | Discovery and characterization of the first fully human Phosphopeptide Tumor Target-specific T cell receptor | Xavier Michelet, PhD; Eleni Chantzoura, PhD; Ekaterina Breous-Nystrom, PhD; Alessandra Franchino; Rachel Smith; Daniel Pollacksmith; Jan Bergmann; Alvaro Sebastian Yague; Paisley T. Myers, PhD; Erin Jeffrey; Benjamin Wolf; Dennis Underwood, PhD; Marc A. Van Dijk, PhD; Arthur A. Hurwitz, PhD; | Cellular Therapies | Adoptive immunotherapy; Leukemia/Lymphoma; Neoantigens; T cell; Targeted therapy; Tumor antigens |
| P204 | Ex vivo-activated allogeneic CD4+ T-cells disrupt immunosuppressive tumor microenvironment, and induce host tumor-specific cytotoxic T-cells in mice | Kazuhiro Mochizuki, MD, PhD; Shogo Kobayashi; Nobuhisa Takahashi; Hideki Sano; Yoshihiro Ohara; Shin Mineishi, MD; Yi Zhang; Atsushi Kikuta; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; Dendritic cell; Inflammation; Monocyte/Macrophage; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P205 | Automated, Closed Bioreactors for T Cell Processing and Dendritic Cell-T Cell Co-Culture | Lekhana Bhandary, BS, PhD; Andrew Kozbial, BS, PhD; Shashi Murthy, BS, PhD; Shashi Murthy, BS, PhD; | Cellular Therapies | CAR T cells; Dendritic cell; Monocyte/Macrophage; Neoantigens; T cell |
| P206 | Transmembrane and linker domain amino acid composition alters chimeric antigen receptor (CAR) membrane residence and may conceal detection of novel functional CAR formats | Dina Schneider, PhD; Virginia Hoglund, MS; Ying Xiong, PhD; Darong Wu, MS; Boro Dropulic, PhD, MBA; Rimas J. Orentas, PhD; Rimas J. Orentas, PhD; Rimas J. Orentas, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; T cell |
| P207 | A patient-driven ex vivo 3D tumor organoid model to assess efficacy of tumor infiltrating T-cell adoptive cell therapy | Jenny Kreahling, PhD; Mibel Pabon, PhD; Mibel Pabon, PhD; Melba Page, PhD; Vijayendra Agrawal, PhD; Soner Altiok, MD, PhD; | Cellular Therapies | Adoptive immunotherapy; Biomarkers; Immune monitoring; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P208 | Impact of combined blockade of PD1 and activation of CD137 on tumor infiltration and tumor cell killing efficacy of TILs in an ex vivo autologous 3D tumoroid model of NSCLC patient samples. | Jenny Kreahling, PhD; Melba Page, PhD; Melba Page, PhD; Mibel Pabon, PhD; Vijayendra Agrawal, PhD; Soner Altiok, MD, PhD; | Cellular Therapies | Adoptive immunotherapy; Antibody; Checkpoint blockade; Cytokine; Immune monitoring; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P209 | Hijacking CAR-CD19 T cells to potently control Her2-positive solid tumors in vitro and in vivo through the use of unique and selective bridging proteins | Paul Rennert, PhD; Christine Ambrose, PhD; Fay Dufort, PhD; Lihe Dufort; Alyssa Birt; Thomas Sanford; Lan Wu; Roy Lobb, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Solid tumors; Tumor antigens; Tumor evasion |
| P210 | Deep phenotypic and functional analysis of transduced anti-CD19 CAR T cells and untransduced T cells in patients treated with axi-cel by single cell mass cytometry | Yohei Arihara, MD, PhD; Caron Jacobson, MD; Philippe Armand, MD; John M. Rossi, MS; Nathalie Scholler, MD, PhD; Stuart Sievers, PhD; Edmund Chang, PhD; Mauro Avanzi, MD, PhD; Adrian Bot, MD, PhD; Jerome Ritz, MD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Clinical study; Immune monitoring; Leukemia/Lymphoma |
| P211 | Combining Deep™ IL-12 Primed and Deep™ IL-15 Primed T cells leverages complementary mechanisms to enhance anti-tumor activity | Katharine Sackton, PhD; Elena Geretti, PhD; Pengpeng Cao, PhD; Shawn P. Carey, PhD; Xiaoyan Liang; Jonathan Nardozzi, PhD; Zishu Gui; Alicia Worthylake; Glenn Leary; Becker Hewes, MD; Tap Maniar, MD; Jonathan B. Fitzgerald, PhD; Andy Rakestraw, PhD; Karsten Sauer, PhD; Douglas Jones, PhD; Thomas L. Andresen, PhD; | Cellular Therapies | Adoptive immunotherapy; Cytokine; Solid tumors; T cell |
| P212 | Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy | Donastas Sakellariou-Thompson, BS; Marie-Andree Forget, PhD; Emily Hinchcliff, MD; Joseph Celestino; Patrick Hwu, MD; Amir A. Jazaeri, MD; Cara Haymaker, PhD; Chantale Bernatchez; | Cellular Therapies | Adoptive immunotherapy; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P213 | Conversion of peripheral blood mononuclear cells into tumor-specific cytolytic cell populations using tumor cells engineered with multiple immunomodulatory factors | Joshua Keegan; James Lederer; Frank Borriello, MD, PhD; Nathan Schomer, MS; James Lederer; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; Costimulation; Cytokine; Immune adjuvant; NK/NK T cell; T cell; T cell lineages; Targeted therapy; Vaccine |
| P214 | T cells precision engineered to express neoepitope-specific TCRs cloned from a patient with colorectal cancer specifically target and kill relevant neoantigen-expressing tumor cells | Barbara Sennino, PhD; Adam Litterman; John Gagnon; Andrew Conroy; Bhamini Purandare; Zheng Pan, PhD; Dalmas Olivier; Kyle Jacoby, PhD; Songming Peng, PhD; Alex Franzusoff, PhD; Stefanie J. Mandl, PhD; | Cellular Therapies | Adoptive immunotherapy; Neoantigens |
| P215 | Depletion of CD45RA-positive cells potentiates the reactivation of EBV-specific T-cells from EBV positive lymphoma patients | Sandhya Sharma, BSc.; Sandhya Sharma, BSc.; Naren Mehta; Kathan Parikh, RA; Cliona M. Rooney, PhD; | Cellular Therapies | Adoptive immunotherapy; Antigen presenting cells; T cell; Tumor antigens |
| P217 | An NK cell line (PD-L1 t-haNK) engineered to target PD-L1 efficiently kills tumor cells and myeloid derived suppressor cells | Kellsye Fabian, PhD; Michelle Padget; Renee N. Donahue, PhD; kristen solocinski, PhD; Clint T. Allen, MD; John Lee, MD; Patrick Soon-Shiong, MD; Jeffrey Schlom, PhD; James W. Hodge, PhD, MBA; | Cellular Therapies | MDSC; NK/NK T cell; Solid tumors; Targeted therapy |
| P218 | A novel, bioluminescent assay for the selective detection of target cell killing in mixed cultures | Richard Somberg, PhD; Brock Binkowski; Aileen Paguio; Peter Stecha; Chris Eggers; Braeden Butler; Michael Beck; Julia Gilden, PhD; Jey Cheng; Mei Cong, PhD; Frank Fan, PhD; | Cellular Therapies | Adoptive immunotherapy; Antibody; CAR T cells; Chemokine; Costimulation; Cytokine; NK/NK T cell; T cell; Targeted therapy |
| P220 | Targeting neoantigens with immunotherapy: Are we limited to pre-existing autologous neoantigen-specific T-cells? | Aline Bracher; Slavoljub Milosevic; Daniel Sommermeyer; Daniel Sommermeyer; | Cellular Therapies | Adoptive immunotherapy; Neoantigens; Tumor antigens |
| P221 | Superior anti-tumor activity of metabolically enhanced bispecific antibody armed CAR-less Bionic T cells | Archana Thakur, PhD; John Scholler; Edwin T. Bliemeister; Carl H. June, MD; Lawrence G. Lum, MD, DSc; | Cellular Therapies | Adoptive immunotherapy; Antibody; Chemokine; Cytokine; Solid tumors; T cell; Targeted therapy |
| P222 | Modulating BRD4 in T cells using self-delivery RNAi to improve adoptive cell therapy of cancer | Jeroen Melief, PhD; Laura L. Van Leeuwe Kirsch, BSc; Esmeralda Hemme; John A. Barrett, PhD; Simon P. Fricker, PhD; Gerrit Dispersyn, PhD; Rolf Kiessling, MD, PhD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; T cell; Tumor infiltrating lymphocytes (TILs) |
| P224 | Case studies of sarcoma and MRCLS following treatment with NY-ESO-1 TCR T Cells (GSK3377794): correlates of predictable response characteristics | Brian Van Tine, MD, PhD; Sandra P. D'Angelo, MD; Alexandra Gyurdieva; Laura Johnson; David C. Turner; Jenna Tress; M. Phillip DeYoung; Yuehui Wu; Aisha N. Hasan, MBBS MD; Dejka Araujo, MD; | Cellular Therapies | Adoptive immunotherapy; Clinical study; Cytokine; T cell |
| P225 | Generating iPSC-derived CAR T cells with an endogenous T cell phenotype and conventional CAR T functionality | Zhiqiang (Daniel) Wang, Ph.D; Zhiqiang (Daniel) Wang, Ph.D; Hellen McWilliams-Koeppen, MS; Christian Huynh, BS; Hernan Reza; Vibhuti Vyas; Xiuli Wang, PhD; Wen-Chung Chang, MS; Julie R. Ostberg, PhD; Renate Starr, MS; Jamie Wagner; Brenda Aguilar, BS; Xiwei Wu; Jinhui Wang; Wei Chen; Chris Seet; Gay Crooks; Christine Brown, PhD; Stephen J. Forman, MD; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma; Stem cell/cancer-initiating cell; T cell; T cell lineages |
| P226 | Iovance Gen2 TIL manufacturing process produces drug products that exhibit favorable quality attributes for adoptive cell transfer across 5 solid tumor indications | Seth Wardell; Seth Wardell; Maritza Lienlaf-Moreno; Lavakumar Karyampudi; Anand Veerapathran, PhD; Ian Frank; Michelle A. Blaskovich, BS; Kenneth Onimus; Arvind Natarajan; Maria Fardis, PhD, MBA; Joe Wypych | Cellular Therapies | Adoptive immunotherapy; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P227 | Co-expression of the metabolic enzyme GOT2 with a GPC3-targeted CAR-T overcomes challenges of the solid tumor microenvironment, substantially improving therapeutic efficacy in solid tumor xenografts | Kathleen R. Whiteman, MS; Kathleen R. Whiteman, MS; Tapasya Pai; Eugene Choi; Taylor Hickman; Tyler Johnson; Luke Barron, PhD; Taylor Friedman; Madaline Gilbert; Binzhang Shen; Seth Ettenberg; Kathleen McGinness; Greg Motz; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; Metabolism; Solid tumors; T cell; Tumor microenvironment |
| P228 | Tumor infiltrating lymphocyte recognition of shared neoantigens from mutated DNA repair/remodeling proteins in a patient with metastatic pancreatic adenocarcinoma | Ghanshyam Singh S. Yadav, PhD; Chetana Bhaskarla, PhD; Smriti Chaurasia, PhD; Joshua Tobin; Xinming Zhuo; Yinghong Pan; Annerose Berndt; Udai S. Kammula, MD, FACS; | Cellular Therapies | Adoptive immunotherapy; Neoantigens; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P229 | The Next Generation “off-the-shelf” Universal CAR for Adoptive Immunotherapy | Weichih Yang, PhD; Yun Ji; Xiaobing Luo; Huijuan Cui; Michael Patrick; Yutian Wei; Shigui Zhu; Jiaqi Huang; Xin Yao; Yihong Yao; Aibing Liang; Ping Li; | Cellular Therapies | Adoptive immunotherapy; CAR T cells; T cell; T cell lineages |
| P230 | Activating Antigen Carriers for Cancer Therapy: Preclinical Immune Responses Drive Tumor Regression | Defne Yarar, PhD; Amritha Ramakrishnan; Katarina Blagovic, PhD; Katherine Seidl; Howard Bernstein, MD, PhD; Armon Sharei; | Cellular Therapies | Adoptive immunotherapy; Immune adjuvant; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |
| P231 | Invariant natural killer T cells as an allogeneic cell therapy platform | Burcu Yigit, PhD; Xavier Michelet, PhD; Simon Yue; Darrian Moskowitz; Mark Exley; Burcu Yigit, PhD; | Cellular Therapies | Adoptive immunotherapy; NK/NK T cell |
| P232 | Characterization of ADCC Resistance in Multiple Cancer Types | David Zahavi, MS, BS; Yongwei ZHANG; Sandra Jablonski, PhD; Louis M. Weiner, MD; | Cellular Therapies | Antibody; NK/NK T cell; Targeted therapy; Tumor antigens; Tumor evasion |
| P233 | RTX-321, an Allogeneic Artificial Antigen Presenting Red Cell Therapeutic, Expressing MHC I-Peptide, 41BBL and IL12, Promotes Antigen-Specific T Cell Expansion and Anti-Tumor Activity in HPV16+ Tumors | Xuqing Zhang, PhD; Tiffany F. Chen; | Cellular Therapies | Antigen presenting cells; Costimulation; Cytokine; T cell; Tumor antigens |
| P234 | DAP10 and DAP12 Signaling Based CAR Circumvents Ligand-dependent Tonic Signaling and Mediates Potent Anti-tumor Response In Vivo | Alan L. Epstein, MD, PhD; Long Zheng, PhD Candidate; | Cellular Therapies | CAR T cells; Immune toxicity; Neoantigens; T cell; Targeted therapy; Tumor antigens |
| P235 | A dense, proliferative myeloid and T cell-rich, immune infiltrate characterizes Immunotherapy-induced skin rash | Cormac Cosgrove, PhD; Cory Kosche; Suyeon Hong; Caroline Le Poole; Jennifer Choi; | Checkpoint Blockade Therapy | Autoimmunity; Checkpoint blockade; Dendritic cell; Immune toxicity; Inflammation; Monocyte/Macrophage; Myeloid cells; T cell |
| P236 | Nivolumab Related Side Effects Based on Patient-Reported Outcomes: A Multicenter Study from Real-life Setting | Canan Karadas; Zehra Gok Metin, Assoc Prof, PhD, RN; Nur Izgu, PhD, RN; Canan Porucu, MSc, RN; Nuri Karadurmus, Prof. Dr, MD; Sadettin Kilickap, Prof. Dr, MD; Umut Demirci, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Targeted therapy |
| P237 | A case of anti-Zic4 antibody-mediated cerebellar toxicity induced by dual checkpoint inhibition in HNSCC | Sunil G. Iyer, MD; Nidah Khakoo, MD; Gabriella Aitcheson, MD; Marina Kushnirsky, MD; Cesar A. Perez, MD; | Checkpoint Blockade Therapy | Autoimmunity; Checkpoint blockade; Immune toxicity; Solid tumors |
| P238 | Longitudinal immune and genomic monitoring reveals signatures of response and Immune-related adverse events in cancer patients receiving checkpoint inhibitor therapy | Shaheen Khan, Ph.D; David Gerber; | Checkpoint Blockade Therapy | Antibody; Autoimmunity; Checkpoint blockade; Cytokine; Genetic polymorphism; Immune monitoring; Immune toxicity |
| P239 | Immune checkpoint inhibitor-associated arthritis: a systematic literature review of case series and case reports | Michael D. Tiongson, BA; Nilasha Ghosh, MD; Carolyn Stewart, BA; Karmela K. Chan, MD; Bridget J. Gatto, MLIS; Anne R. Bass, MD; | Checkpoint Blockade Therapy | Autoimmunity; Checkpoint blockade; Clinical study; Immune toxicity; Inflammation |
| P240 | Quantitative cell-based bioassays to advance immunotherapy programs targeting immune checkpoint receptors | Vanessa Ott, PhD; Jamison J. Grailer, PhD; Jun Wang; Julia Gilden, PhD; Pete Stecha; Denise Garvin; Michael Beck; Jim Hartnett; Frank Fan, PhD; Mei Cong, PhD; Zhi-jie Jey Cheng; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Coinhibition; Costimulation; T cell; Targeted therapy |
| P241 | Single-cell deconvolution identifies T-cell correlates of response to PD-1 blockade treatment in AML | Xingyue An, BS; Jay R Adolacion; Mansour Alfayez; Jairo Matthews; Wilmer Flores; Steven M. Kornblau, MD; Arash Saeedi; Naval Daver, MD; Sreyashi Basu; Navin Varadarajan, PhD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Leukemia/Lymphoma; T cell |
| P242 | Combination of the angiogenesis inhibitor lucitanib with immune checkpoint blockade augments anti-tumor activity in syngeneic models | Rachel Dusek, PhD; Liliane Robillard, PhD; Thomas C. Harding, PhD; Andrew Simmons, PhD; Minh Nguyen; | Checkpoint Blockade Therapy | Angiogenesis; Checkpoint blockade; Gene expression; Targeted therapy; Tumor microenvironment |
| P243 | Modulating the immunogenicity of low-mutation soft tissues sarcomas with epigenetic targeted therapy | himavanth R. gatla, PhD; Maggie Phillips; Brian Ladle; himavanth R. gatla, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Chemotherapy; Cytokine; Gene expression; Pediatric tumors; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |
| P244 | The genomic architecture of serous carcinomas shapes the tumor microenvironment and modulates responses to targeted and immunotherapies. | Sonia Iyer, PhD; Shuang Zhang; Anniina Farkkila; Sean G. Smith, PhD; David Pepin; Raghav Mohan; Tian Xia; Ferenc Reinhardt; Tony Chavarria; Esmee Hoefsmit; Shailja Pathania; Yunlan Zhou; Kevin Elias; Benjamin Neel; Robert Weinberg, PhD; | Checkpoint Blockade Therapy | Carcinogenesis; Checkpoint blockade; Chemokine; Dendritic cell; Immune contexture; Myeloid cells; MDSC; Regulatory T cell (Treg cell); T cell |
| P245 | Durvalumab after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC) – a German radiation oncology survey | Lukas Kaesmann, MD; Chukwuka Eze; Julian Taugner; Olarn Roengvoraphoj; Claus Belka; Farkhad Manapov; | Checkpoint Blockade Therapy | Checkpoint blockade; Chemotherapy; Radiotherapy |
| P246 | Prospective evaluation of outcome and toxicity of durvalumab treatment after chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC) patients | Lukas Kaesmann, MD; Julian Taugner; Lukas Kaesmann, MD; Chukwuka Eze; Olarn Roengvoraphoj; Claus Belka; Farkhad Manapov; | Checkpoint Blockade Therapy | Checkpoint blockade; Chemotherapy; Immune toxicity; Radiotherapy |
| P247 | TLR3-targeting Combinatorial Chemokine Modulation Sensitizes “Cold” Tumors for the Therapeutic Effectiveness of Immune Checkpoint Inhibition | Kathleen M. Kokolus, MS, PhD; Natasa Obermajer, PhD; Per H. Basse, MD, PhD; Pawel Kalinski, MD, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Chemokine; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P248 | Pembrolizumab plus axitinib (P+A) versus other first-line (1L) systemic therapies for advanced/metastatic clear-cell renal cell carcinoma (ccmRCC) by IMDC Risk Status – a network meta-analysis (NMA) | Ian McGovern, MPH; Rohan Shirali, MS; Andrew Simon, ScM; Yichen Zhong, PhD; Rodolfo Perini, MD; Maria Lorenzi, MSc; Oluwakayode Adejoro, MD, MPH; | Checkpoint Blockade Therapy | Checkpoint blockade |
| P249 | Time-dependent blood transcriptomic perturbations differentially associated with mono and combination checkpoint inhibitor therapy | Darawan Rinchai, PhD; Emily Hinchcliff, MD; Wouter RL. Hendrickx, PhD; Jessica Roelands, Master; Damien Chaussabel; Davide Bedognetti, MD, PhD; Amir A. Jazaeri, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Gene expression; Immune monitoring |
| P250 | Combination treatment of the oral CHK1 inhibitor, SRA737 and low dose gemcitabine, enhances the effect of PD-L1 blockade by modulating the immune microenvironment in small cell lung cancer. | Triparna Sen, PhD | Checkpoint Blockade Therapy | Checkpoint blockade; Cytokine; Immune monitoring; Targeted therapy |
| P251 | CTX-8371, a novel bispecific targeting both PD-1 and PD-L1, is more potent than combination anti-PD-1 and PD-L1 therapy and provides enhanced protection from tumors in vivo | Diana I. Albu, PhD; Pearl Bakhru; Wilson Guzman, BS; Michael Ophir; Rachel B. McCrory, BS; William Carson; Jason Kong; Beata Bobrowicz; Pia Muyot; Amanda Oliphant; Dalton Markrush; Rachel Rennard; Cheuk Lun Leung; Sara Haserlat; Michael Schmidt; Jose Gonzalo; Bing Gong; Robert Tighe, BS; Diana I. Albu, PhD; Benjamin Wolf; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Coinhibition; T cell |
| P252 | A Retrospective Study to Evaluate Real-World Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma (mRCC) Treated with Ipilimumab and Nivolumab. | Landon C. Brown, MD; Emily N. Kinsey, MD; Chester Kao, MD; Patrick Healy; Andrew J. Armstrong, MD; Megan A. McNamara, MD; Sundhar Ramalingam, MD; Michael R. Harrision, MD; Daniel J. George, MD; Tian Zhang, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Clinical study; Immune toxicity; Solid tumors |
| P253 | Distinct clinical and immunological responses to αPD-1, ⍺PD-L1 and ⍺PD-L2 immunotherapy in B16 melanoma in aged versus young hosts includes T-cell stem cell effects and PD-L2 expression differences | Myrna G. Garcia, BS; Alvaro Padron; Yilun Deng, MD, PhD; Harshita B. Gupta, PhD; Aravind Kancharla; Tyler Curiel, MD; | Checkpoint Blockade Therapy | Antibody; Antigen presenting cells; Checkpoint blockade; Costimulation; Cytokine; Dendritic cell; Myeloid cells; T cell; Tumor infiltrating lymphocytes (TILs) |
| P254 | Requirement of Fc gamma receptor-mediated myeloid-cell activation for effective cancer immunotherapy with an anti-TIGIT antibody | Jin-hwan Han, PhD; Mingmei Cai; Jeffery Grein; Samanthi Perera, PhD; Hongmei Wang; Mike Bigler; Roenna Ueda; Thomas W. Rosahl; Elaine Pinheiro, PhD; Drake LaFace; Wolfgang Seghezzi; Sybil M. Williams, PhD; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Chemokine; Cytokine; Gene expression; Myeloid cells; T cell |
| P255 | Preclinical characterization and efficacy of MG1124, a Novel Immune Checkpoint Blockade targeting CEACAM1 for cancer therapy | Jae-Chul Lee, Master degree; Jae-Chul Lee, Master degree; Minkyu Hur; Hye-Young Park; Mi-Young Oh; Hye-mi Nam; Hye In Yum; HyungSuk Choi; Jaehwan Kim; Byoung Chul Cho, MD.phD; Yangmi Lim; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Coinhibition; Immune suppression; NK/NK T cell; T cell; Targeted therapy |
| P256 | A novel bifunctional anti-PD-1 / IL-7 fusion protein potentiates effector function of exhausted T cell and disarms Treg suppressive activity | Aurore Morello, PhD; justine durand; Caroline Mary; virginie Thepenier; Margaux Seite; Géraldine Teppaz; Nicolas Poirier; | Checkpoint Blockade Therapy | Checkpoint blockade; T cell; Targeted therapy |
| P257 | Obesity is associated with diminished anti-PD-1-based immunotherapy response rates in renal cancer | Rachael M. Orlandella, BS; Shannon Boi; Justin T. Gibson, BS; William J. Turbitt; Gal Wald; Lewis Thomas; Katlyn E. Norris; Lakshminarayanan Nandagopal, MD; Peng Li, PhD; Eddy Yang, MD, PhD; Tatiana T. Marquez-Lago, PhD; Lyse A. Norian, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Myeloid cells; MDSC; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P258 | Combination of NK Cells and anti-PD-L1 Ab with ADCC enhances the anti-tumor effects in PD-L1 high cancer cells | Ji-Eun Park, BS.; Bhumsuk Keam, MD, PhD; Ha-ram Park; Soyeon Kim, PhD; Chan-Young Ock, MD, PhD; Miso Kim; Tae Min Kim, MD, PhD; Dong-Wan Kim, MD PhD; Dae Seog Heo; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; NK/NK T cell; Targeted therapy |
| P259 | Hydrogel-enabled Intratumoral Co-Delivery of Anti-PD-1 Antibody and Adenosine Deaminase in a Mouse Model of Renal Cell Carcinoma | Ngoc B. Pham, BS; Ketki Velankar, MS; Ngoc B. Pham, BS; Wilson Meng, PhD; Ellen S. Gawalt; Nathan R. Schueller; | Checkpoint Blockade Therapy | Checkpoint blockade; Coinhibition; Immune suppression; Metabolism; Regulatory T cell (Treg cell); Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P260 | Characterization of AB154, a Humanized, Non-depleting α-TIGIT Antibody Undergoing Clinical Evaluation in Subjects with Advanced Solid Tumors | Joanne BL. Tan, PhD; Alejandra Lopez, BSc; Joanne BL. Tan, PhD; Amy Anderson, PhD; Akshata Udyavar, Ph.D; Nell Narasappa, MSC.; Susan J. Lee, PhD; Daniel DiRenzo, PhD; Kristen Zhang, BS; Hema Singh; Sharon Zhao; Kimberline Gerrick; Adam Park; Lisa Seitz, MA; Nigel PC. Walker, PhD; Matthew J. Walters, PhD; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Immune contexture; Immune monitoring; Immune suppression; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P261 | Recruitment of CD103+ DCs via tumor stroma-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy | John-Michael Williford, PhD; Jun Ishihara, PhD; Ako Ishihara; Aslan Mansurov, BChen; Tiffany Marchell; Melody Swartz, PhD; Jeffrey Hubbell; | Checkpoint Blockade Therapy | Antibody; Antigen presenting cells; Checkpoint blockade; Chemokine; Dendritic cell; T cell; Targeted therapy; Tumor microenvironment; Tumor stroma |
| P262 | Schweinfurthins Cause Rapid Induction of Ecto-calreticulin Expression | Ruoheng RZ. Zhang, MBBS; Raymond J. Hohl, MD; Jeffrey D. Neighbors, PhD; Ruoheng RZ. Zhang, MBBS; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune adjuvant |
| P263 | Targeting EZH2 enhances antigen presentation, antitumor immunity and circumvents anti-PD-1 resistance in head and neck cancer | Liye Zhou, PhD; Ravindra Uppaluri, MD, PhD; Tenny Mudianto, BS; Xiaojing Ma, PhD; Rachel Riley, BS; | Checkpoint Blockade Therapy | Checkpoint blockade; Chemokine; Immune monitoring; Solid tumors; T cell |
| P264 | Characterization of a human CD137 (4-1BB) receptor binding monoclonal antibody with differential agonist properties that promotes antitumor immunity | Helen Kotanides; Rose Marie Sattler; Maria B. Lebron; Carmine Carpenito, PhD; Juqun Shen; Jingxing Li; David Surguladze; Jaafar N. Haidar; Colleen Burns; Leyi Shen; Ivan Inigo, BS; Anthony L. Pennello; Amelie Forest, MSc; Xinlei Chen; Darin Chin; Andreas Sonyi; Michael Topper; Lauren Boucher; Prachi Sharma; Yiwei Zhang; Douglas Burtrum; Ruslan D. Novosiadly; Dale L. Ludwig; Gregory D. Plowman; Michael D. Kalos; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Costimulation; T cell |
| P265 | Immune checkpoint inhibitors induce response in a dose-dependent manner while their immune related adverse events are dose-independent, a meta-analysis | Osama E. Rahma, MD; Joshua E. Reuss, MD; Anita Giobbie-Hurder, MS; Ghazaleh Razavi, MD; Pooja Mehra, MD; Seema Gupta; Rawad Elias, MD; Samir Khleif, MD; Osama E. Rahma, MD; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Immune toxicity; Solid tumors |
| P266 | Evaluation of Immunomodulatory Receptor/Ligand Expression on Matched Human Biospecimens | Shawn P. Fahl, PhD; | Checkpoint Blockade Therapy | Bioinformatics; Biomarkers; Checkpoint blockade; Gene expression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P267 | Phenotyping of TIGIT pathway members may be used for cancer selection in the clinical application of anti-TIGIT antibody EOS884448 | Noemie Wald, PhD; Julia Cuende, PhD; Marjorie Mercier; Florence Nyawouame, MSc; Margreet Brouwer, MSc; Erica Houthuys, PhD; Gregory Driessens, PhD; Veronique Bodo, PhD; Catherine Hoofd; | Checkpoint Blockade Therapy | Antibody; Biomarkers; Checkpoint blockade; Coinhibition; Costimulation; Immune contexture; Immune suppression; Regulatory T cell (Treg cell); Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P268 | IPH5401 anti-human C5aR antibody targets suppressive myeloid cells in the TME | Joanna Fares; Léa Simon; Caroline Soulas; Marion Loivet; Elodie Bonnet; Luciana Batista; Romain Remark, PhD; Cécile Bonnafous; Robert ZERBIB, MSc; Mathieu Bléry; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Granulocyte; Monocyte/Macrophage; Myeloid cells; MDSC; Tumor microenvironment |
| P269 | IL-15 together with TIGIT blockade reverses PVR-mediated NK cell dysfunction in melanoma. | Joe-Marc JM. Chauvin, PhD; Mignane Ka; Ornella Pagliano; Carmine Menna; Quanquan Ding; Cindy Sander; Jiajie Hou; Soldano Ferrone, MD, PhD; Diwakar Davar, MD; John M. Kirkwood, MD; Robert Johnston, PhD; Alan J. Korman, PhD; Mark J. Smyth; Hassane M. Zarour, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; NK/NK T cell; Tumor microenvironment |
| P270 | Expression and clinical significance of the CD47/SIRPα pathway as a candidate immunotherapy target in non-small cell lung cancer (NSCLC) | Shruti Desai, PhD; Franz Villarroel-Espindola; Patricia Gaule, PhD; Adam Ducler; Marisa Peluso, MS; Benjamin Lee, MD PhD; Pamela Holland, PhD; Kurt A. Schalper, MD, PhD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Myeloid cells; Solid tumors; Tumor infiltrating lymphocytes (TILs) |
| P271 | Anti-SIRPalpha antibodies exert anti-tumor activity in both CD47-dependent and CD47-independent manners | Hongtao Lu, PhD; Xiaofeng Niu, PhD; Qinglin Du, PhD; Jingfeng Yu; Roumei Xing; Yanfen Hu; Jinfeng Zhao; Fengli Wang; Zhihao Wu, PhD; Yangsheng Qiu; Hongtao Lu, PhD; | Checkpoint Blockade Therapy | Antibody; Antigen presenting cells; Checkpoint blockade; Dendritic cell; Monocyte/Macrophage; Myeloid cells; Tumor evasion |
| P272 | SRF231, a fully human high-affinity anti-CD47 antibody, exerts potent preclinical antitumor activity through engagement of the Fc receptor (FcR), CD32a | Marisa Peluso, MS; Kshama Doshi, PhD; Caroline M. Armet, BS; Li Zhang; Rachel W. O'Connor, BS; Matthew P. Rausch, PhD; Jonathan A. Hill, PhD; Benjamin Lee, MD PhD; Pamela Holland, PhD; Vito J. Palombella, PhD; Alison M. Paterson, PhD; | Checkpoint Blockade Therapy | Antibody; Monocyte/Macrophage; Myeloid cells; Targeted therapy |
| P273 | Blockade of glyco-immune checkpoint using EAGLE to potentiate anticancer immunity | Li Peng, PhD; Lizhi Cao; Jenny Che; Abhishek Das, PhD; Sujata Nerle; Wayne Gatlin; Robert Leblanc; Zakir Siddiquee; Hui Xu; Karl Normington, PhD, MBA; Weiguo Yao; James Broderick; Li Peng, PhD; | Checkpoint Blockade Therapy | Antibody; Biomarkers; Checkpoint blockade; Immune suppression; Targeted therapy; Tumor evasion; Tumor microenvironment |
| P274 | Antibody targeting of tumor associated macrophages in pancreatic cancer and melanoma remodel the tumor microenvironment and revives immune targeting of tumor cells | Dhifaf Sarhan, PhD; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Immune suppression; Monocyte/Macrophage; MDSC; NK/NK T cell; Solid tumors; T cell; Targeted therapy; Tumor microenvironment |
| P275 | Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade | Julie E. Stein, MD; Evan J. Lipson, MD; Tricia Cottrell, MD, PhD; Patrick Forde, MD; Robert A. Anders, MD, PhD; Ashley Cimino-Mathews; Elizabeth D. Thompson, MD PhD; Mohamad E. Allaf, MD; Mark Yarchoan; Josephine L. Feliciano, MD; Elizabeth M. Jaffee, MD; Drew M. Pardoll, MD, PhD; Suzanne L. Topalian, MD; Janis M. Taube, MD, MSC; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Solid tumors; Tumor microenvironment |
| P276 | Efficacy of PD-1/PDL-1 Immune Checkpoint Inhibitors in Elderly Patients with Non-Small-Cell Lung Cancer; A Subgroup Meta-analysis of Randomized Controlled Trials | Faisal S. Ali; Maryam R. Hussain; Arafat Farooqui; Syed H. Jafri, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Chemotherapy; Clinical trial; Immune monitoring; Tumor microenvironment |
| P277 | Utility of PD-L1 Expression in Non-Small-Cell Lung Cancer Patients Treated with PD-1/PDL-1 Immune Checkpoint Inhibitors; A Subgroup Meta-analysis of Randomized Controlled Trials | Faisal S. Ali; Maryam R. Hussain; Arafat Farooqui; Syed H. Jafri, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Clinical study; Clinical trial; Immune monitoring; Solid tumors |
| P278 | PD-1/PDL-1 Immune Checkpoint Inhibitors in Smokers with Non-Small-Cell Lung Cancer; A Subgroup Meta-Analysis of Randomized Controlled Trials | Faisal S. Ali; Bibek Pannu; Maryam R. Hussain; Arafat Farooqui; Taha Alrifai; Phyo T. Myint; Syed H. Jafri, MD; | Checkpoint Blockade Therapy | Carcinogenesis; Checkpoint blockade; Chemotherapy; Tumor microenvironment |
| P279 | PDL-1 is highly expressed in ovarian germ cell tumor and associated with cancer stem cells population expressing CD44 | Kholoud Alwosaibai, PhD; Salmah Alamri; Miral Mashhour; | Checkpoint Blockade Therapy | Checkpoint blockade; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P280 | Impact of tumor mutational burden on overall survival in patients with non-small cell lung cancer treated with immunotherapy | Mark Awad, MD PhD; Navin R. Mahadevan; Andrew Polio; Natalie Vokes; Elizabeth J. Aguilar; Biagio Ricciuti, MD; Giuseppe Lamberti, MD; Gonzalo Recondo, MD; Giulia C. Leonardi; Anika Adeni; Pasi A. Janne, MD PhD; Eliezer Van Allen, MD; Adem Albayrak, M.S.; Renato Umeton; Lynette M. Sholl; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade |
| P281 | Durable response after immunotherapy discontinuation: a multicenter real-life experience | Maria Bassanelli, MD, PhD; Diana Giannarelli, MD; Marco Russano; Fabiana Letizia Cecere; Maria Rita Migliorino; Silvana Giacinti; Viola Barucca; Emilio Bria; Enzo Maria Ruggeri; Fabio Calabrò; Alain Gelibter; Daniele Santini; Anna Ceribelli; | Checkpoint Blockade Therapy | Immune toxicity; Solid tumors |
| P282 | Tumor-targeted T-cell Activation via an Investigational PD-L1 x CD137 Bispecific Molecule | Alexey Berezhnoy, PhD; Ling Huang; Daorong Liu; Jennifer DiChiara; Jonathan Li, PhD; Douglas Smith, PhD; Jill R. Rillema, BS; Valentina Ciccarone, PhD; James K. Tamura, PhD; Ralph F. Alderson, PhD; Gundo Diedrich; Ezio Bonvini, PhD; Paul Moore, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Costimulation; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P283 | Generation and Characterization of a PD-1 Resistant Mouse Tumor Model | Marie Bernardo, PhD; Tatiana Tolstykh; Yu-An Zhang; Dinesh Bangari; Hui Cao, PhD; Joon Sang Lee, PhD; Natalia Malkova; Jack Pollard, PhD; Fangxian Sun; Dmitri Wiederschain; Timothy Wagenaar; | Checkpoint Blockade Therapy | Checkpoint blockade; Gene expression; Tumor microenvironment |
| P284 | Pitfalls in preclinical development of immunotherapies for ER+ breast cancer: estrogen as an immunomodulator potentially influencing pembrolizumab efficacy in a breast cancer model in humanized mice | Tiina E. Kähkönen; Mari I. Suominen; Jenni HE. Mäki-Jouppila; Emrah Yatkin; Philip Dube; Azusa Tanaka; Jussi M. Halleen; Jenni Bernoulli, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune suppression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P285 | Integrated Molecular Characterization of primary resistance mechanisms to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Carcinoma (a-NSCLC) | Benjamin Besse, MD PhD; Caroline Fraslon, PhD; Hui Cao, PhD; Joon Sang Lee, PhD; Stephanie Malyszka, MS; Marielle Chiron, PhD; Anne Caron, PhD; Souâd Naimi, PhD; Laura Mezquita, MD; David Planchard, MD, PhD; Jean-Yves Scoazec, MD; Ludovic Lacroix, PharmD; Etienne Rouleau, MD; Naima Imam-Sghiouar, PhD; Aurélien Marabelle, MD PhD; Eric Angevin, MD; Christophe Massard, MD; Jack Pollard, PhD; | Checkpoint Blockade Therapy | Bioinformatics; Checkpoint blockade; Gene expression; Immune contexture; Myeloid cells; Solid tumors; Systems biology; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P286 | In vivo genetic screens in PD-1 resistant mouse models identified modulators of anti-PD1 response with relevance to pembrolizumab-treated human metastatic melanoma | Aurélie Docquier, PhD; Cécile Déjou; Gilles Alberici; Armand Bensussan, PhD; Jeremy Bastid; Nathalie Bonnefoy, PhD; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Immune suppression |
| P287 | A novel bispecific checkpoint inhibitor antibody to preferentially block PD-1 and LAG-3 on dysfunctional TILs whilst sparing Treg activation | Laura Codarri Deak; Patrick A. Weber, Mr.; Stefan Seeber, Dr.; Mario Perro, Dr.; Xavier Miot, Mr.; Heidi Poulet, Mrs.; Iryna Dekhtiarenko, Dr.; Matthias Füth; Henry Kao, Dr.; Christine McIntyre, Dr.; Francesca Michielin, Dr.; Christian Klein, Dr rer nat; Pablo Umana, PhD; Lin-Chi Chen, Dr.; Christoph Markert, Dr.; Merlind Mücke, Dr.; | Checkpoint Blockade Therapy | Checkpoint blockade; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion |
| P288 | CCR5+CTLA4+ Treg cell subset characterizes renal tumors (RCC) immunosuppressed by PD1 blockade | Agathe Dubuisson; Charles Bayard; Sebastien Lofek; Nicolas Voisin; Séverine Mouraud; Delphine Bredel; Sandrine Susini; Mathieu Rouanne, MD; Hervé Beaumert; Bastien Parier; Aurélien Marabelle, MD PhD; Laurence Zitvogel, MD, PhD; Mélodie Bonvalet; | Checkpoint Blockade Therapy | Biomarkers; Chemokine; Immune monitoring; Immune suppression; Regulatory T cell (Treg cell); Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P289 | Macrophages modulate patient response to immune checkpoint inhibition in a novel lung tumour explant model | Lauren Evans, BSc, MSc; Kate Milward, DPhil; Richard Attanoos, BSc, MB BS, FRCPath; Aled Clayton, PhD; Rachel Errington, PhD; Zsuzsanna Tabi, PhD; | Checkpoint Blockade Therapy | Antigen presenting cells; Checkpoint blockade; Immune suppression; Monocyte/Macrophage; Myeloid cells; Solid tumors; T cell; Tumor microenvironment |
| P290 | Interferon Gamma Production by Regulatory T cells is Necessary for Response to Cancer Immunotherapy | Angela M. Gocher, PhD; Dario A. Vignali, PhD; Creg Workman, PhD; Sanah Handu; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Cytokine; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine |
| P291 | Driving T cell dysfunction in vitro for rational immunotherapy design | Matthew Hancock; Cailin CJ. Joyce, PhD; Thomas Horn; Simarjot Pabla; Benjamin Duckless; Andrew Basinski; Dhan Chand, PhD; Jeremy D. Waight, PhD; Mariana Manrique, PhD; Nicholas S. Wilson; Alex Duncan, PhD; Jennifer S. Buell, PhD; David Savitsky, PhD; Lukasz Swiech; John C. Castle, PhD | Checkpoint Blockade Therapy | Bioinformatics; Checkpoint blockade; Gene expression; Systems biology; T cell; Tumor evasion; Tumor microenvironment |
| P292 | Tissue site of tumor growth dictates anti-tumor immunity and response to checkpoint blockade | Brendan L. Horton, PhD; Stefani Spranger, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune suppression; Tumor microenvironment |
| P293 | Tumor mutational burden (TMB) and genomic predictors of clinical outcomes to PD-1/PD-L1 checkpoint blockade in high-grade gliomas | Bryan Iorgulescu, MD; Mehdi Touat; Yvonne Li; Liam Spurr; Gareth Grant; William Pisano; Mary Jane Lim-Fat; Eudocia Lee; Lakshmi Nayak; E Chiocca; Raymond Huang; Andrew Cherniack; Patrick Wen; Ahmed Idbaih; Franck Bielle; David A. Reardon, MD; Keith Ligon; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Clinical study |
| P294 | Long survival associated with receipt of anti-CTLA-4 in patients with metastatic melanoma from acral lentiginous, mucosal and uveal primary tumors | Nicholas D. Klemen, MD; Melinda Wang, BS; Kelly Olino, MD; James Clune, MD; Stephan Ariyan, MD; Charles Cha, MD; Sarah A. Weiss, MD; Harriet Kluger, MD; Mario Sznol, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Clinical study; Neoantigens; Surgery; Tumor antigens; Tumor evasion |
| P295 | The impact of metastatic sites on checkpoint inhibitor outcomes in patients with cutaneous and unknown primary melanoma | Penina P. Krieger, MPhil; Francisco Sanchez-Vega; Nikolaus Schultz; Alexander N. Shoushtari, MD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade |
| P296 | BMI, irAE and gene expression signatures predict resistance and survival to immune-checkpoint inhibition in renal cell carcinoma | Brian W. Labadie, MD; Ping Liu, PhD; Riyue Bao, PhD; Michael Crist, MD; Ricardo Fernandes, MD; Laura Ferreira Freire; Scott Graupner; Andrew Poklepovic, MD; Ignacio Duran; Saman Maleki Vareki; Arjun V. Balar, MD; Jason J. Luke, MD, FACP; | Checkpoint Blockade Therapy | Angiogenesis; Biomarkers; Checkpoint blockade; Solid tumors; Systems biology; Targeted therapy; Tumor microenvironment |
| P297 | A semi-mechanistic platform model to capture individual animal responses to checkpoint inhibitors in a syngeneic mouse model | Lin Lin, PhD; Alison Betts; Carissa L. Young; Wendy Qiao; Jatin Narula; Peter O’Brien; Derek Bartlett; Andrea Hooper; Jason Williams; John Burke; Joshua Apgar; Lore Gruenbaum, PhD; Fei Hua, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Regulatory T cell (Treg cell); Solid tumors; Systems biology; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P298 | PBRM1 loss defines distinct tumor phenotype associated with immunotherapy resistance in renal cell carcinoma | Xiande Liu, Ph.D; Wen Kong; Christine B. Peterson; Daniel J. McGrail; Anh Hoang; Xuesong Zhang; Truong Lam; Patrick G. Pilie, MD; Haifeng Zhu, PhD; Kathryn E. Beckermann; Scott M. Haake; Sevinj Isgandrova; Margarita Martinez-Moczygemba; Nidhi Sahni; W. Kimryn Rathmell; Eric Jonasch, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune suppression; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P299 | Neuropilin-1 is a T cell memory checkpoint limiting long-term tumor immunity | Chang Liu, PhD; Ashwin Somasundaram, MD; Sasikanth Manne; Angela M. Gocher, PhD; Andrea L. Szymczak-workman; Kate M. Vignali; Daniel P. Normolle, PhD; Robert L. Ferris, MD, PhD; Tullia C. Bruno, PhD; E. John Wherry, PhD; Creg Workman, PhD; Dario A. Vignali, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs) |
| P300 | Real World data analysis related to metastatic melanoma patients treated with immunotherapy from 2012 to 2018 at Istituto Nazionale Tumori IRCCS Fondazione “G. Pascale” of Napoli, Italy | Gabriele Madonna; Mariaelena Capone, MD; Marilena Tuffanelli; Marcello Curvietto, PhD; Miriam Paone, PhD; Assunta Esposito, PhD; Antonio Sorrentino; Marco Palla; Luigi Scarpato; Domenico Mallardo, MD; Ester Simeone, MD; Antonio M. Grimaldi, MD; Kristina Viktorsson; Lisa Villabona; Rolf Lewensohn; Giuseppe V. Masucci, MD, PhD; Paolo Antonio A. Ascierto, MD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Solid tumors; Targeted therapy |
| P301 | Expression of tumor matrix metalloproteases ADAM10 and ADAM17 correlates with low PD-L1 protein-to-mRNA ratio in multiple tumors, predicting poor outcomes. | Jacob Orme, MD PhD; Aaron Mansfield, MD; Jacob Orme, MD PhD; Jacob Orme, MD PhD; Roxana Dronca, MD; Haidong Dong, MD, PhD; | Checkpoint Blockade Therapy | Bioinformatics; Biomarkers; Checkpoint blockade; Gene expression; Immune suppression; Proteomics; Tumor microenvironment |
| P302 | A Reversible T Cell Exhaustion-Like In Vitro Assay to Screen Candidate Drugs | Wushouer Ouerkaxi; Eden Kleiman; Pirouz M. Daftarian; Wushouer Ouerkaxi; | Checkpoint Blockade Therapy | Antibody; Antigen presenting cells; Autoimmunity; Checkpoint blockade; Immune monitoring; Immune tolerance; T cell; Tumor evasion |
| P303 | PD-1 checkpoint blockade in advanced melanoma patients: Neutrophils, NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates | Yago Pico de Coaña; Maria Wolodarski, MD; Irene van der Haar Àvila; Takahiro Nakajima; Stamatina Rentouli; Andreas Lundqvist, PhD; Giuseppe V. Masucci, MD, PhD; Johan Hansson; Rolf Kiessling, MD, PhD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Monocyte/Macrophage; Myeloid cells; MDSC; NK/NK T cell |
| P304 | DNA damage response gene alterations are associated with high tumor mutational burden and clinical benefit from programmed death 1 axis inhibition in non-small cell lung cancer | Biagio Ricciuti, MD; Gonzalo Recondo, MD; Renato Umeton; Giuseppe Lamberti, MD; Mizuki Nishino; Lynette M. Sholl; Michael Cheng; Mark Awad, MD PhD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade |
| P305 | Response to Pembrolizumab and tumor microenvironment composition is associated with IL8 expression in a head and neck squamous-cell carcinoma cohort | Arun Khattri, PhD; Jason W. Reeves; SuFey Ong; Riyue Bao, PhD; Arya Bahrami, PhD; Yi-Hung Carol Tan, PhD; Andrew M. White, BSc; Michael P. Bailey; Heather A. Brauer, PhD; Sarah Warren, PhD; Joseph M. Beechem, PhD; Tanguy Seiwert, MD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Gene expression; Myeloid cells; MDSC; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P306 | Innate immune cells play a role in therapy resistance to anti-PD1 in Hu-mice melanoma model. | Raj Somasundaram, PhD; Meenhard Herlyn, DVM PhD; Raj Somasundaram, PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Tumor microenvironment |
| P307 | The impact of Metformin (M) on the response rates of checkpoint Inhibitors (CPI) | Philip A. Haddad, MD, MPH; David Sommerhalder, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Solid tumors; Tumor microenvironment |
| P308 | The impact of obesity on the response rates of checkpoint Inhibitor (CPI) cancer immunotherapy | Philip A. Haddad, MD, MPH; David Sommerhalder, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Clinical study; Solid tumors; Tumor microenvironment |
| P309 | Older age predicts better outcome to neoadjuvant immune checkpoint blockade in metastatic melanoma | Rohit Thakur; Rohit Thakur; Stephen Douglass, PhD; Beth Helmink, MD PhD; Rodabe N. Amaria, MD; Hussein A. Tawbi, MD, PhD; Jennifer McQuade; Eliza Rozeman; Elizabeth Burton; Sangeetha M. Reddy, MD, MSci; John Wherry; Christian Blank, MD PhD; Georgina Long; Jeffrey E. Gershenwald, MD; Michael Davies, MD, PhD; Michael T. Tetzlaff, MD PhD; Ashani Weeraratna; Jennifer A. Wargo, MD, MMSc; | Checkpoint Blockade Therapy | Antigen presenting cells; Checkpoint blockade; Tumor antigens; Tumor evasion; Tumor microenvironment |
| P310 | Optimal priming prevents the induction of dysfunctional CD8 T-cells in subprimed conditions, reversing resistance to anti-PD-1. | Vivek Verma, PhD; Rahul Nandre, PhD; Jose Lopez; Seema Gupta, PhD; Samir N. Khleif, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Solid tumors; T cell; Tumor microenvironment; Vaccine |
| P311 | Dual antagonism of prostaglandin receptors EP2 and EP4 by TPST-1495 suppresses tumor growth and stimulates anti-tumor immunity | Chan C. Whiting, PhD; Kim Fischer, PhD; Bryan Laffitte, PhD; Lisa Rahbaek, PhD; Nick Stock, PhD; Davorka Messmer, PhD; Austin Chen, PhD; Traci Olafson; Natalie Nguyen; Amanda Enstrom, PhD; Derek Metzger; Brian Francica; Dingzhi Wang, PhD; Raymond Dubois, PhD, MD; Ginna G. Laport, MD; Peppi Prasit, PhD; Thomas W. Dubensky, Jr., PhD; | Checkpoint Blockade Therapy | Checkpoint blockade; Dendritic cell; Immune suppression; Inflammation; Monocyte/Macrophage; Myeloid cells; Metabolism; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P312 | Ipilimumab treatment immunophenotypic changes are associated with progression of disease with sequential nivolumab therapy in metastatic melanoma | David M. Woods, PhD; Andressa Sodre Laino, PhD; Aidan Winters; Jason Alexandre; Jeffrey S. Weber, MD, PhD; Pratip Chattopadhyay; David M. Woods, PhD; | Checkpoint Blockade Therapy | Bioinformatics; Biomarkers; Checkpoint blockade; T cell |
| P313 | Single-cell secretome assessment of metastatic melanoma patient peripheral T-cells reveals a pharmacokinetic signature of patient response to nivolumab therapy. | David M. Woods, PhD; Andressa Sodre de Castro Laino; Daniel Freeman; Jeffrey S. Weber, MD, PhD; Pratip Chattopadhyay; | Checkpoint Blockade Therapy | Bioinformatics; Biomarkers; Checkpoint blockade; Cytokine; T cell |
| P314 | Alterations of DNA damage response signaling in the development of antibody-dependent cellular cytotoxicity (ADCC) resistance | Yongwei Zhang; Louis M. Weiner, MD; Yongwei ZHANG; Dalal Aldeghaither; David Zahavi, MS, BS; | Checkpoint Blockade Therapy | Adoptive immunotherapy; Antibody; Biomarkers; Checkpoint blockade; Chemotherapy; Gene expression; Neoantigens; NK/NK T cell; Solid tumors; Targeted therapy |
| P315 | The expression of programmed death ligand 2 (PD-L2) in immunosuppressive tumor microenvironment of non-small cell lung cancer (NSCLC) and its potential association with immunotherapy | Qu Zhang, PhD; Stefan Bentink; Vinay Pawar; Farzad Sekhavati, PhD; Keith E. Steele, DVM, PhD; Jason Hipp; Song Wu, PhD; | Checkpoint Blockade Therapy | Biomarkers; Clinical trial; Gene expression; Immune suppression; T cell; Tumor microenvironment |
| P316 | MG1131, a novel TIGIT-targeted monoclonal antibody, induces T cell activation and anti-tumor immune response and suppresses Treg cell activity | Hyemi Nam, MS; Hye-Young Park; Eun Jung Song; Eunhee Lee; Hye In Yum; Munkyung Kim; Jeewon Lee, Ph D; So Jung Lim; Okjae Lim; Yangmi Lim; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Immune suppression; Regulatory T cell (Treg cell); T cell; Tumor microenvironment |
| P317 | Utilization of Second-Line Immuno-Oncology Agents and Associated Health Outcomes Among United States Veterans with Advanced Non-Small Cell Lung Cancer | Mina A. Allo, PharmD, MPH; Lin Gu, MS; Vishal Vashistha, MD; Ashlyn Press, MPH; Michael J. Kelley, MD; Christina Williams, PHD, MPH; Mina A. Allo, PharmD, MPH; | Checkpoint Blockade Therapy | Checkpoint blockade; Chemotherapy; Epidemiology |
| P318 | Large-scale evaluation of concordance of genomic scores in whole exome sequencing and Foundation Medicine comprehensive genomic platform across cancer types | Deepti Aurora-Garg; Andrew Albright, PhD; Ping Qiu, PhD; Yongjin Li; Xiaoqiao Liu; David Fabrizio, PhD; Lixin Lang; Jared Lunceford, PhD; Razvan Cristescu, PhD; | Checkpoint Blockade Therapy | Biomarkers; Checkpoint blockade; Solid tumors |
| P319 | Changes in Fatigue Severity, Health Related, and Dermatology Related Quality of Life in Melanoma Patients Receiving Nivolumab: Preliminary Results of a Prospective Study from Real-life Experience | Canan Karadas; Nur Izgu, PhD, RN; Zehra Gok Metin, Assoc Prof, PhD, RN; Canan Porucu, MSc, RN; Nuri Karadurmus, Prof. Dr, MD; Sadettin Kilickap, Prof. Dr, MD; Umut Demirci, MD; | Checkpoint Blockade Therapy | Checkpoint blockade; Targeted therapy |
| P320 | Novel in vivo preclinical humanized models for the evaluation of human specific immune checkpoint inhibitors | Anya Avrutskaya; Fabienne Sonego; Jacob Hauser; Emily O’Koren; Robin Ball; Gaëlle Martin; Julie Chaix; Thi Bui; Ian Belle; Elizabeth Reap; Patrick Fadden, PhD; Chassidy Hall; Kader Thiam; Paula Miliani de Marval; | Checkpoint Blockade Therapy | Checkpoint blockade; Tumor infiltrating lymphocytes (TILs) |
| P321 | Real-world clinical outcomes among patients with advanced non-small cell lung cancer who initiated first-line regimens | Eric Nadler, MD; Eric Nadler, MD; Bhakti Arondekar, PhD; Kathleen M. Aguilar; Jie Zhou; Jane Chang; Xinke Zhang; Vivek Pawar; | Checkpoint blockade therapy | Checkpoint blockade; Chemotherapy; Clinical study; Solid tumors; Targeted therapy |
| P322 | COM902, a Novel Therapeutic Antibody Targeting TIGIT Augments T Cell Function and the Activity of PVRIG Pathway Blockade In Vitro and In Vivo | Maya Kotturi, BS, PhD; Eran Ophir, PhD; Eran Ophir, PhD; Sarah Whelan, PhD; Spencer Liang; Kathryn Logronio, BS PhD; Kyle Hansen, BS; Zoya Alteber, PhD; Mark White, BS, PhD; | Checkpoint Blockade Therapy | Antibody; Checkpoint blockade; Coinhibition; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P323 | IPH5301, a CD73 blocking antibody targeting the adenosine immunosuppressive pathway for cancer immunotherapy. | Ivan Perrot; Caroline Denis, PhD; Marc Giraudon-Paoli; Severine Augier; Rachel Courtois; Diana Jecko; Violette Breso; Thomas Arnoux; Nicolas Gourdin, PhD; Romain Remark, PhD; Cecile Bonnafous; Ariane Morel, PhD; Eric Vivier; Yannis Morel, PhD; Pascale Andre; Carine Paturel, PhD; | Checkpoint Blockade Therapy | Antibody; Immune suppression; Solid tumors; T cell; Tumor microenvironment |
| P324 | Pan-tumor analysis of the association of cancer and immune biology-related gene expression signatures with response to pembrolizumab monotherapy | Razvan Cristescu, PhD; Michael Nebozhyn, PhD; Chunsheng Zhang, PhD; Andrew Albright, PhD; Julie Kobie, PhD; Lingkang Huang; Qing Zhao, MD PhD; Anran Wang; Hua Ma; Andrea Webber; Petar Jelinic; Mohini Rajasagi; Sandra C. Souza; Raluca Predoiu; Z. Alexander Cao; Junshui Ma; Michael Morrissey; Clemens Krepler, MD; Stephen Keefe; Jonathan Cheng, MD; Vassiliki Karantza; Sukrut Shah; Rodolfo Perini, MD; Antoni Ribas, MD, PhD; Petros Grivas, MD, PhD; David Cescon; Terrill K. McClanahan, PhD; Alexandra Snyder, MD; Mark Ayers, PhD; Jared Lunceford, PhD; Andrey Loboda, PhD; | Clinical Trial Completed | Angiogenesis; Biomarkers; Checkpoint blockade; Clinical study; Gene expression; Immune suppression; Solid tumors; Tumor microenvironment; Tumor stroma |
| P325 | Tumor Infiltrating Lymphocytes (TILs) in triple-negative breast cancer: High Immunoscore is associated with pathological CR in patients receiving neoadjuvant chemotherapy. | Bernardo L. Rapoport, MD; Simon Nayler; Jerome Galon, Dr; T Mlecnik; Teresa Smit; Jacqui Barnard-Tidy; Aurelie Fugon; Marine Martel; Ronald Anderson, Professor; Carol Benn; | Clinical Trial Completed | Chemotherapy; Clinical study; Immunoscore; T cell; Tumor infiltrating lymphocytes (TILs) |
| P326 | A Retrospective Analysis of DNA Plasmid and Peptide-Based Vaccine Therapy in Treatment of HER-2/neu+ Breast Cancer | Aaron W. Stewart, BS; William R. Gwin, MD; Mary L. Disis, MD, FACP; Jennifer S. Childs; James Y. Dai; Doreen M. Higgins, RN, BSN, OCN; Angela Kask; | Clinical Trial Completed | Clinical trial; Targeted therapy; Tumor antigens; Vaccine |
| P327 | Evaluation of PD-L1 and cutoff selection to define a predictive biomarker for pembrolizumab monotherapy in esophageal cancer using KEYNOTE-180 | Mary Savage; Serafino Pantano; Qi Liu; Jared Lunceford, PhD; Peter Kang; Pooja Bhagia, MBBS, MD; Kenneth Emancipator, MD; | Clinical Trial Completed | Biomarkers; Checkpoint blockade; Solid tumors |
| P328 | A phase IIB study of Pembrolizumab plus BL-8040 in metastatic pancreatic cancer: Clinical outcomes and biological correlates. | David R. Fogelman, MD; Michael Overman, MD; Robert Wolff; Milind Javle, MD; Shubham Pant, MBBS; Gauri Varadhachary; Rachna T. Shroff; Ignacio Wistuba, MD; Carmelia M. Barreto, PhD; Renganayaki K. Pandurengan, MS; Sandesh Subramanya, PhD; Debora A. Ledesma, PhD; Abi Vainstein-Haras, MD; Ella Sorani, PhD; Tzipora M. Lustig; Osnat Kashtan; Yosi Gozlan; Steven M. Townson, PhD; Jeanne M. Fahey, PhD; James Yao, MD; | Clinical Trial Completed | Antibody; Checkpoint blockade; Chemokine; Clinical trial; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P329 | PolyPEPI1018 off-the shelf vaccine as add-on to maintenance therapy achieved durable treatment responses in patients with microsatellite-stable metastatic colorectal cancer patients (MSS mCRC) | Joleen M. Hubbard, MD; Chiara Cremolini, MD; Rondell Graham, MD; Roberto Moretto, MD; Jessica Mitchell, CNP; Jaclynn Wessling; Eniko Toke; Zsolt Csiszovszki, PhD; Orsolya Lorincz; Levente Molnár; Eszter Somogyi; Mónika Megyesi; Kata Pántya; József Tóth; Péter Páles; István Miklós; Alfredo Falcone, MD; Joleen M. Hubbard, MD | Clinical Trial Completed | Clinical trial; Solid tumors; Vaccine |
| P330 | Results from the completed dose-escalation of the alloSHRINK phase I study evaluating the allogeneic NKG2D-based CAR T-cell therapy CYAD-101 in metastatic colorectal cancer patients | Hans Prenen, MD; Marika Rasschaert, MD; Alain Hendlisz, MD; Leila Shaza, MD; Erik Alcantar-Orozco, MD, PhD; Emilie Cerf, PhD; Florence Renard; Caroline Lonez, PhD; Anne Flament; Jeroen Dekervel, MD; Eric Van Cutsem, MD, PhD; | Clinical Trial Completed | Adoptive immunotherapy; CAR T cells; Chemotherapy; Clinical study; Solid tumors |
| P331 | Results from the completed dose-escalation phase I SHRINK study evaluating the autologous NKG2D-based CAR T-cell therapy CYAD-01 in metastatic colorectal cancer patients | Leila Shaza, MD; Alain Hendlisz, MD; Ahmad Awada, MD, PhD; Jean-Luc Canon, MD; Javier Carrasco; Eric Van Cutsem, MD, PhD; Jeroen Dekervel, MD; Erik Alcantar-Orozco, MD, PhD; Florence Renard; Emilie Cerf, PhD; Caroline Lonez, PhD; Anne Flament; Marc Van den Eynde, MD; Jean-Pascal Machiels, MD, PhD; | Clinical Trial Completed | Adoptive immunotherapy; CAR T cells; Chemotherapy; Clinical study; Solid tumors |
| P332 | Cancer vaccine against prostate cancer antigen TARP induces antigen-specific CD8+ T cells with upregulation of activation marker PD1 in patients with decreased PSA velocity in D0 prostate cancer. | Hoyoung M. Maeng, MD; Brittni Moore; Lauren V. Wood, MD; Seth Steinberg; Katherine McKinnon, MS; Masaki Terabe, PhD; Purevdorj Olkhanud; Ira H. Pastan, MD; Jay A. Berzofsky, MD, PhD; | Clinical Trial Completed | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; T cell; Targeted therapy; Tumor antigens; Vaccine |
| P333 | Timed anti-tumor vaccination during chemotherapy induces strong T-cell immunity and prolonged survival of late stage cervical cancer patients. | Marij J. Schoenmaekers-Welters, PhD; Marij JP. Welters, PhD; Cornelis J. Melief, MD, PhD; Ignace Vergrote; Judith Kroep, MD, PhD; Gemma G. Kenter, MD,PhD; Nelleke Ottevanger; Wiebren AA. Tjalma; Hannelore Denys; Mariette van Poelgeest, MD, PhD; Hans Nijman; Anna KL. Reyners; Thierry Velu; Frederic Goffin; Roy I. Lalisang; Nikki M. Loof; Sanne Boekestijn; Willem Jan Krebber; Leon Hooftman; Sonja Visscher; Brent A. Blumenstein, PhD; Richard B. Stead; Winald R. Gerritsen; Sjoerd H. van der Burg, PhD; | Clinical Trial Completed | Biomarkers; Clinical study; Clinical trial; Cytokine; Immune monitoring; Solid tumors; T cell; Targeted therapy; Tumor antigens; Vaccine |
| P334 | Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Safety results of a phase I/II study | Christine H. Chung, MD; Marcelo Bonomi, MD; Conor Steuer, MD; Michael Schell; Jiannong Li; Matthew Johnson; Caitlin McMullen; J. Trad Wadsworth; Krupal Patel; Julie A. Kish, MD; Jameel Muzaffar, MD; Kedar Kirtane; James Rocco; Nabil F. Saba, MD; | Clinical Trial Completed | Checkpoint blockade; Clinical trial; Targeted therapy |
| P335 | The tumor immune microenvironment and its association with pCR in NRG Oncology/NSABP B-52: Quantification of PD-1, PD-L1, CD8, FOXP3, and CD68 by multiplex fluorescent-immunohistochemistry | Marion E. Joy, PhD; Ying Wang; Rim S. Kim; Nan Song; Ashok Srinivasan; Huichen Feng; Corey Lipchik; Reena S. Cecchini; Samuel A. Jacobs; Joseph P. Costantino; Sandra M. Swain; Eleftherios P. Mamounas; Priya Rastogi; Soonmyung Paik; C. Kent Osborne; Norman Wolmark; Peter C. Lucas; Mothaffar F. Rimawi; Katherine L. Pogue-Geile; | Clinical Trial Completed | Bioinformatics; Checkpoint blockade; Clinical study; Clinical trial; Monocyte/Macrophage; T cell; Tumor microenvironment |
| P336 | Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with acute lymphoblastic leukemia | Amita Kulshrestha; Haneen Shalabi, Do; Vandana Sachdev; Douglas R. Rosing; Stanislav Sidenko; Crystal L. Mackall, MD; Brandon Wiley; Daniel W. Lee; Nirali N. Shah; | Clinical Trial Completed | Adoptive immunotherapy; CAR T cells; Immune monitoring; Pediatric tumors; T cell |
| P337 | Survival prolongation by dendritic cell vaccination in combination with OK-432, gemcitabine and/or S-1 in patients with advanced pancreatic cancer | Masahiro Ogasawara, MD, PhD; Shuichi Ota, MD PhD; | Clinical Trial Completed | Clinical trial; Dendritic cell; Tumor antigens; Vaccine |
| P338 | 2-year follow-up from JAVELIN Lung 200, an open-label, randomized, phase 3 study of avelumab vs docetaxel in patients with platinum-treated advanced non-small cell lung cancer (NSCLC) | Fabrice Barlesi, MD, PhD; Mustafa Özgüroglu; Johan Vansteenkiste; David Spigel; James Yang; Hidenobu Ishii; Marina Garassino; Filippo de Marinis; Aleksandra Szczesna; Andreas Polychronis; Ruchan Uslu; Maciej Krzakowski; Jong-Seok Lee; Luana Calabro, MD; Osvaldo Aren Frontera; Barbara Ellers-Lenz; Marcis Bajars; Mary Ruisi; Keunchil Park; | Clinical Trial Completed | Checkpoint blockade; Clinical trial; Solid tumors; Targeted therapy |
| P339 | Survival is improved by antigen-specific cytotoxic T lymphocytes (CTL) responses after treatment with the vaccine Tedopi in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients | Benjamin Besse, MD PhD; Enriqueta Felip, MD PhD; Giuseppe Giaccone; Rafal Dziadziuszko; Elisabeth Quoix, MD; Werner Hilgers; Federico Cappuzzo; Christophe Borg; Jordi Remon; Nicolas Poirier; Dominique Costantini; Bérangère Vasseur; Santiago Viteri; | Clinical Trial Completed | Antigen presenting cells; Biomarkers; Clinical study; Clinical trial; Immune monitoring; Neoantigens; Solid tumors; T cell; Tumor antigens; Vaccine |
| P340 | Region-focused Deep Survival Learning on PD-L1 stained Tissue Samples for Data-driven Stratification of Durvalumab-treated NSCLC Patients | Nicolas Brieu, PhD; Ansh Kapil; Armin Meier, PhD; Keith E. Steele, DVM, PhD; Marlon C. Rebelatto, DVM, PhD, DACVP; Guenter Schmidt, PhD; | Clinical Trial Completed | Bioinformatics; Biomarkers; Checkpoint blockade; Immune contexture |
| P341 | Activation of toll-like receptors via PS-targeting monoclonal antibodies | Rolf A. Brekken, PhD; | Clinical Trial Completed | Angiogenesis; Antibody; Checkpoint blockade; Clinical study; Immune adjuvant; Immune suppression; MDSC; Tumor infiltrating lymphocytes (TILs); TLR; Tumor microenvironment |
| P342 | Long term outcomes of a Phase I Study with UV1, a Second Generation Telomerase Based Vaccine, in Patients with advanced Non-Small Cell Lung Cancer | Wenche Rasch, PhD; Paal F. Brunsvig, MD PhD; Martha Nyakas, MD; Clau Reisse, MD; Jon Amund Kyte; Hedvig Vidarsdotter Juul; Steinar Aamdal; Gustav Gaudernack, PhD; Else Marit Inderberg; | Clinical Trial Completed | Clinical study; Immune monitoring; Solid tumors; Tumor antigens; Vaccine |
| P343 | Initial results from a Phase II study (TACTI-002) in non-small cell lung cancer, or head and neck cancer patients receiving eftilagimod alpha (LAG-3 fusion protein) and pembrolizumab | Julio Peguero, MD; Enriqueta Felip, MD PhD; Bernard Doger; Margarita Majem; Enric Carcereny; Tim Clay; Pawan Bajaj; Matthew G. Krebs, MD PhD; Frederic Triebel, MD, PhD; | Clinical Trial Completed | Checkpoint blockade; Clinical study; Clinical trial; Costimulation; Dendritic cell; Monocyte/Macrophage |
| P344 | A randomized multi-center phase 2 study of combined PD-L1/CTLA-4 inhibition with or without radiation in non-small cell lung cancer patients who progressed on PD-(L)1 directed therapy: ETCTN 10021 | Arta M. Monjazeb, MD, PhD; Anita Giobbie-Hurder, MS; Ana Lako; Mark Awad, MD PhD; Ryan D. Gentzler, MD; Carrie Lee; Joleen Hubbard; James L. Abbruzzese, MD; Salma K. Jabbour, MD; Nataliya Uboha; Kevin Stephans; Jennifer Johnson, MD; Haeseong Park; Liza C. Villaruz, MD; Katrina Kao; Elad Sharon, MD, MPH; David Raben, MD; Raymond Mak; Howard Streicher, MD; Helen Chen, MD; Mansoor M. Ahmed, PhD; Scott J. Rodig, MD, PhD; F. Stephen Hodi, Jr., MD; Jonathan Schoenfeld, MD, MPH; | Clinical Trial Completed | Checkpoint blockade; Clinical study; Clinical trial; Radiotherapy |
| P345 | PARP inhibition when combined with PD-L1 inhibition has a suppressive effect on T cells in patients with relapsed or recurrent small cell lung cancer | Nobuyuki Takahashi, MD, PhD; Vinodh N. Rajapakse; Min-Jung Lee; Akira Yuno; Sunmin Lee; Sehyun Kim; Rasa Vilimas; Samantha Nichols; Jane B. Trepel; Anish Thomas; | Clinical Trial Completed | Checkpoint blockade; Clinical study; Clinical trial; Immune monitoring; Immune suppression; Regulatory T cell (Treg cell); Solid tumors; T cell |
| P346 | Comparison of TMEs from melanoma and NSCLC patients refractory or resistant to anti–PD-(L)1 therapies | George Locke; Cherie Taglienti, PhD; Laureen S. Ojalvo; Christoph Helwig, MSc; Alex Rolfe; Olaf Christensen; Isabelle Dussault, PhD; Isabelle Dussault, PhD; | Clinical Trial Completed | Antibody; Biomarkers; Checkpoint blockade; Gene expression; Immune contexture; Immune suppression; T cell; Tumor antigens; Tumor microenvironment |
| P347 | Immunomodulation in tumor and peripheral blood following Toca 511 & Toca FC treatment in patients with solid tumors | Gerald S. Falchook, MD; Jordi Rodon; Shree Venkat; Arthur Donahue; Peder Horner; Amber Thomassen; William Accomando; Maria Rodriquez-Aguirre; Cornelia Bentley; Daniel Hogan; Derek Ostertag; Sharon Yavrom; Thian Khoeh; Douglas Jolly, PhD; Harry Gruber, MD; Jolene S. Shorr; Jaime Merchan; | Clinical Trial Completed | B cell; Clinical trial; Immune monitoring; Immune suppression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P348 | A Phase 1 Dose Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies | Aparna Hegde, MD; Priyamvada Jayaprakash, PhD; Elizabeth Sumner; Di Nguyen; Hira Zain; Sarina A. Piha-Paul, MD; Daniel Karp; Jordi Rodon; Shubham Pant, MBBS; Siqing Fu, MD, PhD; Ecaterina I. Dumbrava, MD; Timothy A. Yap, MD PhD; Vivek Subbiah, MD; Priya Bhosale, MD; Jack P. Higgins, PhD; Eric T. Williams; Thomas F. Wilson; Funda Meric-Bernstam, MD; Michael A. Curran, PhD; David S. Hong, MD; | Clinical Trial Completed | Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; MDSC; Solid tumors; T cell; Tumor microenvironment; Tumor stroma |
| P349 | Effects of bintrafusp alfa (M7824) and radiation combination therapy on antitumor activity, immune response, and radiation-induced fibrosis in multiple cancer models | Yan Lan, MD; Chunxiao Xu, PhD; Huakui Yu; Guozhong Qin; Bo Marelli; Jin Qi; Rachel E. Fontana; Amit Deshpande; George Locke; Alex Rolfe; Molly H. Jenkins; Joern-Peter Halle; Kin-Ming Lo; | Clinical Trial Completed | Antibody; Checkpoint blockade; Gene expression; Radiotherapy; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P350 | Clinical Signal/Profile in a Phase I Study of T-Cell Receptor (TCR) Affinity-Enhanced Specific T-Cells (TAEST) in Advanced Cancer Patients | Zhaosheng Han, MD, PhD; Xing Zhang, MD; Jian Zhang; Chengzhi Zhou; Haiping Gong; Desheng Weng, MD; Jianchuan Xia, PhD MD; Johnson YN. Lau; Shiyue Li; Weiliang Zhu; Zhaosheng Han, MD, PhD; | Clinical Trial Completed | Adoptive immunotherapy; Clinical study; Clinical trial; T cell; Tumor antigens |
| P351 | Association between response assessment using RECIST and irRECIST in 1765 patients with advanced solid tumors treated with avelumab monotherapy | Juliane Manitz, PhD; Julian Manitz; Peter Eggleton; Marcis Bajars; Oliver Bohnsack, MD, PhD, MBA; James L. Gulley, MD, PhD, FACP; | Clinical Trial Completed | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors |
| P352 | Workflow for Immune Monitoring during Clinical Trials by using unsupervised high dimensional augmented intelligence assisted analysis | Alessandra Metelli, PhD; Carsten Krieg, PhD; Luis E. Cardenas, BS.; Alessandra Metelli, PhD; | Clinical Trial Completed | Checkpoint blockade; Clinical study |
| P353 | Phase 1 pilot study of RRx-001 + nivolumab in advanced metastatic cancer (PRIMETIME) | Corey A. Carter, MD; Bryan Oronsky, MD PhD; Mary Quinn; Jane Trepel; Nacer Abrouk, PhD; Jeff Skinner, MD; | Clinical Trial Completed | Checkpoint blockade; Clinical trial; Coinhibition; Costimulation; Immune adjuvant; Immune suppression; Immune toxicity; Monocyte/Macrophage; Regulatory T cell (Treg cell); T cell |
| P354 | Exploring correlates of clinical and immune response to cancer immunotherapy using FAUST, a novel unbiased cell population discovery method, in whole blood flow cytometry | Steven P. Fling, PhD; Nirasha Ramchurren, PhD; Leonard D'Amico; Martin A. Cheever, MD; Evan Greene; Greg Finak; Raphael Gottardo, PhD; | Clinical Trial Completed | Biomarkers; Clinical study; Immune monitoring; Myeloid cells; T cell; Tumor antigens; Vaccine |
| P355 | Multicenter, open-label, phase 1 study of DSP-7888 Dosing Emulsion (DSP-7888) in patients with advanced malignancies | Alexander I. Spira, MD, PhD, FACP; Morris D. Groves; Aaron Hansen; Wael A. Harb; Kelly K. Curtis, MD; Erina Koga-Yamakawa; Makoto Origuchi; Zhonggai Li; Jose Iglesias; Walid L. Shaib, MD; Alexander I. Spira, MD, PhD, FACP; | Clinical Trial Completed | Clinical study; Clinical trial; Leukemia/Lymphoma; Solid tumors |
| P357 | Phase I/II clinical and immune responses for locally advanced or metastatic pancreatic cancer using anti-CD3 x anti-EGFR bispecific antibody armed T cells (BATs) | Lawrence G. Lum, MD, DSc; Tri Le; Minsig Choi; Archana Thakur, PhD; Matthew Reilly; Paul R. Kunk, MD; Abhinav Deol, MD; Karen Ballen, MD; Tamila Kindwall-Keller, DO; Dana L. Schalk; Ewa Kubicka; Manley Huang, PhD; Philip A. Philip, MD; Hussein Aoun; Gregory Dyson, PhD; Qin Liu; Anthony F. Shields, MD PhD; | Clinical Trial Completed | Adoptive immunotherapy; Antibody; Chemotherapy; Clinical study; Clinical trial; Immune monitoring; Solid tumors; Targeted therapy; Tumor antigens; Tumor microenvironment |
| P358 | Phase 1 trial of NY-ESO-1-specific adoptive T-cell therapy with GSK3377794 in patients with advanced synovial sarcoma | Sandra P. D'Angelo, MD; George Demetri; Brian Van Tine, MD, PhD; Mihaela Druta; John Glod, MD; Warren Chow; Jenna Tress; M. Phillip DeYoung; Aisha N. Hasan, MBBS MD; Yuehui Wu; David C. Turner; Ran Ji; Alexandra Gyurdieva; Dejka Araujo, MD; | Clinical Trial Completed | Adoptive immunotherapy; CAR T cells; Clinical trial; Gene expression; T cell |
| P359 | Tracking and profiling of NY-ESO-1 TCR-transgenic T cells upon adoptive transfer in patients with NY-ESO-1-expressing solid tumors: in vivo differentiation associated with response | Michael Fehlings; Alessandra Nardin, DVM; Faris Kairi; Evan Newell, PHD; Yoshihiro Mihayara; Shinichi Kageyama; Hiroshi Shiku, MD; | Clinical Trial Completed | Adoptive immunotherapy; Clinical trial; Immune monitoring; Solid tumors; T cell; Tumor antigens |
| P360 | The Influence of Durvalumab/Tremelimumab Combination Therapy on Sarcomas Immune Microenvironment Profile in a Phase II clinical trial (NCT02815995) | Edwin R. Parra, MD., PhD; Carmelia M. Barreto, PhD; Ruth Salazar, MD; Cara Haymaker, PhD; Heather Lin; Carmen Behrens, MD; Mei Jiang; Luisa Solis, MD; Krishna R. Pandurenga, MS; Sandesh Subramanya, PhD; Young U. Kim, PhD; Chantale Bernatchez; Jack Lee, PhD; Taylor Tate; Teresa Simmons; Alexander J. Lazar, MD, PhD; Wei-Lien Wang; Zachary A. Cooper, PhD; Jaime Rodriguez-Canales, MD; Jean C. Soria, MD; Anthony P. Conley, MD; Ignacio Wistuba, MD; Neeta Somaiah, MD, MBBS; | Clinical Trial Completed | Clinical trial; Immune contexture; Immune tolerance; Immunoscore; Inflammation; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P361 | Molecular and Immunologic Profiling of CD8+ T Cell Responses in Patients Receiving a Multiple Antigen-Engineered Dendritic Cell Vaccine | Juraj Adamik, PhD; Patricia M. Santos, PhD; Samuel Du, BS; Lazar Vujanovic, PhD; Timothy Howes; Sarah Warren, PhD; Andrea Gambotto, MD; John M. Kirkwood, MD; Lisa H. Butterfield, PhD; | Clinical Trial Completed | Antigen presenting cells; Checkpoint blockade; Clinical trial; Dendritic cell; Gene expression; Immune adjuvant; Immune monitoring; T cell; Tumor antigens; Vaccine |
| P362 | First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: primary analysis after ≥15 months of follow-up from JAVELIN Merkel 200, a registrational phase 2 trial | Sandra P. D'Angelo, MD; Celeste Lebbé; Laurent Mortier; Andrew S. Brohl, MD; Nicola Fazio; Jean-Jacques Grob; Natalie Prinzi; Glenn Hanna; Jessica C. Hassel, MD; Felix Kiecker; Barbara Ellers-Lenz; Marcis Bajars; Meliessa Hennessy, MPH; Paul Nghiem, MD, PhD; | Clinical Trial Completed | Checkpoint blockade; Clinical trial; Solid tumors |
| P364 | A gp100 targeting TCR-based soluble T cell engaging bispecific induces mobilisation and activation of peripheral T cells in patients with metastatic melanoma | Sion M. Lewis, BSc MSc PhD; Mariantonella Vardeu; Jacob Hurst, PhD; Cheryl McAlpine, MSN; | Clinical Trial Completed | Biomarkers; Chemokine; Clinical study; Immune monitoring; Solid tumors; T cell; T cell lineages |
| P365 | A trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund’s adjuvant, cyclophosphamide, and polyICLC (Mel63) | Craig L. Slingluff, Jr., MD; Gina R. Petroni, PhD; Kimberly A. Chianese-Bullock, PhD; Nolan A. Wages, PhD; Walter C. Olson, PhD; Kelly T. Smith; Lynn T. Dengel, MD; Anna Dickinson; Caroline Reed; Elizabeth M. Gaughan, MD; William W. Grosh, MD; Varinder Kaur, MD; Nikole Varhegyi; Mark E. Smolkin; Nadejda V. Galeassi; Donna H. Deacon, BS; | Clinical Trial Completed | Antibody; Clinical trial; Immune adjuvant; Solid tumors; T cell; TLR; Tumor antigens; Vaccine |
| P366 | A phase 1 study of NY-ESO-1 vaccine + ipilimumab (ipi) in patients with unresectable or metastatic melanoma | Craig L. Slingluff, Jr., MD; Hassane M. Zarour, MD; Michael Postow, MD; Philip Friedlander, MD PhD; Craig E. Devoe, MD; Ileana S. Mauldin, PhD; Kelly T. Smith; Mary Macri, BSc; | Clinical Trial Completed | Antibody; Clinical trial; Immune adjuvant; Immune monitoring; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); TLR; Tumor antigens; Tumor microenvironment |
| P367 | A multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in post-resection melanoma patients at high risk of recurrence. | Craig L. Slingluff, Jr., MD; Brent A. Blumenstein, PhD; Karl D. Lewis, MD; Robert H. Andtbacka, MD, CM, FACS, FRCSC; John Hyngstrom, MD; Mohammed Milhem, MBBS; Svetomir N. Markovic, MD, PhD; Omid Hamid, MD; Leonel Hernandez-Aya, MD PhD; Tawnya Bowles, MD; Prejesh Philips, MD; Joel Claveau, MD; Sekwon Jang, MD; Jose Lutzky, MD, FACP; Anna Bar, MD; Peter Beitsch, MD; | Clinical Trial Completed | Clinical trial; Solid tumors; Vaccine |
| P368 | ZI-H04 - A novel MHC class II restricted TCR based cellular therapy targeting hTERT to treat solid tumours | Jens-Peter Marschner, MD; Mona Welschof, PhD; Miguel Forte; Eva Kristine Klemsdal; Sylvie Pollmann; Namir Hassan; Inês Cardoso, PhD | Clinical Trial In Progress | Adoptive immunotherapy; Clinical study; Clinical trial; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| P369 | Feasibility of a phase I personalized adoptive T-cell therapy in patients with relapsed/refractory solid tumors | Apostolia M. Tsimberidou, MD, PhD; Ali Mohamed; Stephen L. Eck, MD, PhD; Harpreet Singh; Patrick Hwu, MD; Cassian Yee, MD; Borje Andersson, MD, PhD; | Clinical Trial In Progress | Adoptive immunotherapy; Biomarkers; Clinical trial; Solid tumors; T cell |
| P370 | The positive correlation between baseline absolute eosinophil count (AEC) in blood and clinical benefit to PD-(L)1 inhibition monotherapy | Danni Yu, PhD; Anna M. Szpurka, PhD; Michelle Carlsen; Danni Yu, PhD; Antoine Hollebecque, MD; Hyun Cheol Chung, MD, PhD; Amita Patnaik; Johanna Bendell, MD; Antoine Italiano, MD; Yung-Jue Bang, MD PhD; Chia-Chi Lin, MD, PhD; Marcus O. Butler, MD; Timothy A. Yap, MD PhD; María José de Miguel, MD; María José de Miguel, MD; Jean-Pascal Machiels, MD, PhD; Marc Peeters, MD, PhD; Wu-Chou Su, MD; Victor Moreno, MD; Yumin Zhao, PhD; Erik Rasmussen, PhD; Xiaojian Xu, MD; | Clinical Trial In Progress | Antibody; Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Immune suppression; Solid tumors |
| P371 | Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade | John Lynes, MD; Victoria Sanchez; Anthony Nwankwo; Gifty A. Dominah; Xiang Wang, MS; Isac Kunnath; Samantha Dill; Gretchen K. Scott; Christi Hayes; Tianxia Wu; Marta Penas-Prado; Jing Wu; Eric Burton; John Heiss; Christopher S. Hourigan, MD, PhD; Mark R. Gilbert; Edjah K. Nduom, MD; John Lynes, MD; Edjah K. Nduom, MD; | Clinical Trial In Progress | Biomarkers; Checkpoint blockade; Chemokine; Cytokine; Immune monitoring; Immune suppression; Proteomics; Surgery; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P372 | Circulating Immune Cell Biomarkers Predict Response to Immune Checkpoint Inhibitor Therapy in Metastatic Breast Cancer | Jin Sun L. Bitar, MD; Colt Egelston, PhD; Susan Yost; Wanqiu Hou; Padam Simran; Paul Frankel, PhD; Mina Sedrak; Jana Portnow, MD; Joanne Mortimer, MD; Christina Yeon, MD; Arti Hurria, MD; Aileen Tang; Norma Martinez; Peter P. Lee, MD; Yuan Yuan; | Clinical Trial In Progress | Biomarkers; Checkpoint blockade; Clinical trial; Immune monitoring; T cell; Tumor microenvironment |
| P373 | A window-of-opportunity Study of pelareorep in Early Breast Cancer (AWARE-1) | Luis Manso; Patricia Villagrasa; Nuria Chic; Juan M. Cejalvo; Yann Izarzugaza; Blanca Cantos; Salvador Blanch; Manel Juan; Blanca Gonzalez; Rita Laeufle; Gerard Nuovo; Grey A. Wilkinson, PhD; Matt Coffey; Azucena Gonzalez; Patricia Galvan; Laia Paré; Jordi Canes; Xavier Gonzalez; Aleix Prat, MD PhD; Aleix Prat, MD PhD; Joaquín Gavilá; | Clinical Trial In Progress | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Immune adjuvant; Inflammation; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P374 | TCR repertoires from peripheral blood correlate with prognostic response in TNBC cancer vaccine immunotherapy | Sadanand Vodala, PhD; Andrew Nguyen, PhD; Noe Rodriguez; Peter Sieling; Charles J. Vaske; Jon Van Lew; kayvan Niazi; John H. Lee, MD; Patrick Soon-Shiong, MD, FRCS, FACS; Shahrooz Rabizadeh; | Clinical Trial In Progress | Biomarkers; Checkpoint blockade; Clinical study; Immune monitoring; Immune suppression; NK/NK T cell; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |
| P375 | Margetuximab combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) +/- chemotherapy in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction (GEJ) or gastric cancer (GC) | Daniel V. Catenacci, MD; Minori Rosales; Jon M. Wigginton, MD; Hyun Cheol Chung, MD, PhD; Harry Yoon; Lin Shen; Yoon-Koo Kang; Markus Moehler; | Clinical Trial In Progress | Adoptive immunotherapy; Antibody; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; T cell; Tumor antigens |
| P376 | NOUS-209: A Phase I, First-In-Human, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors | Anna Gorrasi, PhD; Elisa Scarselli; Maria Teresa Catanese; Cinzia Traboni; Paola Antonini; Denis Brkic; | Clinical Trial In Progress | Bioinformatics; Biomarkers; Checkpoint blockade; Clinical trial; Immune monitoring; Neoantigens; Solid tumors; T cell; Tumor antigens; Vaccine |
| P377 | Safety and anti-tumor activity of the transforming growth factor β receptor I kinase inhibitor, vactosertib, in combination with pembrolizumab in patients with metastatic colorectal or gastric cancer. | Keun-Wook Lee, MD; Young Suk Park, MD, PhD; Joong Bae Ahn; Sun Young Rha; Hark Kyun Kim; Park Young Lee; Min-Hee Ryu; Jeeyun Lee, MD, PhD; Jin Kyung Lee; Sunjin Hwang; Seong-Jin Kiim; Tae Won Kim, MD, PhD; | Clinical Trial In Progress | Checkpoint blockade; Chemotherapy; Clinical study; Solid tumors; Tumor microenvironment; Tumor stroma |
| P378 | Phase II Study of Combination Ipilimumab, Nivolumab, and Panitumumab in Patients with KRAS, NRAS, and BRAF Wild-Type (WT) Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) | Michael S. Lee, MD; Patrick J. Loehrer, MD; Iman Imanirad, MD; Stacey Cohen, MD; Kristen Ciombor, MD; Cheryl A. Carlson, MD/PhD; Hanna K. Sanoff, MD; Autumn J. McRee, MD; | Clinical Trial In Progress | Antibody; Checkpoint blockade; Clinical trial; Solid tumors; Targeted therapy |
| P379 | Title: Phase 1 Safety Study in Healthy Volunteers of AB680, a Small-Molecule Inhibitor of CD73 and Rationale for Combination Therapy in Patients with Gastrointestinal Malignancies | Devika Ashok, PhD; Irene Luu; Akshata Udyavar, Ph.D; Lixia Jin; Lijuan Fu; Elaine Ginn; Ken Lawson; Jenna Jeffrey, PhD; Manmohan R. Leleti, PhD; Jay P. Powers, PhD; Eric Connor; Andy Pennell; Daniel DiRenzo, PhD; Dana Piovesan, MSc; Joanne BL. Tan, PhD; Amanda Garofalo; Wade Berry, BA; Matthew J. Walters, PhD; Steve W. Young, PhD; Fangfang Yin, PhD; Dominic Lai; Lisa Seitz, MA; | Clinical Trial In Progress | Bioinformatics; Biomarkers; Clinical study; Clinical trial; Immune suppression; Tumor microenvironment |
| P380 | Phase 1b/2 study of BXCL701, a small molecule inhibitor of dipeptidyl peptidases, with bempegaldesleukin (bempeg, NKTR-214) and avelumab (anti-PD-L1) in unresectable or metastatic pancreatic cancer | Louis M. Weiner, MD; Benjamin A. Weinberg, MD; Stina Singel; Cedric Burg; Diane Healey; Jonathan Zalevsky, PhD; Chetan Lathia; Willem W. Overwijk, PhD; Cristian Massacesi; Joyce Acbay; John MacDougall, PhD; Vincent O'Neill; | Clinical Trial In Progress | Checkpoint blockade; Chemokine; Clinical study; Clinical trial; Cytokine; Monocyte/Macrophage; Solid tumors; Tumor microenvironment; Tumor stroma |
| P381 | Phase 1b/2 study of BXCL701, a small molecule inhibitor of dipeptidyl peptidases (DPP), with pembrolizumab, (anti-PD-1) monoclonal antibody, in small cell neuroendocrine prostate cancer (SCNC, NEPC) | Diane Healey; Rahul Aggarwal, MD; Vincent O'Neill; Cedric Burg; Jiaoti Huang; Johann S. De Bono, MD; Eric J. Small; | Clinical Trial In Progress | Checkpoint blockade; Chemokine; Clinical study; Clinical trial; Cytokine; Monocyte/Macrophage; Solid tumors; Tumor microenvironment; Tumor stroma |
| P382 | KEYNOTE-365 cohort D: phase 1b/2 study of pembrolizumab plus abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer | Leonard J. Appleman, MD, PhD; Josep Piulats; Nataliya Mar; José A. Arranz; Anthony Joshua, MD; Tina M. Mayer; Neal Shore, MD; Haiyan Wu, PhD; Charles Schloss; Evan Y. Yu; | Clinical Trial In Progress | Clinical trial |
| P384 | A phase I dose escalation and expansion study of HPN424, a PSMA-targeting T cell engager, in patients with advanced prostate cancer refractory to androgen therapy | Johanna Bendell, MD; Mark Stein, MD; Johann de Bono, MD; Richard Austin, PhD; Sue Hirabayashi; Che-Leung Law, PhD; Bryan Lemon, PhD; Holger Wesche, PhD; Aaron Weitzman, MD FACP; Lawrence Fong, MD; | Clinical Trial In Progress | Antibody; Biomarkers; Clinical study; Clinical trial; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| P385 | Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: phase 3 KEYNOTE-641 study | Julie Nicole Graff; Joseph Burgents; Li Wen Liang; Arnulf Stenzl; | Clinical Trial In Progress | Clinical trial |
| P387 | A Multicenter, Open-Label, Exploratory Platform Study to Evaluate Biomarkers and Immunotherapy Combinations for the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer (PORTER) | Leo Nissola, MD; Karen Autio, MS, MD; Nina Bhardwaj, MD, PhD; Matthew D. Galsky, MD; Kristopher Wentzel, MD; Vanessa M. Lucey; Cheryl Selinsky, PhD; Christopher Perry; Christopher Cabanski, PhD; Ari J. Bitton; Justin Fairchild; Christine E. Horak, PhD; Jeffrey M. Skolnik, MD; Michael Yellin, MD; Ute Dugan, MD, PhD; Ramy Ibrahim, MD; Lawrence Fong, MD; | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Clinical trial; Immune monitoring; Immune tolerance; Radiotherapy; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine |
| P388 | Pembrolizumab plus docetaxel and prednisone for enzalutamide- or abiraterone acetate–pretreated patients with metastatic castration-resistant prostate cancer: phase 3 KEYNOTE-921 study | Neal Shore, MD; Daniel P. Petrylak, MD; Mostefa Bennamoun; Raffaele Ratta; Josep Piulats; Ben Li; Charles Schloss; Karim Fizazi; | Clinical Trial In Progress | Clinical trial |
| P389 | A Phase I Trial of Interleukin-2 (IL-2) and Pembrolizumab (Pembro) Combination Therapy for Patients with Advanced Renal Cell Carcinoma | Scott S. Tykodi, MD, PhD; Johanna Whitney; Sumia Dakhil; Eleanor L. Bergren; Vivian T. Nguyen; Samantha M. Kiriluk; Shailender Bhatia, MD; John A. Thompson, MD; | Clinical Trial In Progress | Checkpoint blockade; Clinical trial; Cytokine; Regulatory T cell (Treg cell); Solid tumors; T cell |
| P390 | Pembrolizumab plus olaparib vs enzalutamide or abiraterone in patients with metastatic castration-resistant prostate cancer who experienced progression on chemotherapy: phase 3 KEYLYNK-010 study | Evan Y. Yu; Se Hoon Park; Yi-Hsiu Huang; Mostefa Bennamoun; Lu Xu; Jeri Kim; Emmanuel S. Antonarakis, MD; | Clinical Trial In Progress | Clinical trial |
| P391 | Randomized phase II trial of autologous dendritic cells loaded with autologous tumor cell antigens from self-renewing cancer cells in patients with newly diagnosed stage III or IV ovarian cancer | Lisa A. Abaid, MD; Richard L. Friedman, MD, PhD; John V. Brown, MD; Alberto A. Mendivil, MD; Tiffany L. Beck, MD; Bradley R. Corr; Leslie M. Randall; James R. Mason; Candace Hsieh; Gabriel I. Nistor, MD; Robert O. Dillman, MD, FACP; | Clinical Trial In Progress | Clinical trial; Dendritic cell; Neoantigens; Stem cell/cancer-initiating cell; Tumor antigens; Vaccine |
| P392 | Phase 1 combination study of the CHK1 inhibitor prexasertib (LY2606368) and anti-PD-L1 antibody LY3300054, in patients with high-grade serous ovarian cancer and other advanced solid tumors | Khanh T. Do; Claire Manuszak; Sarah E. Kelland; Allison P. Powers; Adrienne Anderson; Alona Muzikansky; Andrew Wolanski; Mariano Severgnini, MSc; Geoffrey Shapiro, MD, PhD; Khanh T. Do, MD; | Clinical Trial In Progress | Biomarkers; Clinical trial; Solid tumors; Targeted therapy; Tumor antigens |
| P393 | Single agent activity of a novel PD-1 inhibitor AGEN2034 in recurrent ovarian cancer. Subset analysis of phase I dose escalation NCT03104699 study | David M. O'Malley; John Hays; Charles Drescher; Jasgit Sachdev; Wilberto Nieves-Neira; Breelyn Wilky; Marylin Huang; Kathleen N. Moore; Waldo Ortuzar; Anna Wijatyk; Hagop Youssoufian; Remigiusz Kaleta, MD; Inbal Sapir; Christopher Dupont, PhD; Irina Shapiro; Debra Richardson, MD; | Clinical Trial In Progress | Biomarkers; Clinical study; Immune contexture; Solid tumors; Targeted therapy |
| P394 | A Phase 1 study of INCMGA00012, a PD-1 inhibitor, in patients with advanced solid tumors: Preliminary results for patients with advanced cervical cancer (POD1UM-101) | Janice J. Mehnert, MD; Luis Paz Ares, MD, PhD; Joanna Pikiel, Dr n. med.; Udai Banerji, PhD; Anna Kryzhanivska, MD; Nehal Lakhani, MD, PhD; Sebastian Ochsenreiter, Dr. med.; Tobias Arkenau, MD, PhD; Nawel Bourayou, MD; Deanna Kornacki, PhD; Chuan Tian, PhD; Thomas Condamine, PhD; Itziar Gardeazabal González; | Clinical Trial In Progress | Checkpoint blockade; Clinical trial; Solid tumors |
| P395 | Phase 2/3 open-label trial of enoblituzumab in combination with MGA012, with and without chemotherapy, in the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma | Fernanda I. Arnaldez; Charu Aggarwal, MD MPH; Scott Currence; Jan Baughman, MPH; Paul Moore, PhD; George R. Blumenschein, Jr., MD; Jon M. Wigginton, MD; Robert L. Ferris, MD, PhD; | Clinical Trial In Progress | Checkpoint blockade; Clinical trial; Solid tumors; Targeted therapy |
| P396 | A Phase 2 Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Adults with Head and Neck Cancer | Ezra Cohen, MD; Robert L. Ferris, MD, PhD; Douglas Adkins, MD; Dan P. Zandberg, MD; Arkadiusz Dudek, MD, PhD; Matthen Mathew; Lara Dunn, MD; Juneko E. Grilley-Olson, MD; Ammar Sukari, MD; Rebecca Redman, MD; Julie E. Bauman, MD, MPH; John M. Kaczmar, MD; Lisle Nabell, MD; Nabil F. Saba, MD; Eric Nadler, MD; Young J. Kim, MD; Ranee Mehra, MD; Nitya Nair, PhD; Somayeh Honarmand, MS; Richard E. Cutler Jr.; Barbara A. Burtness, MD; | Clinical Trial In Progress | Antigen presenting cells; Checkpoint blockade; Clinical trial; Immune adjuvant; T cell |
| P397 | Interim analysis of the combination of durvalumab and cetuximab in a phase II trial of patients with recurrent and metastatic head and neck squamous cell carcinoma. | Shuchi Gulati, MD; Sarah Palackdharry; Layne Weatherford; Sarah Wilson; Shireen Desai; Aubrey Steele; Kashif M. Riaz; Vinita Takiar; Trisha W. Draper; | Clinical Trial In Progress | Checkpoint blockade; Clinical trial; NK/NK T cell; Solid tumors; Targeted therapy |
| P398 | miRNA-A and programmed death ligand 1 (PD-L1) expression in oral squamous cell carcinoma | Hong J. Hyung, MD. PhD; Yoon Ho Ji. Ko; Lee Hee JIn; Sang Hoon Jeon; | Clinical Trial In Progress | Immune suppression; Tumor microenvironment |
| P399 | Instructive conclusions from performing immune correlatives on IO trials: a meta-analysis of patient tumor and blood samples. | Patrick Lizotte, PhD; Megan Cavanaugh; Melissa Jean; Cloud Paweletz, PhD; | Clinical Trial In Progress | Checkpoint blockade; Immune monitoring |
| P400 | Sitravatinib and Nivolumab for resectable Oral cavity squamous cell carcinoma Window of opportunity study (SNOW) | Marc Oliva Bernal, MD; Douglas Chepeha, MD; Amy AP. Prawira, MD; Anna Spreafico, MD PhD; Scott Bratman, MD; Tina Shek, MD; John De Almeida, MD; Ivan Yeung, MD; Aaron Hansen; Andrew Hope, MD; David Goldstein, MD; Ralph Gilbert, MD; Doug Vines, BSc, MRT(N), CNMT; Patrick Gullane; Dale H. Brown, MD; Ilan Weinreb, MD; Bayardo Perez-Ordoñez, MD; Trevor Pugh, PhD; Pamela S. Ohashi, PhD; Ben Wang, PhD; Jonathan Irish, MD; Hirak Der-Torossianh, MD; Isan Chen, MD; Lillian Siu, MD; | Clinical Trial In Progress | Angiogenesis; Checkpoint blockade; Clinical trial; Monocyte/Macrophage; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| P401 | Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in patients with resectable, locally advanced head and neck squamous cell carcinoma (HNSCC): the phase 3 KEYNOTE-689 study | Ravindra Uppaluri, MD, PhD; Nancy Y. Lee, MD; William Westra; Ezra Cohen, MD; Robert I. Haddad; Stephane Temam; Christophe Le Tourneau; Rebecca Chernock; Sufia Safina; Arkadiy Klochikhin; Amichay Meirovitz; Irene Brana, MD; Joy Yang Ge; Ramona F. Swaby, MD; Cecilia Pinheiro; Douglas Adkins, MD; | Clinical Trial In Progress | Checkpoint blockade; Clinical trial; Immune adjuvant; Radiotherapy |
| P402 | BELINDA : A phase 3 study evaluating the safety and efficacy of tisagenlecleucel versus standard of care in adult patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma | Michael R. Bishop, MD; Ian Flinn, MD; Peter Borchmann; Ulrich Jaeger; Jason R. Westin, MD; Nada Hamad; Duncan Purtill; Richard Greil; Simone Thomas; Takanori Teshima; Hideo Harigae; Carlos G. Garcia; Pere Barba; Abhinav Deol, MD; Paul Shaughnessy; Jessie Gu; Giovanna Andreola; Marcela Martinez Prieto; Lida Pacaud; Stephen J. Schuster, MD; | Clinical Trial In Progress | CAR T cells; Clinical trial; Leukemia/Lymphoma |
| P403 | Serum soluble CD25 may predict the early therapeutic response in pediatric patients with B-cell non-Hodgkin's lymphoma（B-NHL）during autologous chimeric antigen receptor T cell(CAR-T) therapy | Jing X. Guo; Yonghong Zhang, Professor; Juan Du, MD; Juan Du, MD; | Clinical Trial In Progress | B cell; CAR T cells; Clinical study; Cytokine; Leukemia/Lymphoma; Pediatric tumors |
| P404 | Developing canine CART-19 to fully leverage comparative oncology and inform human clinical trials | Kumudhini P. Haran, M.S; Ailian Xiong; Enrico Radaelli; Patrick J. Savickas; Avery Posey; Donald Siegel; Nicola Mason, B.Vet Med PhD; | Clinical Trial In Progress | Adoptive immunotherapy; CAR T cells; Leukemia/Lymphoma |
| P405 | CASSIOPEIA: A phase 2 study evaluating efficacy and safety of tisagenlecleucel in first-line therapy for high-risk pediatric and young adult patients with B-ALL who are MRD positive at the EOC | Shannon L. Maude, MD, PhD; Hunger Stephen, MD; Jochen Buechner, MD; Stephen A. Grupp, MD; Susana Rives; Andre Baruchel; John Levine; Joerg Krueger; Theodore W. Laetsch; Marianne RS. Ifversen; Aiesha Zia; Jaclyn Davis; Eric Bleickardt; Mignon Loh; | Clinical Trial In Progress | B cell; CAR T cells; Clinical trial; Leukemia/Lymphoma; T cell |
| P406 | Interleukin-1 blockade to prevent severe immune effector cell-associated neurotoxicity syndrome; Trial in progress | Caspian Oliai, MD; Anna Crosetti; John M. Timmerman, MD | Clinical Trial In Progress | CAR T cells; Cytokine; Inflammation; Leukemia/Lymphoma |
| P407 | Phase 3 KEYNOTE-937: adjuvant pembrolizumab versus placebo in patients with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation | Masatoshi Kudo, MD, PhD; Andrew Zhu; Arndt Vogel; Thomas Yau; Jian Zhou; Erluo Chen; Usha Malhotra; Abby Siegel; Ann-Lii Cheng, MD PhD; | Clinical Trial In Progress | Checkpoint blockade; Clinical trial; Immune adjuvant; Solid tumors |
| P408 | LEAP-002: phase 3 study of first-line lenvatinib plus pembrolizumab for patients with advanced hepatocellular carcinoma | Josep M. Llovet; Masatoshi Kudo, MD, PhD; Ann-Lii Cheng, MD PhD; Richard Finn; Peter Galle; Shuichi Kaneko, MD PhD; Tim Meyer; Shukui Qin; Corina E. Dutcus; Erluo Chen; Leonid Dubrovsky; Abby Siegel; Andrew Zhu; | Clinical Trial In Progress | Antibody; Checkpoint blockade; Clinical trial; Coinhibition; Targeted therapy |
| P409 | A case report of personalized neoantigen peptide vaccine in treating patients with biliary tract cancer | Fang Yong; Fan Mo; Jiawei Shou; Huimin Wang; Lin Chen; Shanshan Zhang; Hongsen Li; Weidong Han; Hongming Pan; Shuqing Chen; | Clinical Trial In Progress | Bioinformatics; Clinical trial; Neoantigens; Solid tumors; Vaccine |
| P410 | Safety and anti-tumor activity of the transforming growth factor β receptor I kinase inhibitor, vactosertib, in combination with durvalumab in patients with advanced non-small cell lung cancer (NSCLC) | Ji-Youn Han, MD, PhD; Kyoung-Ho Pyo; Jea Hwan Kim; Chun-Feng Xin; Jin Kyung Lee; Sunjin Hwang; Seong-Jin Kim; Byoung Chul Cho, MD.phD; Byoung Chul Cho, MD.phD; | Clinical Trial In Progress | Checkpoint blockade; Chemotherapy; Clinical study; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P411 | Treating advanced non-small lung cancer (NSCLC) patients after checkpoint inhibitor treatment failure with a novel combination of Viagenpumatucel-L (HS-110) plus nivolumab | Daniel Morgensztern, MD; Saiama Waqar, MD; Lyudmila Bazhenova, MD; Rachel E. Sanborn, MD; Lori Mcdermott, RN, MSc; Jeff Hutchins, PhD; Luis E. Raez, MD, FACP, FCCP; Corey J. Langer, MD; Roger Cohen, MD; | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Clinical trial; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment; Tumor stroma; Vaccine |
| P412 | Validation of a Single-Blinded (Patients Only) Study Design for the Prevention of Premature Patient Consent Withdrawal in the Immuno-Oncology Trial DUBLIN-3 | Ramon Mohanlal, MD, PhD, MBA; Huang Lan, PhD; Ramon Mohanlal, MD, PhD, MBA; | Clinical Trial In Progress | Antigen presenting cells; Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; Dendritic cell |
| P413 | A Phase 1b/2 study of galunisertib in combination with nivolumab in solid tumors and NSCLC | Ernest Nadal, MD, PhD; Mansoor N. Saleh, MD; Santiago Ponce Aix, MD; Maria Ochoa de Olza; Sandip P. Patel, MD; Scott J. Antonia, MD, PhD; Yumin Zhao, PhD; Ivelina Gueorguieva, PhD; Michael Man, PhD; Shawn T. Estrem, PhD; Emin Avsar; Wen Hong Lin; Karim Benhadji; Susan Guba; Inmaculada Ales Diaz; Ernest Nadal, MD, PhD; | Clinical Trial In Progress | Antibody; Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Gene expression; Immune suppression; Solid tumors |
| P414 | Interim results from CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced non-small cell lung cancer patients | Michael Shafique, MD; Terrence L. Fisher, Jr., PhD; Elizabeth E. Evans, PhD; John E. Leonard, MD PhD; Desa Rae Pastore; Crystal Mallow, BS; Ernest S. Smith, PhD; Andreas Schroeder, MD, PhD; Kevin Chin; Joseph Beck; Megan A. Baumgart, MD; Ramaswany Govindan, MD; Nashat Y. Gabrail, MD; Jonathan W. Goldman, MD; Rachel E. Sanborn, MD; Alexander I. Spira, MD, PhD, FACP; Nagashree Seetharamu; Yanyan Lou, MD; Aaron Mansfield, MD; Maurice Zauderer, PhD; PhD; Terrence L. Fisher, Jr., PhD; | Clinical Trial In Progress | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Coinhibition; Immune monitoring; Myeloid cells; MDSC; Regulatory T cell (Treg cell); Tumor microenvironment |
| P415 | Tumor Treating Fields (TTFields, 150 kHz) concurrent with standard of care treatment for stage 4 non-small cell lung cancer (NSCLC) in Phase 3 LUNAR Study | Uri Weinberg, MD PhD; Ori Farber; Moshe Giladi; Ze'ev Bomzon; Eilon D. Kirson; Uri Weinberg, MD PhD; Uri Weinberg, MD PhD; | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Coinhibition; Solid tumors |
| P416 | A phase 1 dose escalation with expansion study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of AMV564 in subjects with advanced solid tumors | Raghad M. Abdul Kairm, MD; Anthony Tolcher, MD; Victoria Smith; Sterling C. Eckard, PhD; Jeanmarie Guenot; Patrick Chun; | Clinical Trial In Progress | Clinical trial; Immune suppression; Myeloid cells; MDSC; Solid tumors; T cell; Targeted therapy |
| P417 | ATLAS™ identifies relevant neoantigens for therapeutic anti-tumor vaccination and may serve as a biomarker for efficacy of immunotherapy of solid tumors | Parul Agnihotri; Tulin Dadali; Parul Agnihotri, PhD; | Clinical Trial In Progress | Antigen presenting cells; Biomarkers; Clinical study; Clinical trial; Dendritic cell; Neoantigens; Solid tumors; T cell; Targeted therapy; Vaccine |
| P418 | Intratumoral IL-12 plus pembrolizumab combination therapy in treatment refractory solid tumors: a safety and biomarker analysis | Pablo Fernandez-Penas, MD, PhD; Matteo S. Carlino, MBBS, PhD, BMedSC, F; Victoria Atkinson, MD; Melinda Telli; Rohit Joshi; Sajev Thomas; Katy Tsai, MD; Rachel Roberts-Thomson; Andrew Haydon, MBBS PhD; Andrew Mant; Tom Van Hagen; Katharine Cuff; Bianca Devitt; Igor Puzanov, MD, MSCI, FACP; Marcus O. Butler, MD; Catalin Mihalcioiu; Hatem Soliman, MD; John Hyngstrom, MD; Mecker Moller; Gregory A. Daniels, MD, PhD; Eric D. Whitman, MD, FACS; Erica Browning, BS; Reneta Hermiz; Lauren Svenson; Jack Y. Lee; Donna Bannavong; Jendy Sell; Kellie Malloy; David A. Canton, PhD; Christopher G. Twitty; Adil Daud, MBBS MD; Alain Algazi, MD; | Clinical Trial In Progress | Biomarkers; Checkpoint blockade; Clinical trial; Cytokine; Immune monitoring; MDSC; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P419 | A phase 1/2 study of GB1275, a novel CD11b modulator, as monotherapy and with an anti-PD-1 antibody in specified advanced solid tumors or with chemotherapy in metastatic pancreatic cancer (mPDAC) | Johanna Bendell, MD; Drew Rasco, MD; Wungki Park, MD; Lei Zhou, MD, MS; Anna Galkin, PhD; Debbie Slee, PhD; Laura L. Carter, PhD; David Nickle, PhD; Rebecca Tran, MS; Jack Li, PhD; Beatrice Ferguson, MS; Jakob Dupont, MD; Vineet Gupta, PhD; Eileen O'Reilly; | Clinical Trial In Progress | Antibody; Immune suppression; MDSC; Solid tumors |
| P420 | Broad immunogenicity from GEN-009, a neoantigen vaccine using ATLAS™, an autologous immune assay, to identify immunogenic and inhibitory tumor neoantigens | Roger Cohen, MD; Melissa L. Johnson, MD; Przemyslaw Twardowski, MD; Mark Stein, MD; Ulka N. Vaishampayan, MD; Maura L. Gillison, MD, PhD; Lisa K. McNeil, PhD; Louisa Dowal, PhD; James Foti, PhD; Parul Agnihotri, PhD; Daniel DeOliveira, PhD; Manish Jain, MS; Jessica Price; Richard Hernandez; Arthur P. DeCillis, MD; Narinderjeet Singh, MS, MBA; Thomas A. Davis, MD; Jessica B. Flechtner, PhD; | Clinical Trial In Progress | Clinical trial; Immune adjuvant; Immune monitoring; Immune suppression; Neoantigens; Solid tumors; T cell; T cell lineages; Tumor antigens; Vaccine |
| P421 | Phase 1 study of the safety, tolerability and preliminary anti-tumor activity of COM701 monotherapy in patients with advanced solid tumors. | Ecaterina I. Dumbrava, MD; Gini F. Fleming, MD; Erika P. Hamilton, MD; Ryan J. Sullivan, MD; Amita Patnaik, MD FRCP(C); Kyriakos P. Papadopoulos, MD; Adam ElNaggar, MD; John Hunter, PhD; Judy Olweny; Adeboye H. Adewoye, MD; Bartosz Chmielowski, MD, PhD; Dale Shepard, MD PhD; Manish R. Sharma, MD; Emerson Lim, MD; Daniel Vaena, MD; Drew Rasco, MD; | Clinical Trial In Progress | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Immune toxicity; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P422 | Phase 1 study of COM701 monotherapy and in combination with nivolumab in patients with advanced solid tumors. | Ecaterina Dumbrava, MD; Gini Fleming, MD; Erika P. Hamilton, MD; Ryan J. Sullivan, MD; Amita Patnaik, MD FRCP(C); Kyriakos P. Papadopoulos, MD; Adam ElNaggar, MD; John Hunter, PhD; Judy Olweny; Adewoye H. Adewoye, MD; Adeboye H. Adewoye, MD; Bartosz Chmielowski, MD, PhD; Dale Shepard, MD PhD; Manish R. Sharma, MD; Emerson Lim, MD; Daniel Vaena, MD; Drew Rasco, MD; | Clinical Trial In Progress | Antibody; Biomarkers; Checkpoint blockade; Clinical trial; NK/NK T cell; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P423 | SURPASS trial design: A phase 1 dose escalation trial to assess safety and efficacy of ADP-A2M4CD8 in HLA-A2+ patients with MAGE-A4+ tumors | Paula M. Fracasso, MD, PhD; David S. Hong, MD; Marcus Butler; Melissa L. Johnson, MD; Tanner Johanns; Francine Brophy; Rebecca Dryer-Minnerly, PhD; Trupti Trivedi, MS; Rafael Amado, MD; Paula M. Fracasso, MD, PhD; | Clinical Trial In Progress | Adoptive immunotherapy; Clinical study; Clinical trial; Costimulation; Solid tumors; T cell; T cell lineages; Targeted therapy; Tumor antigens |
| P424 | Preliminary safety, efficacy and immunogenicity results from a phase 1/2a study (DIRECT-01) of cancer neoantigen DNA vaccine VB10.NEO in patients with locally advanced or metastatic solid tumors | Jürgen Krauss; Angela Krackhardt; Elke Jaeger; Anja Williams; Reza Rafiyan; LIsa Gerner; Monika Sekelja; Agnete B. Fredriksen, PhD; Karoline W. Schjetne; Mads Axelsen; Agnete B. Fredriksen, PhD; Hedda Wold, MSc; | Clinical Trial In Progress | Antigen presenting cells; Checkpoint blockade; Clinical study; Clinical trial; Immune monitoring; Neoantigens; Solid tumors; T cell; Vaccine |
| P425 | Phase 1b study of GX-I7, a long-acting interleukin-7, evaluating the safety, pharmacokinetics and pharmacodynamics profiles in patients with advanced solid cancers | Minkyu Heo; Tae Won Kim, MD, PhD; | Clinical Trial In Progress | Biomarkers; Chemokine; Clinical study; Clinical trial; Cytokine; Immune adjuvant; Immune monitoring; Solid tumors; T cell |
| P426 | A first-in-human phase 1, multicenter trial of toll-like receptor (TLR) 7 agonist DSP-0509 as monotherapy and in combination with pembrolizumab in adult patients with advanced solid tumors | Shadia Jalal, MD; Jared Weiss, MD; Anthony J. Olszanski, MD, RPh; Jordan Berlin, MD; Makoto Origuchi; Zhonggai Li; Bella Ertik; Hongliang Cai; Daniel Clancy; Jose Iglesias; Vivek Subbiah, MD; Shadia Jalal, MD; | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; TLR |
| P427 | A Phase 1 Study of IMC-001, Novel Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors | Bhumsuk Keam, MD, PhD; Tae Min Kim, MD, PhD; Do-Youn Oh, MD, PhD; Chan-Young Ock, MD, PhD; Won Ki Kang, MD, PhD; Yeon Hee Park, MD, PhD; Jeeyun Lee, MD, PhD; Ji Hye Lee, MD; Yun Jeong Song, MD; Young Suk Park, MD, PhD; | Clinical Trial In Progress | Adoptive immunotherapy; Antibody; Clinical study; Clinical trial; Solid tumors; T cell |
| P428 | A phase 1 study evaluating BI 765063, a first in class selective myeloid SIRPa inhibitor, as stand-alone and in combination with BI 754091, a PD-1 inhibitor, in patients with advanced solid tumours | Nuria Kotecki, MD; Philippe Cassier; Jean-Pierre Delord, MD; Stéphane Champiat; Christiane Jungels; Armelle Vinceneux; Iphigenie Korakis; Richard Huhn; Nicolas Poirier; Dominique Costantini; Bérangère Vasseur; Aurélien Marabelle; | Clinical Trial In Progress | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Coinhibition; Monocyte/Macrophage; Myeloid cells; Solid tumors; T cell; Targeted therapy |
| P429 | A phase 1/2a dose escalation and expansion study of HPN536, a mesothelin-targeting T cell engager, in patients with advanced cancers expressing mesothelin who have failed standard therapy | Erika P. Hamilton, MD; Richard Austin, PhD; Sue Hirabayashi; Che-Leung Law, PhD; Bryan Lemon, PhD; Holger Wesche, PhD; Debra Richardson, MD; | Clinical Trial In Progress | Antibody; Clinical study; Clinical trial; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| P430 | Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and in Combination with a PD-1 Inhibitor in Adult Subjects with Advanced or Metastatic Solid Tumors | David Luo; Raghad Abdul-Karim, MD; Arun Azad, MD; Joanna Bendell, MD; Hui Gan, MBBS PhD; Filip Janku, MD, PhD; Shiraj Sen, MD, PhD; Tira Tan, MBBS; Judy S. Wang, MD; Lisa Schechet; Lauren Baker, PhD; Joseph A. Leveque, MD; Tarek Meniawy, MBBS FRACP; | Clinical Trial In Progress | Clinical study; Clinical trial; Cytokine; Inflammation; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P431 | Semi-mechanistic PK and target-occupancy modeling to support dose justification for anti-PD-L1 clinical candidate CK-301 (TG-1501) in oncology patients | Lin Lin, PhD; James Hilbert; Leonid Gorelik; Jian-Ping Tang; James Oliviero; Joshua Apgar; Lore Gruenbaum, PhD; John Burke; | Clinical Trial In Progress | Antibody; Checkpoint blockade; Clinical study; Solid tumors; Systems biology; T cell; Tumor infiltrating lymphocytes (TILs) |
| P432 | A phase 1 dose-escalation study of safety, tolerability, and pharmacokinetics (PK) of ABBV-368 monotherapy and combination in patients (pts) with locally advanced or metastatic solid tumors | Christophe Le Tourneau; Wu-Chou Su, MD; Ki Y. Chung, MD; Patricia LoRusso, DO; Chia-Chi Lin, MD, PhD; Fabrice Barlesi, MD, PhD; Her-Shyong Shiah; Eric Angevin, MD; Alexander I. Spira, MD, PhD, FACP; Amita Patnaik, MD FRCP(C); John D. Powderly, II, MD, CPI; Dimitrios Colevas; Helen Chew, MD; Maulik Patel, PharmD, PhD; Stacie L. Lambert; Yan Li; Daniel Da Costa; Martha E. Blaney, PharmD; Michael A. McDevitt, MD, PhD; Philippe Cassier; | Clinical Trial In Progress | Antibody; Clinical trial; Regulatory T cell (Treg cell); Solid tumors |
| P433 | Initial results of the phase 1 portion of an ongoing phase 1/2 study of RP1 as a single agent and in combination with nivolumab in patients with solid tumors | M R. Middleton, MD PhD; Joseph Sacco; Jaime Merchan; Amber Thomassen; Brendan D. Curti, MD; Ari M. VanderWalde, MD, MPH, MBioeth; Anna C. Olsson-Brown, MBChB (Hons), BSc (Hons); Francesca Aroldi; Nicos Fotiadis; Scott Baum; Howard L. Kaufman, MD, FACS; Kevin Harrington, MD; | Clinical Trial In Progress | Clinical study; Tumor microenvironment |
| P434 | A phase 1/1b study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent, in combination with CPI-444, and in combination with pembrolizumab in adult patients with advanced cancers | Mehrdad Mobasher; Richard A. Miller; Brian Munneke; Deborah Strahs; Gabriel Luciano; Emily C. Piccione, PhD; Suresh Mahabhashyam; Jaime Merchan; John D. Powderly, II, MD, CPI; Lauren Harshman, MD; Minal Barve; Walter Stadler, MD; Patricia LoRusso, DO; Melissa Johnson; Abhishek Tripathi, MD; Sumanta K. Pal, MD; Ben Markman, MBBS FRACP; Jason J. Luke, MD, FACP; Thomas U. Marron, MD PhD; | Clinical Trial In Progress | Antibody; Antigen presenting cells; B cell; Checkpoint blockade; Clinical trial; Leukemia/Lymphoma; Solid tumors; Targeted therapy |
| P435 | A Window of Opportunity Trial Using Intratumoral Injection of Glatiramer as an Immune Modulator in Patients with Resectable Head and Neck and Cutaneous Squamous Cell Cancer | Ghulam Rehman Mohyuddin, MD; Joaquina C. Baranda, MD; Andres Bur; Lisa Shnayder; Kiran Kakarala; Terry Tsue; Prakash Neupane; Gregory Gan; Joshua Mammen; Daniel Aires; Sufi Thomas; Stephen Williamson; Nelli Lakis; Rashna Madan; Prabhakar Chalise; Scott Weir; Andrew Godwin; Greg Reed; Cory Berkland; | Clinical Trial In Progress | Biomarkers; Clinical trial; NK/NK T cell; Solid tumors; T cell; Tumor microenvironment; Tumor stroma |
| P436 | Phase 2 study of lenvatinib plus pembrolizumab in previously treated patients with solid tumors: LEAP-005 | Ravit Geva, MD; Seock-Ah Im; Zarnie Lwin; Susan Weil; Lei Xu; Anne Morosky; Kevin G. Norwood, MD; Hyun Cheol Chung, MD, PhD; | Clinical Trial In Progress | Antibody; Checkpoint blockade; Clinical trial; Solid tumors; Targeted therapy |
| P437 | Disease-related biomarkers are associated with extended progression free survival after treatment with NEO-PV-01 in combination with anti-PD1 in patients with metastatic cancers | Patrick A. Ott, MD, PhD; Ramaswamy Govindan, MD; Aung Naing, MD, FACP; Terence Friedlander, MD; Kim A. Margolin, MD; Jessica J. Lin, MD; Nina Bhardwaj, MD, PhD; Matthew Hellmann, MD; Mark Awad, MD PhD; Amy Wanamaker; Lisa D. Cleary; Michael Rooney; Julian Scherer, PhD; Meghan E. Bushway; Melissa Moles; Zakaria Khondker; Richard B. Gaynor, MD; Lakshmi Srinivasan, Ph.D; Andrew Chi; Joel Greshock; Siwen Hu-Lieskovan, MD, PhD; | Clinical Trial In Progress | Bioinformatics; Biomarkers; Clinical study; Clinical trial; Immune monitoring; Neoantigens; T cell; Tumor antigens; Tumor microenvironment; Vaccine |
| P438 | Phase 2 Multicenter Trial of ICOS agonist vopratelimab and a CTLA-4 inhibitor in PD-1/PD-L1 inhibitor experienced adult subjects with Non-small Cell Lung Cancer or Urothelial Cancer (EMERGE) | Russell Pachynski, MD; Ramaswamy Govindan, MD; Ellen Hooper, MD; Christopher Harvey, PhD; Amanda Hanson; Sean M. Lacey, MA Biostatistics; Rachel McComb; Courtney Hart; Haley Laken; Johan Baeck; Elizabeth G. Trehu, MD; | Clinical Trial In Progress | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Costimulation; Cytokine; Immune suppression; T cell; Targeted therapy; Tumor antigens |
| P439 | Phase 1 First in Human Study of Programmed Cell Death Receptor-1(PD-1) Inhibitor Monoclonal Antibody (mAb) JTX-4014 in Adult Subjects with Advanced Refractory Solid Tumor Malignancies | Kyriakos P. Papadopoulos, MD; Gerald S. Falchook, MD; Nehal Lakhani, MD, PhD; Gosia Riley; Jian Xu, PhD; Johan Baeck; Gilad S. Gordon; Elizabeth G. Trehu, MD; Judy S. Wang, MD; | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Clinical trial; Immune suppression; Solid tumors; T cell |
| P440 | Phase 1/1b Multicenter Trial of TPST-1120, a Peroxisome Proliferator-Activated Receptor Alpha (PPARα) Antagonist as a Single Agent (SA) or in Combination in Subjects with Advanced Cancers | John D. Powderly, II, MD, CPI; Saurin Chokshi, MD; Johanna Bendell, MD; Leisha A. Emens, MD, PhD; Jason J. Luke, MD, FACP; Brian Francica; Chan C. Whiting, PhD; Thomas W. Dubensky, Jr., PhD; Ginna G. Laport, MD; | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Clinical trial; Metabolism; Solid tumors; Tumor microenvironment |
| P441 | ARTISTRY-2: a phase 1/2 study of subcutaneously administrated ALKS 4230 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors | John D. Powderly, II, MD, CPI; Bradley C. Carthon, MD, PhD; Marc S. Ernstoff, MD; Anthony J. Olszanski, MD, RPh; Stephen V. Liu, MD; Kelly K. Curtis, MD; Yangchun Du, PhD; Lei Sun, PhD; Emily L. Putiri, PhD; Yan Wang, PhD; Heather C. Losey, PhD; Bruce J. Dezube, MD; Ulka N. Vaishampayan, MD; | Clinical Trial In Progress | Checkpoint blockade; Cytokine; Immune suppression; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors |
| P442 | A phase 1 study of FPT155, a first-in-class CD80 extracellular domain-Fc fusion protein, in patients with advanced solid tumors | Amy AP. Prawira, MD; Jermaine Coward; Hui Gan, MBBS PhD; James Kuo; Michael Millward; Gary Richardson; Wei Deng; Siddhartha Mitra; Maike Schmidt; Hong Xiang, PhD; Lisa Horvath; Amy AP. Prawira, MD; | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Clinical trial; Costimulation; Solid tumors; T cell |
| P443 | Expansion cohorts of non-small cell lung cancer (NSCLC) and castration resistant prostate cancer (CRPC) in COSMIC-021, a phase 1b study of cabozantinib plus atezolizumab | Nick Salgia, PhD; Sumanta K. Pal, MD; Santiago Ponce Aix, MD; Yohan Loriot; Robert Dreicer; Ulka N. Vaishampayan, MD; Toni K. Choueiri; Patrick Schöffski; Giri Ramsingh; Amy Liu; Farah L. Lim; Joel Neal, MD, PhD; Neeraj Agarwal, MD; | Clinical Trial In Progress | Clinical trial; Solid tumors |
| P444 | The Quest for Highly Potent Human Papillomavirus-Specific T Lymphocytes for Adoptive Immunotherapy of HPV-Associated Malignancies | Pei Yun Teo, PhD; Sandhya Sharma, BSc.; Alex Salyer; Dimitrios L. Wagner; Benjamin Shin; Sachin Thakar; Li-Chun Huang; Shian Jiun Shih; Carlos Ramos; Cliona M. Rooney, PhD; | Clinical Trial In Progress | Adoptive immunotherapy; Clinical study; Clinical trial; Solid tumors; T cell; Targeted therapy |
| P445 | Preliminary results of a Phase 1 trial with a personalized neoantigen vaccine (ADXS-NEO) in advanced and refractory cancer patients | Frank Y. Tsai, MD; Jonathan W. Goldman, MD; Marc R. Matrana; Sumitra Sheeri; John Heyburn; Megan Parsi; Andres A. Gutierrez, MD PhD; Joel R. Hecht; Joel R. Hecht; | Clinical Trial In Progress | Antigen presenting cells; Biomarkers; Clinical study; Neoantigens; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment; Vaccine |
| P446 | A Novel Regulatory T Cell-Targeted Immunotherapy by targeting their Crucial Signal by HSP90 Inhibitors | Ayaka Tsuge, MD; Yosuke Togashi, MD, PhD; Kohei Shitara, MD; Hiroyoshi Nishikawa, MD, PhD; | Clinical Trial In Progress | Checkpoint blockade; Chemotherapy; Clinical trial; Regulatory T cell (Treg cell); Solid tumors; Tumor microenvironment |
| P447 | ALKS 4230, an engineered IL-2 fusion protein, in monotherapy dose-escalation and combination therapy with pembrolizumab in patients with solid tumors: ARTISTRY-1 trial | Ulka N. Vaishampayan, MD; Jameel Muzaffar, MD; Vamsidhar Velcheti, MD, FACP; Christopher J. Hoimes, DO; Lucy Gilbert, MD; David F. McDermott, MD; Anna Spreafico, MD PhD; Quincy Chu, MD; Kelly K. Curtis, MD; Yangchun Du, PhD; Harald Mackenzie, MB; Lei Sun, PhD; Emily L. Putiri, PhD; Heather C. Losey, PhD; Bruce J. Dezube, MD; Marc S. Ernstoff, MD; | Clinical Trial In Progress | Checkpoint blockade; Cytokine; Immune suppression; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors |
| P448 | Phase I Study of Veliparib and Nivolumab in Adults with Refractory Advanced Solid Tumor and Lymphoma | Young Kwang Chae, MD; Pedro Viveiros, MD; Sheetal Kircher; Valerie Nelson; Aparna Kalyan; Devalingam Mahalingam; | Clinical Trial In Progress | Checkpoint blockade; Clinical trial; Immune adjuvant |
| P449 | Pharmacodynamic biomarker characterization of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy | Hong Wan, PhD; Laura Q. Chow, MD; Justin F. Gainor, MD; Nehal Lakhani, MD, PhD; Hyun C. Chung, MD, PhD; Keun-Wook Lee, MD; Jeeyun Lee, MD, PhD; Patricia LoRusso, DO; Yung-Jue Bang, MD PhD; Stephen Hodi; Wells Messersmith, MD; Philip Fanning, PhD; Pierre Squifflet; Feng Jin; Tracy Kuo; Sangeetha Bollini; Jaume Pons, PhD; Sophia S. Randolph, MD, PhD; | Clinical Trial In Progress | Biomarkers; Checkpoint blockade; Clinical trial; Immune suppression; Monocyte/Macrophage; Myeloid cells; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P450 | A Phase I/IIa, Open-label, Dose-Escalation and expansion study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TJ107 in Chinese Patients with Advanced Solid Tumors | Jin Li; Ye Guo; Wei Peng; Junli Xue; Wei Zhao; Xiaoxiao Ge; Liqiong Xue; Wenbo Tang; Li Zhou; Min Zhang; Bingshi Guo; Liping Wang, MD; Jiyuan Guo; Feifei Cui, PhD; Haiyun Suo; | Clinical Trial In Progress | Clinical trial; Cytokine; Solid tumors; T cell |
| P451 | First-in-human study of CD40 agonist MEDI5083 in advanced solid tumors with durvalumab administered sequentially or concurrently | Ben Tran, MBBS FRACP; Mark Voskoboynik; Johanna Bendell, MD; Martin Gutierrez, MD; Charlotte R. Lemech, MBBS BSc(med) MD(res); Daphne Day; Sophia Frentzas; Ignacio Garrido-Laguna; Chris DelNagro; Fujun Wang; Charles Ferte, MD, PhD; Mayukh Das; Benedito A. Carneiro, MD; Ben Tran, MBBS FRACP; | Clinical Trial In Progress | Antibody; Antigen presenting cells; Checkpoint blockade; Clinical trial; Solid tumors; T cell; Targeted therapy |
| P452 | SPEARHEAD-1 trial design: A phase 2, single arm, open-label clinical trial of ADP-A2M4 SPEAR T-cells in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma | Dejka Araujo, MD; Jean-Yves Blay; Sandra Strauss; Claudia Valverde; Erin Van Winkle; Malini Iyengar, PhD; Rafael Amado, MD; | Clinical Trial In Progress | Adoptive immunotherapy; Clinical study; Clinical trial; Solid tumors; T cell; Targeted therapy |
| P453 | Autologous T cells with NY-ESO-1-specific T-cell receptor (GSK3377794) in HLA-A*02+ previously-treated and -untreated advanced metastatic/unresectable synovial sarcoma: A master protocol study design | Sandra P. D'Angelo, MD; Jean-Yves Blay; Warren Chow; George D. Demetri; Fiona Thistlethwaite, MD, PhD; Michael Wagner; David Loeb; Steven Attia; Albiruni R. Razak; John Haanen, MD PhD; Aisha N. Hasan, MBBS MD; Julia Billiard; Laura Pearce; Yuehui Wu; Ran Ji; Laura Johnson; Chandra Srinath; Aiman Shalabi; Sandra Strauss; Katherine Thornton; Crystal L. Mackall, MD; William Tap; Brian Van Tine, MD, PhD; | Clinical Trial In Progress | Adoptive immunotherapy; CAR T cells; Clinical trial; T cell; Targeted therapy |
| P454 | Induction of serum CXCL10 by tebentafusp, a gp100-CD3 bispecific fusion protein, was associated with survival in uveal melanoma in a Phase I/II Study | Marcus O. Butler, MD; Brandon W. Higgs; Cheryl McAlpine, MSN; Joseph Sacco; Jessica C. Hassel, MD; Shaad E. Abedin, MD, FACP; Koustubh Ranade, PhD; Richard Carvajal, MD; | Clinical Trial In Progress | Biomarkers; Clinical study; Clinical trial; Solid tumors; Tumor antigens |
| P455 | A randomized phase 2 study of neoadjuvant talimogene laherparepvec (T-VEC) plus surgery vs surgery for resectable stage IIIB-IVM1a melanoma: 2-year primary analysis of recurrence-free survival (RFS) | Reinhard Dummer, MD; David E. Gyorki; John Hyngstrom, MD; Adam C. Berger, FACS, MD; Robert M. Conry, MD; Lev Demidov; Anjali Sharma; Sheryl A. Treichel; Kevin Gorski; Abraham Anderson, PhD; Mark Faries; Merrick Ross, MD; | Clinical Trial In Progress | Biomarkers; Clinical study; Clinical trial; Immune contexture; Inflammation; Solid tumors; Surgery |
| P456 | KEYNOTE-630: phase 3 study of adjuvant pembrolizumab versus placebo in patients with high-risk, locally advanced cutaneous squamous cell carcinoma | Jessica L. Geiger; Gregory A. Daniels, MD, PhD; Ezra Cohen, MD; Joy Yang Ge; Burak Gumuscu, MD PhD; Ramona F. Swaby, MD; Anne Lynn S. Chang; | Clinical Trial In Progress | Checkpoint blockade; Clinical study; Clinical trial; Immune adjuvant; Solid tumors |
| P457 | Randomized Phase II Neoadjuvant Study: PD-1 Inhibitor TSR-042 vs. Combination PD-1 Inhibitor TSR-042 and Tim-3 Inhibitor TSR-022 in Borderline Resectable Stage III or Oligometastatic Stage IV Melanoma | Zahra Kelly, DO; Yana G. Najjar, MD; Hassane M. Zarour, MD; John M. Kirkwood, MD; Suthee Rapisuwon, MD; Hong Wang; Marc S. Ernstoff, MD; Joseph J. Drabick, MD, FACP, FIDSA; Diwakar Davar, MD; Mohan Bala; | Clinical Trial In Progress | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Costimulation; Solid tumors; T cell |
| P458 | A phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+ myeloid dendritic cells plus talimogene laherparepvec (T-VEC) in patients with advanced melanoma | Julia Katharina Schwarze, MD, MSc; Gil Awada; Louise Cras; Inès Dufait; Ramses Forsyth; Ivan Van Riet; Bart Neyns; | Clinical Trial In Progress | Antigen presenting cells; Clinical study; Clinical trial; Dendritic cell; Solid tumors; Tumor microenvironment; Vaccine |
| P459 | New Generation Chimeric Antigen Receptor T-Cell Therapy (CoupledCAR) Induces High Rate Remissions in Solid Tumor | Chengfei Pu; Lei Xiao, PhD; | Clinical Trial In Progress | CAR T cells; Checkpoint blockade; Clinical study; Solid tumors; Targeted therapy; Tumor antigens |
| P460 | A Randomized, Placebo-Controlled Phase II Study of Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men with Stage D0 Prostate Cancer | Hoyoung M. Maeng, MD; Lauren V. Wood, MD; Seth Steinberg; David F. Stroncek, MD; Masaki Terabe, PhD; Jay A. Berzofsky, MD, PhD; | Clinical Trial In Progress | Antigen presenting cells; Clinical study; Clinical trial; Dendritic cell; Solid tumors; T cell; Tumor antigens; Vaccine |
| P461 | Phase 1b study of INCMGA00012, a programmed cell death-1 (PD-1) inhibitor, in combination with chemotherapy in patients with advanced solid tumors (POD1UM-105) | David Planchard, MD, PhD; Jill Bowman; Nawel Bourayou, MD; | Clinical Trial In Progress | Checkpoint blockade; Chemotherapy; Clinical trial; Solid tumors |
| P462 | ImmTAC®-chemotherapy combination: A preclinical evaluation shows potential benefits | Adel Benlahrech, BSc PhD; Filipa Bravo-Lopes; Nora Rippaus; Kristina Petrovic; Francesca Amicarella; Adam Taylor; Laure Humbert; Rupert Kenefeck; Adel Benlahrech, BSc PhD; | Combination Immunotherapies | Chemotherapy; T cell; Targeted therapy |
| P463 | Immunotherapy combinations for betel-nuts related HNSCC: one institutional experiences in Taiwan | Jo-Pai Chen, MD; Ruey-Long Hong, MD, PhD; Wei-Chen Lu, MD; | Combination Immunotherapies | Checkpoint blockade |
| P464 | IFN-α and 5-Aza-2’-deoxycytidine enhance the anti-tumor efficacy of a dendritic-cell targeting MIP3α-Gp100-Trp2 DNA vaccine by affecting T-cell and Dendritic Cell recruitment into tumor | James Gordy, PhD; Richard Markham, BS MD; | Combination Immunotherapies | Antigen presenting cells; Chemokine; Chemotherapy; Dendritic cell; Immune adjuvant; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |
| P465 | Immune-mediated mechanisms involved in the synergistic anti-tumor efficacy of NHS-IL12 combined with the class I HDAC inhibitor entinostat. | Kristin C. Hicks, PhD; Yohei Ozawa, MD, PhD; Karin M. Knudson, PhD; Jeffrey Schlom; Sofia Gameiro, PharmD, PhD; | Combination Immunotherapies | Cytokine; Immune adjuvant; Immune suppression; Monocyte/Macrophage; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P466 | Carboplatin and paclitaxel after anti-PD1 or anti-PDL1 therapy: A retrospective study in patients with squamous cell carcinoma of the head and neck | Audrey Humphries, BS; Madeleine Welsh, BA; Alain Algazi, MD; | Combination Immunotherapies | Checkpoint blockade; Chemotherapy |
| P467 | ALPN-202, a Conditional CD28 Costimulator and Dual Checkpoint Inhibitor, Enhances the Activity of Multiple Standard of Care Modalities | Katherine E. Lewis, PhD; Mark F. Maurer, BS; Sherri Mudri, BS; Kayla N. Susmilch, MS; Fariha Ahmed-Qadri, MS; Chelsea J. Gudgeon, BS; Steven D. Levin, PhD; Martin Wolfson, BS; Stacey R. Dillon, PhD; Kristine M. Swiderek, PhD; Stanford L. Peng, MD, PhD; | Combination Immunotherapies | Checkpoint blockade; Chemotherapy; Costimulation; Immune monitoring; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P468 | Targeting the ICOS pathway in combination with chemotherapy to enhance T-cell mediated anti-tumor immune responses | Tamer Mahmoud, PhD; Jeffrey M. Riggs; Madhu Ramaswamy, PhD; Leigh Hostetler; Brian Naiman; Ilyssa Ramos; Sean Turman; Fernanda Pilataxi; Christopher A. Morehouse, MD; Alex Alfaro; Norman Peterson; Ryan Fleming; Nazzareno Dimasi; Kyle Kuszpit; Ronald Herbst; Gianluca Carlesso, PhD; | Combination Immunotherapies | Antibody; Chemotherapy; Costimulation; Metabolism; Regulatory T cell (Treg cell); Solid tumors; T cell |
| P469 | Chemotherapy enhances effector T cell responses to tumor associated antigens in human and mouse pancreatic cancer | Francesco Novelli, PhD; Giorgia Mandili, PhD; Claudia Curcio, PhD; Sara Bulfamante, MS; Laura Follia, MS; Daniele Giordano, MD; Rossella Spadi, MD; Maria Antonietta Satolli, MD; Paola Cappello, PhD MS; Francesco Novelli, PhD; | Combination Immunotherapies | Antibody; Chemotherapy; Proteomics; T cell; Targeted therapy; Tumor antigens; Vaccine |
| P470 | Impact of treatment-induced necrosis in the anti-tumor efficacy of Entinostat combined with the immunocytokine NHS-IL12 | Yohei Ozawa, MD, PhD; Kristin C. Hicks, PhD; Karin M. Knudson, PhD; Jeffrey Schlom; Sofia Gameiro, PharmD, PhD; | Combination Immunotherapies | Cytokine; Monocyte/Macrophage; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P471 | Combination of BL-8040, anti PD-1 and chemotherapy significantly reduced pancreatic tumor growth and changed the balance between CD4+/FOXP3+ cells and CD8+ cells in the tumor | Amnon Peled, PhD; | Combination Immunotherapies | Checkpoint blockade; Chemokine; Chemotherapy; Immune suppression; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P472 | STAT3 ASO and Cisplatin combination sensitizes protected tumor microenvironments to checkpoint-mediated therapy | Theresa Proia, PhD; Maneesh Singh, PhD; Nanhua Deng; Minwei Ye; Frank McGrath; Douglas Ferguson; Simon Barry; | Combination Immunotherapies | Antigen presenting cells; Checkpoint blockade; Chemotherapy; Myeloid cells; Tumor microenvironment |
| P473 | Adoptive transfer of Deep IL-12 Primed T cells increases sensitivity to PD-L1 blockade for superior efficacy in checkpoint refractory tumors | Gulzar Ahmad, PhD; Jonathan Nardozzi, PhD; Lars R. Petersen, PhD; Esben Christensen, MSc; Ditte Jaegher; James Suchy, PhD; Karsten Sauer, PhD; Douglas S. Jones, PhD; Thomas L. Andresen, PhD; | Combination Immunotherapies | Adoptive immunotherapy; Cytokine; MDSC; Solid tumors; T cell; Tumor microenvironment |
| P474 | Efficacy and toxicity evaluation of anti-human CD47 and SIRPa antibodies in genetically humanized B-hSIRPa/hCD47 mice | Frank An; Yanan Guo; Jie Xiang; Chaoshe Guo; | Combination Immunotherapies | Antibody; Immune toxicity; T cell |
| P475 | PD1 and LAG3 converge to limit polyfunctionality and systemic immunity. | Lawrence P. Andrews, PhD; Sasikanth Manne; E. John Wherry, PhD; Creg Workman, PhD; Dario A. Vignali, PhD; | Combination Immunotherapies | Checkpoint blockade; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P476 | The combination of a STING agonist with cytokines results in robust anti-tumor effects in autochthonous tumor models | Cristina Blaj, PhD; Yingjoy Li; Allen Chen; Anthony L. Desbien, PhD; Brian Francica, PhD; Sarah McWhirter; Lora Picton; K. Christopher Garcia; David Raulet, PhD; | Combination Immunotherapies | Cytokine; NK/NK T cell; Solid tumors; T cell; Tumor microenvironment |
| P477 | Isoform-specific blockade of active TGFb1 with mAb 13A1 enhances the efficacy of PD-L1 checkpoint therapy in a EMT6 mouse tumor model | Matteo Brioschi; Jacques Van Snick, PhD; Catherine Uyttenhove; Pamela Cheou; George Coukos, MD, PhD; Gerd Ritter; Steven M. Dunn, PhD; Steven M. Dunn, PhD | Combination Immunotherapies | Antibody; Checkpoint blockade; Coinhibition; Cytokine; Immune contexture; Immune suppression; Solid tumors; Tumor evasion; Tumor microenvironment; Tumor stroma |
| P478 | SEMA4D antibody blockade overcomes mechanisms of immune suppression and combination immunotherapy including TGFβ blockade promotes efficient tumor regression | Elizabeth E. Evans, PhD; Terrence L. Fisher, Jr., PhD; Crystal Mallow, BS; Holm Bussler, PhD; Sebold Torno, BS; Desa Rae Pastore; Alan Howell, MS; Luis I. Ruffolo, MD; Nicholas Ullman; Brian A. Belt, JD; Joe Bucukovski; Christine Reilly, BS; Benjamin Dale; Ernest S. Smith, PhD; David C. Linehan, MD; Maurice Zauderer, PhD; Elizabeth E. Evans, PhD; | Combination Immunotherapies | Antibody; Checkpoint blockade; Clinical trial; Immune suppression; Myeloid cells; MDSC; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P479 | Evaluation of a TNFR2 antibody with and without anti-PD-1 therapy in two murine colon cancer models | Katie L. Case; Lisa Tran; Hui Zheng; Michael Yang; Denise L. Faustman, MD, PhD; | Combination Immunotherapies | Antibody; Checkpoint blockade; Regulatory T cell (Treg cell); Solid tumors; Tumor microenvironment |
| P480 | Heterologous Prime-Boost Vaccination Safely Enhances Antitumor Immunity to the Colorectal Antigen GUCY2C | John C. Flickinger, Jr., BS; Robert carlson; Jagmohan Singh; Trevor Baybutt, BS; Elinor Leong; Alicja Zalewski; Amanda Pattison; Jeffrey Rappaport; Joshua Barton; Scott A. Waldman; Adam E. Snook, PhD; John C. Flickinger, Jr., BS; | Combination Immunotherapies | Solid tumors; Targeted therapy; Tumor antigens; Vaccine |
| P481 | Obesity impairs immunotherapeutic efficacy in pre-clinical breast cancer | Justin T. Gibson, BS; Rachael M. Orlandella, BS; William J. Turbitt; Robert E. Sorge, PhD; Lyse A. Norian, PhD; | Combination Immunotherapies | Immune suppression; MDSC; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P482 | STACT: A Novel Therapeutic Platform that Delivers Immunomodulatory Payloads to Tumor-Resident Myeloid Cells After IV Dosing and Demonstrates Potent Anti-Tumor Efficacy in Preclinical Studies | Laura H. Glickman, PhD; Christopher Rae, PhD; Alexandre Iannello, PhD; Anastasia M. Makarova, PhD; Haixing Kehoe, MS; John Faulhaber; Bill Hanson; Christopher Thanos, PhD; | Combination Immunotherapies | Chemokine; Cytokine; Monocyte/Macrophage; Myeloid cells; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); TLR; Tumor microenvironment |
| P483 | TLR enhanced GVAX elicits tumor-specific tissue resident memory T cells independent of T cell priming | Michael J. Korrer; David Taylor; Young J. Kim, MD, PhD; Michael J. Korrer, PhD; | Combination Immunotherapies | Antigen presenting cells; Immune adjuvant; Myeloid cells; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); TLR; Vaccine |
| P484 | CB-708, an orally bioavailable small molecule inhibitor of CD73 with immunostimulatory and anti-tumor activity | Clarissa Lee, PhD; Deepthi Bhupathi; Roland Billedeau; Jason Chen; Lijing Chen; Rosalyn Dang; Matthew Gross; Tony Huang; Weiqun Li, PhD; Yong Ma; Andrew MacKinnon; Gisele Marguier, MS; Silinda Neou, MS; Francesco Parlati, PhD; Natalija Sotirovska, MS; Sandra Spurlock; Timothy Stanton; Susanne Steggerda, PhD; Jing Zhang; Winter Zhang; Jim Li; | Combination Immunotherapies | Checkpoint blockade; Chemotherapy; Immune suppression; Solid tumors; T cell; Tumor microenvironment |
| P485 | Synergistic efficacy of anti-PD-L1/IL-15 fusion protein in combination with anti-CTLA-4 antibody in a murine orthotopic 4T1 breast carcinoma model | Stella Martomo, PhD; Dan Lu, MA; Jeegar Patel; Zhanna Polonskaya; Xenia Luna; Kevin McCracken; | Combination Immunotherapies | Antibody; Checkpoint blockade; Cytokine; Gene expression; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P486 | Releasing the break on T cell activation through novel small molecule inhibition of HPK1 | Minhui Shen; Gayathri Bommakanti, PhD; Deanna A. Mele, PhD; Deanna A. Mele, PhD; Neil Grimster, PhD; | Combination Immunotherapies | T cell; Tumor evasion |
| P487 | Combining an engineered costimulatory vaccine with NK cells induces an anti-tumor effect against murine neuroblastoma in vitro and after bone marrow transplant in vivo | Nicholas R. Mohrdieck, BS.; Paul Bates; Sean P. Rinella; Katharine E. Tippins; Christian M. Capitini, MD; | Combination Immunotherapies | Adoptive immunotherapy; Costimulation; Cytokine; Immune adjuvant; NK/NK T cell; Pediatric tumors; Solid tumors; Vaccine |
| P488 | IPH5201, a blocking antibody targeting the CD39 immunosuppressive pathway, unleashes immune responses in combination with cancer therapies. | Pascale Andre; Ivan Perrot; Caroline Denis, PhD; Marc Giraudon-Paoli; Severine Augier; Rachel Courtois; Diana Jecko; Thomas Arnoux; Violette Breso; Nicolas Gourdin, PhD; Nadia Luheshi, PhD; Ariane Morel, PhD; Yannis Morel, PhD; Eric Vivier; Carine Paturel, PhD; | Combination Immunotherapies | Antibody; Checkpoint blockade; Coinhibition; Immune suppression; Solid tumors; T cell; Tumor microenvironment |
| P489 | Identification and characterization of MCLA-145 (CD137 x PD-L1): A bispecific antibody that requires PD-L1 binding to activate CD137. | Simon E. Plyte; Cecile Geuijen; John de Kruif; Pieter Fokko van Loo, PhD; Paul Tacken; vanessa Zondag-vander Zande; Rinse klooster; hans van Maaden; Erik Rovers; steef engels; floris franzen; abdul basmeleh; willem bartelink; Mark Throsby; Patrick Mayes; Horacio Nastri; shaun stewart; jing zhou; steve wang; Chen-yen Huang; thomas codamine; ashwini kularni; yao bin lui; arpita mondal; leslie hall; soeon kim; marina martinez; shaun o'brien; edmund moon; steven albelda; | Combination Immunotherapies | Antibody; Checkpoint blockade; Costimulation; T cell; Targeted therapy |
| P490 | Antibody derived from an elite responder to checkpoint inhibitor therapy relieves immunosuppression by tumor associated macrophages | Randi Simmons; Siddarth Chandrasekaran; Melissa Conerly; Tyrel Smith; Sam Lam; Jacqueline Pham; Ray Fox; Darbie Whitman; Meghan Zuck; Sara Carbonetti; Kamal D. Puri, PhD; | Combination Immunotherapies | Antibody; Checkpoint blockade; Immune suppression; Monocyte/Macrophage; Myeloid cells; MDSC; T cell; Targeted therapy; Tumor evasion; Tumor microenvironment |
| P491 | Preclinical Development of a Novel TNFRSF25 Agonist Antibody, PTX-35, for Cancer Immunotherapy Combinations | Matthew M. Seavey, PhD; Jayalakshmi Miriyala, MS; Jason Rose, MS; Vikas Tahiliani, PhD; Patrick Dillon, PhD; Elena Gorovits, PhD; Jeff Hutchins, PhD; Rahul R. Jasuja, PhD; | Combination Immunotherapies | Antibody; Immune adjuvant; Inflammation; Regulatory T cell (Treg cell); Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Vaccine |
| P492 | A new generation anti-TGFβ antibody, SAR439459, relieves immunosuppression and improves anti-tumor efficacy of PD1 blockade | Rita M. Greco; Hongjing Qu; Joachim Theilhaber; Gary Shapiro; Richard Gregory, PhD; Christopher Winter; Natalia Malkova; Lily Pao; Mikhail Levit; Alexei Protopopov; Jack Pollard, PhD; Tun Tun Lin, MD; Dmitri Wiederschain; Sharad Sharma, PhD; | Combination Immunotherapies | Coinhibition; Immune suppression; T cell; Tumor microenvironment |
| P493 | High-Dimensional Analysis Delineates Modulation of Myeloid and Lymphoid Compartments with STAT3 ASO and PDL-1 combination Therapy | Theresa Proia, PhD; Maneesh Singh, PhD; Larissa S. Carnevalli, PhD; Gayathri Bommakanti, PhD; Nanhua Deng; Matthew Griffin; Lukasz Magiera; Adina Hughes; Laura Prickett; Patricia McCoon, PhD; Corinne Reimer; Simon Barry, PhD; | Combination Immunotherapies | Checkpoint blockade; Immune suppression; Monocyte/Macrophage; Myeloid cells; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P494 | A Novel TNFRSF25 Agonist, PTX35, Synergizes with Gp96-Ig/OX40L-Ig to Enhance Effector and Memory Anti-Tumor CD8+ T Cell Responses and Delay Tumor Growth | Vikas Tahiliani; Patrick Dillon, PhD; Jayalakshmi Miriyala, MS; Jason Rose, MS; Anh Trinh; Rahul R. Jasuja, PhD; Jeff Hutchins, PhD; Matthew M. Seavey, PhD; | Combination Immunotherapies | Antibody; Immune adjuvant; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment; Vaccine |
| P495 | Secondary immune resistance mechanisms induced by therapeutic cancer vaccines which prevent tumor regression and foster recurrences. | Sjoerd H. Van der Burg, PhD; Elham Beyranvand Nejad; Camilla Labrie; Suzanne van Duikeren, Ing; Ramon Arens, PhD; Thorbald van Hall, PhD; Sjoerd H. van der Burg, PhD; | Combination Immunotherapies | Checkpoint blockade; Cytokine; Immune contexture; Inflammation; Myeloid cells; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment; Tumor stroma; Vaccine |
| P496 | Inhibition of Autophagy Enhances Multifunctional Genetically-Engineered NK cell-Based Immunotherapy of Glioblastoma | Jiao Wang, PhD; Sandro Matosevic, PhD; Jiao Wang, PhD; | Combination Immunotherapies | Adoptive immunotherapy; Antibody; Checkpoint blockade; Chemokine; Immune suppression; NK/NK T cell; Solid tumors; Targeted therapy; Tumor evasion; Tumor microenvironment |
| P497 | DRP-104, A Novel Broad Acting Glutamine Antagonist, Induces Distinctive Immune Modulation Mechanisms and Synergistic Efficacy in Combination with Immune Checkpoint Blockade | Yumi Yokoyama, PhD; Michael Nedelcovych, PhD; Robert Wild, PhD; | Combination Immunotherapies | Checkpoint blockade; Monocyte/Macrophage; Metabolism; NK/NK T cell; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P498 | Blockade of PD-1 and LAG-3 on CD8+ T cells, induced by vaccination, elicits superior anti-tumor efficacy | Christopher W. Zahm, PhD; Douglas G. McNeel, MD, PhD; Laurne E. Delmastro; | Combination Immunotherapies | Antigen presenting cells; Checkpoint blockade; Dendritic cell; Solid tumors; T cell; Tumor evasion; Tumor microenvironment; Vaccine |
| P499 | Nano-Pulse Stimulation in combination with the TLR 7/8 agonist, resiquimod, synergizes to eliminate murine melanoma through innate and adaptive immune responses | Joel Benjamin, PhD; Amanda McDaniel, BA; Kristin von Rothstein; Sasha Farina; Bruce Freimark, PhD; Richard Nuccitelli, MS, PhD; | Combination Immunotherapies | Antigen presenting cells; Biomarkers; Dendritic cell; Immune adjuvant; TLR; Tumor antigens; Tumor microenvironment; Vaccine |
| P500 | Targeting PARP-1 with metronomic therapy as a new approach to modulate MDSC function and enhance anti-PD1 immunotherapy in colon cancer | Salome Valentina Ibba, PhD; Mohamed Ghonim; Abdelmetalab Tarhuni; Matthew Dean; Hamid Boulares, PhD; Augusto C. Ochoa, MD; Youssef Errami; Ali Elbahraway; Ilyes Benslimane; Dorota Wyczechowska; Luis Del Valle, MD; Amir Al-Khami; Hanh Luu; | Combination Immunotherapies | Checkpoint blockade; Cytokine; Gene expression; Immune suppression; Inflammation; MDSC; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P501 | Dietary deprivation of non-essential amino acids improves anti-PD-1 immunotherapy in murine colon cancer | Xiyan Li, PhD; Zehui Li, PhD; Grace X. Yang, PhD; Shuang Zhou, PhD; Xin Wang, MD, PhD; Xiyan Li, PhD; | Combination Immunotherapies | Metabolism; Solid tumors |
| P502 | In Vitro and In Vivo RRx-001 Synergy with Regorafenib and In Vivo Attenuation of Regorafenib-Induced Toxicity | Bryan Oronsky, MD PhD; Tony Reid, MD PhD; Corey A. Carter, MD; Christopher Larson, MD PhD; Pedro Cabrales, PhD; | Combination Immunotherapies | Costimulation; Immune adjuvant; Immune tolerance; Immune toxicity; Solid tumors |
| P503 | Local treatment with adenovirus expressing TNF-α and IL-2 proteins promotes abscopal effect in mice receiving anti-PD-1 immunotherapy | Dafne C. Quixabeira; Victor Cervera-Carrascon, MS; Joao M. Santos, MS; Riikka Havunen; Akseli Hemminki, MD, PhD; | Combination Immunotherapies | Checkpoint blockade; Cytokine; Solid tumors; T cell; Tumor microenvironment |
| P504 | ¬Arginase therapy combines effectively with checkpoint blockade or agonist anti-OX40 immunotherapy to control tumor growth | William L. Redmond, PhD; Annah S. Rolig, Ph. D; Scott Rowlinson, PhD; Melissa J. Kasiewicz, BS; Mark D. Badeaux, PhD; William L. Redmond, PhD; Giulia Agnello, PhD; Leslie Priddy, BS; Danlee Enzler, BS; Jason F. Wiggins, BS; Christopher Daige; Jessica Van Cleef; | Combination Immunotherapies | Antigen presenting cells; Checkpoint blockade; Costimulation; Monocyte/Macrophage; Myeloid cells; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P505 | Abscopal immunity achieved via in situ vaccination using a novel combination of cryoablation and Interleukin-12 | Maura R. Vrabel; Francis B. Gillam, PhD; Jared J. Hopkins; Khue G. Nguyen, PhD; David A. Zaharoff, PhD; David A. Zaharoff, PhD; | Combination Immunotherapies | Immune adjuvant; Inflammation; Neoantigens; Solid tumors; Tumor antigens; Tumor microenvironment; Vaccine |
| P506 | Targeting inflammation in the tumor micro-environment to improve radiation and immunotherapy | Debashree Basudhar, PhD; Veena Somasundaram, PhD; Robert Cheng; David A. Scheiblin; Erika Palmieri; William F. Heinz; Noemi Kedei; Jinqiu Chen; Daniel W. McVicar, PhD; Stephen J. Lockett; David A. Wink; Lisa Ridnour, PhD; Debashree Basudhar, PhD; | Combination Immunotherapies | Biomarkers; Checkpoint blockade; Immune suppression; Inflammation; Monocyte/Macrophage; Radiotherapy; T cell; Targeted therapy; Tumor microenvironment |
| P508 | Combination of a radiation-enhancing nanoparticle, radiotherapy,and immune checkpoint inhibitors for treating metastasized lung cancer in mice | Yun Hu; James Welsh; Sébastien PARIS; Angelica M. Cortez; | Combination Immunotherapies | Checkpoint blockade; Radiotherapy; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs) |
| P509 | Myeloid Cell-Selective STAT3 Inhibition Sensitizes Head and Neck Cancers to Radiation Therapy and Stimulates T-cell-Dependent Tumor Regression | Marcin Kortylewski, PhD; Dayson F. Moreira, PhD; Marcin Kortylewski, PhD; Sagus Sampath; Haejung Won; Chongkai Wang; Peter P. Lee, MD; Ellie Maghami; Erminia Massarelli, MD, PhD, MS; William C. Spanos, MD; Seok White; | Combination Immunotherapies | Clinical study; Immune suppression; Monocyte/Macrophage; Myeloid cells; MDSC; Radiotherapy; Solid tumors; TLR; Tumor microenvironment |
| P510 | Treatment of murine mammary carcinoma with focal radiation and immune checkpoint inhibition results in reduced immune suppression and enhanced cytotoxic immune cell activity | Philip E. Lapinski, PhD; Maryland Franklin, PhD; David Draper, PhD; Scott Wise, BS; | Combination Immunotherapies | B cell; Checkpoint blockade; Immune suppression; NK/NK T cell; Radiotherapy; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P511 | Mechanistic insights into combination low dose targeted radionuclide and checkpoint blockade treatment to turn a “cold” tumor “hot” | Ravi Patel, MD, PhD; Reinier Hernandez, PhD; Peter M. Carlson, BS; Ryan Brown; Luke Zangl; Amber Bates; Ian Arthur; Justin C. Jagodinsky; Joseph Grudinski; Amy K. Erbe, PhD; Jamey Weichert; Paul M. Sondel, MD, PhD; Zachary S. Morris, MD, PhD; Ravi Patel, MD, PhD; | Combination Immunotherapies | Checkpoint blockade; Radiotherapy; Solid tumors; Targeted therapy; Tumor microenvironment |
| P512 | Efficacy of combined radio- and immuno-therapies vs. radiotherapy alone in the treatment of brain metastases: a systematic review and meta-analysis | Kirill Peskov; Veronika Voronova; Svetlana Lebedeva; Marina Sekacheva; Gabriel Helmlinger, PhD; | Combination Immunotherapies | Immune tolerance; Radiotherapy; Solid tumors |
| P513 | Radiation therapy as a tool to optimize immunomodulation by cell cycle inhibitors in HR+ breast cancer | Giulia Petroni; Aitziber Buqué Martinez; Maurizio Di Liberto; Takahiro Yamazaki, PhD; Norma Bloy; Ai Sato; Selina Chen-Kiang; Silvia Formenti, MD; Lorenzo Galluzzi; | Combination Immunotherapies | Cytokine; Radiotherapy; Solid tumors; Targeted therapy |
| P514 | Molecularly targeted radionuclide therapy modulates the composition of the murine prostate cancer microenvironment | Hemanth K. Potluri, BA; Reinier Hernandez, PhD; Christopher W. Zahm, PhD; Joseph Grudzinski, PhD; Christopher Massey; Jamey Weichert, PhD; Douglas G. McNeel, MD, PhD; | Combination Immunotherapies | MDSC; Radiotherapy; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine |
| P515 | Defining the TCR repertoire and functional differentiation of tumor-infiltrating T cells in mice responding to radiotherapy and CTLA-4 blockade | Nils-Petter Rudqvist, PhD; Claire Lhullier, PhD; Erik Wennerberg, PhD; Jennifer Sims, PhD; Sandra Demaria, MD; | Combination Immunotherapies | Checkpoint blockade; Immune monitoring; Radiotherapy; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P516 | Radiation-driven changes in immunomodulatory DNA cargo of exosomes produced by cancer cells | Sheila Spada, PhD; Sandra Demaria, MD; Sheila Spada, PhD; Nils-Petter Rudqvist, PhD; Tuo Zhang, PhD; | Combination Immunotherapies | Dendritic cell; Immune contexture; Radiotherapy; Solid tumors |
| P517 | Potent anti-tumor effect of systemically administered nanoparticles containing a TLR7 agonist in combination with radiotherapy | Camilla Stavnsbjerg, MSc; Esben Christensen, MSc; Rasmus Münter, MSc; Andreas Kjær, MD, PhD; Svetlana Panina, MD, PhD; Martin Bak, PhD; Jonas R. Henriksen, PhD; Simon Jensen, PhD; Anders E. Hansen, DVM, PhD; Thomas L. Andresen, PhD; | Combination Immunotherapies | Antigen presenting cells; Immune adjuvant; Myeloid cells; Radiotherapy; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); TLR; Tumor antigens; Tumor microenvironment |
| P518 | Testing a new platform for precision use of radiation therapy to induce in situ vaccination in breast cancer | Samantha J. Van Nest, PhD; Tasnim Anika; Adriana Irizarry; Laura Martin; Giorgio Inghirami; Silvia Formenti, MD; Sandra Demaria, MD; Samantha J. Van Nest, PhD; | Combination Immunotherapies | Biomarkers; Checkpoint blockade; Radiotherapy; Vaccine |
| P519 | Immunogel - an intratumoral multi-drug sustained release technology that polarizes the tumor microenvironment towards a proinflammatory and immunosupportive state | Trine B. Engel, PhD; Jennifer S. Jørgensen, PhD; Lars Ringgaard, PhD; Fredrik Melander, PhD; Sophie B. Jensen, MSc; Linda M. Bruun, PhD; Camilla Stavnsbjerg, MSc; Andreas Tue I. Jensen, PhD; Julianna Thuróczy, DVM, PhD, Dipl. ECAR; Lajos Balogh, DVM, PhD; Frederikke P. Fliedner, MSc; Martin Bak, PhD; Andreas Kjær, MD, PhD; Jonas R. Henriksen, PhD; Anders E. Hansen, DVM, PhD; Thomas L. Andresen, PhD; | Combination Immunotherapies | Checkpoint blockade; Chemotherapy; Radiotherapy; Solid tumors; Tumor infiltrating lymphocytes (TILs); TLR; Tumor microenvironment |
| P520 | Matching-adjusted indirect comparison of pembrolizumab plus axitinib versus nivolumab plus ipilimumab for the first-line treatment of advanced/ metastatic renal cell carcinoma | Yufei Wang; Yichen Zhong, PhD; Shahrul Mt-Isa; Rodolfo Perini, MD; Oluwakayode Adejoro, MD, MPH; Oluwakayode Adejoro, MD, MPH; Oluwakayode Adejoro, MD, MPH; | Combination Immunotherapies | Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; Targeted therapy |
| P521 | MEK inhibition enhances oncolytic herpes virus immunotherapy | Praveen K. Bommareddy, MS, PhD; Andrew Zloza, MD, PhD; Samuel Rabkin, PhD; Howard L. Kaufman, MD, FACS; | Combination Immunotherapies | Checkpoint blockade; Dendritic cell; Gene expression; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor microenvironment |
| P522 | Preclinical development of M4112, an IDO1/TDO2 dual selective and orally bioavailable small molecule inhibitor, and combination with avelumab, for treatment of solid tumors | Jieqing Chen, MD; Chia Lin Chu, PhD; Feng Jiang, PhD; Chunxiao Xu, PhD; Yanping Zhang; Sireesha Yalavarthi; Molly Coop; Hong Wang; Yanyan Wang; Bettina Hanschke; Anindya Siddharta; Sen Zhang; Amit Deshpande; Bartholomew Naughton, PhD; Filippos Porichis; Tai-An Lin, PhD; Joern-Peter Halle; Tilo Senger; Brian Sherer; Jacques Moisan; | Combination Immunotherapies | Checkpoint blockade; Coinhibition; Immune suppression; Metabolism; Solid tumors; Tumor evasion; Tumor microenvironment |
| P523 | Immunotherapy plus gene therapy: A tumor-targeting nanomedicine carrying the TP53 gene crosses the blood–brain barrier and enhances anti-PD-1 immunotherapy in mouse models of glioblastoma | Joe B. Harford, PhD; Sang-Soo Kim, PhD; Manish Moghe; Caroline Doherty; Esther H. Chang, PhD; | Combination Immunotherapies | Biomarkers; Checkpoint blockade; Dendritic cell; Gene expression; Immune suppression; NK/NK T cell; Regulatory T cell (Treg cell); T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| P524 | CRISPR CAS9 mediated BRCA1 knockout modulates the tumor infiltrating lymphocytes landscape and cytokine profile in a murine breast cancer model | Julia Schuler; Anya Avrutskaya; Kanstantsin Lashuk; Mariette Heins, PharmD; Cordula Tschuch; Astrid Jensen; Gerhard Kelter; Anne-Lise Peille; Maycee Robinson; William Durham; Armin Mayer; Anne-Marie Zuurmond; | Combination Immunotherapies | Checkpoint blockade; Monocyte/Macrophage; MDSC; NK/NK T cell; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P525 | Dose-dependent sensitization of combined anti-angiogenic and PD-1 blockade in breast cancer | Wen Jiang, MD, PhD; Yifan Wang, PhD; Betty Y. Kim; Jieqiong Liu, MD, PhD; | Combination Immunotherapies | Angiogenesis; T cell; Targeted therapy; Tumor microenvironment |
| P526 | Combination cabozantinib and nivolumab treatment in patients with refractory metastatic renal cell carcinoma (mRCC) | Emily N. Kinsey, MD; Landon C. Brown, MD; Chester Kao, MD; Patrick Healy; Michael R. Harrison, MD; Megan A. McNamara, MD; Andrew J. Armstrong, MD; Sundhar Ramalingham, MD; Daniel J. George, MD; Tian Zhang, MD; | Combination Immunotherapies | Checkpoint blockade; Immune toxicity; Solid tumors; Targeted therapy |
| P527 | IgE-based therapeutic strategy against pancreatic cancer | Kamiya Mehla, PhD; Ragupathy Madiyalakan, PhD; Christopher Nicodemus, MD; Thomas Caffrey; Michael A. Hollingsworth, PhD; kelly A. O' connell; | Combination Immunotherapies | Antibody; Dendritic cell; Immune adjuvant; NK/NK T cell; Solid tumors; T cell; Targeted therapy; TLR; Tumor antigens; Tumor microenvironment |
| P528 | Combination antibody treatment targeting PD-L1 and 4-1BB leads to reduced anti-tumor immunity against CT26 tumors in B-cell deficient JH-/- mice | Zhengming Yan; Heather Llewellyn; Kerry Kelleher; Bernadette Pascual; Angela Stauffer; Ying Ding; Xiaorong Li; Mark Ozeck; Jeffrey Toste; Han Yang; Haikuo Zhang; Sripad Ram, PhD; Sripad Ram, PhD; Sripad Ram, PhD; Cathy Zhang; | Combination Immunotherapies | Antibody; B cell; Checkpoint blockade; Immune contexture; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| P529 | A tumor microenvironment-recognizable polymeric conjugate for antigen delivery and cancer immunotherapy | Jung Min Shin; Seok Ho Song; Jae Ah Lee; Jae Hyung Park, PhD; | Combination Immunotherapies | T cell; Targeted therapy; Tumor microenvironment; Vaccine |
| P530 | Blockade of IDO/TDO downstream effectors restricts a Treg-macrophage suppressive axis and resistance to anti-PD-1 therapy | Luis F. Campesato, PhD; Sadna Budhu, PhD; Jeremy H. Tchaicha, PhD; Mathieu Gigoux, PhD; Ivan Cohen; Levi M. Mangarin, BS; David Redmond; Stephane Pourpe; Cailian Liu, MD; Roberta Zappasodi, PhD; Dmitriy Zamarin, MD, PhD; Mark Manfredi, PhD; Karen McGovern, PhD; Taha Merghoub, PhD; Jedd D. Wolchok, MD, PhD; Luis F. Campesato, PhD; | Combination Immunotherapies | Checkpoint blockade; Immune suppression; Immune tolerance; Monocyte/Macrophage; Myeloid cells; Metabolism; Regulatory T cell (Treg cell); Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P531 | A Tumor PD-L1-NLRP3 Inflammasome Signaling Axis Drives Adaptive Resistance to Anti-PD-1 Immunotherapy | Balamayooran Theivanthiran, PhD; Kathy Evans, BS; Nicholas DeVito, MD; Michael Plebanek, PhD; Michael Sturdivant, BS.; Alisha H. Holtzhausen, PhD; Luke P. Wachsmuth, BS.; April Salama, MD; Yubin Kang, MD; David Hsu, MD, PhD; Justin M. Balko, PhD, PharmD; Douglas B. Johnson, MD, MSCI; Mark Starr, BS.; Andrew Nixon, PhD; Brent A. Hanks, MD, PhD; | Combination Immunotherapies | Checkpoint blockade; Chemokine; Gene expression; Immune suppression; MDSC; Proteomics; Solid tumors; TLR; Tumor evasion; Tumor microenvironment |
| P532 | Increased adiposity reduces the response rate to a combinatorial CTLA-4 based therapy in diet-matched, renal tumor-bearing mice without substantially altering intra-tumoral T cell profiles | William J. Turbitt, Jr., PhD; Shannon Boi; Rachael M. Orlandella, BS; Justin T. Gibson, BS; Lyse A. Norian, PhD; | Combination Immunotherapies | Checkpoint blockade; Gene expression; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P533 | The genomic architecture of serous carcinomas shapes the tumor microenvironment and modulates responses to targeted and immunotherapies. | Sonia Iyer, PhD; Shuang Zhang; Anniina Farkkila; David Pepin; Raghav Mohan; Sean G. Smith, PhD; Tian Xia; Ferenc Reinhardt; Tony Chavarria; Esmee Hoefsmit; Shailja Pathania; Yunlan Zhou; Kevin Elias; Benjamin Neel; Robert Weinberg, PhD; | Combination Treatments | Checkpoint blockade; Chemotherapy; Immune contexture; Immune suppression; Myeloid cells; MDSC; Regulatory T cell (Treg cell); Targeted therapy; Tumor evasion; Tumor microenvironment |
| P535 | The automated subset assignment pipeline (ASAP) for data-driven clustering and automated analysis of flow cytometry immunophenotyping | Lisa K. Blum, PhD; Isabelle G. Solman, MS; Ann Mongan, PhD; Lisa K. Blum, PhD; | Data Sharing, Handling, and Access | Bioinformatics; Immune monitoring; Leukemia/Lymphoma |
| P536 | Orbital tumor board: life saver or time waster ? | Ayesha Butt, Medical Student; Irfan Jeeva, MBBS, MRCOphth (UK), FRCOphth (UK), FEBO (EU), CCT; Ayesha Butt, Medical Student; | Education and Treatment Management | Chemotherapy; Pediatric tumors; Radiotherapy; Solid tumors; Surgery |
| P537 | A Case of Subacute Cutaneous Lupus Erythematosus with Adjuvant Nivolumab for Resected Stage IV Melanoma | Logan Rhea, DO; Pragya Singh, MD; Jeff Harvell; Suraj Venna, MD FAAD; Sekwon Jang, MD; Logan Rhea, DO; | Education and Treatment Management | Checkpoint blockade; Immune toxicity |
| P538 | Outcomes of a Newly Formed Multidisciplinary Retinoblastoma Service | Ayesha Butt, Medical Student; Irfan Jeeva, MBBS, MRCOphth (UK), FRCOphth (UK), FEBO (EU), CCT; | Education and Treatment Management | Pediatric tumors; Radiotherapy; Solid tumors; Surgery |
| P539 | Management of Melanoma: Education Improving Clinical Decisions of Oncologists | Kinjal Parikh, PharmD; Haleh Kadkhoda, MS; Jeffrey S. Weber, MD, PhD; Charlotte Warren; Ann Carothers, MEd; | Education and Treatment Management | Checkpoint blockade; Solid tumors |
| P540 | Understanding oncologist preferences for chemotherapy and immunotherapy monotherapy and combinations for first-line treatment of metastatic non-small cell lung cancer: a discrete choice experiment | Candice Yong, PhD; Brian Seal, RPh, MBA, PhD; Kathleen Beusterien, MS; M. Janelle Cambron-Mellott, PhD; Martine C. Maculaitis, PhD; Kelly Clapp; Emily Mulvihill, MBA; Ion Cotarla, MD, PhD; Ranee Mehra, MD; | Education and Treatment Management | Adoptive immunotherapy; Chemotherapy; Targeted therapy |
| P541 | Informing and Empowering Cancer Caregivers about Immunotherapy: Results from a Psychoeducational Workshop on Immunotherapy | Maria B. Gonzalo; Claire Saxton, MBA; Claire Saxton, MBA; Alexandra Zaleta, PhD; Kirstin Fearnley; | Education and Treatment Management | Targeted therapy |
| P542 | Case of an outstanding anti-cancer immune response in a microsatellite stable metastatic colon cancer | Thomas Duhen, PhD; Carmen Ballesteros Merino, PhD; Venkatesh Rajamanickam; Brady M. Bernard, PhD; Bernard A. Fox, PhD; Eric C. Anderson, MD, PhD; Philippa H. Newell, MD; | Immune Cell Biology | Chemotherapy; Neoantigens; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P543 | A transcriptional signature of exhausted CD8+ T cells predicts relapse-free outcome in ER+ breast cancer patients | Colt Egelston, PhD; Weihua Guo; Christian Avalos; Min Hui Lim; Diana L. Simons; Peter P. Lee, MD; Colt Egelston, PhD; | Immune Cell Biology | Gene expression; T cell; Tumor infiltrating lymphocytes (TILs) |
| P544 | The generation of memory CD8 T cells is regulated by intracellular Galectin-3 | Mohammad Farhad, MS; William L. Redmond, PhD; Mohammad Farhad, MS; | Immune Cell Biology | Costimulation; Cytokine; T cell |
| P545 | Expression of retention integrins by human CD4+ T cells | Kevin Lynch, MD; Marit M. Melssen, MSc; Walter C. Olson, PhD; Craig Slingluff; Kevin Lynch, MD; | Immune Cell Biology | Cytokine; T cell |
| P546 | Immunoprofiling myeloid-derived suppressor cells in non-small cell lung carcinomas using multiplex immunofluorescence and image analysis approaches | Edwin R. Parra, MD., PhD; Mei Jiang; Cara Haymaker, PhD; Jiexin Zhang, PhD; Tong Li; Carmen Behrens, MD; Chantale Bernatchez; Auriole Tamegnon; Renganayaki K. Pandurenga; Jack Lee, PhD; John V. Heymach; Cesar Moran, MD; Ignacio Wistuba, MD; | Immune Cell Biology | Biomarkers; Granulocyte; Immune suppression; Inflammation; Monocyte/Macrophage; MDSC; Tumor microenvironment |
| P547 | Distinct B cell signatures and tertiary lymphoid structures are driven by two etiologies in head and neck cancer | Ayana Ruffin, MS; Anthony R. Cillo, PhD; Sayali Onkar; Sheryl R. Kunning; Robert L. Ferris, MD, PhD; Dario A. Vignali, PhD; Tullia C. Bruno, PhD; | Immune Cell Biology | B cell; Immune contexture; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P548 | Beyond a cell metabolite: Glutamate receptor signaling improves antitumor T cell immunity | Anil Shanker, PhD; Maria Teresa P. De Aquino, PhD; Thomas Hodo, MS; Roman V. Uzhachenko, PhD MD; Anil Shanker, PhD; | Immune Cell Biology | Adoptive immunotherapy; Costimulation; Immune adjuvant; Immune suppression; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P549 | Identifying the host immune response in adult undifferentiated pleomorphic sarcoma | Rosanna L. Wustrack, MD; Evans Shao; Ross Okimoto; Lawrence Fong, MD; | Immune Cell Biology | Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P550 | An Immune-CRISPRomics platform enabling genome-scale and pair-wise combination in vivo T-cell function screens enables comprehensive identification of novel therapeutic targets | Isabelle F. Le Mercier, PhD; Jason J. Merkin; Sean Keegan; Conor Calnan; Anja Hohmann, PhD; Nick Colletti; Eric Fagerberg; Sol Shenker; Caroline Bullock; Christopher Wrocklage; Noah J. Tubo, PhD; Tianlei Xu; Matt Noyes; Rami Rahal; Sean Arlauckas; Aria Pearlman Morales; Frank P. Stegmeier, PhD; Louise Cadzow; Mike Schlabach, PhD; Gregory Kryukov; Micah J. Benson, PhD; | Immune Cell Biology | Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P551 | Bone marrow infiltrating lymphocytes possess a resident memory, stem-like phenotype that may account for enhanced anti-tumor efficacy in multiple myeloma–implications for adoptive T cell therapy | Luca Biavati, MD; Megan K. Heimann, PhD candidate; Elizabeth Zawidzka; Amy Thomas; Ervin Griffin; Danielle Dillard; Bruno Paiva; Ivan M. Borrello, MD; | Immune Cell Biology | Adoptive immunotherapy; Immune monitoring; Immune tolerance; T cell; T cell lineages; Tumor evasion; Tumor microenvironment |
| P552 | A translational platform to assess immunomodulation of the tumor microenvironment | Louise S. Brackenbury, PhD; Robert Nunan; Anna Willox; Michelle Yap; Laura McMillan; Louise Brackenbury; S. Rhiannon Jenkinson, PhD; | Immune Cell Biology | Biomarkers; Monocyte/Macrophage; Myeloid cells; NK/NK T cell; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P553 | Platelets as immune suppressors in anti-cancer immune responses | Ana Micaela M. Carnaz Simoes, MSc; Morten O. Holmström, PhD; Mads H. Andersen, PhD; Per Thor Straten, PhD; | Immune Cell Biology | Immune contexture; Immune suppression; T cell; Tumor evasion |
| P554 | Divergent fates of antigen-specific CD8+ T cell clones in mice with acute myeloid leukemia | Xiufen Chen, PhD; Blake Flood, BS; Brendan W. MacNabb; Bruce R. Blazar, MD; Justin P. Kline, MD; | Immune Cell Biology | Antigen presenting cells; Dendritic cell; Immune suppression; Immune tolerance; Leukemia/Lymphoma; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| P555 | Neuropilin-1 Stabilizes Human Tregs in Cancer Patients Thereby Potentiating Their Suppressive Function | Christopher A. Chuckran, BS; Anthony R. Cillo, PhD; Ashwin Somasundaram, MD; Jessica Moskovitz, MD; John M. Kirkwood, MD; Francesmary Modugno, PhD; Robert P. Edwards, MD; Robert Schoen, MD; Robert L. Ferris, MD, PhD; Tullia C. Bruno, PhD; Dario A. Vignali, PhD; | Immune Cell Biology | Checkpoint blockade; Coinhibition; Costimulation; Cytokine; Immune suppression; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P556 | Sex-based differences of the intratumoral immune-infiltrate. | Fabio Conforti; Laura Pala; Vincenzo Bagnardi; Eleonora Pagan; Giuseppe Viale; Tommaso De Pas, MD; Elisabetta Penacchioli; Paola Queirolo; Emilia Cocorocchio; Pier Francesco F. Ferrucci, MD; Filippo de Marinis; Adriana Albini; Richard Gelber; Aron Goldhirsch; Fabio Conforti, MD; | Immune Cell Biology | Solid tumors; Tumor microenvironment |
| P557 | A2bR contributes to adenosine-mediated immunosuppression, which is relieved by the dual A2aR/A2bR antagonist AB928 | Daniel DiRenzo, PhD; Kristen Zhang, BS; Sean Cho, PhD; Sachie Marubayashi; Dana Piovesan, MSc; Jesus Banuelos; Joanne BL. Tan, PhD; Akshata Udyavar, Ph.D; Jenna Jeffrey, PhD; Manmohan R. Leleti, PhD; Jay P. Powers, PhD; Matthew J. Walters, PhD; | Immune Cell Biology | Antigen presenting cells; Dendritic cell; Immune suppression; Monocyte/Macrophage; Myeloid cells; Tumor microenvironment |
| P558 | Novel gene expression programs of immune-tumor-stroma identified in inflamed Head and Neck Cancer microenvironment profiling using single cell RNA sequencing (scRNAseq) | Cornelius Kürten, MD; Aditi Kulkarni; Lazar Vujanovic, PhD; Xueer Chen; Anthony R. Cillo, PhD; Xinghua Lu; Robert L. Ferris, MD, PhD; | Immune Cell Biology | Immune contexture; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P559 | Metastatic osteosarcoma utilizes multiple inhibitory checkpoint molecules and immunosuppressive myeloid cells to inhibit the cytotoxic effect of tumor-infiltrating lymphocytes | John A. Ligon, MD; Teniola F. Oke; Woonyoung Choi; Gady Cojocaru; Ludmila Danilova; Megan H. Fong; Adam Levin; Daniel S. Rhee; Carol D. Morris; Nicholas Siegel; Emily HC. Hsiue; Christian F. Meyer; David J. McConkey; Robert A. Anders, MD, PhD; Drew M. Pardoll, MD, PhD; Nicolas J. Llosa, MD; | Immune Cell Biology | Checkpoint blockade; Immune suppression; Immune tolerance; Monocyte/Macrophage; Myeloid cells; MDSC; Pediatric tumors; Solid tumors; Tumor evasion; Tumor microenvironment |
| P560 | Cancer patients can be categorized by a uniform and mutually exclusive pattern of expression of PD-1 or PD-L1 on their tumor infiltrating T lymphocytes | Séverine Mouraud; Aurelien Marabelle, MD, PhD; Séverine Mouraud; | Immune Cell Biology | Immune monitoring; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P561 | Formation and function of and CD49b+ CD8 T cells CD49a+ in a murine breast cancer model | Marit M. Melssen, MSc; Robin Lindsay; Amanda Briegel; Anthony Rodriguez; Salwador Cyranowski; Cornelis J. Melief, MD, PhD; Sjoerd H. van der Burg; Craig Slingluff, Jr; Victor Engelhard; | Immune Cell Biology | Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P562 | BTN2A, A New Immune-checkpoint Targeting Vgamma9Vdelta2 T cell Cytotoxicity | Carla E. Cano, PhD; Christine Pasero, PhD; Aude de Gassart; Sophie Agaugué; René HOET; Emmanuel Scotet; Erwan Mortier; Agnès Quemeneur; Chirine Rafia; Antoine Briantais; Anne-Charlotte Le Floch; Daniel Olive, MD, PhD,; | Immune Cell Biology | Antibody; Leukemia/Lymphoma; Solid tumors; T cell |
| P563 | Profiling regulatory and cytotoxic T cell relationships in the tumor microenvironment of non-small cell lung cancer FFPE samples | Bonnie Phillips, PhD; Mark Burton, HTL ASCP; Katir K. Patel, PhD; Mael Manesse, PhD; Sean R. Downing, PhD; | Immune Cell Biology | Biomarkers; Immune monitoring; Immune suppression; Regulatory T cell (Treg cell); Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P564 | How tumor-specific CD8 T cell activation in draining lymph nodes supports the anti-tumor CD8 T cell response | Nataliya Prokhnevska, BS; Rajesh Valanparambil; Caroline S. Jansen, BS; Viraj A. Master, MD, PhD; Martin Sanda; Haydn T. Kissick; | Immune Cell Biology | Antigen presenting cells; T cell; Tumor infiltrating lymphocytes (TILs) |
| P565 | B cells serve as primary antigen presenting cells for DNA vaccines | Ichwaku Rastogi, BE, MS; Douglas G. McNeel, MD, PhD; Ichwaku Rastogi, BE, MS; | Immune Cell Biology | Antigen presenting cells; B cell; Dendritic cell; T cell; Vaccine |
| P566 | Does Loss of BAP-1 influences the activation of Non-canonical NFκB pathway in uveal melanoma with inflammation? | Mithalesh Kr. Singh; Lata Singh, PhD; Seema Kashyap; Neelam Pushker, MD; Seema Sen, MD; Rachna K. Meel, M.D; | Immune Cell Biology | Biomarkers; Clinical study; Cytokine; Gene expression; Inflammation; Monocyte/Macrophage; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P567 | Characterizing myeloid-derived suppressor cells in the tumor microenvironment of colorectal cancer FFPE samples | Angela Vasaturo, PhD; Angela Vasaturo, PhD; Katir K. Patel, PhD; Mael Manesse, PhD; Sean R. Downing, PhD; | Immune Cell Biology | Biomarkers; Immune monitoring; Immune suppression; MDSC; Solid tumors; Tumor microenvironment; Tumor stroma |
| P568 | Terminally exhausted CD8+ T cells potentiate the tolerogenic tumor microenvironment as functional suppressors | Paolo DA. Vignali, BA; McLane Watson, BS; Ashley Menk, MS; Nicole E. Scharping, PhD; Kristin DePeaux, BS; Greg M. Delgoffe, PhD; | Immune Cell Biology | Immune suppression; Metabolism; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P569 | Immune tumor microenvironment dictates clinical outcome of oropharyngeal carcinoma upon standard therapy. | Marij J. Schoenmaekers-Welters, PhD; Saskia Santegoets; Chantal Duurland; Vanessa J. van Ham; Ilina Ehsan; Sjoerd H. van der Burg, PhD; | Immune Cell Biology | Biomarkers; Cytokine; Immune contexture; Immune suppression; Inflammation; Myeloid cells; Regulatory T cell (Treg cell); Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P570 | Assay the interaction of 1000s of individual T cells and antigen-presenting cells for CAR-T or TCR screening in 24hrs. | Mark White, PhD; | Immune Cell Biology | Adoptive immunotherapy; CAR T cells; Cytokine; Immune monitoring; T cell |
| P571 | NGS evaluation of colorectal cancer reveals interferon gamma dependent expression of immune checkpoint genes and novel genes associated with immune suppression | Lai Xu; Amy Rosneberg; Lorraine Pelosof; | Immune Cell Biology | Bioinformatics; Biomarkers; Checkpoint blockade; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P572 | IFNgamma-induced Nitric Oxide Cell Death is Inhibited by L-arginine Depletion in Renal Cell Carcinoma. | Arnold H. Zea, PhD; Charity F. Silvester, MD Student; Paula Datri, BS; Arnold H. Zea, PhD; | Immune Cell Biology | Costimulation; Cytokine; Immune monitoring; Immune suppression; Immune toxicity; Metabolism; Solid tumors; Targeted therapy; Tumor evasion; Tumor microenvironment |
| P574 | Remodeling Translation Primes CD8+ T Cell Anti-Tumor Immunity | Jessica E. Thaxton, PhD, MSCR; Kiley A. Lawrence; Katie E. Hurst; Lauren Ball, PhD; Lee Leddy, MD, MsCR; Dongjun Chung, PhD; | Immune Cell Biology | Adoptive immunotherapy; Metabolism; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P575 | Targeting the Stress Response Kinase GCN2 to Restore Immunity in the Tumor Microenvironment | Lisa A. Marshall, M.S.; Buvana Ravashankar; Lavanya Adysumilli; Deepika Kaveri; Deepa Pookot; Thant Zaw; Raashi Sreenivasan; Mikhail Zibinsky; Jeffrey Jackson; Grant Shibuya; Paul Leger; Anqi Ma; Anton Shakhmin; Andrew Ng; Omar Robles; Oezcan Talay; Delia Bradford; Christophe Colas; Scott Jacobson; Jerick Sanchez; Justy Guagua; Steve Wong; Martin Brovarney; Angela Wadsworth; Goerge Katibah; Gene Cutler; David Wustrow; Paul Kassner; Dirk Brockstedt; Lisa A. Marshall, M.S. | Immune Cell Biology | Monocyte/Macrophage; Myeloid cells; MDSC; Metabolism; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P576 | Tumor-infiltrating regulatory T cell function is metabolically supported through lactate-mediated symbiosis with the tumor microenvironment | McLane Watson, BS; Paolo DA. Vignali, BA; Steven Mullet; Natalie Rittenhouse; Ashley Menk, MS; Ryan D. Whetstone, MS, PhD; Brett Morrison; Jeffrey Rothstein; Amanda Poholek; Stacy Wendell, PhD; Greg Delgoffe, PhD; | Immune Cell Biology | Immune suppression; Regulatory T cell (Treg cell); Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P577 | HDACi differentially affect distinct T-cell subsets and cytokine production | Nisha Holay, BS.; Uma Giri; Carla Van Den Berg, PharMD; Gail Eckhardt, MD; Todd A. Triplett, PhD; | Immune Cell Biology | Cytokine; T cell; T cell lineages |
| P578 | In Vitro Assessment of the Impact of Chemotherapy Agents on Immune Cell Function | Dana Banas; Dawn Stetsko; Miye Jacques; Sium Habte; Matthew Loya; Xiaodong Wang; Krishna M. Vasudevan, DVM, PhD; Laurence Menard, PhD; Julie Carman, PhD; | Immune Cell Biology | Antigen presenting cells; Chemotherapy; Dendritic cell; Immune toxicity; T cell |
| P579 | Predictive and prognostic relevance of CD8+ tumor-infiltrating lymphocyte density combined with PD-L1 expression in locally advanced rectal cancer patients receiving preoperative chemoradiotherapy | Changhoon Song, MD; Yoonjin Kwak; Hye Seung Lee; Sung-Bum Kang; Jae-Sung Kim; | Immune Cell Biology | Biomarkers; Chemotherapy; Clinical study; Radiotherapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P580 | Immunogenomic landscape of Neuroendocrine Prostate Cancer | Bhavneet Bhinder, MS; Olivier Elemento, PhD; Bhavneet Bhinder, MS; Himisha Beltran, MD; Alison Ferguson; | Immune Cell Biology | Bioinformatics; Checkpoint blockade; Cytokine; Gene expression; Immune contexture; Immune suppression; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P581 | Identification of prime Master Regulators for Immunologic Constant of Rejection at Pan-Cancer Scale using Network Analysis | Raghvendra Mall, PhD; Mohamad Saad, PhD; Jessica Roelands, Master; Wouter RL. Hendrickx, PhD; Michele Ceccarelli; Davide Bedognetti, MD, PhD; | Immune Cell Biology | Bioinformatics; Gene expression; Immune contexture; Immunoscore; Tumor evasion; Tumor microenvironment |
| P582 | Characterization of abscopal effect in cryoablation-treated kidney cancer patients | Taigo Kato, MD, PhD; Motohide Uemura; Kazuma Kioytani; Norio Nonomura; | Immune Cell Biology | Gene expression; Immune monitoring; T cell |
| P583 | Building a translational pathway using pharmacodynamic and syngeneic tumour models in conjunction with gene expression to enable the development of cancer immune therapies | Louise S. Brackenbury, PhD; Tommaso Iannitti; Louise Harvey, BSc; Robert Nunan; Louise Brackenbury; Clio Andreae, PhD, Bsc (Hons); S. Rhiannon Jenkinson, PhD; | Immune Cell Biology | Gene expression; Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment; Vaccine |
| P584 | Functional cytomic targeting of PD-L1 at the surface of living cells to investigate resistance to immunotherapy in multiple myeloma | Jolene A. Bradford, MLS, SCYM(ASCP); Laura G. Rico; Jordi Juncà; Jorge Bardina; Àngel Bistué-Rovira; Michael D. Ward; Jordi Petriz; | Immune Cell Biology | Checkpoint blockade; Immune suppression; MDSC; T cell; Targeted therapy; Tumor microenvironment |
| P585 | Extracellular matrix gene expression and cytotoxic T lymphocyte infiltration in the tumor microenvironment in non-small cell lung cancer | Na Li, PhD; Hongzhe Sun; Xin Wang; Ying Zhou; Zhifu Zhang; Anushka Dikshit, PhD; Courtney M. Anderson, PhD; Xiao-Jun Ma; | Immune Cell Biology | Cytokine; T cell; Tumor microenvironment; Tumor stroma |
| P586 | Comprehensive immune profiling of clinical samples from subjects with advanced recurrent epithelial ovarian cancer treated with a novel T cell activating therapy, DPX-Survivac | Brennan S. Dirk, PhD; Heather Torrey, PhD; Yogesh Bramhecha, PhD; Olga Hrytsenko, PhD; Stéphan Fiset; Marianne Stanford, PhD; | Immune Cell Biology | Immune monitoring; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P587 | Collagen density regulates the activity of tumor-infiltrating T cells | Dorota E. Kuczek, MSc; Anne Mette Hvid Larsen, M.Sc; Marco Carretta, PhD; Adrija Kalvisa, MSc; Majken S. Siersbæk; Ana Micaela M. Carnaz Simoes, MSc; Anne Roslind; Lars Engelholm; Marco Donia, MD, PhD; Inge Marie Svane, MD; Per t. Straten; Lars Grøntved; Daniel Hargboel Madsen; Dorota E. Kuczek, MSc; | Immune Cell Biology | Immune suppression; T cell; Tumor microenvironment; Tumor stroma |
| P588 | Development of in vitro immune effector function assays to better approximate the in vivo behavior of biotherapeutics and cell therapies | Chris Langsdorf, BS; | Immune Cell Biology | Antibody; Leukemia/Lymphoma; Monocyte/Macrophage; NK/NK T cell; Solid tumors; T cell |
| P589 | IL-15 deficient colon carcinomas have decreased cytolytic lymphocytes and skewed myeloid cell populations. | Kimberly S. Schluns, PhD; Chih-Chien Chou, PhD; Rosa M. Santana-Carrero; R. Eric Davis, PhD; Kimberly S. Schluns, PhD; | Immune Cell Biology | Cytokine; Gene expression; Immunoscore; Myeloid cells; MDSC; NK/NK T cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P590 | The use of in vitro T cell assays to accelerate cancer development of immunotherapy and immune checkpoint inhibitors | Amin Osmani; Thibault Jonckheere; Juliette Lamy; Thibaut Janss; Mayuko Oh; Sofie Pattijn; Thibaut Janss; | Immune Cell Biology | Antigen presenting cells; Dendritic cell; Immune suppression; Immune tolerance; Monocyte/Macrophage; Myeloid cells; MDSC; Neoantigens; Regulatory T cell (Treg cell); T cell |
| P591 | In Vitro Functional Suppressive Bioassays for Evaluating Candidate Therapeutic Effectiveness in Immuno-Oncology | Amin Osmani; Thibaut Janss; Juliette Lamy; Thibault Jonckheere; Severine Giltaire; Sofie Pattijn; Thibaut Janss; | Immune Cell Biology | Immune suppression; Immune tolerance; Monocyte/Macrophage; Myeloid cells; MDSC; Neoantigens; Regulatory T cell (Treg cell); T cell |
| P592 | TGFβR1 antagonism improves radiation efficacy by enhancing CXCR3 dependent tumor recruitment of CD8+ T cells | Andrew J. Gunderson, PhD; Tomoko Yamazaki, PhD; Kayla McCarty, BS; Nathaniel Fox; Michaela Phillips, BA; Alejandro Alice, PhD; Tiffany Blair; Mary McCormick, RN; Andrea Burt, RN; Iliana L. Gonzalez, BS; Mark Whiteford, MD; David O'Brien; Rehan Ahmad; Maria X. Kiely, MD; Amanda V. Hayman, MD, MPH; Rui Li, MD, PhD; Todd Crocenzi, MD; Michael J. Gough, PhD; Marka R. Crittenden, MD, PhD; Kristina H. Young, MD, PhD; | Immune Cell Biology | Chemokine; Chemotherapy; Clinical trial; Radiotherapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P593 | Rituximab treatment induces long lasting potentiation of degranulation responses by NK cells in non-Hodgkin lymphoma patients | Dmitry Zhigarev, MS; Alexander W. Macfarlane; Mowafaq Jillab; R. Katherine Alpaugh, PhD; Adam D. Cohen, MD; Kerry S. Campbell; | Immune Cell Biology | Antibody; Leukemia/Lymphoma; NK/NK T cell |
| P594 | Targeting immune-suppressive myeloid cell pathways for the treatment of cancer | Jesus Banuelos; Susan J. Lee, PhD; Tim Park; Nell Narasappa, MSc; Dana Piovesan, MSc; Yu Chen; Jenna Jeffrey, PhD; Jarek Kalisiak; Kimberline Gerrick; Hema Singh; Annette Becker, PhD; Jie Chen; Sean Cho, PhD; Bryan Handlos; Akshata Udyavar, Ph.D; Steve W. Young, PhD; Jay P. Powers, PhD; Matthew J. Walters, PhD; Jo BL. Tan; | Immune Cell Biology | Antigen presenting cells; Gene expression; Granulocyte; Immune suppression; Inflammation; Monocyte/Macrophage; Myeloid cells; MDSC; Tumor microenvironment |
| P595 | Gene editing and protein expression in innate immunity cells by electroporation | Jian Chen, PhD; George Sun; | Immune Cell Biology | Gene expression; Immune monitoring; Immune suppression; Monocyte/Macrophage; Myeloid cells; Neoantigens; NK/NK T cell; Tumor microenvironment |
| P596 | Targeted IRAK-M degradation as a novel approach in cancer immunotherapy overcoming innate-driven immunosuppression | Kanae Gamo, MS; Naomi Kitamoto; Tomoaki Hayashi; Yoshihide Tomata; Yusuke Tominari; | Immune Cell Biology | Cytokine; Immune suppression; Immune tolerance; Monocyte/Macrophage; Myeloid cells; MDSC; Targeted therapy; TLR; Tumor evasion; Tumor microenvironment |
| P597 | Myeloid-specific inflammasome signaling promotes tumor growth | Cara Lang; Young J. Kim, MD; | Immune Cell Biology | Checkpoint blockade; Myeloid cells; MDSC; Tumor microenvironment |
| P598 | Glioblastoma-associated myeloid cells promote regulatory T and B-cell function via transfer of microvesicle | Catalina Lee-Chang, PhH; Aida Rashidi; Jason Miska; Peng Zhang; Katarzyna Pituch; David Hou; Irina V. Balyasnikova, PhD; Maciej Lesniak, MD; | Immune Cell Biology | B cell; Immune suppression; Monocyte/Macrophage; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P599 | Unveiling tumor-associated macrophages (TAMs) heterogeneity and plasticity by a fully automated sequential chromogenic multiplex assay | Anna Martirosyan, Dr; Jacques Fieschi, PhD; | Immune Cell Biology | Biomarkers; Immune contexture; Immune suppression; Inflammation; Monocyte/Macrophage; Tumor microenvironment; Tumor stroma |
| P600 | AL008 enhances myeloid anti-tumor function by coupling SIRPα antagonism with Fc receptor-mediated activation. | Andrew PINCETIC, PhD; Jerry Yang; Isaiah Deresa; We-Hsien Ho; Hua Long; Daniel Maslyar; Spencer Liang; Arnon Rosenthal; | Immune Cell Biology | Antibody; Checkpoint blockade; Immune suppression; Monocyte/Macrophage; Myeloid cells; Tumor microenvironment |
| P601 | Expression of an immune checkpoint receptor VSIG4 defines new subsets of mouse peritoneal macrophages | Dariusz T. Stepniak; Kanako Lewis, PhD; Chau Nguyen; Robert Navert; Ryan Gerhart; Sonja Zahner; Castle Funatake; Homero Sepulveda; Dariusz T. Stepniak; | Immune Cell Biology | Checkpoint blockade; Monocyte/Macrophage; Myeloid cells |
| P602 | A Distinctive Lineage Negative Cell Population Produces IL-17A in Cutaneous Squamous Cell Carcinoma | Lillian Sun, BS; Jennifer Ko, MD and PhD; Allison Vidimos, MD; Shlomo Koyfman, MD; Brian R. Gastman, MD; | Immune Cell Biology | Cytokine; Immune suppression; Inflammation; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor stroma |
| P603 | Deciphering immune checkpoint interactions between immune and non-immune cells in head and neck squamous cell carcinoma by single-cell RNA sequencing | Lazar Vujanovic, PhD; Aditi Kulkarni; Cornelius Kurten, MD; Patricia M. Santos, PhD; Umamaheswar Duvvuri; Seungwon Kim, MD; Anthony R. Cillo, PhD; Robert L. Ferris, MD, PhD; | Immune Cell Biology | Antigen presenting cells; Bioinformatics; Immune tolerance; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment; Tumor stroma |
| P604 | Hypoxia and TGF-β1 induce tissue resident memory phenotype cells from human peripheral blood T-cells in vitro | Farah Hasan, BSc; Rebecca M. Shaw; Yulun Chiu; Junmei Wang; Cassian Yee, MD; | Immune Cell Biology | T cell; T cell lineages |
| P605 | Severity of Cytokine Release Syndrome as a Predictor of Infections after T-cell replete Haploidentical Hematopoietic Cell Transplantation (haploHCT) | Muhammad Bilal Abid, MD, MRCP (UK); Parameswaran Hari, MBBS, MD, MRCP; Aniko Szabo; Mehdi Hamadani; Mary Beth Graham; Saurabh Chhabra; | Immune Cell Biology | Chemotherapy; Clinical study; Cytokine; Immune toxicity; Inflammation; Leukemia/Lymphoma; T cell |
| P606 | ICOSL on human dendritic cells is critical for priming T cell responses | Deena M. Maurer, MS; Juraji Adamik, PhD; Patricia M. Santos, PhD; Jian Shi, MD; Jennifer L. Taylor, PhD; Michael R. Shurin, phD; John M. Kirkwood, MD; Walter J. Storkus, PhD; Lisa H. Butterfield, PhD; | Immune Cell Biology | Antigen presenting cells; Clinical study; Costimulation; Dendritic cell; T cell; Vaccine |
| P607 | Tumor derived IL-6 promotes early-stage myeloid derived suppressor cells(eMDSCs) via SOCS3 deficiency-related differentiation arrest in breast cancer | Jinpu Yu; Wenwen Zhang; Jinpu Yu; | Immune Cell Biology | Immune suppression; MDSC; Tumor microenvironment |
| P608 | ATOR-1017, a 4-1BB antibody developed for tumor-directed immunotherapy of cancer | Doreen Werchau, BS; Anna Rosen, MSc; Mia Eriksson; Sofia Järnum, PhD; Christina Furebring, PhD; Karin Enell Smith, PhD; | Immune-stimulants and immune modulators | Antibody; Costimulation; NK/NK T cell; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| P609 | Fc-silenced bispecific antibodies targeting PD-L1 and 4-1BB combine checkpoint blockade and T-cell co-stimulation to promote anti-tumor activity | Alexander Muik, PhD; Isil Altintas, PhD; Friederike Gieseke; Theodora Salcedo; Saskia Burm; Mustafa Diken; Christian Grunwitz; Danita Schuurhuis; Sebastian Kreiter; David Satijn; Özlem Türeci; Esther Breij, PhD; Ugur Sahin; Maria Jure-Kunkel; | Immune-stimulants and immune modulators | Antibody; Checkpoint blockade; Costimulation |
| P610 | Claudin18.2 bispecific T-cell engager for gastric cancer immunotherapy | Sribalaji Lakshmikanthan, PhD; Swarna Pandian, PhD; Zusheng Li; Eugene Chan, MD; Robert Markelewicz, MD; Timothy L. Wyant, PhD; Sribalaji Lakshmikanthan, PhD; | Immune-stimulants and immune modulators | Antibody; Solid tumors; T cell; Targeted therapy |
| P611 | Layer-by-Layer nanoparticles for interleukin-12 delivery | Antonio E. Barberio, BSE; Sean G. Smith, PhD; Santiago Correa; Cathy Nguyen; Paula T. Hammond; Darrell J. Irvine, PhD; Mariane Melo; Talar Tokatlian; | Immune-stimulants and immune modulators | Cytokine; Immune toxicity; Solid tumors; Tumor microenvironment |
| P612 | Using a novel synthetic biology platform to generate a homogenous dipegylated IL-10 with native potency | Carolina E. Caffaro, PhD; Jerod L. Ptacin, PhD; Yelena Pavlova; Jasmine T. Nguyen; Kristine San Jose-Galli; Gavin Hong; Lina Ma, PhD; Nicole Acuff; Taylor Ismaili, MS; Kelsea Loescher; Ingrid B. Joseph, PhD; Jill Mooney, PhD; Joseph Leveque, MD; Marcos E. Milla, PhD; | Immune-stimulants and immune modulators | Cytokine; Immune adjuvant; NK/NK T cell; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P613 | Discovery of pharmacologically differentiated Interleukin 15 (IL-15) agonists employing a synthetic biology platform | Carolina E. Caffaro, PhD; Jerod L. Ptacin, PhD; Robert W. Herman; Lina Ma, PhD; David B. Chen; Ingrid B. Joseph, PhD; Marcos E. Milla, PhD; | Immune-stimulants and immune modulators | Adoptive immunotherapy; CAR T cells; Checkpoint blockade; Cytokine; Immune adjuvant; NK/NK T cell; Solid tumors; T cell; T cell lineages; Tumor microenvironment |
| P614 | Development of a cancer gene therapy approach based on encoding a single chain IL-12 transgene in an oncolytic T-SIGn virus vector | Sam Illingworth; Manuela Zonca; Ana Silva; Alicia Belmonte; Nalini Marino; Carla Cerqueira; Lorna Slater; Katy West; Sara Siebel; Samantha Bucktrout; Fred Ramsdell, PhD; Paul Cockle; Brian R. Champion, PhD; | Immune-stimulants and immune modulators | Cytokine; Gene expression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P615 | Novel immune-cell targeted IL2v to deliver IL-2R signaling to tumor reactive T cells via PD-1 whilst blocking the PD-1 pathway | Laura Codarri Deak; Valeria Nicolini; Laura J. Lauener, Mrs.; Stefan Seeber, Dr.; Marine Richard; Esther Bommer; Maria Karagianni, Mrs.; Johannes Sam, Dr.; Ramona Schlenker, Dr.; Marisa Mariani, Dr.; Petra Schwalie, Dr.; Sylvia Herter, PhD; Marina Bacac, Dr.; Inja Waldhauer, Dr.; Anne Freimoser-Grundschober, Dr.; Volker Teichgräber, Dr.; Christian Klein, Dr rer nat; Pablo Umana, PhD; | Immune-stimulants and immune modulators | Antibody; Checkpoint blockade; Cytokine; Tumor infiltrating lymphocytes (TILs) |
| P616 | A novel anti-tumor anti-PDL1-IL7 immunocytokine targeting lymphocytes | Feifei Cui, PhD; Lei Fang; Haijuan Gu; Yuanyuan Yang; Zhengyi Wang; Bingshi Guo; | Immune-stimulants and immune modulators | Antibody; Checkpoint blockade; Cytokine; T cell |
| P617 | Delivery of Interleukin-2 to the Acidic Tumor Microenvironment by Ultra-pH Sensitive Nanoparticles for Immunotherapy | Xinliang Ding, PhD; Jason B. Miller, PhD; Ashley Campbell; Jonathan Almazan; Tian Zhao; | Immune-stimulants and immune modulators | Cytokine; Solid tumors; Targeted therapy; Tumor microenvironment |
| P618 | MK1169, a peptide unrelated to IL-2, is a potent IL-2Rβγc receptor agonist | William J. Dower, PhD; Steven E. Cwirla, BA; Blake M. Williams, MS; Praechompoo Pongtornpipat, MS; Prarthana Joshi, ME; Sandra M. Wang, BSc; Alice V. Bakker, BA; Michael C. Needels, PhD; Ronald W. Barrett, PhD; | Immune-stimulants and immune modulators | Cytokine; T cell |
| P619 | NKTR-255, a polymer-conjugated IL-15 receptor agonist, enhances efficacy of therapeutic monoclonal antibodies with ADCC activity in solid tumor models | Saul Kivimae, PhD; Takahiro Miyazaki, MS; Rhoneil Pena; Wildaliz Nieves, PhD; Andrew Moffett; Phi Quach, BS PhD; Lawrence Chinn; Marlene Hennessy, BS; Loui Madakamutil; Jonathan Zalevsky, PhD; | Immune-stimulants and immune modulators | Cytokine; NK/NK T cell; Solid tumors |
| P620 | Complementary effects of RNA encoded, extended half-life IL2 and IL7 synergize in modulating T cell responses and antitumoral efficacy. | Lena M. Kranz; Lena M. Kranz; Mathias Vormehr, PhD; Jan Dieckmann, PhD; Claudia Lindemann; David Eisel; Alexander Muik, PhD; Sina Fellermeier-Kopf; Friederike Gieseke; Bodo Tillmann; Sonja Witzel; Marlen Lepper; Mustafa Diken; Sebastian Kreiter, MD; Veronika Jahndel; Özlem Türeci; Ugur Sahin; | Immune-stimulants and immune modulators | Cytokine; Immune adjuvant; T cell; Vaccine |
| P621 | Nanoparticle-mediated Tumor Cell Expression of mIL-12 via Systemic Gene Delivery Treats Syngeneic Models of Murine Lung Cancers | Hye-Hyun Ahn, PhD; Christine Carrington; Heng-wen Liu; Yizong Hu; Christy Ng; Hwanhee Nam; Andrew Park; Catherine Stace; Will West, PhD; Hai-Quan Mao, PhD; Martin Pomper, MD, PhD; Chris G. Ullman, PhD; IL Minn, PhD; | Immune-stimulants and immune modulators | Cytokine; Gene expression; Immune adjuvant; Solid tumors |
| P622 | Characterization and comparison of NKTR-255, a polymer-conjugated IL-15 versus IL-15 superagonist | Takahiro Miyazaki, MS; Mekhala Maiti, PhD; Sara Sheibani; Joanna Wilczek; Olga Zemska; Peiwen Kuo, PhD; Saul Kivimäe; Marlene Hennessy, BS; Phi Quach, BS PhD; Ping Zhang, MS PhD; Thomas Chang, PhD; Loui Madakamutil; Jonathan Zalevsky, PhD; | Immune-stimulants and immune modulators | Cytokine; NK/NK T cell; T cell |
| P623 | Bempegaldesleukin in combination with local radiation and systemic checkpoint blockade induces a robust systemic anti-tumor immunity. | Alexander Pieper, BS.; Alexander L. Rakhmilevich, MD, PhD; Dan Spiegelman; Ravi Patel, MD, PhD; Claire Baniel; Amy K. Erbe, PhD; Jacquelyn A. Hank, PhD; Deborah Charych, PhD; Willem W. Overwijk, PhD; Zachary S. Morris, MD, PhD; Paul M. Sondel, MD, PhD; | Immune-stimulants and immune modulators | Checkpoint blockade; Cytokine; Radiotherapy; Solid tumors; T cell; Vaccine |
| P624 | Layer-by-layer nanoparticles for the non-toxic delivery of interleukin-12 to orthotopic ovarian cancer | Sean G. Smith, PhD; Antonio E. Barberio, BSE; Sean G. Smith, PhD; Darrell J. Irvine, PhD; Santiago Correa; Cathy Nguyen; Mariane Melo; Talar Tokatlian, PhD; Paula T. Hammond; | Immune-stimulants and immune modulators | Cytokine; Immune adjuvant; Immune toxicity; Solid tumors |
| P625 | KY1043, a novel PD-L1 IL-2 immunocytokine directed towards CD25, delivers potent anti-tumour activity in vitro and in vivo | Cassandra H. Van Krinks, PhD; Timothy Malcolm; Morgane Lecointre; Richard Brown; Hanif Ali; Hannah Craig; Dirk Zahn; Siobhan O'Leary; Lucy Hepburn; Rachael Kimber; Nikole Sandy; Alla Fane-Dremucheva; Jamie Campbell, PhD, BS; Volker Germaschewski, PhD, MSc; Stephen D. Gillies, PhD; Matthew J. McCourt, BSc; Matthew J. McCourt, BSc; | Immune-stimulants and immune modulators | Checkpoint blockade; Cytokine; T cell; T cell lineages; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P626 | Substantial improvement of cancer immunotherapy by an RNA encoded extended half-life Interleukin-2 variant. | Mathias Vormehr, PhD; Lena M. Kranz; Alexander Muik, PhD; Sina Fellermeier-Kopf; Nadja Salomon; Jan Diekmann; Claudia Lindemann; Sonja Witzel; Marlen Lepper; Friederike Gieseke; Veronika Jahndel; Özlem Türeci; Ugur Sahin; | Immune-stimulants and immune modulators | Checkpoint blockade; Cytokine; Immune adjuvant; Neoantigens; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor antigens; Vaccine |
| P627 | Comparing the functionality of Proleukin® and Akron Interleukin-2 through an analysis of key T cell subsets | Claudia Zylberberg, PhD; John Koreth, MBBS, DPhil; Jerome Ritz, MD; | Immune-stimulants and immune modulators | Adoptive immunotherapy; Autoimmunity; Biomarkers; CAR T cells; Cytokine; Immune adjuvant; Immune toxicity; Regulatory T cell (Treg cell); T cell; Targeted therapy |
| P628 | Inhibition of histone deacetylase enhances CD8 T-cell functionality and metabolic fitness resulting in strong anti-tumor response. | Pankaj Gaur, PhD; Vivek Verma, PhD; Rahul Nnadre; Fatmah Alolaqi; Peter Ordentlich, PhD; Lei Wang, PhD; Seema Gupta, PhD; Samir N. Khleif, MD; | Immune-stimulants and immune modulators | Gene expression; Metabolism; Regulatory T cell (Treg cell); T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment; Vaccine |
| P629 | Therapeutic Vascular Normalization to Promote Tumor-Associated Tertiary Lymphoid Structures | Jessica Filderman, BS; Walter J. Storkus, PhD; Jessica Filderman, BS; | Immune-stimulants and immune modulators | Angiogenesis; Dendritic cell; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P630 | Induction of antitumor immune response by selective HDAC6 inhibition | Gianluca Fossati, Dr; Chiara Ripamonti; Gianluca Caprini; Andrea Stevenazzi; Barbara Vergani; Luigi Aurisicchio; Fabio Palombo, PhD; Antonella Conforti; Christian Steinkuhler; Gianluca Fossati, Dr; | Immune-stimulants and immune modulators | Neoantigens; Solid tumors; T cell; Targeted therapy |
| P631 | Immunotherapy plus gene therapy: A novel nanomedicine carrying the RB94 gene that suppresses tumor growth in non-small-cell lung cancer by inducing immunogenic cell death & modulating host immunity | Joe B. Harford, PhD; Caroline Doherty; Manish Moghe; Antonina Rait, PhD; Steven Metallo, PhD; Kathleen F. Pirollo, PhD; Esther H. Chang, PhD; Sang-Soo Kim, PhD; | Immune-stimulants and immune modulators | Biomarkers; Checkpoint blockade; Gene expression; Immune suppression; NK/NK T cell; Solid tumors; Targeted therapy; Tumor evasion; Tumor microenvironment |
| P632 | Acute myeloid leukemia induced T cell suppression can be reversed by inhibition of the MAPK pathway | Kaycee Moshofsky, BS, MCR; Kyle A. Romine, BS; Yoko Kosaka, PhD; Guanming Wu; Shannon McWeeney, PhD; Evan F. Lind, PhD; | Immune-stimulants and immune modulators | Immune suppression; Leukemia/Lymphoma; T cell; Tumor evasion; Tumor microenvironment |
| P633 | BPM31510, a Metabolic Modulating Anti-Cancer Agent, Demonstrates Immune Potentiating Properties by Promoting Cytotoxic T Cells and Reversing Indices of Exhaustion and Immunosuppression | Maria-Dorothea Nastke, PhD; Maria-Dorothea Nastke, PhD; Shiva Kazerounian, PhD; Anne R. Diers, PhD; Stephane Gesta, PhD; Vivek Vishnudas, PhD; Niven R. Narain, PhD; Rangaprasad Sarangarajan, PhD; | Immune-stimulants and immune modulators | Checkpoint blockade; Cytokine; Immune adjuvant; Immune suppression; Immune tolerance; Metabolism; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P634 | Predicting radiation-induced immune trafficking and activation in localized prostate cancer | Simon P. Keam; Heloise Halse; ThuNgoc Nguyen; Catherine Mitchell; Franco Caramia; David J. Byrne; Sue Haupt; Georgina Ryland; Phillip K. Darcy; Shahneen Sandhu, MBBS FRACP; Piers Blombery; Ygal Haupt; Scott G. Williams; Paul J. Neeson, PhD; | Immune-stimulants and immune modulators | B cell; Immune contexture; Immune suppression; Monocyte/Macrophage; Radiotherapy; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P635 | The impact of beta blockers on survival outcomes in non-small cell lung cancer patients treated with immune checkpoint inhibitors | Michael S. Oh, MD; Alex Guzner; Derek A. Wainwright, PhD; Nisha A. Mohindra, MD; Young Kwang Chae, MD; Amir Behdad; Victoria Villaflor, MD; | Immune-stimulants and immune modulators | Immune adjuvant; Solid tumors |
| P636 | Inhibitors of Ataxia-Telangiectasia Related (ATR) protein lead to innate immune pathway activation and enhanced response to immune therapy in prostate cancer | Patrick G. Pilie, MD; Zhe Tang; Sanghee Park; Cheng Wu; Zhenyang Dong; Timothy A. Yap, MD PhD; Paul Corn; Timothy C. Thompson; | Immune-stimulants and immune modulators | Autoimmunity; Checkpoint blockade; Costimulation; Solid tumors; Targeted therapy |
| P637 | Immunomodulation of solid tumors by carbon-ion therapy versus conventional photon therapy | Catherine S. Spina, MD, PhD; Chizuru Tsuruoka; Wendy Mao; Masaaki Sunaoski; Mathew Chaimowitz; Yi Shang; Shizuko Kakinuma; Charles G. Drake, MD, PhD; Catherine S. Spina, MD, PhD; | Immune-stimulants and immune modulators | Radiotherapy; Tumor infiltrating lymphocytes (TILs) |
| P638 | Integrin-mediated augmentation of antigenic immunity | Upendra K. Marathi, Ph.D; Yared Hailemichael, PhD; Nandadeva Lokugamage; Michael Schotsaert; Angela Choi; Imran Chwdhury; Nisha Garg; Adolfo Garcia-Sastre; Lionel Lewis; Siddhartha De; Peter Vanderslice, PhD; Jeffrey Actor; Darren G. Woodside, PhD; | Immune-stimulants and immune modulators | Adoptive immunotherapy; Antibody; Antigen presenting cells; B cell; Checkpoint blockade; Costimulation; Immune adjuvant; T cell; Vaccine |
| P639 | Depth of tumor implantation predicts response to in situ vaccination in a syngeneic melanoma model - an important variable influencing response to immunotherapy | Peter M. Carlson, BS; Manasi Mohan; Mat Rodriguez; Vladimir Subbotin; Amy K. Erbe, PhD; Zachary S. Morris, MD, PhD; Alexander L. Rakhmilevich, MD, PhD; Paul M. Sondel, MD, PhD; | Immune-stimulants and immune modulators | Antigen presenting cells; Dendritic cell; Radiotherapy; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment; Vaccine |
| P640 | Intratumoral application of the RNA-based TLR-7/-8 and RIG-I agonist CV8102 promotes a pro-inflammatory tumor microenvironment and causes a durable anti-tumor response | Michael Meister, PhD; Mohamed Habbeddine, PhD; Katja Fiedler; Johannes Lutz; Mallika Ramakrishnan; Regina Heidenreich; Michael Meister, PhD; | Immune-stimulants and immune modulators | Checkpoint blockade; Chemokine; Cytokine; Gene expression; Immune adjuvant; TLR; Tumor microenvironment |
| P642 | Potent tumor-directed T cell activation and tumor inhibition induced by ALG.APV-527, a 4-1BB x 5T4 ADAPTIR™ bispecific antibody | Michelle H. Nelson, PhD; Robert Miller; Robert Bader; Doreen Werchau, BS; Anneli Nilsson; Lill Ljung; Adnan Deronic, PhD; Allison Chunyk; Lena Schultz; Catherine McMahan; David Bienvenue; Anna Dahlman; Sara Fritzell; Maria Askmyr; Gabriela Hernandez-Hoyos; | Immune-stimulants and immune modulators | Antibody; Costimulation; NK/NK T cell; T cell; Targeted therapy; Tumor antigens |
| P643 | Harnessing pre-existing anti-viral immunity for tumor therapy | Cuburu Nicolas, PhD; Lukas Bialkowski; Sergio Pontejo, PhD; Rina Kim, BS; Alexander Bell; Cynthia D. Thompson; Douglas R. Lowy, MD; John Schiller, PhD; | Immune-stimulants and immune modulators | Immune adjuvant; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); TLR; Tumor antigens; Tumor microenvironment; Vaccine |
| P644 | Collagen anchoring of intratumorally administered agonist antibodies improves efficacy and limits toxicities | Joseph R. Palmeri, BS; Karl D. Wittrup, PhD; | Immune-stimulants and immune modulators | Costimulation; Immune toxicity; Solid tumors; T cell; Tumor microenvironment |
| P645 | A tumor necrosis factor alpha mimetic as anti-tumor immune adjuvant | Ketki Velankar, MS; Ngoc B. Pham, BS; Ellen S. Gawalt; Wilson Meng, PhD; | Immune-stimulants and immune modulators | Antigen presenting cells; Costimulation; Dendritic cell; Immune adjuvant; Immune suppression; Monocyte/Macrophage; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment; Vaccine |
| P646 | Reprogramming CD8 cells into metabolically fit stem cell memory with superior therapeutic activity by MEK1/2 manipulation. | Vivek Verma, PhD; Pankaj Gaur, PhD; Jose Lopez; Fatmah Alolaqi; Seema Gupta, PhD; Samir N. Khleif, MD; | Immune-stimulants and immune modulators | Adoptive immunotherapy; Stem cell/cancer-initiating cell; Solid tumors; T cell; Targeted therapy; Tumor microenvironment |
| P647 | Is intracellular STING expression a biomarker for oncolytic herpes virus immunotherapy? | Praveen K. Bommareddy, MS, PhD; Samuel Rabkin, PhD; Andrew Zloza, MD, PhD; Howard L. Kaufman, MD, FACS; | Immune-stimulants and immune modulators | Biomarkers; T cell; Tumor microenvironment |
| P648 | Therapeutic efficacy of oncolytic vaccinia virus requires infection and removal of deleterious host immune cells | Kristin DePeaux, BS; Greg M. Delgoffe, PhD; Saumendra Sarkar, PhD; Steve Thorne, PhD; Paolo DA. Vignali, BA; Dayana Rivadeneira, PhD; Kristin DePeaux, BS; | Immune-stimulants and immune modulators | Immune suppression; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P649 | Targeting Subtypes of Circulating Myeloid Cells during Oncolytic Vaccinia Virus Therapy | Tae-Ho Hwang, PhD, DDS; Bora Lee; Fen Jiang; Mong Cho, MD, PhD; Euna Cho; Tae-Ho Hwang, PhD, DDS; | Immune-stimulants and immune modulators | Immune adjuvant; Myeloid cells; Solid tumors |
| P650 | Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas Induced by Oncolytic Adenovirus Delta-24-RGDOX | Hong Jiang, PhD; Dong Ho Shin; Teresa Nguyen, BS; Frederick Lang, MD; Candelaria Gomez-Manzano, MD; Juan Fueyo; | Immune-stimulants and immune modulators | Antigen presenting cells; Costimulation; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |
| P651 | Oncolytic Vaccinia virus contains a potent CD80/CD86 ligand whose deletion confers higher tolerance, and potential synergy with immune arming | Eric Quemeneur, PharmD, PhD; Patricia Kleinpeter, MSc; Jean Baptiste Marchand, PhD; Laetitia Fend; | Immune-stimulants and immune modulators | Checkpoint blockade; Costimulation; Immune contexture; Immune suppression; Tumor microenvironment; Vaccine |
| P652 | The fully human antibody SRF617 is a potent enzymatic inhibitor of CD39 with strong immunomodulatory activity | Michael C. Warren; Sonia Das; Austin Dulak; Tauqeer H. Zaidi; Erik Devereaux; Jamie Strand; Benjamin Lee, MD PhD; Secil Koseoglu; Pamela Holland, PhD; Vito J. Palombella, PhD; Andrew C. Lake, PhD; | Immune-stimulants and immune modulators | Antibody; Dendritic cell; Immune suppression; Inflammation; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| P653 | Labeling method for flow cytometric analysis of radioactive tumors following immunotherapy and molecular targeted radionuclide therapy (mTRT): demonstration of augmented immune infiltrate | Peter M. Carlson, BS; Manasi Mohan; Ravi Patel, MD, PhD; Lauren Nettenstrom; Dagna Sheerar; Kathryn Fox; Mat Rodriguez; Anna Hoefges, MS; Reinier Hernandez, PhD; Chris Zahm, PhD; Douglas G. McNeel, MD, PhD; Jamey Weichert, PhD; Zachary S. Morris, MD, PhD; Paul M. Sondel, MD, PhD; | Immune-stimulants and immune modulators | Immune adjuvant; Immune monitoring; Radiotherapy; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment; Vaccine |
| P654 | CD137 agonists as an adjunct to immune checkpoint inhibitors to overcome resistance in melanoma | Sreedevi Danturti, PhD; Lena Sophie Mayer, MD; Sreedevi Danturti, PhD; Vesselin Tomov; | Immune-stimulants and immune modulators | Adoptive immunotherapy; Checkpoint blockade; Chemokine; Costimulation; Cytokine; Monocyte/Macrophage; Myeloid cells; T cell; T cell lineages; Targeted therapy |
| P655 | EOS100850, an A2A receptor antagonist demonstrates efficacy in murine syngeneic tumor models regardless of adenosine concentrations | Romain Pirson, MSc; Anne Catherine Michaux; Diane Jamart; Julie Preillon, MSc.; Lucas Chaible; Chiara Martinoli, PhD; Gregory Driessens, PhD; Erica Houthuys, PhD; Stefano Crosignani, PhD; Reece Marillier, PhD; | Immune-stimulants and immune modulators | Chemotherapy; Immune suppression; Immune tolerance; Metabolism; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P656 | PEGylated cationic liposomal-oxaliplatin display impressive anti-cancer efficacy by dual-targeting of immunosuppressive populations and cancer-cells | Lars R. Petersen, PhD; Lars Ringgaard, PhD; Fredrik Melander, PhD; Ragnhild G. Østrem, PhD; Kasper Kristensen, PhD; Jonas R. Henriksen, PhD; Dennis R. Elema, PhD; Andreas Kjær, MD, PhD; Thomas L. Andresen, PhD; | Immune-stimulants and immune modulators | Chemotherapy; Monocyte/Macrophage; Myeloid cells; MDSC; Solid tumors; Tumor antigens; Tumor microenvironment |
| P657 | Selective T cells Redirection Proteins (STR) Enhance the Anti-Tumor Activity of Checkpoint Inhibitors (CPIs) and can Lead to Long-Lasting Immunity Against the Tumor | Meir Azulay, Ph.D; | Immune-stimulants and immune modulators | Antibody; Antigen presenting cells; Checkpoint blockade; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| P658 | Co-delivery of synergistic immune agonists via systemic nanoparticles for interferon β-driven anti-tumor immunity and prevention of metastasis | Prabhani Atukorale; Chris J. Hoimes, MD; Prabhani Atukorale; Efstathios Karathanasis; | Immune-stimulants and immune modulators | Antigen presenting cells; Cytokine; Dendritic cell; Immune adjuvant; Monocyte/Macrophage; T cell; Tumor infiltrating lymphocytes (TILs); TLR; Tumor microenvironment; Vaccine |
| P659 | ENPP1 antagonists in combination with radiation or checkpoint inhibitors demonstrate antitumor activity in syngeneic mice models of pancreatic adenocarcinoma, neuroblastoma, TNBC, and colon cancer | Lingyin Li, PhD; Mark Smith, PhD; Betty Chang, PhD; | Immune-stimulants and immune modulators | Antigen presenting cells; Dendritic cell; Radiotherapy; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P660 | TNF-alpha suppresses the Immunogenicity of STING-agonists | Anthony L. Desbien, PhD; Kelsey E. Sivick Gauthier; Ed Lemmens; Weiqun Liu, PhD; Brian Francica, PhD; Gabrielle L. Reiner; Charles Cho; Steven L. Bender; Jeffry M. Mckenna, DPhil; Yan Feng, PhD; Lianzing Zheng, Phd; Andrea van Elsas; Sarah McWhirter; | Immune-stimulants and immune modulators | Immune adjuvant; T cell |
| P661 | Development and characterization of next generation small molecule STING agonists | Stefan Chmielewski, PhD; Magdalena Zawadzka; Jolanta Mazurek; Karolina Gluza; Katarzyna Wójcik-Jaszczynska; Maciej Kujawa; Grzegorz Topolnicki; Grzegorz Cwiertnia; Aleksandra Poczkaj; Eliza Zimolag; Magdalena Mroczkowska; Agnieszka Gibas; Marcin Les; Sylwia Sudol; Marek Wronowski; Kinga Michalik; Katarzyna Banaszak; Katarzyna Wiklik; Federico Malusa; Michal Combik; Karolina Wiatrowska; Lukasz Dudek; Jose Alvarez; Anna Rajda; Maciej Rogacki; Faustyna Gajdosz; Aniela Golas; Katarzyna Wnuk-Lipinska; Ewelina Gabor-Worwa; Charles Fabritius; Luigi Stasi; Peter Littlewood; Krzysztof Brzózka; Monika Dobrzanska; | Immune-stimulants and immune modulators | Antigen presenting cells; Cytokine; Dendritic cell; Inflammation; Monocyte/Macrophage; Tumor evasion; Tumor microenvironment |
| P662 | Inhibiting DNA methylation can reverse epigenetic silencing of STING in melanoma and enhance antitumor T-cell activity | Rana Falahat, PhD; James Mulé, PhD; Anders E. Berglund, PhD; Patricio Perez-Villarroel; Shota Aoyama, MD; Shari A. Pilon-Thomas, PhD; Glen N. Barber, PhD; | Immune-stimulants and immune modulators | Adoptive immunotherapy; Bioinformatics; Chemokine; Cytokine; Immune suppression; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion |
| P663 | Evaluating loss of cGAS and STING expression using a novel multiplex immunohistochemistry detection approach | Jeanette Rheinhardt; Adam Markman; Hideki Goda, PhD; Etsuko Futaya; Masaru Takahashi; Hiroyuki Yokota; Kenji Nishikawa; Hisatake Okada; Kenneth Bloom; George Abe; Joseph Krueger; Apollina Goel, PhD; | Immune-stimulants and immune modulators | Biomarkers; Immune adjuvant; Immune contexture; Tumor infiltrating lymphocytes (TILs) |
| P664 | Development of small molecule STING agonists that can evoke host anti-cancer immune defences following local or systemic delivery | Nicole M. Haynes, PhD; Theresa Connor; Ben Morrow, PhD; Judy Doherty; Matthew Dennis, PhD; Jonathan Hubert, PhD; Sukhdeep Spall; Anthony Cuzzupe; Karen White, PhD; Susan Charman, PhD, Professor; Aaron Lock; Vicky M. Avery, PhD, Professor; Stewart Nuttall; Tom S. Peat, PhD; Olan Dolezal, PhD; Pat Pilling; Jezrael Revalde; Tin Yow; Greg Arndt; Hendrik Falk, PhD; Mark Devlin, PhD, COO; Ian P. Street, PhD; Poh S. Khoo, PhD; Paul A. Stupple, PhD; Brendon J. Monahan, PhD, CSO; | Immune-stimulants and immune modulators | Antigen presenting cells; Cytokine; Dendritic cell; Immune adjuvant; Inflammation; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P665 | Enhancing IFN-β production through synergy between the STING and TLR pathways | Emily Higgs, BA; Thomas F. Gajewski, MD, PhD; | Immune-stimulants and immune modulators | Antigen presenting cells; Dendritic cell; Immune adjuvant; TLR |
| P666 | Selective activation of antigen presenting cells by exoSTING enhances tumor antigen-specific immune response | Su Chul Jang, PhD; Kelvin Zhang; Nuruddeen Lewis, PhD; Tong Zi; Joanne Lim; Rane Harrison; Raymond J. Moniz; Katherine Kirwin; Chang Ling Sia; Christine McCoy; Kevin Dooley; Ke Xu; Jorge Sanchez-Salazar; Raymond W. Bourdeau; Agata Villiger-Oberbek; William K. Dahlberg; Shil Patel; Kyriakos Economides; Sriram Sathyanarayanan; | Immune-stimulants and immune modulators | Antigen presenting cells; Checkpoint blockade; Dendritic cell; Gene expression; Monocyte/Macrophage; Myeloid cells; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P667 | Neoadjuvant STING agonists combined with systemic immunotherapy block metastatic recurrence in orthotopic breast tumors | Lauren Milling, BS; Darrell J. Irvine, PhD; | Immune-stimulants and immune modulators | Cytokine; Dendritic cell; Surgery; T cell; Tumor microenvironment |
| P668 | TTI-10001, a next generation small molecule STING agonist, demonstrates potent anti-tumor activity in mice following oral or intravenous administration | Natasja Viller; Peter Dove; David Rosa; Bolette Bossen, BSc; Tran Truong; Tapfuma Mutukura; Debbie Jin; Marilyse Charbonneau; Laura Brinen; Karen Dodge; Gloria HY. Lin; Jeff Winston; Robert A. Uger; Malik Slassi; Zezhou Wang, PhD; | Immune-stimulants and immune modulators | Adoptive immunotherapy; Antigen presenting cells; Cytokine; Dendritic cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P669 | Pharmacological evaluation of the ubiquitin ligase CBL-B as a small molecule, tumor immunotherapy target | Jennifa Gosling, MS; Christoph W. Zapf; Ryan Rountree; Chenbo Wang; Thomas Cummins; Frederick Cohen; Hiroko Tanaka; Dahlia Weiss; Mario Cardozo; Christopher Karim; May Tan; Austin Tenn-McClellan; Szerenke Kiss von Soly; Julie Sheung; Ketki Dhamnaskar; Katherine Kurylo; Neil Bence; Arthur Sands; | Immune-stimulants and immune modulators | Cytokine; NK/NK T cell; T cell |
| P670 | Pharmacodynamic response in vitro and in vivo of novel orally administered Toll-like Receptor 7 agonists for systemic immunotherapy of cancer | James R. Appleman, PhD; Stephen E. Webber; | Immune-stimulants and immune modulators | Chemokine; Cytokine; Dendritic cell; TLR |
| P671 | Delivery of TLR7 agonists by Deep-Primed™ T cells induces immune activation and improves anti-tumor activity in mice while circumventing systemic toxicity | Austin W. Boesch, PhD; Vasily Rybakin; Nathan Westcott; Ji Young Hwang; Kira Jørgensen; Rasmus Lassen; Martin Kraemer; Martin Bak, PhD; Gael Veiga; Jonas Bruun, PhD; Carlos Tassa; Harrison Rodts; Manny Sequeira; Glenn Leary; Santina Caruso; Becker Hewes, MD; Jonathan B. Fitzgerald, PhD; Karsten Sauer, PhD; Thomas L. Andresen, PhD; | Immune-stimulants and immune modulators | Adoptive immunotherapy; Antigen presenting cells; Cytokine; Dendritic cell; Immune toxicity; MDSC; T cell; TLR; Tumor antigens; Tumor microenvironment |
| P672 | Activation of CD8+ T cells in the presence of multiple TLR agonists differently affects the expression of T-cell checkpoint receptors | Donghwan Jeon, MS; Christopher W. Zahm, PhD; Douglas G. McNeel, MD, PhD; Donghwan Jeon, MS; | Immune-stimulants and immune modulators | Dendritic cell; Immune adjuvant; TLR |
| P673 | Targeted delivery system for toll-like receptor agonists to repolarize the immunosuppressive phenotype of tumor-associated macrophages | Hyewon Ko; Soyoung Son; Sol Shin; Jae Hyung Park, PhD; | Immune-stimulants and immune modulators | Antigen presenting cells; Checkpoint blockade; Immune adjuvant; Immune suppression; Monocyte/Macrophage; Targeted therapy; TLR; Tumor microenvironment |
| P674 | In situ vaccination using a tumor-binding polymeric glyco-adjuvant for the induction of anti-tumor immunity | Tiffany Marchell; David S. Wilson; Aaron Alpar; Jeffrey Hubbell; | Immune-stimulants and immune modulators | Immune adjuvant; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); TLR; Tumor microenvironment; Vaccine |
| P675 | Multimodal intratumoral immunotherapy potentiates complete immunologic tumor elimination of breast cancer origin diffuse liver metastases | Erik R. Soule; Jason R. Williams, MD; | Immune-stimulants and immune modulators | Antibody; Biomarkers; Checkpoint blockade; Immune adjuvant; Neoantigens; Regulatory T cell (Treg cell); Stem cell/cancer-initiating cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); TLR; Tumor antigens; Vaccine |
| P676 | Intratumoral delivery of TransCon™ TLR7/8 Agonist provides potent anti-tumor activity as a monotherapy and in combination with IL-2 while minimizing systemic cytokine induction | Luis A. Zuniga, PhD; Torben Leßmann; Lars Holten-Andersen; Nicola Bisek; Joachim Zettler; Sebastian Stark; Frank Faltinger; Oliver Kracker; Samuel Weisbrod; Robin Müller; Tobias Voigt; Kornelia Bigott; Mohammad A. Tabrizifard; Vibeke Breinholt; Kennett Sprogøe; Juha Punnonen; | Immune-stimulants and immune modulators | Antigen presenting cells; Immune suppression; Inflammation; Monocyte/Macrophage; Myeloid cells; MDSC; Solid tumors; Tumor infiltrating lymphocytes (TILs); TLR; Tumor microenvironment |
| P677 | Warehouse approach for the development of personalized cancer vaccines by using Personal Antigen Selection Calculator (PASCal) without need for tumor biopsy | Zsolt Csiszovszki, PhD; Levente Molnár; Péter Páles; József Tóth; Orsolya Lorincz; Katalin Pántya; Eszter Somogyi; István Miklós; Wolfgang Schönharting; Sybille Urban; Tim Röhnisch; Mónika Megyesi; Eniko R. Toke; | Immune-stimulants and immune modulators | Bioinformatics; Immune adjuvant; Solid tumors; T cell; Tumor antigens; Vaccine |
| P678 | Vaccine neoantigens empirically identified through the ex vivo ATLAS platform promote potent therapeutic responses to cancer in mice | Victoria L. DeVault, PhD; Hanna Starobinets, PhD; Sanmit Adhikari; Brendan Classon, PhD; Jessica B. Flechtner, PhD; Hubert Lam, PhD; | Immune-stimulants and immune modulators | Antigen presenting cells; Immune suppression; Immune tolerance; Neoantigens; Regulatory T cell (Treg cell); T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |
| P679 | Scheduling androgen deprivation with AR-targeted vaccination affects anti-tumor efficacy in prostate cancer | Melissa Gamat-Huber, PhD; Douglas G. McNeel, MD, PhD; Melissa Gamat-Huber, PhD; | Immune-stimulants and immune modulators | Immune adjuvant; Solid tumors; T cell; Vaccine |
| P680 | Discovery of immunogenic ERV-derived antigens as targets for melanoma immunotherapy | Ray Jupp, PhD; George Kassiotis; Nicola Ternette; George Young; Duncan Howie; Fabio Marino; Matthew Davies; Hayden Selvadurai; Alvaro Sanchez; Jonathan Dodd; Laura Lozza; Elizabeth Soilleux; Peter W. Mason; Kevin Pojasek; | Immune-stimulants and immune modulators | T cell; Tumor antigens; Vaccine |
| P681 | DNA Methyltransferase Inhibition Immunosensitizes Diffuse Intrinsic Pontine Gliomas to Peptide Vaccine through Augmentation of EphA2 and MHC I Expression. | Rajeev Kumar; Lauren McCarl; Alexandra Foster; Shubhanchi Nigam; Xinjuan Ma; Marissa Campagna; Alberto Broniscer; Katherine Warren; Ian Pollack; Gary Kohanbash; | Immune-stimulants and immune modulators | Pediatric tumors; Tumor antigens; Vaccine |
| P682 | AI-augmented design of effective therapeutic cancer vaccines and adoptive cell therapies | Piotr Stepniak; Giovanni Mazzocco, M.Sc.; Alexander Myronov, M.Sc.; Iga Niemiec, M.Sc.; Katarzyna Gruba, M.Sc.; Piotr Skoczylas, M.Sc.; Anna Sanecka-Duin, PhD; Michal Drwal, M.Sc.; Jan Kaczmarczyk, PhD; Giovanni Mazzocco, M.Sc.; | Immune-stimulants and immune modulators | Adoptive immunotherapy; Bioinformatics; Immune adjuvant; Neoantigens; T cell; Vaccine |
| P683 | Incomplete Freund’s Adjuvant reduces Arginase, enhances a Th1 dominant cytokine environment, and supports CD40 L expression | Karlyn E. Pollack, MD; Max O. Meneveau, MD; Alexander F. Koeppel; Samuel J. Young; Stephen D. Turner; Katia Sol-Church, MD; Ileana S. Mauldin, PhD; Craig L. Slingluff, Jr., MD; | Immune-stimulants and immune modulators | Chemokine; Dendritic cell; Gene expression; Immune adjuvant; Solid tumors; T cell; TLR; Vaccine |
| P684 | Highly efficient selection of tumor neoantigens improves therapeutic cancer vaccine efficacy | Guilhem Richard, PhD; Gad Berdugo, MSc, MBA; Michael F. Princiotta, MS, PhD; Leonard Moise, PhD; Matthew Ardito, BA; Christine Boyle; Dominique Bridon; William Martin, BA MD; Anne S. de Groot, MD; | Immune-stimulants and immune modulators | Bioinformatics; Neoantigens; Regulatory T cell (Treg cell); Solid tumors; T cell; Targeted therapy |
| P685 | Inhibition of EZH2 enhances tumor immunogenicity through diversification of tumor antigen presentation | Jing Qiu, PhD; Thomas Paul; | Immune-stimulants and immune modulators | Immune suppression; Neoantigens; Vaccine |
| P686 | The NCI PREVENT Program portfolio for precision cancer immunoprevention | Shizuko Sei, MD; Altaf Mohammed, PhD; Jennifer Fox, PhD; Romaine I. Fernando, PhD; Daniel Boring, RPh, PhD; Mark Miller, PhD; Robert Shoemaker, PhD; | Immune-stimulants and immune modulators | Neoantigens; Tumor infiltrating lymphocytes (TILs); TLR; Tumor antigens; Tumor microenvironment; Vaccine |
| P687 | Novel vaccination strategies using tumour-independent antigens to induce anti-tumour immunity in solid tumours. | Vinod Sommandas; Satwinder K. Singh; Erik Manting; Satwinder K. Singh; | Immune-stimulants and immune modulators | Immune adjuvant; Solid tumors; Vaccine |
| P688 | Lysosomal-associated membrane protein-1-targeting of a poly-neoepitope DNA vaccine elicits potent immune responses and inhibits tumor growth | Pratima Sinha, PhD; Matthew Ardito, BA; Guilhem Richard; Leonard Moise, PhD; Gad Berdugo, MSc, MBA; Teri Heiland; | Immune-stimulants and immune modulators | Bioinformatics; Neoantigens; Regulatory T cell (Treg cell); Solid tumors; T cell; Targeted therapy; Vaccine |
| P689 | Amphiphile-modifications target mKRAS-antigen and adjuvant to lymph nodes and enable polyfunctional mKRAS-specific immune responses with potent cytolytic activity | Martin Steinbuck; Peter DeMuth, PhD; Lochana Seenappa, MS; Martin Steinbuck; | Immune-stimulants and immune modulators | Immune adjuvant; T cell; Tumor antigens; Vaccine |
| P690 | Improving the immunogenicity of modified vaccinia virus Ankara (MVA) vaccine vector by deletion of the vaccinia E5R gene encoding a dominant cGAS inhibitor | Liang Deng, PhD, MD; Ning Yang; Yi Wang, MS; Peihong Dai; Stewart Shuman, MD PhD; | Immune-stimulants and immune modulators | Dendritic cell; Immune adjuvant; Tumor antigens |
| P691 | Monoclonal microbial EDP1503 induces anti-tumor responses via gut-mediated activation of both innate and adaptive immunity | Humphrey A. Gardner, MD; Shubhra Kashyap, MS; Peter Sandy, PhD; Holly Ponichtera, PhD; Shannon Argueta, PhD; Chris Davitt, PhD; Michael Goldberg, PhD; Mark Carlson, MS; Maria Sizova, PhD; Valeria Kravitz, MS; Erin Troy, PhD; Sam Andrewes, MS; Mark Bodmer, PhD; Loise Francisco-Anderson, PhD; | Immune-stimulants and immune modulators | Antigen presenting cells; Immune adjuvant; NK/NK T cell; Tumor infiltrating lymphocytes (TILs) |
| P692 | Blockade of PGE2 Production and Signaling Enhances the Magnitude and Selectivity of BCG-Promoted Immune Responses in the Human Bladder Cancer Microenvironment | Omar M. Ibrahim, BPharm; Melissa Grimm, PhD; Weijan Jiang; Khurshid Guru; Gurkamal S. Chatta, MD; Pawel Kalinski, MD, PhD; | Immune-stimulants and immune modulators | Inflammation; TLR; Tumor microenvironment |
| P693 | Cooperative targeting of immunotherapy-resistant melanoma and lung cancer models by an AXL-targeting antibody-drug conjugate and immune checkpoint blockade | Julia Boshuizen, MD; Nora Pencheva; Oscar Krijgsman, PhD; Maarten Janmaat; Patricia Garrido Castro; Elke Gresnigt-Van den Heuvel; Andreas Lingnau; Maria Jure-Kunkel; Daniel Peeper, PhD; | Immuno-conjugates and chimeric molecules | Adoptive immunotherapy; Antibody; Checkpoint blockade; T cell; Tumor evasion |
| P694 | Engineering extracellular matrix-binding checkpoint inhibitor antibodies to achieve localized cancer therapy | Jun Ishihara, PhD; Ako Ishihara; John Michael Williford; Jeffrey Hubbell; | Immuno-conjugates and chimeric molecules | Antibody; Autoimmunity; Checkpoint blockade; Immune toxicity; Targeted therapy |
| P695 | Tumor targeting of a STING agonist with an antibody-drug conjugate elicits potent anti-tumor immune responses | Naniye Malli Cetinbas, PhD; Kalli C. Catcott, PhD; Kenneth Avocetien; Keith Bentley, PhD; Tyler Carter, PhD; Chen-Ni Chin, PhD; Susan Clardy, PhD; Timothy Eitas, PhD; Brian Jones, PhD; Eoin Kelleher; Rebecca Mosher, MD; Mark Nazzaro; Barrett Nehilla, PhD; Marina Protopopova, PhD; Pamela Shaw; Kelly Slocum; LiuLiang Qin; Josh Thomas, PhD; Liping Yang; Dorin Toader, PhD; Marc Damelin, PhD; Jeremy Duvall, PhD; Raghida Bukhalid, PhD; Timothy Lowinger, PhD; | Immuno-conjugates and chimeric molecules | Antigen presenting cells; Chemokine; Cytokine; Dendritic cell; Monocyte/Macrophage; Myeloid cells; MDSC; Solid tumors; Targeted therapy |
| P696 | Efficacy Studies of a Novel Multi-targeted Systemic Therapy (αPD-L1/ODN1826) and Deep-Immune Profiling of Metastatic Murine Mammary Adenocarcinoma in Syngeneic Immunocompetent Models | Alan L. Epstein, MD, PhD; Alison Smith, MDPhD candidate; | Immuno-conjugates and chimeric molecules | Antibody; Antigen presenting cells; Checkpoint blockade; Immune adjuvant; Immune monitoring; Immune suppression; Solid tumors; Targeted therapy; TLR; Tumor antigens |
| P697 | Pre-clinical characterization of the mechanism of action of a CD25-targeted pyrrolobenzodiazepine dimer-based antibody-drug conjugate targeting regulatory T cells in solid cancers | Francesca Zammarchi, PhD; Simon Chivers; Patrick H. van Berkel, Ph.D; Francesca Zammarchi, PhD; | Immuno-conjugates and chimeric molecules | Antibody; Checkpoint blockade; Chemotherapy; Clinical trial; Immune suppression; Regulatory T cell (Treg cell); Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P698 | Chimeric protein MICA-G129R Bridges Breast Cancer Cells and Natural Killer Cells | Hui Ding, PhD candidate; Yanzhang Wei; | Immuno-conjugates and chimeric molecules | Costimulation; NK/NK T cell; Solid tumors; Targeted therapy |
| P699 | DSP107—a first in class, bifunctional fusion protein targeting both innate and adaptive immunity | Adam Foley-Comer, MD; Shirley Greenwald; Ewa Cendrowicz; Rinat Tabakman; Shira Amsili; Alexandra Aronin; Liat Ben-Gigi-Tamir; Elina Zorde-Khvalevsky; Yosi Gozlan; Michal Dranitzki-Elhalel; Ayelet Chajut; Amnon Peled, PhD; Edwin Bremer; | Immuno-conjugates and chimeric molecules | Costimulation; Monocyte/Macrophage; Myeloid cells; T cell; Targeted therapy; Tumor microenvironment |
| P700 | Combining CD27 costimulation and PD-1 blockade into a bispecific antibody improves T cell activation and anti-tumor activity over combination of individual antibodies | Laura Vitale, BS; Lawrence Thomas, PhD; Thomas O'Neill, BA; Jenifer Widger, BA; Laura Mills-Chen; Andrea Crocker, BS; Colleen Patterson; Anna Wasiuk; Eric Forsberg; James Boyer; Crystal Sisson; Jeffrey Weidlick, BS; Shannon Renn-Bingham; Ioannis Papayannopoulos; Russ Hammond; Joel Goldstein, PhD; Henry C. Marsh, Jr.; Li-Zhen He, MD; Michael Yellin, MD; Tibor Keler, PhD; | Immuno-conjugates and chimeric molecules | Antibody; Checkpoint blockade; Coinhibition; Costimulation; T cell |
| P701 | A next generation bispecific antibody platform for effective tumor cell killing with minimal cytokine release | Udaya Rangaswamy, PhD; Harbani K Malik-Chaudhry, PhD; Udaya Rangaswamy, PhD; Brian Avanzino, PhD; Aarti Balasubramani; Andrew Boudreau, BA; Benjamin Buelow; Kevin Dang, BA; Laura Davison, PhD; Kathrine Harris; Sharon Hartstein; Brett Jorgensen, BA; Hannes Kehm; Yuping Li; Kyle Lorentsen, PhD; Harish Medlari; Duy Pham, BA; Kirthana Prabhakar; Ute Schellenberger, PhD; Harshad Ugamraj, BA; Nathan Trinklein, PhD; Roland Buelow, PhD; Suhasini Iyer, PhD; | Immuno-conjugates and chimeric molecules | Antibody; Leukemia/Lymphoma; T cell |
| P702 | Informing rational immunotherapy combinations for enhancing therapeutic activity of Bi-Specific T cell Engager (BiTE®) antibody constructs in solid tumors | Deepali V. Sawant, PhD; Brian Belmontes; Famke Aeffner; Olivier Nolan-Stevaux; Jackson Egen; Jason DeVoss, PhD; | Immuno-conjugates and chimeric molecules | Antibody; Solid tumors; T cell; Tumor antigens; Tumor microenvironment |
| P703 | Co-stimulation of OX40 or LTβR Reprograms Exhausted Lymphocytes to Acquire an Effector Phenotype in the Setting of Combined TIGIT and Checkpoint Blockade | George J. Fromm, Jr., PhD; Suresh De Silva, PhD; Arpita Patel, BA; Kyung Jin Yoo; Kellsey Johannes, BS; Kaiwen Huang; Taylor H. Schreiber, MD, PhD; | Immuno-conjugates and chimeric molecules | Checkpoint blockade; Costimulation; T cell |
| P704 | An Fc Effector Enhanced EGFR/cMet Bispecific Antibody (JNJ-61186372), mediates EGFR/cMet Downmodulation and Therapeutic Efficacy Through Monocyte and Macrophage Trogocytosis | Smruthi Vijayaraghavan, PhD; Lorriane Lipfert; Kristen Chevalier; Barbara Bushey, BS; Benjamin Henley; Ryan Lenhart; Jocelyn Sendecki, MS; Marilda Beqiri; Hillary Millar, MS; Kathryn Packman, PhD; Matthew V. Lorenzi, PhD; Sylvie Laquerre; Sheri Moores, PhD; | Immuno-conjugates and chimeric molecules | Antibody; Chemokine; Monocyte/Macrophage; Myeloid cells; Solid tumors; Targeted therapy; Tumor antigens |
| P705 | A chimeric adenoviral vector overcomes pre-existing adenoviral immunity to elicit antitumor immunity to the colorectal cancer antigen GUCY2C | Jagmohan Singh; John Flickinger; Robert carlson; Trevor Baybutt; Elinor Leong; Ellen Caparosa; Jamin Roh; Amanda Pattison; Jeffrey Rappaport; Joshua Barton; Tingting Yang; Scott A. Waldman; Adam E. Snook, PhD; | Immuno-conjugates and chimeric molecules | Solid tumors; Targeted therapy; Vaccine |
| P706 | A TCR-CD3 bispecific fusion protein mediates increased presentation of peptide-HLA which associates with improved T cell activation and tumour cell killing | Duncan M. Gascoyne, PhD; David Depoil, Ph D; Karolina A. Rygiel; Nathaniel Davies, Ph D; Cheryl McAlpine, MSN; Rupert Kenefeck; | Immuno-conjugates and chimeric molecules | Antigen presenting cells; Cytokine; Gene expression; Inflammation; Solid tumors; T cell; Tumor antigens; Tumor evasion |
| P707 | Matrix-binding IL-12 enhances tumor inflammation and drives complete remission in established cold murine tumors | Aslan Mansurov, BChen; Jeffrey Hubbell; Jun Ishihara, PhD; | Immuno-conjugates and chimeric molecules | Cytokine; Immune toxicity; Solid tumors; Targeted therapy; Tumor stroma |
| P708 | Real world evidence of patient clinical profiles with advanced solid tumor malignancies receiving immune checkpoint inhibitors to investigate potential predictors for immune-related adverse events. | Stephanie Berg, DO; Joseph I. Clark, MD; Jose Guevara; Elizabeth Elliott, DO; Stephanie Berg, DO; Stephanie Berg, DO; Michael Wesolowski; Blaine Knox, MD; Daniel Linden, DO; Courtney Wagner, MD; | Immunotherapy Toxicities | Biomarkers; Checkpoint blockade; Clinical study; Immune toxicity; Solid tumors |
| P709 | Immunotherapy Adverse Events Predict Treatment Response | Diana V. Maslov; Katherine Thomas, MD, MS; Victoria Simenson, MD; Caitlin Sullivan, MD; Alaa Mohammed, MPH; Jessica Boyce; Jonathan Lu, MD; John Kucharczyk, MD; Marc R. Matrana; | Immunotherapy Toxicities | Checkpoint blockade; Immune tolerance; Immune toxicity; Solid tumors; Targeted therapy |
| P710 | Immune Checkpoint Inhibitors increase the risk of Hypothyroidism in Patients with Primary Head and Neck Cancer Compared to Other Cancers | Omar A. Alaber, MD; Apoorva K. Chandar; Prateek Mendiratta, MD; Monaliben Patel, MD; Chris J. Hoimes, MD; Pierre Lavertu, MD; Ankit Mangla, MD | Immunotherapy Toxicities | Checkpoint blockade; Epidemiology; Immune toxicity; Radiotherapy; Solid tumors; Targeted therapy |
| P711 | Single-Center Analysis of Safety and Efficacy of Immune Checkpoint Inhibitors (ICI) in Non-Hematologic Malignancies: Effects of Age and Eosinophilia | Justin T. Moyers, MD; Dhanu Desai; Jasmine Mitchell; Jeffrey Ahn; Steven Hardin; Mie Mie Thinn; | Immunotherapy Toxicities | Checkpoint blockade; Immune monitoring; Immune toxicity |
| P712 | Conditional immune toxicity rate with immune checkpoint inhibitors | Pier Vitale Nuzzo, MD, PhD; Gregory Russell Pond, M.Sc, PhD; Amin Nassar, MD; Sarah Abou Alaiwi, MD; Ronan Flippot, MD; Catherine Curran; Kerry Kilbridge, MD; Xiao Wei, MD; Bradley Mcgregor, MD; Lauren Harshman, MD; Toni K. Choueiri; Guru Sonpavde, MD; | Immunotherapy Toxicities | Biomarkers; Checkpoint blockade; Immune monitoring; Immune toxicity; Targeted therapy |
| P714 | Immunological features of immune-related adverse events during anti-PD-1/PD-L1 immune checkpoint inhibition | Meghali Goswami, MPhil; Gege Gui; Katherine E. Lindblad; Jaydira Del Rivero, MD; Jennifer Marte, BS MD; Pradeep K. Dagur, PhD; Christin B. Destefano, MD; Julie Thompson, RN; Bogdan Popescu, MD; Laura Dillon, PhD; Cheryl D. Johnson; Steven J. Soldin, PhD; Catherine Lai, MD, MPH; James L. Gulley, MD, PhD, FACP; Christopher S. Hourigan, MD, PhD; | Immunotherapy Toxicities | Autoimmunity; Checkpoint blockade; Clinical study; Clinical trial; Gene expression; Immune toxicity; Leukemia/Lymphoma; T cell |
| P715 | Strategies to mitigate immune-related adverse events of efficacious combination immunotherapies in preclinical models of cancer | Célia Jacoberger-Foissac, PhD; Stephen J. Blake; Célia Jacoberger-Foissac, PhD; Jing Liu; Stacey Allen; Juming Yan; Heidi Harjunpaa; Mark J. Smyth; Michele W. Teng, PhD; | Immunotherapy Toxicities | Antibody; Autoimmunity; Cytokine; Immune suppression; Immune toxicity; Regulatory T cell (Treg cell); Solid tumors |
| P716 | An In Vivo PBMC Humanized Mouse Model for Determining Checkpoint and Bispecific Antibody Treatment Related Cytokine Release Syndrome | Chunting Ye; Mingshan Cheng; Michael Brehm; Dale Greiner; Leonard Shultz; James Keck, PhD; | Immunotherapy Toxicities | Checkpoint blockade; Cytokine; Immune toxicity |
| P717 | Involvement of IL17 in a case of fatal neuroendocrine toxicity associated with dual immune checkpoint blockade | Luca Mazzarella, MD PhD; Silvia Giugliano; Paolo D'Amico; Carmen Belli; Bruno Duso; Giuseppe Curigliano, MD, PhD; Maria Rescigno, MD, PhD; Luca Mazzarella, MD PhD; | Immunotherapy Toxicities | Checkpoint blockade; Cytokine; Dendritic cell; Immune toxicity |
| P718 | A case of dual-mechanism hematologic immune-related adverse event in a patient with metastatic melanoma treated with combined nivolumab and ipilimumab | Daniel J. Olson, MD; Melissa Tjota, MD, PhD; Padma Rajagopal, MD; Girish Venkataraman, MD; Jason J. Luke, MD, FACP; Thomas F. Gajewski, MD, PhD; | Immunotherapy Toxicities | Autoimmunity; Checkpoint blockade; Immune toxicity |
| P719 | CD8+ Tcell integrin α4β7expression: a potential predictor of severity and steroid sensitivity in checkpoint inhibitor induced colitis | Anna C. Olsson-Brown, MBChB (Hons), BSc (Hons); Joseph Sacco, MSc, MBChB, MRCP, Ph; Sandra CP. Cachinho; Carol Jolly; Vanessa Fontana; Rosemary Lord; Mark Coles; Munir Pirmohamed; | Immunotherapy Toxicities | Immune toxicity; Inflammation; Solid tumors; T cell |
| P720 | The use of in vitro assays to reduce the risk of unwanted immunogenicity | Amin Osmani; Thibault Jonckheere; Sofie Pattijn; Mayuko Oh; Thibaut Janss; | Immunotherapy Toxicities | Dendritic cell; Immune suppression; Immune tolerance; Immune toxicity; Monocyte/Macrophage; Myeloid cells; MDSC; Regulatory T cell (Treg cell); T cell |
| P721 | Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis | Hamzah Abu-Sbeih, MD; Lauren N. Herrera; Tenglong Tang, MD; Mehmet Altan; Anne-Maria P. Chaftari; Pablo C. Okhuysen; Robert Jenq, MD; Yinghong Wang, MD, PhD; | Immunotherapy Toxicities | Autoimmunity; Checkpoint blockade; Immune toxicity; Inflammation; Microbiome |
| P722 | Opportunistic Infection Outcomes in Patients Receiving Corticosteroids for Immune Checkpoint Inhibitor Toxicity | Michael R. Cook, MD; Michael B. Atkins, MD; | Immunotherapy Toxicities | Checkpoint blockade; Immune suppression; Immune toxicity |
| P723 | Interleukin-6 blockade to de-couple CTLA-4 blockade colitis from anti-tumor efficacy | Yared Hailemichael, PhD; Daniel H. Johnson, MD; Wai C. Foo; Kenneth R. Hess, BS, MS, PhD; Cara Haymaker, PhD; Chantal M. Saberian, MD; Salah E. Bentebibel; Elizabeth Burton; Yinghong Wang, MD, PhD; Scott Woodman; Patrick Hwu, MD; Adi Diab, MD; | Immunotherapy Toxicities | Autoimmunity; Checkpoint blockade; Chemokine; Cytokine; Immune toxicity; Inflammation; Monocyte/Macrophage; Myeloid cells; T cell; Tumor infiltrating lymphocytes (TILs) |
| P724 | Analysis of healthcare provider management of immune-related adverse events and concordance with NCCN Guidelines® | Megan Cartwright, PhD; Krista Marcello, BA; Jillian L. Scavone, PhD; Kevin L. Obholz, PhD; Timothy A. Quill, PhD; John A. Thompson; | Immunotherapy Toxicities | Autoimmunity; Checkpoint blockade; Immune toxicity |
| P725 | Clinical features of immune checkpoint inhibitor-related adrenal insufficiency: a retrospective analysis | Qinwen Zhou, MD; Sandip P. Patel, MD; Qinwen Zhou, MD; Vala Hamidi; Qinwen Zhou, MD; | Immunotherapy Toxicities | Autoimmunity; Checkpoint blockade; Immune monitoring; Immune toxicity; Solid tumors |
| P726 | Applying deep learning classification for tumor identification across immunohistochemical markers on serial sections to eliminate the need for image co-registration | Mark Anderson, BSc; Karen McClymont; Lorcan Sherry, PhD; Alison Bigley, CSci, FIBMS; | Machine Learning, Artificial Intelligence, and Computational Modeling | Biomarkers; Immune contexture; T cell; Tumor microenvironment; Tumor stroma |
| P727 | Single-cell systems neuroimmunology reveals immunosuppressive checkpoint blockade receptor expression correlates with ventricular stem cell niche contact in human glioblastoma | Todd Bartkowiak, PhD; Sierra Barone, BS.; Allison R. Greenplate, PhD; Justine Sinnaeve, BS.; Nalin Leelatian; Akshitkumar M. Mistry, MD; Caroline E. Roe, BS.; Bret C. Mobley, MD; Lola B. Chambless, MD; Reid C. Thompson, MD; Kyle D. Weaver, MD; Rebecca A. Ihrie, PhD; Jonathan M. Irish, PhD; | Machine Learning, Artificial Intelligence, and Computational Modeling | Bioinformatics; Biomarkers; Immune monitoring; Immune suppression; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P728 | Inference of immunotherapy response-predictive biomarkers in lung adenocarcinoma from hematoxylin and eosin (H&E) stained images | Kimary Kulig, PhD, MPH; Cory Batenchuk, PhD; Peter Cimermancic; Huang-Wei Chang, PhD; Eunhee S. Yi, MD; Vanessa A. Velez; Hardik L. Patel; Ali Behrooz; Kamilla Tekiela; Robert Findlater; Cory Batenchuk, PhD; | Machine Learning, Artificial Intelligence, and Computational Modeling | Biomarkers; Checkpoint blockade; Tumor microenvironment |
| P730 | An empirical framework for validating artificial intelligence-derived PD-L1 positivity predictions using samples from patients with urothelial carcinoma | Andrew Beck, MD, PhD; Benjamin Glass; Hunter Elliott; Jennifer K. Kerner; Aditya Khosla; Abhik Lahiri; Harsha Pokkalla; Dayong Wang; Ilan Wapinski; George Lee, PhD; Vipul Baxi, MS; Cyrus Hedvat, MD, PhD; Dimple Pandya; Michael Montalto; | Machine Learning, Artificial Intelligence, and Computational Modeling | Bioinformatics; Inflammation; Monocyte/Macrophage |
| P731 | Identification and Validation of Shared Neoantigens for Cancer Immunotherapy | Jennifer Busby, PhD; Melissa Rotunno; Tyler Murphy; William Brinton; Michael Zhong; Lina Kim; Abu Jalloh; Amanda Costa; Michael Fray; Aaron Yang; Meghan Hart; Matthew Davis; Rita Zhou; Elizabeth Maloney; Alexis Mantila; Karin Jooss, PhD; Aleksandra Nowicka; Christine D. Palmer, PhD; James Sun; Roman Yelensky, PhD; Jennifer Busby, PhD; | Machine Learning, Artificial Intelligence, and Computational Modeling | Bioinformatics; Neoantigens; Proteomics |
| P732 | Reverse causal inferencing on lung adenocarcinoma patients reveals a stem cell-like molecular subtype associated with pack year history | Renee M. Deehan; Sergey Korkhov; Alexis Foroozan; Scott Marshall, Ph.D; Renee M. Deehan; Nimisha Schneider; | Machine Learning, Artificial Intelligence, and Computational Modeling | Bioinformatics; Biomarkers; Checkpoint blockade; Solid tumors |
| P733 | Quantitative systems pharmacology modeling of B-cell acute lymphoblastic leukemia treatment with bispecific T-cell engaging antibodies for investigation of bell-shaped dose response | Oleg Demin Jr, MSc; | Machine Learning, Artificial Intelligence, and Computational Modeling | Antibody; Leukemia/Lymphoma; Systems biology; T cell |
| P734 | Prediction of target occupancy in tumor after treatment with anti-PD1 antibodies using physiologically based pharmacokinetic modeling | Oleg Demin Jr, MSc; Dmitry Shchelokov; | Machine Learning, Artificial Intelligence, and Computational Modeling | Antibody; Checkpoint blockade; T cell |
| P735 | Accelerating biomarker discovery using AI powered multi- omics approaches | Madhuri Gadekar; Mohan Uttarwar; Shruti Desai; Sanjay Khare; | Machine Learning, Artificial Intelligence, and Computational Modeling | Bioinformatics; Biomarkers; Clinical trial; Immune monitoring; Immunoscore |
| P736 | Combining Multiplexed Ion Beam Imaging (MIBI) with Convolutional Neural Networks to accurately segment cells in human tissue | Noah F. Greenwald, BA; Leeat Keren; Shirley Greenbaum; Mara Fong; Gautam Chaudhry; Zion Abraham; Jackson Moseley; David Van Valen; Michael Angelo, MD, PhD; | Machine Learning, Artificial Intelligence, and Computational Modeling | Bioinformatics; Solid tumors; Tumor microenvironment; Tumor stroma |
| P737 | Model-Based Meta-Analysis of the Exposure-Response and Clinical Efficacy across Approved Anti-PD(L)1 Agents | Apurvasena Parikh, PhD; Sreeneeranj Kasichayanula, PHD; Rajeev Menon; Megan Gibbs; Sven Mensing; Benjamin Engelhardt; | Machine Learning, Artificial Intelligence, and Computational Modeling | Antibody; Checkpoint blockade; Solid tumors |
| P738 | Artificial intelligence-based tumor purity assessment of digitized histology samples in multiple tumor types from clinical trials of nivolumab | George Lee, PhD; Sujaya Srinivasan; Natallia Kalinava; Ariella Sasson; Vipul Baxi, MS; | Machine Learning, Artificial Intelligence, and Computational Modeling | Bioinformatics; Biomarkers; Clinical trial; Tumor stroma |
| P739 | Analysis of H&E Images Using Deep Learning for the Prediction of Distant Metastatic Recurrence in Early Stage Melanoma | Michael R. Moore, BA; Eric J. Robinson, BA; Prathamesh M. Kulkarni, PhD; Robyn Gartrell, MD; Jaya Pradhan, DMD, MPH; Emanuelle M. Rizk, BA; Chen Yang, MD; Acs Balazs, PhD; Robert Phelps, MD; Tammie Ferringer, MD; Andrew X. Chen, BS; Raúl Rabadán, PhD; Bethany Rohr, MD; Basil A. Horst, MD; David L. Rimm, MD, PhD; Jing Wang, MD; Yvonne Saenger, MD; | Machine Learning, Artificial Intelligence, and Computational Modeling | Bioinformatics; Biomarkers; Solid tumors; T cell; Tumor microenvironment; Tumor stroma |
| P740 | Leveraging Artificial Intelligence to Advance Immuno-oncology Drug Development using Functional Ex-Vivo 3D-Tumor Organoid Platforms of Fresh Patient Tissue Samples. | Jenny Kreahling, PhD; Daniel N. Santiago, PhD; Vijayendra Agrawal, PhD; Mibel Pabon, PhD; Soner Altiok, MD, PhD; Melba Page, PhD; | Machine Learning, Artificial Intelligence, and Computational Modeling | Bioinformatics; Biomarkers; Checkpoint blockade; Gene expression; Immune monitoring; Solid tumors; Systems biology; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P741 | Prediction of biomarkers and combinational therapies for anti-PD1 therapy using a computational network approach | Chia Chin Wu, PhD; Andrew Futreal; Jianhua Zhang; Chia-Chin Wu; | Machine Learning, Artificial Intelligence, and Computational Modeling | Bioinformatics; Biomarkers; Carcinogenesis; Checkpoint blockade; Immune suppression; Immunoscore; Systems biology; Targeted therapy |
| P742 | Computational analysis of feedback regulations of TIM-3 | Jian Zhu, PhD; Rebecca L. Zhu; | Machine Learning, Artificial Intelligence, and Computational Modeling | Bioinformatics; Biomarkers; Checkpoint blockade; Regulatory T cell (Treg cell); Systems biology |
| P743 | Impact of IDO1 expression and inhibition on the sensitivity of anti-PD-1 | Jian Zhu, PhD; Rebecca L. Zhu; | Machine Learning, Artificial Intelligence, and Computational Modeling | Bioinformatics; Biomarkers; Checkpoint blockade; Systems biology |
| P744 | Physical fitness influences the composition of human T cell populations | Michael P. Gustafson, PhD; Courtney M. Wheatley-Guy, PhD; Svetlana Bornschlegl; Allan B. Dietz, PhD; Dennis A. Gastineau, MD; Emmanuel Katsanis, MD; Richard J. Simpson, PhD; Bruce D. Johnson, PhD; | Microbiome and other environmental factors | Immune monitoring; Immune suppression; T cell |
| P745 | Tumor cell metabolism as a barrier to immunotherapy in melanoma | Ashley Menk, MS; Greg M. Delgoffe, PhD; Yana G. Najjar, MD; Ashley Menk, MS; John M. Kirkwood, MD; | Microbiome and other environmental factors | Adoptive immunotherapy; Checkpoint blockade; Metabolism; Tumor microenvironment |
| P746 | Global metabolomics of advanced gastric cancer patients identifies signatures associated with response and clinical benefit from nivolumab | Carrie B. Brachmann, PhD; Daniel Cooper; Kari Wong; Ethan Grant; Daniel V. Catenacci, MD; David Cunningham; Jean-Philippe Metges; Eric Van Cutsem, MD, PhD; Zev Wainberg, MD; Dung Thai; Pankaj Bhargava; Emon Elboudwarej; Ondrej Podlaha; Wadud Khan; Jennifer A. Wargo, MD, MMSc; Manish Shah, MD; | Microbiome and other environmental factors | Bioinformatics; Biomarkers; Checkpoint blockade; Clinical trial; Metabolism; Microbiome; Solid tumors |
| P747 | Leveraging the Second Genome platform to develop microbiome-derived cancer immunotherapies | Dhwani Haria; Jayamary D. Ravichandar; Lynn Yamamoto; Cheryl-Emiliane Chow; Bernat Raja; Joanna Dreux; Kareem Graham; Kathryn Iverson; Shoko Iwai; Sunit Jain; Yuliya Katlinskaya; Sabina Lau; Jina Lee; Michelle Lin; Paul Loriaux; Nicole Narayan; Erica Rutherford; Connor Skennerton; Thomas Weinmaier; Michi Wilcoxon; Yonggan Wu; Todd DeSantis; Toshihiko Takeuchi; Karim Dabbagh; Helena Kiefel, PhD; | Microbiome and other environmental factors | Microbiome; Solid tumors; Tumor microenvironment |
| P748 | A rationally-designed consortium of human gut commensals induces IFNg+ CD8+ T cells and enhances tumor immunity | Amanda Prince, PhD; Johnny Lightcap; Amit Reddy; Sachin K. Deshmukh; Steve McClellan; Bruce L. Roberts, PhD; Rose Szabady; Arthur E. Frankel; | Microbiome and other environmental factors | Checkpoint blockade; Dendritic cell; Microbiome; T cell; Tumor infiltrating lymphocytes (TILs) |
| P749 | Investigation of immune-microbiota interaction in lung cancer using genetically engineered mouse models | Chengcheng Jin, PhD; Tyler Jacks, PhD; Georgia Lagoudas; | Microbiome and other environmental factors | Cytokine; Granulocyte; Immune contexture; Inflammation; Myeloid cells; Microbiome; Solid tumors; Tumor microenvironment |
| P750 | Predicting response to anti-PD1 therapy from metagenomic sequencing data with machine learning | Jan Majta, MSc; Krzysztof Odrzywolek; Agata Szymanek; Monika Majchrzak-Gorecka; Szymon Wojciechowski; Zuzanna Karwowska; Kaja Milanowska; | Microbiome and other environmental factors | Bioinformatics; Checkpoint blockade; Microbiome |
| P751 | A targeted next generation sequencing assay to analyze and characterize the gut microbiome for health research | Anna McGeachy, PhD; David Merrill; Shrutii Sarda; Birgit Drews; Wing Lee; Heesun Shin; Janice Au-Young; Rajesh K. Gottimukkala, MS; Aren Ewing; Fiona Hyland; | Microbiome and other environmental factors | Autoimmunity; Bioinformatics; Biomarkers; Carcinogenesis; Checkpoint blockade; Immune monitoring; Inflammation; Metabolism; Microbiome |
| P752 | Antitumor activity of neoantigen cancer vaccine delivered by DNA electroporation is driven by the microbiota | Lucia Lione; Erika Salvatori; Antonella Conforti; Gennaro Ciliberto; Luigi Aurisicchio; Fabio Palombo, PhD | Microbiome and other environmental factors | Microbiome; Neoantigens; T cell |
| P753 | Trial in progress: A phase I study of live biotherapeutic MRx0518 in the neoadjuvant setting for patients awaiting surgical removal of solid tumours | John D. Weinberg, MD; Jonathan Krell, PhD, MRCP, MBChB, BSc; | Microbiome and other environmental factors | Clinical study; Clinical trial; Cytokine; Microbiome; Regulatory T cell (Treg cell); Solid tumors; T cell |
| P754 | Using advanced imaging techniques to study the interactions among malignant cells, immune system, and microbiota in lung adenocarcinoma | Chen Zhao, MD; Weizhe Li; Chengcheng Jin, PhD; Tyler Jacks; Ronald N. Germain, MD, PhD; | Microbiome and other environmental factors | Solid tumors; Tumor microenvironment |
| P755 | Microbiome spatial patterns as markers of cancer immune therapy response | Bokai Zhu, BS; Yunhao Bai, BS; Sizun Jiang, PhD; Xavier Rovira-Clave; Justin Sonnenburg; Garry Nolan; | Microbiome and other environmental factors | Immune monitoring; Microbiome |
| P756 | HER2-targeting TLR7/8 immune-stimulating antibody conjugates elicit robust myeloid activation and anti-tumor immune responses in a TLR- and FcR- dependent manner. | Shelley E. Ackerman, PhD; Joseph C. Gonzalez; Cecelia I. Pearson; Shelley E. Ackerman, PhD; Justin A. Kenkel; Po Y. Ho; Angela Luo; Murray N. Nguyen; Jason C. Paik, MD PhD; Arthur Lee; Richard P. Laura; Hai Li; Cindy Kreder; Karla A. Henning; Steve J. Chapin; Bruce H. Devens; Brian S. Safina; David Y. Jackson; Edgar Engleman; David Dornan, PhD; Michael N. Alonso; | Novel Single-Agent Immunotherapies | Antibody; Antigen presenting cells; Dendritic cell; Immune adjuvant; Monocyte/Macrophage; Myeloid cells; Solid tumors; Targeted therapy; TLR; Tumor antigens |
| P757 | Novel SIRP antibodies with differentiated characteristics for targeting innate immunity in cancer | Gabriela Andrejeva, PhD; Benjamin J. Capoccia, PhD; Michael J. Donio, MS; Ronald R. Hiebsch, BS; Robyn J. Puro, PhD; Myriam N. Bouchlaka, PhD; Daniel S. Pereira, PhD; | Novel Single-Agent Immunotherapies | Antibody; Checkpoint blockade; Monocyte/Macrophage; Targeted therapy |
| P758 | COBRA: A novel conditionally active bispecific antibody that regresses established solid tumors in mice | Anand Panchal; Andisheh Bagheri, MS; Maia Vinogradova; Tim Chen; Russell Wall; Stéphanie Levon; Pui Seto; Jessica Krakow; Brian Hillier; Ying Zhu; Danielle Dettling; Jeremiah Degenhardt; Aakash Datt; Eilene Kwok; Lucy Quach; Patricia A. Culp; Chad May; Bob DuBridge; | Novel Single-Agent Immunotherapies | Antibody; Antigen presenting cells; Cytokine; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor microenvironment |
| P759 | DZD2269, a novel A2AR antagonist capable of overcoming high adenosine induced immunosuppression | Yu Bai, M.Sc; Xin Zhang; Jie Zheng; Yingchun Wang; Lingli Zhang; Yu Bai, M.Sc; Yu Bai, M.Sc; Zhenfan Yang; | Novel Single-Agent Immunotherapies | Checkpoint blockade; Chemotherapy; Cytokine; Immune suppression; Radiotherapy; Solid tumors; T cell; Targeted therapy; Tumor evasion; Tumor microenvironment |
| P760 | Local modulation of T cell PD-1 using self-delivering RNAi as a potential immunotherapeutic | John A. Barrett, PhD; James Cardia; Melissa Maxwell; Mani D. Kadiyala, M.S>; Dingxue Yan, PhD; Winnie Tam; Simon P. Fricker, PhD; Gerrit Dispersyn, PhD; | Novel Single-Agent Immunotherapies | Checkpoint blockade; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P761 | Tumor-targeted bacterial nanocells carrying a super-cytotoxic drug elicit an anti-tumor immune response, long-term survival, prolonged tumor remission, and resistance to tumor re-challenge | Himanshu Brahmbhatt, PhD; | Novel Single-Agent Immunotherapies | Antigen presenting cells; Chemokine; Cytokine; Monocyte/Macrophage; NK/NK T cell; T cell; Targeted therapy; Tumor microenvironment |
| P762 | Antibodies to ILT3 (LILRB4) abrogate myeloid immunosuppression and combine with PD1 blockade to enable T cell activation and function. | Philip E. Brandish, PhD; Jeanne Baker; Alan Byford; MIchael Caniga; Craig Chappell; Holly Cherwinski; Daniel J. Cua; Laurence Fayadat-dilman; Brian Hall; Barbara Joyce-Shaikh, BS.; Veronica Juan; Carl Mieczkowski; Anthony Palmieri; Yujie Qu, MD; Latika Singh; Peter Stiivers; Jie Zhang-Hoover; | Novel Single-Agent Immunotherapies | Antigen presenting cells; Dendritic cell; Immune suppression; Immune tolerance; Monocyte/Macrophage; Myeloid cells; MDSC; Tumor evasion |
| P763 | Target Engagement and PK/PD quantification in humanized tumor model for anti-ILT3 mAb discovery | Alan J. Byford, MSc.; Yujie Qu, MD; Xiaoyan Du; Daping Zhang; Yvonne Yannoni; Laurence Fayadat-dilman; Brian Hall; Jeanne Baker; Michael Meehl; Scott Pruitt, MD, PhD; Lily Moy; Philip Brandish; Jie Zhang-Hoover; | Novel Single-Agent Immunotherapies | Biomarkers; Myeloid cells; Tumor infiltrating lymphocytes (TILs) |
| P764 | Directly targeting FOXP3 with AZD8701, a first-in-class high affinity antisense oligonucleotide to relieve immunosuppression in cancer. | Larissa S. Carnevalli, PhD; Alexey Revenko; Charles So. Sinclair; Alison Peter; Molly A. Taylor; Anisha Solanki, PhD; Melissa Chapman; James Yates; Helen K. Angell, BSc PhD; Frederick Goldberg; Robert MacLeod; Larissa S. Carnevalli, PhD; | Novel Single-Agent Immunotherapies | Checkpoint blockade; Regulatory T cell (Treg cell); T cell; T cell lineages; Tumor evasion; Tumor microenvironment |
| P765 | First in class antibody targeting Galectin-9 promotes anti-tumor response against pancreatic and other solid cancers | Linxiao Chen, PhD; Wei Wang, MD; Akiko Koide, PhD; Adrian Seifert, MD; Lena Seifert; Aleksandra Filipovic, MD, PhD; George Miller; Shohei Koide, PhD; Linxiao Chen, PhD; | Novel Single-Agent Immunotherapies | Antibody; Checkpoint blockade; Immune suppression; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P766 | The distinct binding footprints of bispecific T cell receptors (TCR) and TCR-mimic antibodies underpin their altered pHLA selectivity | David K. Cole; Rory Crean; Johanne Pentier; Ben de Wet; Angharad Lloyd; Bent K. Jakobsen, PhD; Christopher Holland; | Novel Single-Agent Immunotherapies | Antibody; Immune toxicity; T cell; Targeted therapy; Tumor antigens |
| P767 | Single-Cell Cytometry with the Genesis System - A scalable solution for high-parameter epitope detection | Jon Bell, BS, MS; Yad Deol, PhD, MS; Shaun Connor, BS, MBA; Tyler Burns, PhD; | Novel Single-Agent Immunotherapies | Antibody; B cell; Biomarkers; Immune monitoring; Myeloid cells; NK/NK T cell; T cell; Targeted therapy |
| P768 | Antagonism of Signaling through the Vasoactive Intestinal Peptide Receptor as a Novel Immunotherapy in Preclinical Models of Melanoma. | Rohan K. Dhamsania, BS; Sruthi Ravindranathan, PhD; Shuhua Wang, MD; Rebecca A. Pankove, MS; David Francis; Susan N. Thomas, PhD, BS; Brian Pollack; Edmund K. Waller, MD, PhD, FACP; | Novel Single-Agent Immunotherapies | Adoptive immunotherapy; Checkpoint blockade; Immune suppression; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| P769 | Inhibition of arginase in combination with anti-PDL1 leads to increased infiltration and activation of CD8+ T cells, NK cells, and CD103+ dendritic cells in the mouse syngeneic MC38-OVA tumor model | Aatman S. Doshi, MS; Susan Cantin; Michael Secinaro; Yanjun Wang; Laura Prickett; Sharon Tentarelli; Scott Mlynarski; Eric Gangl; M. Raymond V. Finlay; Wenlin Shao, PhD; Alwin Schuller; | Novel Single-Agent Immunotherapies | Checkpoint blockade; Cytokine; Dendritic cell; Immune suppression; Myeloid cells; Metabolism; NK/NK T cell; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P770 | A novel class of multi-specific antibodies targeting NKp30 on innate immune cells | Monia Draghi, PhD; Allison Nelson; Amanda Oliphant; Alan Leung; Jay Vekeria; Zach Frye; Claire Chottin; Sara Haserlat; Rachel Rennard; Caitlin Goshert; Rachel McCrory; Lucy Liu; Kenneth Rogers; Francois Villinger; Piotr Bobrowicz; Michael Schmidt; Jennifer Watkins-Yoon; | Novel Single-Agent Immunotherapies | NK/NK T cell |
| P771 | An anti-carcinoma monoclonal antibody (mAb) NEO-201 can also target and eliminate human immunosuppressive regulatory T cells (Tregs) | Kwong Y. Tsang, PhD; Massimo Fantini, PhD; Justin M. David; M Maria Morelli, MD; Christina M. Annunzata, MD; Philip M. Arlen, MD; | Novel Single-Agent Immunotherapies | Antibody; Immune monitoring; Immune suppression; Regulatory T cell (Treg cell); Targeted therapy; Tumor antigens |
| P772 | Antagonism of TNFR2: Focus on novel antibodies with preference for tumor microenvironment Tregs and oncogenes expressed on the tumor | Michael Khodadoust, MD PhD; Youn H. Kim, MD; Michael Yang; Heather Torrey, PhD; Lisa Tran; Denise L. Faustman, MD, PhD; | Novel Single-Agent Immunotherapies | Antibody; Leukemia/Lymphoma; Regulatory T cell (Treg cell); T cell; Tumor microenvironment |
| P773 | ONCR-177, an oncolytic HSV designed to safely and potently activate systemic anti-tumor immunity | Sonia Feau, Ph.D; Melissa Hayes; Brian Haines; Agnieska Denslow; Jacqueline Gursha; Daniel Wambua; Shreeya Khatiwada; Lingxin Kong; Jacob Spinale; Prajna Behera; Peter Grzesik; Jennifer s. Lee; Terry Farkaly; Edward m. Kennedy; Lorena Lerner; Christophe Queva; | Novel Single-Agent Immunotherapies | Checkpoint blockade; Chemokine; Costimulation; Cytokine; Dendritic cell; Immune adjuvant; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| P774 | Intratumoral depletion of regulatory T cells using CD25 targeted photoimmunotherapy elicits anti-cancer immune activity and synergizes with PD1 checkpoint blockade in immunocompetent mouse models | Michelle A. Hsu; Stephanie M. Okamura; Daniele M. Bergeron; Estela Solis; Dany Gitnick; Roger Heim; Jerry Fong, PhD; Jerry Fong, PhD; Miguel Garcia-Guzman; | Novel Single-Agent Immunotherapies | Antibody; Checkpoint blockade; Immune suppression; Regulatory T cell (Treg cell); T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P775 | Crosslink-Independent CD137 Agonism is Associated with Liver Inflammation | Miguel Gaspar, PhD; John Pravin; Leonor LR. Rodrigues, MSc; Alexander Koers, PhD; Mihriban Tuna, PhD; Neil Brewis, PhD; | Novel Single-Agent Immunotherapies | Antibody; Costimulation; Immune adjuvant; Immune toxicity; Inflammation; Regulatory T cell (Treg cell); T cell |
| P776 | Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity | Laurent Gauthier, PhD; Ariane Morel, PhD; Nadia Anceriz; Benjamin Rossi; Audrey Blanchard-Alvarez; Gwendoline Grondin; Sylvia Trichard; Cédric Cesari; Melody Sapet; Frédéric Bosco; Hélène Rispaud-Blanc; Franceline Guillot; Stéphanie Cornen; Alain Roussel; Béatrice Amigues; Guillaume Habif; Flavien Caraguel; Sandrine Arrufat; Romain Remark, PhD; François Romagné; Yannis Morel, PhD; Eric Vivier; | Novel Single-Agent Immunotherapies | Antibody; NK/NK T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| P777 | Engineered monomeric JAG1 and multimeric DLL1 Notch ligand constructs enhance antitumor immunity by reducing exhaustion of T-effector memory cells | Uttam Laksmi Mounika Goruganthu, M Tech; Anil Shanker, PhD; David P. Carbone, MD, PhD; Elena Tchekneva, MD; Anneliese Antonucci; Michael Koenig; Longzhu Piao; Anwari Akhter, PhD; Parvathi Ranganathan; Nicholas Long; Thomas Magliery; Jason Evans; Rajeswara Arasada; Pierre P. Massion, MD; Mikhail M. Dikov, PhD; Roman V. Uzhachenko, PhD MD; Portia Thomas; Asel K. Biktasova, MD, PhD; Duafalia Dudimah; Maria Teresa P. De Aquino, PhD; | Novel Single-Agent Immunotherapies | Antigen presenting cells; Dendritic cell; Regulatory T cell (Treg cell); Solid tumors; Tumor evasion |
| P778 | ATRC-101: A First-in-Class Engineered Fully Human Monoclonal Antibody that Targets a Tumor-Restricted Ribonucleoprotein Complex | Norman M. Greenberg, PhD; Jeffrey DeFalco, PhD; Daniel Emerling, PhD; Amy Manning-Bog, PhD; Gilson Baia, PhD; Shaun M. Lippow, PhD; Alexander Scholz, PhD; Yanhong Zhu, MD; Guy Cavet, PhD; Wayne Volkmuth, PhD; Ish Dhawan, PhD; Jonathan Benjamin, MD, PhD; William Robinson, MD PhD; Tito A. Serafini, PhD; Norman M. Greenberg, PhD; | Novel Single-Agent Immunotherapies | Antibody; B cell; Bioinformatics; Checkpoint blockade; Targeted therapy; Tumor antigens |
| P779 | HER2/PD-L1/CD3/HSA tetra-specific antibody mediates cytolytic synapse-restricted PD-L1 blockade and potent depletion of HER2+ tumors | Tea Gunde, PhD; Alexandre Simonin; David Urech; Stefan Warmuth; Christian Hess; Matthias Brock; Eva Oswald; Julia Zeberer; Dania Diem; Dana Mahler; Diego Morenzoni; Simone Muntwiler; Benjamin Küttner; Robin Heiz; Naomi Flückiger; Sebastian Meyer; Timothy Egan; | Novel Single-Agent Immunotherapies | Antibody; Checkpoint blockade; Solid tumors; Targeted therapy |
| P780 | Selection and in vitro characterization of ABBV-368, a novel anti-OX40 agonist antibody | Fiona Harding, PhD; Marcia Stickler; Margo Werner; Jennifer Tran; Nicole Belmar, BS; Archana Thakur; Enrico DiGiammarino; David Powers; Fiona Harding, PhD; | Novel Single-Agent Immunotherapies | Antibody; Costimulation; T cell |
| P781 | A new approach used to characterise off target peptide repertoires for T cell receptors that target the cancer testis antigen NY-ESO-1-HLA-A*02:01 | Stephen Harper; Charlotte H. Coles, PhD; Rachel M. Mulvaney; Sunir Malla, PhD; Andrew Walker, PhD; Kathrine J. Smith; Angharad Lloyd; Jane Harper; Zoe Donnelan; Andrew Knox; Andrea R. Stacey; Joseph Dukes; Emma Baston; Suzanne Griffin; | Novel Single-Agent Immunotherapies | T cell; Tumor antigens |
| P782 | A novel fully synthetic dual targeted Nectin-4/4-1BB Bicycle® peptide induces tumor localized 4-1BB agonism | Kristen Hurov, PhD; Punit Upadhyaya; Marianna Kleyman; Jessica Kublin; Tom L. Stephen; Jun Ma; Elizabeth M. Repash; Julia Kristensson; Sophie Watcham; Liuhong Chen; Sailaja Battula, PhD; Johanna lahdenranta; Kevin McDonnell, PhD; Nicholas Keen; | Novel Single-Agent Immunotherapies | Costimulation; Cytokine; Myeloid cells; NK/NK T cell; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P783 | DuoBody®-CD3x5T4 shows potent preclinical anti-tumor activity in vitro and in vivo in a range of cancer indications | Kristel Kemper, PhD; Ellis Gielen; Laura Smits-de Vries; Sandra Verploegen; Mischa Houtkamp; Saskia Burm; Edward van den Brink; Rik Rademaker; Dennis Verzijl; Patrick Engelberts; Bart E.C.G. de Goeij; David Satijn; A. Kate Sasser; Esther Breij, PhD; | Novel Single-Agent Immunotherapies | Antibody; Biomarkers; Cytokine; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| P784 | SBT6050, a HER2-directed TLR8 agonist antibody conjugate, designed to overcome primary resistance to and synergize with checkpoint inhibition in HER2-expressing tumors | Kara Moyes; Jamie Brevik; Damion Winship; Ty Brender; Heather Metz; Yvette Latchman, PhD; Monica Childs; Michael Comeau; Jenny R. Chang; Sean W. Smith; Hengyu Xu; Ben Setter; Ray Carrillo; Li-Qun Fan; Phil Tan; Robert E. DuBose; Peter Baum; Valerie Odegard, PhD; | Novel Single-Agent Immunotherapies | Antibody; Checkpoint blockade; Dendritic cell; Myeloid cells; Solid tumors; T cell; Targeted therapy; TLR; Tumor antigens; Tumor microenvironment |
| P785 | Exosome surface display of IL-12 results in tumor-retained pharmacology with superior potency and limited systemic exposure compared to recombinant IL-12 | Katherine Kirwin; Chang Ling Sia; Sonya Haupt; Ke Xu; Kevin Dooley; Su Chul Jang, PhD; Bryan Choi; Adam Boutin; Christine McCoy; Scott Estes; Kyriakos Economides; Sriram Sathyanarayanan; Nuruddeen Lewis, PhD; | Novel Single-Agent Immunotherapies | Cytokine; Immune adjuvant; NK/NK T cell; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P786 | Network meta-analysis (NMA) and matching-adjusted indirect comparison (MAIC) of pembrolizumab versus atezolizumab for second-line (2L) locally advanced/metastatic urothelial carcinoma (mUC) | Dave Gelb; Yichen Zhong, PhD; Rodolfo Fleury Perini; James Luke Godwin; Yizhen Lai; Stella Arndorfer; Maria Lorenzi, MSc; Haojie Li; Dave Gelb; | Novel Single-Agent Immunotherapies | Checkpoint blockade |
| P787 | Novel humanized CD3ε mouse model for evaluation of bi-specific T-cell engager antibodies | Xiaofei Zhou; Quinn Li; Dirui Li; Rui Huang; Yuelei Shen; | Novel Single-Agent Immunotherapies | Adoptive immunotherapy; Antibody; T cell |
| P788 | Development of ADG116, a novel antagonist anti-CTLA-4 human antibody for cancer immunotherapy | Guizhong Liu, PhD; Felix Fangyong Du; Kristine She; Peter Luo; | Novel Single-Agent Immunotherapies | Antibody; Checkpoint blockade; Costimulation; Regulatory T cell (Treg cell); Tumor infiltrating lymphocytes (TILs) |
| P789 | Vaccination of high-risk neuroblastoma patients with anti-id antibody ganglidiomab to maintain protective immunity after passive immunotherapy with anti-GD2 antibody ch14.18/CHO | Hans Loibner, PhD; Holger N. Lode, MD, PhD; Nikolai Siebert, PhD; Sascha Troschke-Meurer, BS; Oliver Mutschlechner; Holger N. Lode, MD, PhD; | Novel Single-Agent Immunotherapies | Antibody; Immune adjuvant; Pediatric tumors; Tumor antigens; Vaccine |
| P790 | The anti-tumor activity of an anti-CD39 antibody (ES002) in a multiple myeloma model is dependent on NK cells | Yangsheng Qiu; Hongtao Lu, PhD; Qinglin Du, PhD; Meiling Sun; Rui Gao, PhD; Huimin Kong; Roumei Xing; Yufei Shi; Mengying Xu; Zhihao Wu, PhD; Hongtao Lu, PhD; | Novel Single-Agent Immunotherapies | Antibody; Antigen presenting cells; Checkpoint blockade; Dendritic cell; Immune suppression; Myeloid cells; NK/NK T cell; Regulatory T cell (Treg cell); Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P791 | Anti-tumor activity of a small molecule inhibitor of the immuno-suppressive enzyme Interleukin 4 (IL-4)-Induced Gene 1 (IL4I1) | Andy MacKinnon, PhD; Deepthi Bhupathi, MS; Jason Chen; Rosalyn Dang; Tony Huang; Weiqun Li, PhD; Yong Ma; Natalija Sotirovska, MS; Sandra Spurlock; Susanne Steggerda, PhD; Winter Zhang; Francesco Parlati, PhD; | Novel Single-Agent Immunotherapies | Immune suppression; Myeloid cells; Metabolism; Solid tumors; T cell; Targeted therapy; Tumor evasion; Tumor microenvironment |
| P792 | A GUCY2C-CD3 bispecific engages T cells to induce cytotoxicity in gastrointestinal tumors | Divya Mathur, PhD; Adam Root; Bozena Bugaj-Gaweda; Xingzhi Tan; Wei Fang; Stephanie Bisulco; Jonathon Golas; Jessica Kearney; Erik Upeslacis; Johnny Yao; Edward Rosfjord; Chad Stevens; Lindsay King; Jatin Narula; Kerry Kelleher; Cynthia Rohde; Lioudmila Tchistiakova; Anhco Nguyen; Puja Sapra, PhD; | Novel Single-Agent Immunotherapies | Angiogenesis; Antibody; Biomarkers; Checkpoint blockade; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P793 | ALPN-202, a Conditional CD28 Costimulator and Dual Checkpoint Inhibitor, Utilizes Multiple Mechanisms to Elicit Potent Anti-Tumor Immunity Superior to Checkpoint Blockade Alone | Mark F. Maurer, BS; Chelsea J. Gudgeon, BS; Katherine E. Lewis, PhD; Sherri Mudri, BS; Stacey R. Dillon, PhD; Martin Wolfson, BS; Steven D. Levin, PhD; Kristine M. Swiderek, PhD; Stanford Peng, MD, PhD; | Novel Single-Agent Immunotherapies | Antigen presenting cells; Checkpoint blockade; Coinhibition; Costimulation; Immune suppression; T cell; Tumor infiltrating lymphocytes (TILs) |
| P794 | A novel fully synthetic dual targeted EphA2/4-1BB Bicycle® peptide induces tumor localized 4-1BB agonism | Sailaja Battula, PhD; Punit Upadhyaya; Marianna Kleyman; Jessica Kublin; Eric Haines, PhD; Jun Ma; Elizabeth M. Repash; Tom L. Stephen; Julia Kristensson; Liuhong Chen; Kristen E. Hurov; Johanna lahdenranta; Kevin McDonnell, PhD; Nicholas Keen; | Novel Single-Agent Immunotherapies | Costimulation; Cytokine; Myeloid cells; NK/NK T cell; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P795 | Anti-MUC1 monoclonal antibodies derived from the first non-viral prophylactic cancer vaccine clinical trial can target cancer cells and facilitate their immune-mediated elimination | Michelle L. McKeague, PhD; Jason Lohmueller, PhD; Eric Ricci; William Lu; Olivera J. Finn, PhD; | Novel Single-Agent Immunotherapies | Antibody; NK/NK T cell; Vaccine |
| P797 | Novel dual A2A/A2B receptor antagonist reverses adenosine-mediated immune suppression - in vitro and in vivo characterization. | Michal Galezowski; Paulina Wegrzyn; Aneta Bobowska; Katarzyna Dziedzic; Magdalena Bonkowska; Karolina Grycuk; Joanna Szeremeta-Spisak; Marcin Nowogródzki; Grzegorz Satala; Alicja Obara; Iwona Lozinska-Raj; Przemyslaw Wyrebek; Marcelina Dudek; Anita Janiga; Jacek Reus; Marek Wronowski; Magdalena Zastawna; Grzegorz Statkiewicz; Maciej Rogacki; Mateusz Swirski; Jakub Woyciechowski; Kinga Michalik; Agnieszka Adamus; Karolina Wiatrowska; Natalia Literska; Aniela Golas; Olga Haberkiewicz; Luigi Stasi; Peter Littlewood; Krzysztof Brzózka; Mateusz Nowak; | Novel Single-Agent Immunotherapies | Checkpoint blockade; Immune suppression; Inflammation; Metabolism; Tumor evasion; Tumor microenvironment |
| P798 | Think Globally Act Locally: Biodistribution of BETA-PRIME, a Replication-Competent Type 5 Adenovirus Enhanced with a Trap for the Immunosuppressive Cytokine, TGF-Beta | Christopher Larson, MD PhD; Bryan Oronsky, MD PhD; Tony Reid, MD PhD; | Novel Single-Agent Immunotherapies | Immune adjuvant; Immune suppression; Regulatory T cell (Treg cell); T cell |
| P799 | Innate leukocyte chemoattractant chemerin is an intrinsic tumor suppressor in prostate cancer | Zhongping Xu, PhD; Woo Jae Shin, BA; Kevin Kim; Brian Zabel, PhD; Russell Pachynski, MD; | Novel Single-Agent Immunotherapies | Chemokine; Solid tumors; Tumor infiltrating lymphocytes (TILs) |
| P800 | Development of PY314, a monoclonal antibody that selectively depletes tumor-associated macrophages, for the treatment of solid tumors | Mikhail Binnewies; Joshua L. Pollack; Venkataraman Sriram, PhD; Erick Lu; Nadine Jahchan; Xiaoyan Du; Aritra Pal; Evan Greger; Kevin Baker; Michel Streuli, PhD; Len Reyno; Venkataraman Sriram; | Novel Single-Agent Immunotherapies | Antibody; Checkpoint blockade; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor microenvironment; Tumor stroma |
| P801 | Development of the first in class immunotherapy targeting immuno-suppressive δ1 containing γδ T cells for the treatment of pancreatic ductal adenocarcinoma and other solid tumors | Tanya Panchenko, PhD; Wei Wang; Eric Denbaum; Takamitsu Hattori; Akiko Koide, PhD; Aleksandra Filipovic, MD, PhD; George Miller; Tanya Panchenko, PhD; Shohei Koide; | Novel Single-Agent Immunotherapies | Antibody; Immune suppression; Solid tumors; T cell; T cell lineages; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| P802 | Single cell Immuno- and Cancer Marker Profiling of Non-Small Cell Lung Cancer Tissue: Checkpoint Marker Expression on CD103+, CD4+ T-cells Correlates with Circulating Tumor Enumeration | Kaylan Handique, PhD; Bruce Patterson, BS, MD; Lianne McLean, BA; Bruce Patterson, MD; Will Chow, PhD; Priya Gogoi, PhD; Vishal Sharma, PhD; | Novel Single-Agent Immunotherapies | Adoptive immunotherapy; B cell; Biomarkers; Gene expression; Immune monitoring; NK/NK T cell; Proteomics; T cell; T cell lineages; Targeted therapy |
| P803 | CUE-101, a novel HPV16 E7:pMHC:IL-2:Fc fusion protein, enhances tumor antigen specific T cell activation for the treatment of HPV16-driven malignancies | Steven N. Quayle, PhD; Natasha Girgis, PhD; Dharma Raj Thapa; Zohra Merazga, M.S.; Miguel Moreta; Sandrine Hulot, PhD; Alyssa Nelson, BS.; Lauren Kraemer, BS.; Dominic Beal, PhD; Mark Haydock, BS.; Luke Witt, BS.; Jessica Ryabin, BS.; Jonathan Soriano, MSc; Emily Spaulding, PhD; John F. Ross, PhD; Rodolfo Chaparro, PhD; Ronald Seidel, PhD; Anish Suri, PhD; Saso Cemerski; Kenneth J. Pienta, MD; Mary C. Simcox, PhD; | Novel Single-Agent Immunotherapies | Costimulation; Cytokine; T cell; Vaccine |
| P804 | In vivo efficacy of a PD-L1 targeted Engineered Toxin Body (ETB) comprised of direct cytotoxicity and T-cell mediated tumor targeting | Brigitte Brieschke, BS; Sara LeMar; Joseph D. Dekker, PhD; Garrett Cornelison; Asis Sarkar; Garrett L. Robinson; Jay Zhao, PhD; Aimee Iberg, PhD; Jack P. Higgins, PhD; Hilario J. Ramos, PhD; Erin K. Willert, PhD; | Novel Single-Agent Immunotherapies | Antibody; Checkpoint blockade; Solid tumors; T cell; Targeted therapy |
| P805 | SRF388, a first-in-class, fully human monoclonal antibody targeting IL 27, blocks the immunoregulatory effects of IL-27 in immune cells and demonstrates preclinical in vivo antitumor activity | Matthew P. Rausch, PhD; Jing Hua; Devapregasan Moodley; Kerry F. White; Katherine H. Walsh; Christine E. Miller; Jamie Strand; Pamela Holland, PhD; Vito J. Palombella, PhD; Jonathan A. Hill, PhD; | Novel Single-Agent Immunotherapies | Antibody; Cytokine; Immune suppression; T cell |
| P806 | Structural implications for GITR agonism in immunotherapies | Hamsell M. Alvarez, PhD; Bryan M. Rogers, MSc; Sarah Chan; Lance Bigelow; Samuel Cichanowicz; Marc Lake; Russell Judge; Ramesh Iyer; Kenton Longenecker; | Novel Single-Agent Immunotherapies | Antibody; Costimulation; Immune adjuvant; T cell |
| P807 | Characterization of anti-tumor immune responses and Effects on Survival of Neoadjuvant Oncolytic Virotherapy in spontaneous Osteosarcoma | Aish Sathyanarayan; Kelly Makielski, DVM, MS, DACVIM; Aishwarya Sathyanarayan, PhD; Shruthi Naik, PhD; Jaime F. Modiano, VMD, PhD; Stephen J. Russell, MD, PhD; Michael Henson, DVM, PhD; Kathleen Stuebner; Flaviu Alexandru Tabaran; Gerard O; Andrea Eckert; Donna Groschen; Lauren Mills, PhD; Milcah Scott, BS; Aaron L. Sarver, PhD; Michael A. Farrar; Ingrid Cornax, PhD; | Novel Single-Agent Immunotherapies | Cytokine; Immune monitoring; Solid tumors |
| P809 | Preclinical Development of a Novel, Allogeneic, OX40L-Secreting, Therapeutic Cancer Vaccine for use in Combination with a gp96-Secreting Vaccine for Solid Tumors | Matthew M. Seavey, PhD; Jason Rose, MS; Patrick Dillon, PhD; Jayalakshmi Miriyala, MS; Vikas Tahiliani, PhD; Jeff Hutchins, PhD; | Novel Single-Agent Immunotherapies | Immune adjuvant; Tumor antigens; Vaccine |
| P810 | An engineered bi-function fusion protein (CD86-Fc-NKG2a) to reverse NK cell tolerance of malignant cells | Casey W. Shuptrine, PhD; Taylor H. Schreiber, MD, PhD; | Novel Single-Agent Immunotherapies | Checkpoint blockade; Costimulation; Immune tolerance; NK/NK T cell; Tumor evasion; Tumor microenvironment |
| P811 | Utilizing novel oncolytic vaccinia virus for selective expression of immunotherapeutic payloads in metastatic tumors | Adrian Pelin; Mike Huh, PhD; Matthew Tang, PhD; Fabrice Le Boeuf, PhD; Brian Keller; Jessie Duong; Katherine Clark-Knowles, PhD; Victoria A. Jennings, PhD; Julia Petryk; Alan A. Melcher; Mathieu Crupi, PhD; Ragunath Singaravelu, PhD; Larissa Pikor, PhD; Caroline Breitbach, PhD; Steven H. Bernstein, MD; Michael Burgess, MD, PhD; John Bell, PhD; | Novel Single-Agent Immunotherapies | Checkpoint blockade; Chemokine; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P812 | Development of PY159, a monoclonal antibody that repolarizes tumor-associated inhibitory myeloid cells, for the treatment of solid tumors | Michel Streuli, PhD; Linda Liang; Chris Chan; Michel Streuli, PhD; Venkataraman Sriram, PhD; Erick Lu; Joshua L. Pollack; Mikhail Binnewies; Xiaoyan Du; Aritra Pal; Vladi Juric; Evan Greger; Kevin Baker; Len Reyno; | Novel Single-Agent Immunotherapies | Antibody; Checkpoint blockade; Granulocyte; Immune suppression; Monocyte/Macrophage; Myeloid cells; MDSC; Solid tumors; Tumor evasion; Tumor microenvironment |
| P813 | TAS0313, a novel cocktail vaccine of multivalent HLA-A2-, A24- and A3 superfamily-restricted epitopes, demonstrates a synergistic antitumor effect with anti-PD-1 antibody | Yuki Tanaka, MS; Hiroshi Wada, MS; Risa Goto; Toshihiro Osada; Keisuke Yamamura; Satoshi Fukaya; Kazuhisa Minamiguchi; Koichi Ikizawa; Teruhiro Utsugi; | Novel Single-Agent Immunotherapies | Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |
| P814 | Antibody-interferon-gamma fusion protein for the treatment of B-cell lymphomas | Alex Vasuthasawat; Reiko Yamada King; Kham R. Trinh; Neiki Rokni; Sherie L. Morrison, PhD; John M. Timmerman, MD | Novel Single-Agent Immunotherapies | Antibody; Cytokine; Leukemia/Lymphoma; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P815 | Targeting multiple immune checkpoint proteins with novel small molecule inhibitors of Sec61-dependent cotranslational translocation | Jennifer A. Whang, PhD; Janet L. Anderl; Andrea Fan; Christopher J. Kirk; Eric Lowe; Dustin McMinn; Beatriz Millare; Meera Rao; Jack Taunton, PhD; | Novel Single-Agent Immunotherapies | Checkpoint blockade; T cell; Tumor microenvironment |
| P816 | DRP-104 Induces Durable Responses In Vivo by Inhibiting Tumor Glutamine Addiction, Remodeling the Tumor Microenvironment and Stimulating Both the Innate & Adaptive Immune Systems | Yumi Yokoyama, PhD; Michael Nedelcovych, PhD; Robert Wild, PhD; | Novel Single-Agent Immunotherapies | Cytokine; Monocyte/Macrophage; Metabolism; NK/NK T cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P817 | Potent ERAP1 inhibitors modify the immunopeptidome and generate novel neoantigens | Jamie Ware; Kris Clark; Carmen Tong; Jason Shiers; Elisa Lori; Emma Reeves; Henry Leonard; Alihussein Remtulla; Nicola Ternette; Edd James, PhD; Martin Quibell; Lesley Young, PhD; Peter I. Joyce; | Novel Single-Agent Immunotherapies | Checkpoint blockade; Neoantigens; NK/NK T cell; T cell |
| P818 | EGFR Exon-20 Insertion-based Neoantigen Stimulated Effective T-cell Immunity against Non-Small Cell Lung Cancer | Jinpu Yu; Dandan Liu; | Novel Single-Agent Immunotherapies | Neoantigens; Tumor antigens |
| P819 | Regulation of isatuximab-mediated antibody-dependent cellular cytotoxicity of multiple myeloma cells: Rationale for combining isatuximab with anti-PD-1 / anti-TGFβ to enhance anti-myeloma activity | Anlai Wang; Zhili Song; Guang Yang; Rita M. Greco; Joachim Theilhaber; Elvis Shehu; Beatriz Ospina; Fangxian Sun; Yu-Tzu Tai; Kenneth C. Anderson, MD; Chen Zhu; Marielle Chiron, PhD; Francisco J. Adrián; | Novel Single-Agent Immunotherapies | Antibody; Checkpoint blockade; NK/NK T cell; Targeted therapy |
| P820 | Analysis of synergy between early-incorporation immunotherapy and extracranial radiotherapy in stage IV non-small cell lung cancer | Corbin D. Jacobs, MD; Parth A. Chodavadia, BS; Frances Wang, MS; Joseph K. Salama, MD; Christopher R. Kelsey, MD; Jeffrey M. Clarke, MD; Neal E. Ready, MD, PhD; Jordan A. Torok, MD; | Other | Radiotherapy |
| P821 | Induction of anti-tumor immune responses in ovarian cancer with c-MET inhibitor Capmatinib | Maureen Drakes, PhD; Swati Mehrotra, MD; Ronald Potkul, MD; M.Sharon Stack, PhD; Patrick J. Stiff, MD; | Other | Immune suppression; Solid tumors; T cell; Targeted therapy |
| P822 | Evidence that a germline genetic variant impairs a robust anti-tumor immune response in a substrain of C57BL/6 mice | Jessica L. Fessler, BS; Vyara Matson, PhD; Thomas F. Gajewski, MD, PhD; | Other | Genetic polymorphism; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P823 | The Cancer Moonshot Immuno-Oncology Translational Network | Alan D. Hutson, PhD; Song Liu; Martin Morgan; Kunle Odunsi, MD, PhD; | Other | Adoptive immunotherapy; Biomarkers; CAR T cells; Gene expression; Immune suppression; Neoantigens; T cell; Tumor antigens |
| P824 | Development of anti-Globo H Bispecific Antibody for Breast Cancer Therapy | Yow-Sien Lin, PhD; Jei-Hwa Yu; Chia-Cheng Wu; | Other | Antibody; Cytokine; Tumor antigens |
| P825 | Increased and co-localized CD4+FOXP3+ and CD8+ T cells is a strong independent prognostic indicator in gastric cancer | Minyu Wang; Yu-Kuan Huang; Joe Kong; Yu Sun; Daniela Tantalo; Han Xian Aw Yeang; Le Ying; Feng Yan; Dakang Xu; Heloise Halse; Natasha di Costanzo; Ian Gordon; Catherine Mitchell; Laura K. Mackay; Rita Busuttil; Paul J. Neeson, PhD; Alex Boussioutas; | Other | Checkpoint blockade; Gene expression; Immune contexture; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P826 | Preliminary results of a Phase 2 study of INCMGA00012 in patients with squamous carcinoma of the anal canal (SCAC) who have progressed following platinum-based chemotherapy (NCT03597295) | Sheela Rao; Jaume Capdevila; Duncan Gilbert; Stefano Kim; Laetitia Dahan; Talal Kayyal; Marwan Fakih, MD; Anne Demols; Mark Cornfeld, MD, MPH; Chuan Tian, PhD; Melissa Catlett; Jean-Philippe Spano; | Other | Checkpoint blockade; Clinical study; Clinical trial; Solid tumors |
| P827 | Phase 1 study of the CD40 agonist monoclonal antibody (mAb) CDX-1140 alone and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers | Rachel E. Sanborn, MD; Nashat Y. Gabrail, MD; Mark O'Hara, MD; Nina Bhardwaj, MD, PhD; Michael S. Gordon, MD; Ralph J. Hauke, MD; Rodolfo E. Bordoni, MD; Danny Khalil, MD PhD; Tracey Rawls; Laura Vitale, BS; Richard Gedrich; Thomas Hawthorne; Tibor Keler, PhD; Eirc Forsberg, BS; Lawrence Thomas, PhD; Michael Yellin, MD; | Other | Antibody; Antigen presenting cells; Clinical study; Costimulation; Dendritic cell; Immune monitoring |
| P828 | Cytokine release syndrome (CRS) following treatment with tebentafusp, a novel bispecific TCR–anti-CD3 directed against gp100, in patients with advanced melanoma | Alexander N. Shoushtari, MD; Mark R. Middleton; Neil M. Stevens; Thomas J. Evans; Jeffrey R. Infante; Mario Sznol, MD; Alan Anthoney; Avinash Gupta; Victoria Woodcock; Tina Wiseman; Cheryl McAlpine, MSN; Chris Cohen; Omid Hamid, MD; | Other | Biomarkers; Chemokine; Clinical study; Clinical trial; Cytokine; Solid tumors; T cell; Targeted therapy |
| P829 | The pattern of expression of hMENA isoforms impacts tumor immune microenvironment of early node-negative non-small cell lung cancer | Sheila Spada, PhD; Francesca Di Modugno, PhD; Anna Di Carlo; Isabella Sperduti; Enzo Gallo; Mariangela Panetta; Belinda Palermo; Francesca De Nicola; Lorenzo D'Ambrosio; Barbara Antoniani; Paola Trono; Francesco Facciolo; Paolo Visca; Paola Nistico', MD; | Other | B cell; Dendritic cell; Immune contexture; Immunoscore; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P830 | Optimization of RG1-VLP vaccine performance in mice with novel TLR4 agonist-based adjuvants | Jason D. Marshall, PhD; Athina Zacharia, PhD; | Other | Immune adjuvant; Immune monitoring |
| P831 | Inclusion of people living with HIV in anti-PD(L)1 clinical trials: Results of an NCI-driven initiative to broaden eligibility in clinical trial development | Joshua E. Reuss, MD; Diana Stern, MD; Ramya Ramaswami; Kathryn Lurain, MD; Helen Chen, MD; Howard Streicher, MD; Ravie Kem, RPh, Pharm D, MPH; Richard F. Little, MD; Elad Sharon, MD, MPH; | Regulatory, Financial, and Access Considerations | Checkpoint blockade; Clinical trial |
| P832 | Systematic literature review (SLR) of intravenously (IV) administered oncology therapies for which a subcutaneous (SC) formulation has also been developed | Brad Schenkel, MSc; Elise Wu; Ali McBride; Marília Hernani; Robin Wyn; Klaudia Kornalska; | Regulatory, Financial, and Access Considerations | Clinical study; Targeted therapy |
| P833 | Timing of IL-2 treatment delivery after transplantation of B16 melanoma in a murine model differentially influences tumour growth | Brendon J. Coventry, MD PhD; Suzanne Edwards, BSc; Brendon J. Coventry, MD PhD; | Timing of Immunotherapy administration | Cytokine; Immune monitoring; Immune suppression; Immune tolerance |
| P834 | The actin regulatory protein hMENA is a key player in the paracrine TGF-β mediated crosstalk between tumor cells and cancer associated fibroblasts | Paola Nistico', MD; Roberta Melchionna; Paola Trono; Francesca Di Modugno, PhD; Anna Di Carlo; Sheila Spada, PhD; Giuliana Falasca; Isabella Sperduti; Barbara Antoniani; Daniel D'Andrea; Paolo Visca; Gian Luca Grazi; Francesco Facciolo; Aldo Scarpa; Paola Nistico', MD; | Tumor and Stromal Cell Biology | Solid tumors; Tumor microenvironment; Tumor stroma |
| P835 | The role of sialylation in stromal cell mediated immunosuppression in the colorectal tumour microenvironment | Aideen E. Ryan, PhD; Hannah Egan, BSC; Kevin Lynch, PhD; Niamh Leonard, MSc; Michael O; Laurence J. Egan, MD; Thomas Ritter; Oliver Treacy, PhD; Aideen E. Ryan, PhD; | Tumor and Stromal Cell Biology | Immune suppression; Inflammation; Monocyte/Macrophage; Solid tumors; T cell; Tumor stroma |
| P836 | Immunopathological properties of the fibroblastic niche for cancer stem cells and the niche-targeted immunotherapy | Toshihiko Torigoe, MD, PhD; Yoshihiko Hirohashi, MD, PhD; Toshihiko Torigoe, MD, PhD; | Tumor and Stromal Cell Biology | Stem cell/cancer-initiating cell; Solid tumors; Tumor antigens; Tumor microenvironment; Tumor stroma |
| P837 | Roles of nitric oxide synthase and cyclooxygenase inhibition in potentiating immune response in murine models of 4T1 mammary tumor | Veena Somasundaram, PhD; Anne C. Gilmore; Debashree Basudhar; Erika Palmieri; David A. Scheiblin; William F. Heinz; Robert Cheng; Lisa Ridnour, PhD; Stephen J. Lockett; Daniel W. McVicar, PhD; David A. Wink; | Tumor and Stromal Cell Biology | Biomarkers; Inflammation; Myeloid cells; Tumor microenvironment |
| P838 | Disrupting hypoxic tumor niches to sensitize pancreatic cancer to immunotherapy | Arthur J. Liu, BS; Michael A. Curran, PhD; | Tumor and Stromal Cell Biology | Angiogenesis; Immune suppression; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P839 | DNA demethylating agent sensitizes lung cancer cells to immune attack of γδ T cells | Rueyhung R. Weng, PhD; Chien-Ting Lin; Hsuan-Hsuan Lu; Chong-Jen Yu; Hsing-Chen Tsai; | Tumor and Stromal Cell Biology | Chemotherapy; Proteomics; Solid tumors; T cell; Tumor antigens |
| P840 | Characterization of syngeneic tumor models and their microenvironment for immunotherapeutic approaches | Marco Carretta, PhD; Marie Louise Thorseth; Dennis A. Agardy; Silvia Redondo Garcia; Anne Mette Hvid Larsen, M.Sc; Dorota E. Kuczek, MSc; Daniel H. Madsen; | Tumor and Stromal Cell Biology | Solid tumors; Tumor microenvironment |
| P841 | NCG/CRL as a novel (Charles River) humanized mouse model for pre-clinical oncology studies: immunophenotypic characterization and performance monitoring | Jenny Rowe, PhD; Christoph CE. Eberle, PhD; Jenny Rowe, PhD; Robert Mihalek, PhD; Stephen Festin; | Tumor and Stromal Cell Biology | Checkpoint blockade; Immune monitoring; Leukemia/Lymphoma; Myeloid cells; NK/NK T cell; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P843 | Oral cancers expressing Glycoprotein-A repetitions predominant (GARP) show poor prognosis | Rieneke van de Ven, PhD; Jan Kloosterman, Bsc; Irene H. Nauta, M.Sc; Sonja H. Ganzevles, BSc; Elisabeth Bloemena, Prof. Dr.; C. René Leemans, MD, PhD; Ruud H. Brakenhoff, MD, PhD; | Tumor and Stromal Cell Biology | Biomarkers; Immune suppression; Immune tolerance; Solid tumors; Tumor evasion; Tumor microenvironment |
| P844 | Investigating the immunologic landscape and tumor-specific target identification in human clear cell renal carcinoma | Nivedita Chowdhury, MS; Aleksandar Obradovic; David H. Aggen, MD, PhD; Michael Johnson; Charles G. Drake, MD, PhD; | Tumor and Stromal Cell Biology | Neoantigens; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P845 | Targeting of Lactate Dehydrogenase C and its effects on the tumor immune microenvironment: two birds with one stone | Adviti Naik, PhD; Julie Decock, PhD; Aljazi M. Al-Khalifa; | Tumor and Stromal Cell Biology | Carcinogenesis; Cytokine; Gene expression; Immune contexture; Immune suppression; Metabolism; Solid tumors; Tumor antigens; Tumor evasion; Tumor microenvironment |
| P846 | Tumor-infiltrating B cells control the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8+ T cells | Kamila Hladíková; Vladimír Koucký; Jan Boucek; Jan Laco; Marek Grega; Aleš Ryška; Radek Špíšek; Anna Fialová; | Tumor and Stromal Cell Biology | B cell; Carcinogenesis; Checkpoint blockade; Costimulation; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P847 | Macrophages-induced H19 Up-regulation Activate the miR-193b/MAPK1 Axis and Promotes Cell Aggressiveness in Hepatocellular Carcinoma | Yingnan Ye; Jinpu Yu; Yingnan Ye; | Tumor and Stromal Cell Biology | Biomarkers; Monocyte/Macrophage; Tumor microenvironment |
| P848 | MiR-17 Cluster Promoted M2-polarized Tumor Associated Macrophages Related Cell Aggressiveness via Inducing the Imbalance of TGF-β1 /BMP7 Pathways in Hepatocellular Carcinoma | Yingnan Ye; Junya Ning; Jinpu Yu; | Tumor and Stromal Cell Biology | Monocyte/Macrophage; Tumor microenvironment |
| P849 | Melanoma-associated vitiligo skin maintains resident memory CD8 T cells with specific TCR profiles contributing to long-term tumor protection | Jichang Han, PhD candidate; Aleksey Molodtsov; Yanding Zhao; Keisuke Shirai, MD; Mary Jo Turk; Christina V. Angeles, MD; | Immune Cell Biology | Autoimmunity; Bioinformatics; Checkpoint blockade; Clinical study; Gene expression; Immune toxicity; Solid tumors; T cell |
| P850 | Metabolically reprogram MDSCs by targeting Pim kinases to overcome resistance to PD-1 blockade immunotherapy | Gang Xin; Yao Chen; Paytsar Topchyan; Aimin Jiang, PhD; Yiliang Chen; Roy Silverstein; Weiguo Cui; Gang Xin; | Checkpoint Blockade Therapy | Checkpoint blockade; Immune suppression; Monocyte/Macrophage; Myeloid cells; MDSC; Metabolism; Solid tumors; Tumor microenvironment |
Late-Breaking | ||||
| P851 | Identifying potential predictive biomarkers from plasma exosomes and adoptive T cells that differentiate short and long-term metastatic nasopharyngeal cancer survivors treated with chemotherapy and virus-specific T cells | Timothy Shuen, Who-Whong WANG, PhD, Han Chong Toh, MBBChir, Janice Lim, Cherlyn Tan, Jennie Kosasih, Rachael Cheong | Biomarkers, Immune Monitoring, and Novel Technologies | Adoptive immunotherapy; Biomarkers; Gene expression; Solid tumors; T cell |
| P852 | Transcriptomic analysis of dysfunctional CD8+ TILs in melanoma identifies bile acid and MTOR pathways as novel potential immunotherapy targets | Cheryl Cameron, PhD, Brian Richardson, Jackelyn Golden, Lukas Pfannensttiel, Michael Cartwright, Yousef Moustafa, Samjhana Thapaliya, Gustavo Roversi, Yee Peng Phoon, Mark Cameron, Brian Gastman, MD, Cheryl Cameron, PhD | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade; Gene expression; Immune suppression; Immune tolerance; Metabolism; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P853 | Single Cell transcriptome analysis identifies unique features in circulating CD8+ T cells that can predict immunotherapy response in melanoma patients | Chuan Li, Yee Peng Phoon, Keaton Karlinsey, Ye Tian, Samjhana Thapaliya, Lili Qu, Mark Cameron, Cheryl Cameron, PhD, Antoine Menoret, Pauline Funchain, MD, Jung-Min Song, RN, CNS, C. Marcela Diaz-Montero, Annabelle Rodriguez, Christopher Bonin, Anthony Vella, Beiyan Zhou, Brian Gastman, MD | Biomarkers, Immune Monitoring, and Novel Technologies | Bioinformatics; Biomarkers; Checkpoint blockade; Gene expression; Immune suppression; Immune tolerance; Metabolism; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P854 | Construction of the immune landscape of durable response to checkpoint blockade therapy by integrating publicly available datasets | Nils-Petter Rudqvist, PhD , Roberta Zappasodi, PhD, Daniel Wells, PhD, Vésteinn Thorsson, PhD, Alexandria Cogdill, MEng, Anne Monette, PhD, Yana Najjar, MD, Randy Sweis, MD, Erik Wennerberg, PhD, Praveen Bommareddy, PhD0, Cara Haymaker, PhD, Uqba Khan, MD, Heather McGee, MD, PhD, Wungki Park, MD, Houssein Abdul Sater, MD, Christine Spencer, PhD, Nicholas Tschernia, MD, Maria Ascierto, PhD, Valentin Barsan, MD, Vinita Popat, PhD, Sara Valpione, MD, PhD, Benjamin Vincent, MD | Checkpoint Blockade Therapy | Bioinformatics; Checkpoint blockade; Gene expression; Systems biology; Tumor microenvironment |
| P855 | High-resolution maps of heterogeneous antigen expression in glioblastoma and implications for immunotherapy | Michael Barish, PhD, Lihong Weng, Dina Awabdeh, MD, Blake Brewster, Massimo D'Apuzzo, Yubo Zhai, Alfonso Brito, Brenda Chang, Annie Sarkissian, Renate Starr, MS, Wen-Chung Chang, Brenda Aguilar, BS, Araceli Naranjo, Suzette Blanchard, Russell Rockne, PhD, Behnam Badie, MD, Vanessa Jonsson, PhD, Stephen Forman, MD, Christine Brown, PhD , Michael Barish, PhD | Combination Immunotherapies | Adoptive immunotherapy; CAR T cells; Solid tumors; Targeted therapy; Tumor antigens |
| P856 | AVID200, first-in-class TGF-beta1 and beta3 selective inhibitor: Results of a Phase 1 monotherapy dose escalation study in solid tumors and evidence of target engagement in patients | Timothy Yap, MD PhD , Daniel Araujo, Debra Wood, MD, Jean-François Denis, PhD, Tina Gruosso, PhD, Gilles Tremblay, PhD, Maureen O'Connor-McCourt, Ria Ghosh, Sandra Sinclair, Paul Nadler, MD, Lilian Siu, MD, Nehal Lakhani, MD, PhD | Clinical Trial Completed | Biomarkers; Clinical study; Clinical trial; Solid tumors; Tumor microenvironment; Tumor stroma |
| P857 | ONM-500 - A Novel STING-activating therapeutic nanovaccine platform for cancer immunotherapy | Jason Miller, PhD, Min Luo, Hua Wang, Zhaohui Wang, Xinliang Ding, PhD, Ashley Campbell, Jonathan Almazan, Zhijian Chen, Jinming Gao, Tian Zhao | Immune-stimulants and immune modulators | Antigen presenting cells; Immune adjuvant; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |
| P858 | An Open-Label, Multi-center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination with Cemiplimab in Subjects with Newly-Diagnosed Glioblastoma (GBM) | Jeffrey Skolnik, MD , David Reardon, MD, Steven Brem, MD, Arati Desai, Stephen Bagley, Sylvia Kurz, Macarena de la Fuente, Seema Nagpal, Mary Welch, Brian Sacchetta, Sarah Bartra, Amy-Lee Bredlau, Israel Lowy, MD, PhD, Kimberly Kraynyak, BS PhD, Matthew Morrow, Trevor McMullan, Jean Boyer, PhD | Clinical Trial In Progress | Adoptive immunotherapy; Checkpoint blockade; Clinical study; Clinical trial; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |
| P859 | Association of immunopharmacodynamic responses of Imprime PGG plus Pembrolizumab with clinical benefit in metastatic triple negative breast cancer (TNBC) subjects failing front-line chemotherapy | Nadine Ottoson, BS, Nandita Bose, PhD , Anissa Chan, PhD, Xiaohong Qiu, BS, Ben Harrison, MS, Richard Walsh, BS, Paulette Mattson, BFA, Michele Gargano, MS, Joanna Cox, MD, Michael Chisamore, PhD, Mark Uhlik, PhD, Jeremy Graff, PhD | Clinical Trial In Progress | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Immune monitoring; Monocyte/Macrophage; Myeloid cells; Solid tumors |
| P860 | Results from a combination of OX40 (PF-04518600) and 4-1BB (utomilumab) agonistic antibodies in melanoma and non-small cell lung cancer in a Phase 1 dose expansion cohort | Alberto Chiappori, MD , John Thompson, Fredericus Eskens, Jean-Philippe Spano, Toshihiko Doi, MD, PhD, Omid Hamid, MD, Adi Diab, MD, Naiyer Rizvi, MD, Siwen Hu-Lieskovan, MD, PhD, Willeke Ros, MSc0, Jacob Thomas, Alison Forgie, Wenjing Yang, Ken Liao, Ray Li, Farhad Kazazi, Jeffrey Chou, MD PhD, Anthony El khoueiry | Clinical Trial In Progress | Antibody; Clinical trial; Solid tumors; T cell; Targeted therapy |
| P862 | Clinical benefit potentially evident with immunopharmacodynamic responses in prior-checkpoint failed metastatic melanoma patients treated with Imprime PGG and Pembrolizumab | Anissa Chan, PhD, Nandita Bose, PhD , Nandita Bose, PhD, Nadine Ottoson, BS, Xiaohong Qiu, BS, Ben Harrison, MS, Richard Walsh, BS, Paulette Mattson, BFA, Michele Gargano, MS, Joanna Cox, MD, Michael Chisamore, PhD, Mark Uhlik, PhD, Jeremy Graff, PhD | Clinical Trial In Progress | Biomarkers; Checkpoint blockade; Clinical trial; Immune monitoring; Immune suppression; Myeloid cells; T cell |
| P863 | KEYNOTE-022 parts 4 and 5: pembrolizumab plus trametinib for patients with solid tumors or BRAF wild-type melanoma | Michele Maio, MD, PhD , Matteo Carlino, MBBS, PhD, BMedSC, F, Anthony Joshua, Elaine McWhirter, Antoni Ribas, MD, PhD, Paolo Ascierto, Wilson Miller Jr., Marcus Butler, MD, Pier Ferrucci, Robert Zielinski, Michele Del Vecchio0, Eduard Gasal, Razi Ghori, PhD, Scott Diede, MD PhD, Elizabeth Croydon, Omid Hamid, MD | Clinical Trial In Progress | Antibody; Checkpoint blockade; Clinical trial; Solid tumors; Targeted therapy |
| P864 | Combination of fecal microbiota transplantation from healthy donors with anti-PD1 immunotherapy in treatment-naïve advanced or metastatic melanoma patients | Saman Maleki, PhD , John Lenehan, Jeremy Burton, Michael Silverman, Seema Nair Parvathy, Mikal El-Hajjar, Mithunah Krishnamoorthy | Clinical Trial In Progress | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Immune toxicity; Microbiome; T cell |
| P865 | Safety & efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies - independent review committee data update | Amod Sarnaik, MD, Nikhil Khushalani, MD, Jason Chesney, MD, Harriet Kluger, MD, Brendan Curti, MD, Karl Lewis, MD, Theresa Medina, MD, Sajeve Thomas, Anna Pavlick, MD, MBA, Eric Whitman, MD, FACS, Salvador Algarra, Pippa Corrie, PhD, BMBCh, FRCP0, Omid Hamid, MD, Jose Lutzky, MD, FACP, Judit Olah, MD, PhD, Jeffrey Weber, MD, PhD, James Larkin, MD, Wen Shi, Kelly DiTrapani, RN, BSN, Harry Qin, PhD, Mariam Mirgoli, Renee Wu, Toshimi Takamura, BS, Maria Fardis, PhD, MBA, John Kirkwood, MD | Clinical Trial In Progress | Adoptive immunotherapy; Clinical trial; Solid tumors; Tumor infiltrating lymphocytes (TILs) |
© 2019 Society for Immunotherapy of Cancer (SITC). All rights reserved. SITC Meeting Code of Conduct.
